{"6b98d0fa40066d7036ebe9f283a20162a66e1a3b": [["IntroductionHuman rhinoviruses are highly prevalent respiratory picornaviruses of the Enterovirus genus.", [["respiratory picornaviruses", "DISEASE", 52, 78], ["IntroductionHuman rhinoviruses", "ORGANISM", 0, 30], ["Enterovirus genus", "ORGANISM", 86, 103], ["IntroductionHuman rhinoviruses", "PROBLEM", 0, 30], ["the Enterovirus genus", "PROBLEM", 82, 103], ["highly", "OBSERVATION_MODIFIER", 35, 41], ["prevalent", "OBSERVATION_MODIFIER", 42, 51], ["respiratory picornaviruses", "OBSERVATION", 52, 78], ["Enterovirus genus", "OBSERVATION", 86, 103]]], ["They display a single stranded positive sense RNA genome of approximately 7200 nucleotides encoding a single polyprotein which is cleaved by viral proteases into 11 individual proteins.", [["nucleotides", "CHEMICAL", 79, 90], ["single stranded positive sense RNA genome", "RNA", 15, 56], ["viral proteases", "PROTEIN", 141, 156], ["a single stranded positive sense RNA genome", "PROBLEM", 13, 56], ["a single polyprotein", "PROBLEM", 100, 120], ["viral proteases", "PROBLEM", 141, 156], ["RNA genome", "OBSERVATION", 46, 56]]], ["Human rhinoviruses are amongst the most frequent causes of upper respiratory tract infections, and are significantly associated with several lower respiratory tract infections including acute wheezing, pneumonia, and bronchiolitis, and cause about one half of asthma exacerbations (Busse et al., 2010) .", [["upper respiratory tract", "ANATOMY", 59, 82], ["lower respiratory tract", "ANATOMY", 141, 164], ["Human rhinoviruses", "DISEASE", 0, 18], ["respiratory tract infections", "DISEASE", 65, 93], ["respiratory tract infections", "DISEASE", 147, 175], ["wheezing", "DISEASE", 192, 200], ["pneumonia", "DISEASE", 202, 211], ["bronchiolitis", "DISEASE", 217, 230], ["asthma", "DISEASE", 260, 266], ["Human", "ORGANISM", 0, 5], ["rhinoviruses", "ORGANISM", 6, 18], ["upper", "ORGANISM_SUBDIVISION", 59, 64], ["respiratory tract", "ORGANISM_SUBDIVISION", 65, 82], ["Human", "SPECIES", 0, 5], ["Human rhinoviruses", "SPECIES", 0, 18], ["Human rhinoviruses", "PROBLEM", 0, 18], ["upper respiratory tract infections", "PROBLEM", 59, 93], ["several lower respiratory tract infections", "PROBLEM", 133, 175], ["acute wheezing", "PROBLEM", 186, 200], ["pneumonia", "PROBLEM", 202, 211], ["bronchiolitis", "PROBLEM", 217, 230], ["asthma exacerbations", "PROBLEM", 260, 280], ["rhinoviruses", "OBSERVATION", 6, 18], ["upper", "ANATOMY_MODIFIER", 59, 64], ["respiratory tract", "ANATOMY", 65, 82], ["infections", "OBSERVATION", 83, 93], ["lower", "ANATOMY_MODIFIER", 141, 146], ["respiratory tract", "ANATOMY", 147, 164], ["infections", "OBSERVATION", 165, 175], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["wheezing", "OBSERVATION", 192, 200], ["pneumonia", "OBSERVATION", 202, 211], ["bronchiolitis", "OBSERVATION", 217, 230], ["asthma", "OBSERVATION", 260, 266]]], ["One hundred classical serotypes have been defined by 20-fold or greater decrease in antigen cross-reactivity and form two genetically distinct species, A and B. There has recently been a renewed interest in rhinoviruses following the discovery of the highly prevalent and diverse species C group, using novel molecular-based approaches (McErlean et al., 2007; Briese et al., 2008; Kiang et al., 2008; Lee et al., 2007; Lau et al., 2007) .IntroductionSpecies B viruses are generally considered to be rare, with an average prevalence rate of around 7% of total HRV strains (Briese et al., 2008; Miller et al., 2009a) .", [["rhinoviruses", "ORGANISM", 207, 219], ["IntroductionSpecies B viruses", "ORGANISM", 438, 467], ["One hundred classical serotypes", "PROBLEM", 0, 31], ["greater decrease in antigen cross-reactivity", "PROBLEM", 64, 108], ["two genetically distinct species", "PROBLEM", 118, 150], ["rhinoviruses", "PROBLEM", 207, 219], ["IntroductionSpecies B viruses", "PROBLEM", 438, 467], ["total HRV strains", "PROBLEM", 553, 570], ["serotypes", "OBSERVATION", 22, 31], ["20-fold", "OBSERVATION_MODIFIER", 53, 60], ["greater", "OBSERVATION_MODIFIER", 64, 71], ["decrease", "OBSERVATION_MODIFIER", 72, 80], ["distinct", "OBSERVATION_MODIFIER", 134, 142], ["species", "OBSERVATION", 143, 150], ["rhinoviruses", "OBSERVATION", 207, 219], ["viruses", "OBSERVATION", 460, 467]]], ["Several studies suggest that species C viruses are a major cause of wheezing and exacerbation of asthma in children, and may have different clinical outcomes to other species [Lau et al., 2007; Miller et al., 2009b) , however, other studies find no significant differences (Piotrowska et al., 2009; McCulloch et al., 2014) .IntroductionThe recent whole-genome sequencing of all species A and B, and several species C prototype strains provides a very useful framework for the genetic analysis and classification of clinical specimens, from partial or whole sequences (Palmenberg et al., 2009) .", [["specimens", "ANATOMY", 524, 533], ["wheezing", "DISEASE", 68, 76], ["asthma", "DISEASE", 97, 103], ["species C viruses", "ORGANISM", 29, 46], ["children", "ORGANISM", 107, 115], ["B", "GENE_OR_GENE_PRODUCT", 392, 393], ["specimens", "CANCER", 524, 533], ["children", "SPECIES", 107, 115], ["C viruses", "SPECIES", 37, 46], ["Several studies", "TEST", 0, 15], ["species C viruses", "PROBLEM", 29, 46], ["wheezing", "PROBLEM", 68, 76], ["exacerbation", "PROBLEM", 81, 93], ["asthma", "PROBLEM", 97, 103], ["other studies", "TEST", 227, 240], ["all species A and B", "PROBLEM", 374, 393], ["several species C prototype strains", "PROBLEM", 399, 434], ["the genetic analysis", "TEST", 472, 492], ["clinical specimens", "TEST", 515, 533], ["wheezing", "OBSERVATION", 68, 76], ["exacerbation", "OBSERVATION_MODIFIER", 81, 93], ["asthma", "OBSERVATION", 97, 103]]], ["Recently, new criteria have been proposed for the classification of species C viruses, which has simplified the identification of novel genotypes, or ''genetic types.''", [["species C viruses", "ORGANISM", 68, 85], ["C viruses", "SPECIES", 76, 85], ["species C viruses", "PROBLEM", 68, 85], ["novel genotypes", "PROBLEM", 130, 145], ["viruses", "OBSERVATION", 78, 85]]], ["These criteria classify 33 genetic types, and 28 provisional types which require confirmation by additional VP1 gene sequencing .", [["VP1 gene", "DNA", 108, 116], ["These criteria", "TEST", 0, 14], ["confirmation", "TEST", 81, 93], ["additional VP1 gene sequencing", "TREATMENT", 97, 127]]], ["Within A and B species, there is generally a strong adherence to phylogenetic positioning (branching order) between the different structural protein genes, with a few exceptions (Savolainen et al., 2004; McIntyre et al., 2010) .", [["B species", "CELL", 13, 22], ["structural protein genes", "DNA", 130, 154], ["strong", "OBSERVATION_MODIFIER", 45, 51], ["adherence", "OBSERVATION", 52, 61], ["protein genes", "OBSERVATION", 141, 154], ["few", "OBSERVATION_MODIFIER", 163, 166]]], ["Species C viruses cluster in two phylogenetic groups on the 5' untranslated region (5UTR), one with species A (designated in some studies as Ca) and the other as aContents lists available at ScienceDirectInfection, Genetics and Evolution j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / m e e g i d separate C cluster (designated Cc) (Palmenberg et al., 2010; Huang et al., 2009 ).", [["Ca", "CHEMICAL", 141, 143], ["Ca", "CHEMICAL", 141, 143], ["Species C viruses", "ORGANISM", 0, 17], ["5' untranslated region", "DNA", 60, 82], ["5UTR", "DNA", 84, 88], ["Species C viruses cluster", "PROBLEM", 0, 25], ["species A", "PROBLEM", 100, 109], ["a g e", "TEST", 262, 267], ["a t e", "TEST", 310, 315], ["separate C cluster", "TEST", 330, 348], ["viruses", "OBSERVATION_MODIFIER", 10, 17], ["cluster", "OBSERVATION_MODIFIER", 18, 25], ["two", "OBSERVATION_MODIFIER", 29, 32], ["phylogenetic", "OBSERVATION_MODIFIER", 33, 45], ["groups", "OBSERVATION_MODIFIER", 46, 52]]], ["There is a consensus view that partial genome sequencing of at least two regions (VP4/2, VP1 or 3CD genes) of the HRV genome is sufficient for genetic type classification based on nucleotide homology Arden and Mackay, 2010) .", [["nucleotide", "CHEMICAL", 180, 190], ["nucleotide", "CHEMICAL", 180, 190], ["VP4/2", "GENE_OR_GENE_PRODUCT", 82, 87], ["VP1", "GENE_OR_GENE_PRODUCT", 89, 92], ["3CD", "GENE_OR_GENE_PRODUCT", 96, 99], ["VP4", "DNA", 82, 85], ["VP1", "DNA", 89, 92], ["3CD genes", "DNA", 96, 105], ["HRV genome", "DNA", 114, 124], ["a consensus view", "TEST", 9, 25], ["partial genome sequencing", "PROBLEM", 31, 56], ["VP4", "TEST", 82, 85], ["VP1", "PROBLEM", 89, 92]]], ["Several recent studies support classification guidelines based on pairwise nucleotide homology distance thresholds, based on studies across the genome, and these data are supported by serotypical distinctions in A and B species.", [["nucleotide", "CHEMICAL", 75, 85], ["B species", "CELL", 218, 227], ["studies", "TEST", 125, 132], ["these data", "TEST", 156, 166], ["serotypical distinctions in A and B species", "PROBLEM", 184, 227]]], ["The proposed inter-serotype pairwise nucleotide divergence threshold for A and B species is 13% in the VP1 gene and 10% in the VP4/2 gene McIntyre et al., 2010 McIntyre et al., , 2013 Savolainen et al., 2002a; Wisdom et al., 2009a) .", [["nucleotide", "CHEMICAL", 37, 47], ["VP1", "GENE_OR_GENE_PRODUCT", 103, 106], ["VP1 gene", "DNA", 103, 111], ["VP4", "DNA", 127, 130], ["The proposed inter-serotype pairwise nucleotide divergence threshold", "PROBLEM", 0, 68], ["A and B species", "TEST", 73, 88]]], ["These criteria also apply to the inter-genotype distance for species C viruses, which cannot be classified by serology due to their inability to grow in tissue culture McIntyre et al., 2010) .", [["tissue", "ANATOMY", 153, 159], ["tissue", "TISSUE", 153, 159], ["species C viruses", "PROBLEM", 61, 78], ["serology", "TEST", 110, 118]]], ["As a consequence, novel HRV strains were described in the past few years, particularly novel species C viruses (Briese et al., 2008; Renwick et al., 2007; Miller et al., 2009b; McIntyre et al., 2010; Wisdom et al., 2009b; Kistler et al., 2007) .", [["HRV strains", "ORGANISM", 24, 35], ["C viruses", "ORGANISM", 101, 110], ["novel HRV strains", "PROBLEM", 18, 35], ["novel species C viruses", "PROBLEM", 87, 110]]], ["Potentially novel species A viruses are rarely reported, however, recently the strain A101 strain has been observed in several studies worldwide .Contents lists available at ScienceDirectRecombination, which occurs frequently in enteroviruses, was presumed to be uncommon in rhinoviruses, however, several studies have identified that recombination frequently occurs in the 5UTR region Huang et al., 2009; Tapparel et al., 2009) .", [["enteroviruses", "DISEASE", 229, 242], ["rhinoviruses", "DISEASE", 275, 287], ["species A viruses", "ORGANISM", 18, 35], ["strain A101 strain", "ORGANISM", 79, 97], ["rhinoviruses", "ORGANISM", 275, 287], ["A viruses", "SPECIES", 26, 35], ["novel species A viruses", "PROBLEM", 12, 35], ["the strain A101 strain", "PROBLEM", 75, 97], ["enteroviruses", "PROBLEM", 229, 242], ["rhinoviruses", "PROBLEM", 275, 287], ["several studies", "TEST", 298, 313], ["viruses", "OBSERVATION", 28, 35], ["presumed to be", "UNCERTAINTY", 248, 262], ["rhinoviruses", "OBSERVATION", 275, 287]]], ["Several studies have recently compared the location of ''breakpoints'' of recombination, to reveal typical recombination hotspots in the 5UTR Huang et al., 2009) .", [["Several studies", "TEST", 0, 15]]], ["Recombination events in the coding regions seem to be rare Tapparel et al., 2009) .Contents lists available at ScienceDirectIn this work we have evaluated the incidence of acute lower respiratory tract illness (ALRI)-associated rhinoviruses infection during a 3-year hospital-based survey in Cambodia in two distinct geographical locations, and examined the genetic diversity of these viruses.Study population and samples4170 nasopharyngeal respiratory samples were collected from patients of all ages hospitalised in Cambodia's Kampong Cham and Takeo provinces referral hospitals during the period between June 2007 and December 2009.", [["lower respiratory tract", "ANATOMY", 178, 201], ["nasopharyngeal respiratory samples", "ANATOMY", 426, 460], ["lower respiratory tract illness", "DISEASE", 178, 209], ["ALRI", "DISEASE", 211, 215], ["rhinoviruses infection", "DISEASE", 228, 250], ["lower", "ORGANISM_SUBDIVISION", 178, 183], ["respiratory tract", "ORGANISM_SUBDIVISION", 184, 201], ["rhinoviruses", "ORGANISM", 228, 240], ["nasopharyngeal respiratory samples", "CANCER", 426, 460], ["patients", "ORGANISM", 481, 489], ["coding regions", "DNA", 28, 42], ["patients", "SPECIES", 481, 489], ["Recombination events", "PROBLEM", 0, 20], ["acute lower respiratory tract illness", "PROBLEM", 172, 209], ["rhinoviruses infection", "PROBLEM", 228, 250], ["Study population", "TEST", 393, 409], ["samples", "TEST", 414, 421], ["nasopharyngeal respiratory samples", "TEST", 426, 460], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["lower", "ANATOMY_MODIFIER", 178, 183], ["respiratory tract", "ANATOMY", 184, 201], ["rhinoviruses", "OBSERVATION_MODIFIER", 228, 240], ["infection", "OBSERVATION", 241, 250], ["viruses", "OBSERVATION", 385, 392]]], ["The case definition of ALRI was as follows; for patients aged <5 years, ALRI was defined as an illness of <10 days duration that consisted of cough or difficult breathing, plus tachypnea.", [["ALRI", "DISEASE", 23, 27], ["ALRI", "DISEASE", 72, 76], ["cough", "DISEASE", 142, 147], ["tachypnea", "DISEASE", 177, 186], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["ALRI", "PROBLEM", 72, 76], ["cough", "PROBLEM", 142, 147], ["difficult breathing", "PROBLEM", 151, 170], ["tachypnea", "PROBLEM", 177, 186]]], ["For patients aged between 5 and 14 years, case definition included the above symptoms as well as a fever >38\u00b0C. For patients 15 years or older ALRI was defined as a fever >38\u00b0C, plus chest pain or tachypnea or auscultatory crackles (Mardy et al., 2009) .", [["chest", "ANATOMY", 183, 188], ["fever", "DISEASE", 99, 104], ["ALRI", "DISEASE", 143, 147], ["fever", "DISEASE", 165, 170], ["38\u00b0C", "DISEASE", 172, 176], ["chest pain", "DISEASE", 183, 193], ["tachypnea", "DISEASE", 197, 206], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 116, 124], ["the above symptoms", "PROBLEM", 67, 85], ["a fever", "PROBLEM", 97, 104], ["a fever", "PROBLEM", 163, 170], ["chest pain", "PROBLEM", 183, 193], ["tachypnea", "PROBLEM", 197, 206], ["auscultatory crackles", "PROBLEM", 210, 231], ["chest", "ANATOMY", 183, 188], ["crackles", "OBSERVATION", 223, 231]]], ["A severe case for patients <5 years of age was defined as ALRI in addition to: respiratory rate P60/mn (age <2 months), respiratory rate P50/mn (age <11 months), respiratory rate P40/mn (aged between 1 and 5 years), saturation <93%, cardiac frequency >180 bpm (age <1 year), cardiac frequency >140 bpm (aged between 1 and 5 years), clinical respiratory distress, according to World Health Organisation (WHO) guidelines (WHO, 2005) .RT-PCR and sequencingSamples were screened for the presence of 18 common and novel viral respiratory pathogens, including HRSV, human metapneumovirus (HMPV), human bocavirus (HBoV), influenza A and B viruses, human coronaviruses OC43, 229E, HKU1, and NL63, severe acute respiratory syndrome-associated coronavirus (SARS-CoV), parainfluenza viruses 1 to 4, adenoviruses, human rhinoviruses, and enteroviruses, by multiplex reverse transcriptase PCR (RT-PCR)/PCR, as previously reported (Buecher et al., 2010; Arnott et al., 2011 Arnott et al., , 2013a Arnott et al., , 2013b .", [["respiratory", "ANATOMY", 79, 90], ["respiratory", "ANATOMY", 120, 131], ["respiratory", "ANATOMY", 162, 173], ["cardiac", "ANATOMY", 233, 240], ["cardiac", "ANATOMY", 275, 282], ["respiratory", "ANATOMY", 341, 352], ["ALRI", "DISEASE", 58, 62], ["respiratory distress", "DISEASE", 341, 361], ["respiratory pathogens", "DISEASE", 521, 542], ["human metapneumovirus", "DISEASE", 560, 581], ["influenza A", "DISEASE", 614, 625], ["acute respiratory syndrome-associated coronavirus", "DISEASE", 696, 745], ["SARS-CoV)", "DISEASE", 747, 756], ["parainfluenza viruses", "DISEASE", 758, 779], ["human rhinoviruses", "DISEASE", 802, 820], ["enteroviruses", "DISEASE", 826, 839], ["patients", "ORGANISM", 18, 26], ["cardiac", "ORGAN", 233, 240], ["cardiac", "ORGAN", 275, 282], ["HRSV", "ORGANISM", 554, 558], ["human metapneumovirus", "ORGANISM", 560, 581], ["HMPV", "ORGANISM", 583, 587], ["human bocavirus", "ORGANISM", 590, 605], ["HBoV", "ORGANISM", 607, 611], ["influenza A and B viruses", "ORGANISM", 614, 639], ["human", "ORGANISM", 641, 646], ["coronaviruses OC43", "ORGANISM", 647, 665], ["229E", "GENE_OR_GENE_PRODUCT", 667, 671], ["HKU1", "GENE_OR_GENE_PRODUCT", 673, 677], ["NL63", "GENE_OR_GENE_PRODUCT", 683, 687], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 689, 745], ["SARS-CoV", "ORGANISM", 747, 755], ["parainfluenza viruses 1", "ORGANISM", 758, 781], ["adenoviruses", "ORGANISM", 788, 800], ["human", "ORGANISM", 802, 807], ["rhinoviruses", "ORGANISM", 808, 820], ["patients", "SPECIES", 18, 26], ["HRSV", "SPECIES", 554, 558], ["human", "SPECIES", 560, 565], ["metapneumovirus", "SPECIES", 566, 581], ["human", "SPECIES", 590, 595], ["human", "SPECIES", 641, 646], ["parainfluenza", "SPECIES", 758, 771], ["human", "SPECIES", 802, 807], ["HRSV", "SPECIES", 554, 558], ["human metapneumovirus", "SPECIES", 560, 581], ["HMPV", "SPECIES", 583, 587], ["human bocavirus", "SPECIES", 590, 605], ["HBoV", "SPECIES", 607, 611], ["influenza A", "SPECIES", 614, 625], ["B viruses", "SPECIES", 630, 639], ["human coronaviruses", "SPECIES", 641, 660], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 689, 745], ["SARS-CoV", "SPECIES", 747, 755], ["human rhinoviruses", "SPECIES", 802, 820], ["respiratory rate", "TEST", 79, 95], ["respiratory rate", "TEST", 120, 136], ["respiratory rate", "TEST", 162, 178], ["saturation", "TEST", 216, 226], ["cardiac frequency", "TEST", 233, 250], ["cardiac frequency", "TEST", 275, 292], ["clinical respiratory distress", "PROBLEM", 332, 361], ["RT-PCR", "TEST", 432, 438], ["sequencingSamples", "TEST", 443, 460], ["novel viral respiratory pathogens", "PROBLEM", 509, 542], ["HRSV", "PROBLEM", 554, 558], ["human metapneumovirus (HMPV", "PROBLEM", 560, 587], ["human bocavirus (HBoV", "PROBLEM", 590, 611], ["influenza A and B viruses", "PROBLEM", 614, 639], ["human coronaviruses OC43", "TEST", 641, 665], ["HKU1", "TEST", 673, 677], ["NL63", "TEST", 683, 687], ["severe acute respiratory syndrome", "PROBLEM", 689, 722], ["associated coronavirus (SARS", "PROBLEM", 723, 751], ["parainfluenza viruses", "PROBLEM", 758, 779], ["adenoviruses", "PROBLEM", 788, 800], ["human rhinoviruses", "PROBLEM", 802, 820], ["enteroviruses", "PROBLEM", 826, 839], ["transcriptase PCR", "TEST", 862, 879], ["RT-PCR", "TEST", 881, 887], ["PCR", "PROBLEM", 889, 892], ["severe", "OBSERVATION_MODIFIER", 2, 8], ["respiratory", "ANATOMY", 79, 90], ["respiratory", "ANATOMY", 120, 131], ["respiratory", "ANATOMY", 162, 173], ["cardiac", "ANATOMY", 233, 240], ["cardiac", "ANATOMY", 275, 282], ["respiratory distress", "OBSERVATION", 341, 361], ["viral", "OBSERVATION_MODIFIER", 515, 520], ["respiratory pathogens", "OBSERVATION", 521, 542], ["metapneumovirus", "OBSERVATION", 566, 581], ["severe", "OBSERVATION_MODIFIER", 689, 695], ["acute", "OBSERVATION_MODIFIER", 696, 701], ["respiratory syndrome", "OBSERVATION", 702, 722], ["coronavirus", "OBSERVATION", 734, 745], ["parainfluenza viruses", "OBSERVATION", 758, 779], ["rhinoviruses", "OBSERVATION", 808, 820]]], ["The RT-PCR step was amplifying an approximately 549 bp fragment of the human rhinoviruses VP4/VP2 and 5 0 -non-coding region (Savolainen et al., 2002b) and the subsequent semi-nested PCR was producing a 450 bp amplicon (Bellau-Pujol et al., 2005) .RT-PCR and sequencingSamples positive for rhinoviruses were amplified in the 5UTR and VP4/2 regions using the primers VP4/2F and VP4/2R (Supplementary Table 1 ) (Lau et al., 2007; Huang et al., 2009) .", [["human", "ORGANISM", 71, 76], ["rhinoviruses", "ORGANISM", 77, 89], ["VP4", "GENE_OR_GENE_PRODUCT", 90, 93], ["VP2", "GENE_OR_GENE_PRODUCT", 94, 97], ["rhinoviruses", "ORGANISM", 290, 302], ["549 bp fragment", "DNA", 48, 63], ["human rhinoviruses VP4/VP2 and 5 0 -non-coding region", "DNA", 71, 124], ["450 bp amplicon", "DNA", 203, 218], ["5UTR and VP4/2 regions", "DNA", 325, 347], ["primers VP4/2F and VP4/2R", "DNA", 358, 383], ["human", "SPECIES", 71, 76], ["human rhinoviruses", "SPECIES", 71, 89], ["The RT-PCR step", "TEST", 0, 15], ["bp fragment", "TEST", 52, 63], ["the human rhinoviruses", "TEST", 67, 89], ["VP4", "TEST", 90, 93], ["VP2", "TEST", 94, 97], ["the subsequent semi-nested PCR", "TEST", 156, 186], ["a 450 bp amplicon", "TREATMENT", 201, 218], ["RT-PCR", "TEST", 248, 254], ["sequencingSamples", "TEST", 259, 276], ["rhinoviruses", "PROBLEM", 290, 302], ["VP4/2 regions", "TREATMENT", 334, 347], ["the primers VP4", "TEST", 354, 369], ["VP4", "TEST", 377, 380], ["VP2", "ANATOMY", 94, 97], ["rhinoviruses", "OBSERVATION", 290, 302]]], ["Certain samples could not be amplified using these primers and were amplified separately in the 5UTR and VP4/2 region (Supplementary Table 1 ).", [["samples", "ANATOMY", 8, 15], ["samples", "CANCER", 8, 15], ["5UTR and VP4/2 region", "DNA", 96, 117], ["Certain samples", "TEST", 0, 15], ["these primers", "TEST", 45, 58]]], ["For VP1 amplification, RNA was reverse transcribed with random hexamer primers (Promega, United Kingdom) using the superscript III reverse transcriptase (Invitrogen).", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["superscript III reverse transcriptase", "GENE_OR_GENE_PRODUCT", 115, 152], ["VP1", "DNA", 4, 7], ["superscript III reverse transcriptase", "PROTEIN", 115, 152], ["VP1 amplification", "TREATMENT", 4, 21], ["RNA", "TEST", 23, 26], ["random hexamer primers", "TREATMENT", 56, 78], ["the superscript III reverse transcriptase (Invitrogen)", "TREATMENT", 111, 165]]], ["PCR was then conducted using Gotaq polymerase (Promega), and species-specific primers which have been previously described (Supplementary Table 1 ) (Tapparel et al., 2009) .", [["Gotaq polymerase", "GENE_OR_GENE_PRODUCT", 29, 45], ["Promega", "GENE_OR_GENE_PRODUCT", 47, 54], ["Gotaq polymerase", "PROTEIN", 29, 45], ["PCR", "TEST", 0, 3], ["Gotaq polymerase", "TREATMENT", 29, 45], ["species-specific primers", "PROBLEM", 61, 85]]], ["For VP1 region amplification we used primers VP1 1.2F and VP1 1.18R (and nested PCR VP1 1.55F and VP1.18R) for species A, VP1 1.57F and VP1 2.19R (and nested PCR VP1 1.57F and VP1 1.18R for species B), VP1 P1.160F and VP1 2.68R (and nested VP1 P1.161F and VP1 2.69R) for species C. A touch-down program (annealing temp of 55-1\u00b0C per cycle for 10 cycles, then 30 cycles at 45\u00b0C) was used for both primary and nested PCRs.", [["VP1 1.2F", "GENE_OR_GENE_PRODUCT", 45, 53], ["VP1", "ORGANISM", 122, 125], ["VP1 2.19R", "GENE_OR_GENE_PRODUCT", 136, 145], ["VP1 P1", "GENE_OR_GENE_PRODUCT", 202, 208], ["160F", "GENE_OR_GENE_PRODUCT", 209, 213], ["VP1 2.68R", "GENE_OR_GENE_PRODUCT", 218, 227], ["VP1 region", "DNA", 4, 14], ["primers VP1 1.2F", "DNA", 37, 53], ["VP1 1.18R", "DNA", 58, 67], ["nested PCR VP1 1.55F", "DNA", 73, 93], ["VP1", "DNA", 98, 101], ["18R", "PROTEIN", 102, 105], ["VP1 1.57F", "PROTEIN", 122, 131], ["VP1 2.19R", "PROTEIN", 136, 145], ["nested PCR VP1 1.57F", "DNA", 151, 171], ["VP1", "PROTEIN", 176, 179], ["VP1 P1", "PROTEIN", 202, 208], ["160F", "DNA", 209, 213], ["VP1 2.68R", "PROTEIN", 218, 227], ["nested VP1 P1", "DNA", 233, 246], ["161F", "PROTEIN", 247, 251], ["VP1 2.69R", "PROTEIN", 256, 265], ["VP1 region amplification", "TREATMENT", 4, 28], ["VP1", "TEST", 45, 48], ["VP1", "TEST", 58, 61], ["nested PCR VP1", "TEST", 73, 87], ["VP1", "TEST", 98, 101], ["species", "PROBLEM", 111, 118], ["VP1", "TEST", 122, 125], ["VP1", "TEST", 136, 139], ["nested PCR", "TEST", 151, 161], ["VP1", "TEST", 162, 165], ["VP1", "TEST", 176, 179], ["VP1", "TEST", 218, 221], ["VP1", "TEST", 256, 259], ["species", "PROBLEM", 271, 278], ["A touch", "TEST", 282, 289], ["annealing temp", "TEST", 304, 318]]], ["DNA products were separated by agarose gel electrophoresis and extracted using the QIAquick Gel Extraction Kit (Qiagen, Germany).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["agarose", "SIMPLE_CHEMICAL", 31, 38], ["DNA products", "TREATMENT", 0, 12], ["agarose gel electrophoresis", "TREATMENT", 31, 58], ["the QIAquick Gel Extraction", "TREATMENT", 79, 106]]], ["Products were ligated into TOPO-TA vectors (Invitrogen, Carlsbad, CA).", [["TOPO", "CHEMICAL", 27, 31], ["TOPO", "GENE_OR_GENE_PRODUCT", 27, 31], ["CA", "GENE_OR_GENE_PRODUCT", 66, 68], ["TOPO-TA vectors", "DNA", 27, 42], ["Products", "TREATMENT", 0, 8], ["TOPO-TA vectors", "TREATMENT", 27, 42]]], ["At least two plasmids were sequenced for each clinical sample.", [["plasmids", "ANATOMY", 13, 21], ["plasmids", "DNA", 13, 21], ["two plasmids", "TREATMENT", 9, 21], ["each clinical sample", "TEST", 41, 61], ["plasmids", "OBSERVATION", 13, 21]]], ["At least two recombinant clones were sequenced on an ABI3730 XL automatic DNA sequencer by Macrogen (Seoul, South Korea).Sequence alignment and phylogenetic analysisAlignments were conducted with Muscle, in SeaView 4.2.6 (Gouy et al., 2010) .", [["Muscle", "ANATOMY", 196, 202], ["clones", "CELL", 25, 31], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["Muscle", "TISSUE", 196, 202], ["recombinant clones", "CELL_LINE", 13, 31], ["Sequence alignment", "TEST", 121, 139], ["phylogenetic analysisAlignments", "TEST", 144, 175], ["recombinant clones", "OBSERVATION", 13, 31], ["Muscle", "ANATOMY", 196, 202]]], ["Owing to the very high level of genome saturation detected, no Maximum-Likelihood analysis was conducted for building trees.", [["genome saturation", "TEST", 32, 49], ["Likelihood analysis", "TEST", 71, 90]]], ["Trees were therefore built using a neighbour-joining approach.", [["a neighbour-joining approach", "TREATMENT", 33, 61]]], ["The robustness of nodes was assessed with 500 bootstrap replicates.Genetic and sequence polymorphism analysesGenetic similarity and difference matrices were constructed using Muscle in SeaView 4.2.6 (Gouy et al., 2010) .", [["nodes", "ANATOMY", 18, 23], ["Muscle", "ANATOMY", 175, 181], ["nodes", "MULTI-TISSUE_STRUCTURE", 18, 23], ["Muscle", "TISSUE", 175, 181], ["The robustness of nodes", "PROBLEM", 0, 23], ["Genetic and sequence polymorphism analyses", "TEST", 67, 109], ["nodes", "OBSERVATION", 18, 23], ["Muscle", "ANATOMY", 175, 181]]], ["Sequence polymorphism, subsequent tests and statistical tests were performed using functions from the DnaSP 5.10.01 package (Librado and Rozas, 2009 ).", [["Sequence polymorphism", "TEST", 0, 21], ["subsequent tests", "TEST", 23, 39], ["statistical tests", "TEST", 44, 61]]], ["Sequence polymorphism was investigated by calculation of several measures.", [["Sequence polymorphism", "TEST", 0, 21]]], ["Nucleotide diversity, Pi (p), the average number of nucleotide differences per site between two sequences was calculated, using the Jukes and Cantor correction.", [["nucleotide", "CHEMICAL", 52, 62], ["nucleotide", "CHEMICAL", 52, 62], ["Nucleotide diversity", "PROBLEM", 0, 20], ["nucleotide differences", "PROBLEM", 52, 74], ["the Jukes and Cantor correction", "TREATMENT", 128, 159], ["diversity", "OBSERVATION_MODIFIER", 11, 20]]], ["Theta (Watterson's mutation parameter) was calculated for the whole sequence from S. Eta (g) is the total number of mutations, and S is the number of polymorphic sites.", [["Theta (Watterson's mutation parameter", "TREATMENT", 0, 37], ["mutations", "PROBLEM", 116, 125]]], ["Ka (the number of non-synonymous substitutions per non-synonymous site), and Ks (the number of synonymous substitutions per synonymous site) for any pair of sequences were calculated.", [["non-synonymous substitutions per non-synonymous site", "TREATMENT", 18, 70], ["synonymous substitutions per synonymous site", "TREATMENT", 95, 139], ["any pair of sequences", "TEST", 145, 166]]], ["Tajima's D test was used for statistical testing the hypothesis that all mutations are selectively neutral.Genetic and sequence polymorphism analysesStatistical tests D \u2044 and F \u2044 were used for testing the hypothesis that all mutations are selectively neutral.Ethics statementThe project (SISEA) was approved by the National Ethics Committee of Cambodia.", [["Tajima's D test", "TEST", 0, 15], ["statistical testing", "TEST", 29, 48], ["Genetic and sequence polymorphism analyses", "TEST", 107, 149], ["Statistical tests D \u2044 and F \u2044", "TEST", 149, 178]]], ["All patients/parents of sick children who participated provided written informed consent.Nucleotide sequence accession numbersThe sequences described in this study were deposited in Genbank under the following accession numbers: VP1: KF034075, KF034076, KF034078 to KF034081, KF034083, LN623979 to LN623997, KM986111, KM986112 VP 2/4: KF034009 to KF034074 5 0 UTR sequences use for recombination were deposited under accession numbers KF033904 to KF034008.HRV sample screening and detection in two provincial hospital sitesThe SISEA project (Surveillance of Infection in South East Asia) was established for surveillance of respiratory viruses in Cambodia, Vietnam, and Laos.", [["LN623997", "CHEMICAL", 298, 306], ["KM986111", "CHEMICAL", 308, 316], ["KF034008", "CHEMICAL", 447, 455], ["Infection", "DISEASE", 558, 567], ["respiratory viruses", "DISEASE", 624, 643], ["KF034081", "CHEMICAL", 266, 274], ["KF034083", "CHEMICAL", 276, 284], ["LN623979", "CHEMICAL", 286, 294], ["LN623997", "CHEMICAL", 298, 306], ["KM986112", "CHEMICAL", 318, 326], ["KF034008", "CHEMICAL", 447, 455], ["patients", "ORGANISM", 4, 12], ["children", "ORGANISM", 29, 37], ["KF034074 5 0 UTR sequences", "DNA", 347, 373], ["patients", "SPECIES", 4, 12], ["children", "SPECIES", 29, 37], ["this study", "TEST", 153, 163], ["VP1", "TEST", 229, 232], ["KF034076", "TEST", 244, 252], ["KF034078", "TEST", 254, 262], ["KF034081", "TEST", 266, 274], ["KF034083", "TEST", 276, 284], ["KM986111", "TEST", 308, 316], ["KM", "TEST", 318, 320], ["VP", "TEST", 327, 329], ["KF034074", "TEST", 347, 355], ["UTR sequences", "TEST", 360, 373], ["KF034008", "TEST", 447, 455], ["HRV sample screening", "TEST", 456, 476], ["detection", "TEST", 481, 490], ["Infection", "PROBLEM", 558, 567], ["respiratory viruses", "PROBLEM", 624, 643], ["Infection", "OBSERVATION", 558, 567], ["respiratory viruses", "OBSERVATION", 624, 643]]], ["Over a three-year period (2007-2009), we collected a total of 4170 respiratory samples from in-patients hospitalised with acute lower respiratory tract illness (ALRI) at two provincial hospitals in Cambodia (Takeo, southern Cambodia and Kampong Cham, central-north Cambodia).HRV sample screening and detection in two provincial hospital sitesAmongst the samples taken from Takeo hospital there were 977 children and 2279 adults.", [["respiratory samples", "ANATOMY", 67, 86], ["lower respiratory tract", "ANATOMY", 128, 151], ["samples", "ANATOMY", 354, 361], ["acute lower respiratory tract illness", "DISEASE", 122, 159], ["ALRI", "DISEASE", 161, 165], ["patients", "ORGANISM", 95, 103], ["tract", "ORGANISM_SUBDIVISION", 146, 151], ["children", "ORGANISM", 403, 411], ["patients", "SPECIES", 95, 103], ["children", "SPECIES", 403, 411], ["acute lower respiratory tract illness", "PROBLEM", 122, 159], ["HRV sample screening", "TEST", 275, 295], ["detection", "TEST", 300, 309], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["lower", "ANATOMY_MODIFIER", 128, 133], ["respiratory tract", "ANATOMY", 134, 151]]], ["From the Kampong Cham hospital there was 584 children and 227 adults.", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53]]], ["RNA was extracted from nasopharyngeal (NPS) samples, and amplified by real time PCR to detect the presence of 18 viruses, as described in previous studies (Buecher et al., 2010) .", [["nasopharyngeal (NPS) samples", "ANATOMY", 23, 51], ["nasopharyngeal", "CANCER", 23, 37], ["RNA", "RNA", 0, 3], ["nasopharyngeal (NPS) samples", "TEST", 23, 51], ["real time PCR", "TEST", 70, 83], ["18 viruses", "PROBLEM", 110, 120], ["nasopharyngeal", "ANATOMY", 23, 37], ["viruses", "OBSERVATION", 113, 120]]], ["From 4170 patient samples, 1105 samples tested positive for one or more virus.", [["samples", "ANATOMY", 18, 25], ["samples", "ANATOMY", 32, 39], ["patient", "ORGANISM", 10, 17], ["samples", "CANCER", 32, 39], ["patient", "SPECIES", 10, 17], ["patient samples", "TEST", 10, 25], ["1105 samples", "TEST", 27, 39], ["more virus", "PROBLEM", 67, 77]]], ["HRV was detected in 455 samples, representing the most frequently detected virus (10.9% of all patients, and 41.2% of patients positive for viral detections), consistent with evidence that rhinoviruses are usually highly prevalent (Miller et al., 2009a; Huang et al., 2009; Buecher et al., 2010; Follin et al., 2009; Loens et al., 2006; Vong et al., 2013; Guerrier et al., 2013) .", [["samples", "ANATOMY", 24, 31], ["samples", "CANCER", 24, 31], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 118, 126], ["rhinoviruses", "ORGANISM", 189, 201], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 118, 126], ["HRV", "TEST", 0, 3], ["viral detections", "TEST", 140, 156], ["rhinoviruses", "PROBLEM", 189, 201], ["consistent with", "UNCERTAINTY", 159, 174], ["rhinoviruses", "OBSERVATION", 189, 201]]], ["Two hundred sixty-one of these patients were male, 194 female.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39]]], ["Two hundred thirty-seven patients were under the age of 2 years (52%), with 273 (60%) under the age of 5, and 80 patients over the age of 50 (17.6%).", [["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 113, 121]]], ["As previously reported, ALRI in general and HRV infections in particular were observed throughout the year, without clear seasonality (Guerrier et al., 2013) .", [["ALRI", "DISEASE", 24, 28], ["HRV infections", "DISEASE", 44, 58], ["ALRI", "PROBLEM", 24, 28], ["HRV infections", "PROBLEM", 44, 58], ["infections", "OBSERVATION", 48, 58]]], ["In addition to typical symptoms of ALRI recorded for all patients, supplementary comprehensive clinical data was available from 94 patients, which allowed us report on typical symptoms associated with disease (Table 1) , and also to form a case definition to identify severe rhinoviral infection.", [["ALRI", "DISEASE", 35, 39], ["rhinoviral infection", "DISEASE", 275, 295], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 131, 139], ["typical symptoms", "PROBLEM", 15, 31], ["ALRI", "PROBLEM", 35, 39], ["typical symptoms", "PROBLEM", 168, 184], ["disease", "PROBLEM", 201, 208], ["severe rhinoviral infection", "PROBLEM", 268, 295], ["severe", "OBSERVATION_MODIFIER", 268, 274], ["rhinoviral", "OBSERVATION_MODIFIER", 275, 285], ["infection", "OBSERVATION", 286, 295]]], ["This definition included the following criteria; no bacterial infection (sputum-negative) or viral co-infection.", [["bacterial infection", "DISEASE", 52, 71], ["viral co-infection", "DISEASE", 93, 111], ["bacterial infection", "PROBLEM", 52, 71], ["sputum", "TEST", 73, 79], ["viral co-infection", "PROBLEM", 93, 111], ["no", "UNCERTAINTY", 49, 51], ["bacterial", "OBSERVATION_MODIFIER", 52, 61], ["infection", "OBSERVATION", 62, 71], ["viral co-infection", "OBSERVATION", 93, 111]]], ["For children >5 years, or adults, was the inclusion of at least two of the following; a systolic blood pressure of 690 mmHg, a cardiac frequency of P120 bpm, a respiratory rate of P30/mn, saturation of 693%, or a temperature of 635\u00b0C or P40\u00b0C. The criteria for children 65 years was a respiratory rate of either P60/mn (aged < 2 months), P50/mn (aged between 2 and 12 months), P40/mn (aged between 1 and 5 years), oxygen saturation of <93%, a cardiac frequency of >180 bpm (aged <1 year), or >140 bpm (aged between 1 and 5 years), and signs of severe respiratory distress.", [["blood", "ANATOMY", 97, 102], ["cardiac", "ANATOMY", 127, 134], ["cardiac", "ANATOMY", 443, 450], ["respiratory", "ANATOMY", 551, 562], ["oxygen", "CHEMICAL", 414, 420], ["respiratory distress", "DISEASE", 551, 571], ["oxygen", "CHEMICAL", 414, 420], ["children", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["cardiac", "ORGAN", 127, 134], ["children", "ORGANISM", 261, 269], ["oxygen", "SIMPLE_CHEMICAL", 414, 420], ["cardiac", "ORGAN", 443, 450], ["children", "SPECIES", 4, 12], ["children", "SPECIES", 261, 269], ["a systolic blood pressure", "TEST", 86, 111], ["a respiratory rate", "TEST", 158, 176], ["saturation", "TEST", 188, 198], ["a temperature", "TEST", 211, 224], ["a respiratory rate", "TEST", 283, 301], ["oxygen saturation", "TEST", 414, 431], ["a cardiac frequency", "TEST", 441, 460], ["severe respiratory distress", "PROBLEM", 544, 571], ["cardiac", "ANATOMY", 127, 134], ["cardiac", "ANATOMY", 443, 450], ["severe", "OBSERVATION_MODIFIER", 544, 550], ["respiratory distress", "OBSERVATION", 551, 571]]], ["From this analysis 16 samples fulfilled the criteria for severe rhinoviral infection (approximately 17%).Genetic typing of the clinical detectionsIn order to evaluate the genetic diversity of HRV circulating in the considered human population and the potential involvement of variants or novel types in the occurrence of the severe forms recorded, samples were analysed by PCR.", [["samples", "ANATOMY", 22, 29], ["samples", "ANATOMY", 348, 355], ["rhinoviral infection", "DISEASE", 64, 84], ["human", "ORGANISM", 226, 231], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["this analysis", "TEST", 5, 18], ["severe rhinoviral infection", "PROBLEM", 57, 84], ["Genetic typing", "TEST", 105, 119], ["the clinical detections", "TEST", 123, 146], ["HRV", "PROBLEM", 192, 195], ["the severe forms", "PROBLEM", 321, 337], ["PCR", "TEST", 373, 376], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["rhinoviral", "OBSERVATION_MODIFIER", 64, 74], ["infection", "OBSERVATION", 75, 84], ["severe", "OBSERVATION_MODIFIER", 325, 331]]], ["PCR amplification was targeted on the VP1 gene and the VP4/2 gene region.", [["VP1", "GENE_OR_GENE_PRODUCT", 38, 41], ["VP4/2", "GENE_OR_GENE_PRODUCT", 55, 60], ["VP1 gene", "DNA", 38, 46], ["VP4/2 gene region", "DNA", 55, 72], ["PCR amplification", "TEST", 0, 17], ["VP4", "ANATOMY", 55, 58], ["2 gene", "ANATOMY_MODIFIER", 59, 65], ["region", "ANATOMY_MODIFIER", 66, 72]]], ["A total of 28 VP1 sequences were obtained and genotyped ( Table 2) .", [["VP1", "ORGANISM", 14, 17], ["VP1 sequences", "DNA", 14, 27], ["A total of 28 VP1 sequences", "TEST", 0, 27]]], ["The VP1 PCR failed on a number of samples, suggesting sequence divergence from the primer sequences used.", [["samples", "ANATOMY", 34, 41], ["samples", "CANCER", 34, 41], ["VP1 PCR", "DNA", 4, 11], ["primer sequences", "DNA", 83, 99], ["The VP1 PCR", "TEST", 0, 11], ["sequence divergence", "PROBLEM", 54, 73], ["the primer sequences", "TEST", 79, 99]]], ["Out of these 28 viruses 21 belonged to species A, 5 were members of species B and 2 corresponded to species C. Altogether, 5 viruses met the pairwise distance thresholds defined by McIntyre et al. (2013) to be recognised as novel types.", [["species B and 2", "PROBLEM", 68, 83]]], ["2 belonged to species A (i.e. D386 and K590 with 19.7% and 16.6% distance, respectively) and 2 others belonged to species B (i.e. K606 and P128 with 17% and 22.9% distance, respectively).", [["K590", "TEST", 39, 43], ["K606", "TEST", 130, 134], ["P128", "TEST", 139, 143]]], ["The last sample corresponding to a new type, i.e. R005, belonged to species C and displayed a pairwise distance to the closest relative of 30.9%.Genetic typing of the clinical detectionsThe VP4/2 sequence was also considered for genotyping the viruses.", [["VP4", "GENE_OR_GENE_PRODUCT", 190, 193], ["R005", "DNA", 50, 54], ["VP4/2 sequence", "DNA", 190, 204], ["The last sample", "TEST", 0, 15], ["Genetic typing", "TEST", 145, 159], ["the clinical detections", "TEST", 163, 186], ["The VP4/2 sequence", "TEST", 186, 204], ["genotyping the viruses", "PROBLEM", 229, 251], ["viruses", "OBSERVATION", 244, 251]]], ["Sixty VP4/2 sequences were obtained which were distributed into 31, 11 and 18 sequences for species A, B and C, respectively (Table 3) .", [["VP4", "GENE_OR_GENE_PRODUCT", 6, 9], ["B", "CELL", 103, 104], ["VP4/2 sequences", "DNA", 6, 21], ["31, 11 and 18 sequences", "DNA", 64, 87], ["Sixty VP4/2 sequences", "TEST", 0, 21]]], ["We also detected one enterovirus (EV68), which was previously recognised as HRV87 until it was reclassified as a variant of EV68 (Ishiko et al., 2002) .", [["enterovirus", "ORGANISM", 21, 32], ["EV68", "ORGANISM", 34, 38], ["HRV87", "GENE_OR_GENE_PRODUCT", 76, 81], ["EV68", "SPECIES", 34, 38], ["one enterovirus", "PROBLEM", 17, 32], ["enterovirus", "OBSERVATION", 21, 32]]], ["Viruses which were defined as clinically severe are highlighted in Table 3 .", [["Viruses", "PROBLEM", 0, 7]]], ["Sixteen viruses in species A displayed pairwise distances at nucleic acid level to the closest relative ranging from 10% to 19.9%.", [["nucleic acid", "CHEMICAL", 61, 73], ["Sixteen viruses in species", "PROBLEM", 0, 26], ["nucleic acid level", "TEST", 61, 79], ["viruses", "OBSERVATION", 8, 15]]], ["With respect to species B, 10 viruses out of 11 displayed pairwise distances ranging from 15.8% to 18.8%.", [["species B, 10 viruses", "TEST", 16, 37], ["pairwise distances", "TEST", 58, 76]]], ["The only virus from species C showing a VP4/2 pairwise distance above the 10% threshold to the closest relative was R005 (29.1%) which was identified as a novel type based on VP1 sequence distances.", [["species C", "TEST", 20, 29], ["a VP4", "TEST", 38, 43], ["virus", "OBSERVATION", 9, 14]]], ["Interestingly, the VP4/2 closest relative, i.e. HRV-C15, was different than the VP1 closest relative, i.e. HRV-C23.", [["VP4", "GENE_OR_GENE_PRODUCT", 19, 22], ["2", "GENE_OR_GENE_PRODUCT", 23, 24], ["HRV-C15", "GENE_OR_GENE_PRODUCT", 48, 55], ["HRV-C23", "GENE_OR_GENE_PRODUCT", 107, 114], ["VP4", "PROTEIN", 19, 22], ["the VP4", "TEST", 15, 22], ["HRV", "TEST", 48, 51], ["the VP1 closest", "TEST", 76, 91], ["HRV", "TEST", 107, 110]]], ["Several viruses for which the nucleotide pairwise distance with the closest relative was clearly above the 10% threshold displayed a protein sequence 100% identical to that of the same closest virus.", [["nucleotide", "CHEMICAL", 30, 40], ["nucleotide", "CHEMICAL", 30, 40], ["protein sequence", "DNA", 133, 149], ["Several viruses", "PROBLEM", 0, 15], ["a protein sequence", "TEST", 131, 149], ["viruses", "OBSERVATION", 8, 15]]], ["Interestingly, several of these putative new types based on nucleotide distance, ,displayed amino-acid distances lower than sampleTransition/transversion ratio and genome saturationOwing to the variations observed between the nucleic acid and protein distances, nucleotide polymorphism and genome saturation were assessed to determine the solidity of a phylogenetic analysis.", [["nucleotide", "CHEMICAL", 60, 70], ["amino-acid", "CHEMICAL", 92, 102], ["nucleic acid", "CHEMICAL", 226, 238], ["nucleotide", "CHEMICAL", 262, 272], ["nucleotide", "CHEMICAL", 60, 70], ["amino-acid", "CHEMICAL", 92, 102], ["nucleotide", "CHEMICAL", 262, 272], ["nucleotide distance", "TEST", 60, 79], ["amino-acid distances", "TEST", 92, 112], ["sampleTransition/transversion ratio", "TREATMENT", 124, 159], ["the nucleic acid", "TEST", 222, 238], ["nucleotide polymorphism", "TEST", 262, 285], ["genome saturation", "TEST", 290, 307], ["a phylogenetic analysis", "TEST", 351, 374], ["new", "OBSERVATION_MODIFIER", 41, 44], ["nucleic acid", "ANATOMY", 226, 238]]], ["The ratio of observed transition (mutation from a purine nucleotide to another or a pyrimidine nucleotide to another) versus transversion (mutation for a purine nucleotide to pyrimidine one or from a pyrimidine nucleotide to purine one) was calculated as an indicator of genome saturation.", [["purine", "CHEMICAL", 50, 56], ["nucleotide", "CHEMICAL", 57, 67], ["pyrimidine", "CHEMICAL", 84, 94], ["purine", "CHEMICAL", 154, 160], ["nucleotide", "CHEMICAL", 161, 171], ["pyrimidine", "CHEMICAL", 175, 185], ["pyrimidine nucleotide", "CHEMICAL", 200, 221], ["purine", "CHEMICAL", 225, 231], ["purine nucleotide", "CHEMICAL", 50, 67], ["pyrimidine nucleotide", "CHEMICAL", 84, 105], ["purine nucleotide", "CHEMICAL", 154, 171], ["pyrimidine", "CHEMICAL", 175, 185], ["pyrimidine nucleotide", "CHEMICAL", 200, 221], ["purine", "CHEMICAL", 225, 231], ["pyrimidine", "SIMPLE_CHEMICAL", 175, 185], ["purine", "SIMPLE_CHEMICAL", 225, 231], ["observed transition (mutation", "PROBLEM", 13, 42], ["a purine nucleotide", "TREATMENT", 48, 67], ["a pyrimidine nucleotide", "TREATMENT", 82, 105], ["transversion (mutation", "PROBLEM", 125, 147], ["a purine nucleotide to pyrimidine", "TREATMENT", 152, 185], ["a pyrimidine nucleotide to purine", "TREATMENT", 198, 231], ["genome saturation", "TEST", 271, 288], ["genome saturation", "OBSERVATION", 271, 288]]], ["The ratio ranged from 0.714 to 1.086 for the coding sequences depending on the gene and virus species.Transition/transversion ratio and genome saturationOwing to the presence of indels in the VP1 sequences, calculation was done on indel-free segments.", [["VP1 sequences", "DNA", 192, 205], ["The ratio", "TEST", 0, 9], ["the coding sequences", "TEST", 41, 61], ["the gene and virus species", "PROBLEM", 75, 101], ["Transition/transversion ratio", "TREATMENT", 102, 131], ["the VP1 sequences", "TEST", 188, 205], ["calculation", "TEST", 207, 218], ["virus species", "OBSERVATION", 88, 101], ["free segments", "OBSERVATION", 237, 250]]], ["For the 5'UTR, the transition/transversion ratio was 0.515.", [["5'UTR", "DNA", 8, 13], ["the transition/transversion ratio", "TEST", 15, 48]]], ["For reference, the transition/transversion ratio was calculated for the gene E of the dengue DENV-1 virus (Duong et al., 2013) with a value of 14.49.", [["dengue", "DISEASE", 86, 92], ["dengue", "ORGANISM", 86, 92], ["DENV-1 virus", "ORGANISM", 93, 105], ["gene E", "DNA", 72, 78], ["dengue DENV-1 virus", "SPECIES", 86, 105], ["dengue DENV-1 virus", "SPECIES", 86, 105], ["the transition/transversion ratio", "TEST", 15, 48], ["the dengue DENV", "PROBLEM", 82, 97], ["a value", "TEST", 132, 139]]], ["The rate of polymorphic sites (S) ranged from 44.3% to 71.3 5% depending on the sequence while H ranged from 42.8 to 101.8.", [["polymorphic sites", "DNA", 12, 29], ["H", "TEST", 95, 96]]], ["The DENV-1 E gene used as a reference displayed a rate of polymorphic sites of 12.7% and a H value of 40.1.", [["DENV-1 E", "GENE_OR_GENE_PRODUCT", 4, 12], ["DENV-1 E gene", "DNA", 4, 17], ["polymorphic sites", "DNA", 58, 75], ["DENV-1", "SPECIES", 4, 10], ["The DENV", "TEST", 0, 8], ["polymorphic sites", "TEST", 58, 75], ["a H value", "TEST", 89, 98], ["DENV", "OBSERVATION", 4, 8]]], ["The ratio between parsimony informative sites (Pa) and singletons (Si) was strongly biased towards the former with a rate of Pa ranging from 88.5% to 96.1% for the coding regions while it was 84.3% for the 5'UTR.", [["parsimony informative sites", "DNA", 18, 45], ["Pa", "DNA", 47, 49], ["Si", "DNA", 67, 69], ["coding regions", "DNA", 164, 178], ["5'UTR", "DNA", 206, 211], ["a rate", "TEST", 115, 121], ["Pa", "TEST", 125, 127]]], ["For reference, the values of Pa and Si were very close for the DENV-1 gene E, although higher for Si, with rates of 48.7% and 51.3%, respectively.", [["Si", "CHEMICAL", 36, 38], ["Si", "CHEMICAL", 98, 100], ["Pa", "GENE_OR_GENE_PRODUCT", 29, 31], ["DENV-1", "GENE_OR_GENE_PRODUCT", 63, 69], ["Si", "DNA", 36, 38], ["DENV-1 gene E", "DNA", 63, 76], ["DENV-1", "SPECIES", 63, 69], ["the values", "TEST", 15, 25], ["Pa and Si", "TEST", 29, 38], ["the DENV", "TEST", 59, 67], ["rates", "TEST", 107, 112], ["DENV", "OBSERVATION", 63, 67]]], ["A strong bias was also observed in the rate of synonymous replacement (Ns) which ranged from 86.2% to 96.4%, the rate for the DENV-1 E gene being in the same range with 84.9%.", [["DENV-1 E", "GENE_OR_GENE_PRODUCT", 126, 134], ["DENV-1 E gene", "DNA", 126, 139], ["DENV-1", "SPECIES", 126, 132], ["synonymous replacement (Ns", "TREATMENT", 47, 73], ["the rate", "TEST", 109, 117], ["the DENV", "TEST", 122, 130], ["strong", "OBSERVATION_MODIFIER", 2, 8], ["bias", "OBSERVATION", 9, 13], ["synonymous replacement", "OBSERVATION", 47, 69]]], ["Accordingly, a very low value of the Ka/Ks was observed for all sequences.", [["Ka/Ks", "GENE_OR_GENE_PRODUCT", 37, 42], ["the Ka/Ks", "TEST", 33, 42]]], ["No bias was observed on the individual rate of A, T, G and C bases.Phylogenetic analyses and protein polymorphism assessmentPhylogenetic analysis was conducted on VP1 and VP4/2 ( Fig. 1a and b ).", [["VP1", "DNA", 163, 166], ["VP4", "DNA", 171, 174], ["bias", "PROBLEM", 3, 7], ["Phylogenetic analyses", "TEST", 67, 88], ["protein polymorphism assessment", "TEST", 93, 124], ["Phylogenetic analysis", "TEST", 124, 145], ["VP1", "TEST", 163, 166], ["VP4", "TEST", 171, 174], ["bias", "OBSERVATION", 3, 7], ["bases", "ANATOMY_MODIFIER", 61, 66]]], ["Owing to the high level of genome saturation observed when analysing the transition/transversion ratio, the topology of trees based on protein alignments was also determined for the VP1 and VP4/2 proteins in order to assess congruent topologies between nucleic acids and proteins.", [["nucleic acids", "CHEMICAL", 253, 266], ["VP4/2", "GENE_OR_GENE_PRODUCT", 190, 195], ["nucleic acids", "SIMPLE_CHEMICAL", 253, 266], ["VP1 and VP4/2 proteins", "PROTEIN", 182, 204], ["genome saturation", "TEST", 27, 44], ["the transition/transversion ratio", "TEST", 69, 102], ["protein alignments", "TEST", 135, 153], ["the VP1 and VP4/2 proteins", "TEST", 178, 204], ["nucleic acids", "TEST", 253, 266]]], ["The high level of genome saturation could not allow for running relevant evolution models for maximum likelihood analysis and trees were therefore built using the distance neighbour-joining method.", [["genome saturation", "TEST", 18, 35], ["maximum likelihood analysis", "TEST", 94, 121], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["For both VP1 and VP4/2 nucleic acids and protein trees were perfectly congruent (Supplementary Figs.", [["VP1", "GENE_OR_GENE_PRODUCT", 9, 12], ["VP4", "GENE_OR_GENE_PRODUCT", 17, 20], ["VP1 and VP4/2 nucleic acids", "DNA", 9, 36], ["both VP1", "TEST", 4, 12], ["VP4/2 nucleic acids", "TEST", 17, 36], ["protein trees", "TEST", 41, 54]]], ["1 and 2) .Recombination across the 5UTRSeveral studies have examined recombination and found that the region between the VP4/2 and 5UTR could be a ''hotspot'' for recombination events (Huang et al., 2009; Tapparel et al., 2009; McIntyre et al., 2010) .", [["VP4", "GENE_OR_GENE_PRODUCT", 121, 124], ["2", "GENE_OR_GENE_PRODUCT", 125, 126], ["5UTR", "GENE_OR_GENE_PRODUCT", 131, 135], ["VP4", "DNA", 121, 124], ["5UTR", "DNA", 131, 135], ["recombination events", "PROBLEM", 163, 183]]], ["A similar analysis was conducted and the putative recombination breakpoints for the viruses from species A and C observed in this study were found to be located in the same area as previously described (Huang et al., 2009 ) (Data not shown).DiscussionThis work is one of the largest respiratory virus surveillance studies, with more than 4000 clinical samples, providing evidence of the major rank occupied by HRV amongst respiratory viruses causing influenza-like illness.", [["samples", "ANATOMY", 352, 359], ["respiratory viruses", "DISEASE", 422, 441], ["influenza-like illness", "DISEASE", 450, 472], ["samples", "CANCER", 352, 359], ["respiratory viruses", "ORGANISM", 422, 441], ["A similar analysis", "TEST", 0, 18], ["the putative recombination breakpoints", "TREATMENT", 37, 75], ["the viruses", "PROBLEM", 80, 91], ["this study", "TEST", 125, 135], ["the largest respiratory virus surveillance studies", "TEST", 271, 321], ["respiratory viruses", "PROBLEM", 422, 441], ["influenza", "PROBLEM", 450, 459], ["respiratory viruses", "OBSERVATION", 422, 441]]], ["Rhinoviruses are frequently concurrently detected with other respiratory viruses due to their high circulation in the community.", [["Rhinoviruses", "DISEASE", 0, 12], ["respiratory viruses", "DISEASE", 61, 80], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Rhinoviruses", "PROBLEM", 0, 12], ["other respiratory viruses", "PROBLEM", 55, 80]]], ["However, some studies have proposed that despite the frequency of co-detections, rhinoviruses are statistically the least likely to be involved in coinfection and may actually reduce the probability of another virus infecting the host (Duong et al., 2013) .", [["coinfection", "DISEASE", 147, 158], ["rhinoviruses", "ORGANISM", 81, 93], ["some studies", "TEST", 9, 21], ["co-detections", "PROBLEM", 66, 79], ["rhinoviruses", "PROBLEM", 81, 93], ["coinfection", "PROBLEM", 147, 158], ["another virus", "PROBLEM", 202, 215], ["rhinoviruses", "OBSERVATION", 81, 93], ["coinfection", "OBSERVATION", 147, 158]]], ["HRV/HRV co-detections have Table 3 Species classification of clinical detections based on VP4/2 sequences.DiscussionStrains which were obtained from clinically severe hospitalised patients are highlighted in grey.", [["VP4/2", "GENE_OR_GENE_PRODUCT", 90, 95], ["patients", "ORGANISM", 180, 188], ["VP4/2 sequences", "DNA", 90, 105], ["patients", "SPECIES", 180, 188], ["HRV", "TEST", 0, 3], ["clinical detections", "TEST", 61, 80], ["VP4/2 sequences", "TEST", 90, 105]]], ["Novel types identified based on VP1 distances are shown in bold italic. occasionally been reported Renwick et al., 2007; Huang et al., 2009) , although, interestingly no co-detections from the same species have been reported.", [["VP1", "ORGANISM", 32, 35], ["co-detections", "PROBLEM", 170, 183]]], ["In this work we report one HRV/HRV co-detection, and significantly both viruses detected from one patient were species A (HRV78 and HRV81).", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["one HRV", "TEST", 23, 30], ["HRV co-detection", "TEST", 31, 47], ["significantly both viruses", "PROBLEM", 53, 79], ["viruses", "OBSERVATION", 72, 79]]], ["The frequency of HRV co-detections is difficult to assess given that often only a few clones are sequenced and therefore if one virus is present in a lesser proportion than the other, it might not be detected.", [["clones", "CELL", 86, 92], ["HRV co-detections", "TEST", 17, 34], ["a few clones", "PROBLEM", 80, 92], ["one virus", "PROBLEM", 124, 133], ["few", "OBSERVATION_MODIFIER", 82, 85], ["clones", "OBSERVATION", 86, 92], ["lesser", "OBSERVATION_MODIFIER", 150, 156], ["might not be", "UNCERTAINTY", 187, 199]]], ["In this work we analysed 455 viruses and we found out that 35 only out of these 455 were co-detected with other viruses (7.7% of total).", [["other viruses", "PROBLEM", 106, 119]]], ["This percentage is even lower than that reported in previous studies, i.e. 23% of total [40] which were concluding that rhinoviruses were statistically the least likely respiratory virus to be involved in co-infection (Greer et al., 2009) .", [["co-infection", "DISEASE", 205, 217], ["rhinoviruses", "ORGANISM", 120, 132], ["previous studies", "TEST", 52, 68], ["rhinoviruses", "PROBLEM", 120, 132], ["respiratory virus", "PROBLEM", 169, 186], ["co-infection", "PROBLEM", 205, 217], ["lower", "OBSERVATION_MODIFIER", 24, 29], ["rhinoviruses", "OBSERVATION", 120, 132], ["respiratory virus", "OBSERVATION", 169, 186]]], ["This further highlights the independent role of rhinoviruses as major aetiological contributors to severe respiratory disease.DiscussionFew studies to date have been able to link clinical and virological data to identify strains with increased virulence.", [["respiratory", "ANATOMY", 106, 117], ["respiratory disease", "DISEASE", 106, 125], ["rhinoviruses", "ORGANISM", 48, 60], ["rhinoviruses", "PROBLEM", 48, 60], ["severe respiratory disease", "PROBLEM", 99, 125], ["Few studies", "TEST", 136, 147], ["virological data", "TEST", 192, 208], ["strains", "PROBLEM", 221, 228], ["increased virulence", "PROBLEM", 234, 253], ["rhinoviruses", "OBSERVATION", 48, 60], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["respiratory disease", "OBSERVATION", 106, 125]]], ["The viruses from clinically severe patients in this study comprised 6 members of species A, including one sample resembling the A101 novel genetic type , 1 virus from species B, 3 viruses from species C and 1 enterovirus (EV-68).", [["sample", "ANATOMY", 106, 112], ["patients", "ORGANISM", 35, 43], ["1 enterovirus", "ORGANISM", 207, 220], ["EV-68", "ORGANISM", 222, 227], ["patients", "SPECIES", 35, 43], ["EV-68", "SPECIES", 222, 227], ["The viruses", "PROBLEM", 0, 11], ["this study", "TEST", 47, 57], ["one sample", "TEST", 102, 112], ["1 virus from species B", "PROBLEM", 154, 176], ["species C", "TEST", 193, 202], ["1 enterovirus", "PROBLEM", 207, 220], ["EV", "TEST", 222, 224], ["viruses", "OBSERVATION", 4, 11], ["clinically", "OBSERVATION_MODIFIER", 17, 27], ["severe", "OBSERVATION_MODIFIER", 28, 34]]], ["Previous studies have suggested that species C viruses may be associated with increased disease severity (Lauinger et al., 2013) .", [["species C viruses", "ORGANISM", 37, 54], ["Previous studies", "TEST", 0, 16], ["species C viruses", "PROBLEM", 37, 54], ["increased disease severity", "PROBLEM", 78, 104], ["may be associated with", "UNCERTAINTY", 55, 77], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["disease", "OBSERVATION", 88, 95]]], ["However, no identifiable clustering of patterns of the clinically severe viruses could be seen in this work.", [["the clinically severe viruses", "PROBLEM", 51, 80], ["no identifiable", "UNCERTAINTY", 9, 24], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["viruses", "OBSERVATION", 73, 80]]], ["The reported clinically severe viruses were spread in different genotypic groups, indicating that severity might not be an evolutionary pattern strictly related to viruses or sequences analysed in this work.DiscussionSince the characterisation of the prototype strains by serology in the 1960's there have been very few reports of novel viruses from A or B species.", [["B species", "ORGANISM", 355, 364], ["clinically severe viruses", "PROBLEM", 13, 38], ["viruses", "PROBLEM", 164, 171], ["the prototype strains", "PROBLEM", 247, 268], ["serology", "TEST", 272, 280], ["novel viruses", "PROBLEM", 331, 344], ["A or B species", "PROBLEM", 350, 364], ["clinically", "OBSERVATION_MODIFIER", 13, 23], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["viruses", "OBSERVATION", 31, 38], ["viruses", "OBSERVATION", 337, 344]]], ["A recent study sequenced the entire genome of a virus designated A101, which has a nucleotide identity across the genome of only 76.6% with the nearest species A virus (HRV-53) .", [["nucleotide", "CHEMICAL", 83, 93], ["nucleotide", "CHEMICAL", 83, 93], ["A101", "GENE_OR_GENE_PRODUCT", 65, 69], ["nearest species A virus", "ORGANISM", 144, 167], ["HRV-53", "ORGANISM", 169, 175], ["A virus", "SPECIES", 160, 167], ["A recent study", "TEST", 0, 14], ["HRV", "TEST", 169, 172]]], ["Another study conducted in Thailand found species A to be the most common species detected regardless of age groups (Fry et al., 2011) .", [["Another study", "TEST", 0, 13]]], ["Following the standards developed by McIntyre et al. (2013) five novel genotypes were identified in this work with respect to the VP1 gene.", [["VP1", "GENE_OR_GENE_PRODUCT", 130, 133], ["VP1 gene", "DNA", 130, 138]]], ["Two viruses from species A (i.e. D386 and K590), two viruses from species B (i.e. K606 and P128) and one virus from species C (i.e. R005).", [["species B", "CELL", 66, 75], ["Two viruses", "PROBLEM", 0, 11], ["two viruses", "PROBLEM", 49, 60], ["species B", "TEST", 66, 75], ["K606", "TEST", 82, 86], ["P128", "TEST", 91, 95], ["one virus", "PROBLEM", 101, 110], ["viruses", "OBSERVATION", 4, 11]]], ["The divergence at the nucleic acid level was high enough above the threshold set by McIntyre et al. (2013) to consider these viruses actual new genotypes.", [["nucleic acid", "CHEMICAL", 22, 34], ["the nucleic acid level", "TEST", 18, 40], ["these viruses actual new genotypes", "PROBLEM", 119, 153]]], ["This conclusion is strongly supported for three viruses, i.e. D386, P128 and R005, by the high divergence also observed at the protein level.", [["three viruses", "PROBLEM", 42, 55]]], ["This protein divergence was however very limited for the last two VP1 variants (i.e. K606 and K590).", [["VP1 variants", "PROTEIN", 66, 78], ["This protein divergence", "TEST", 0, 23]]], ["A similar situation is encountered when using VP4/2 as a target region for genotyping.", [["VP4/2", "GENE_OR_GENE_PRODUCT", 46, 51], ["VP4/2", "DNA", 46, 51], ["VP4/2", "TREATMENT", 46, 51]]], ["Most of the putative variants identified on nucleotide distance display a very limited divergence with the closest relative at protein level (less than 3%) and in several cases there is a perfect identity.", [["nucleotide", "CHEMICAL", 44, 54], ["nucleotide", "CHEMICAL", 44, 54]]], ["The best example found in this work is perhaps the novel VP1 type, R005, which displays the highest divergence to the closest relative of all novel types based on the VP1 gene and protein sequences and the highest divergence to the closest relative on the VP4/2 gene sequence but 100% VP4/2 protein sequence identity.", [["VP1", "ORGANISM", 57, 60], ["R005", "GENE_OR_GENE_PRODUCT", 67, 71], ["VP1", "GENE_OR_GENE_PRODUCT", 167, 170], ["VP4/2", "GENE_OR_GENE_PRODUCT", 256, 261], ["VP4/2", "GENE_OR_GENE_PRODUCT", 285, 290], ["VP1 gene and protein sequences", "DNA", 167, 197], ["VP4/2 gene sequence", "DNA", 256, 275], ["the VP1 gene and protein sequences", "TEST", 163, 197], ["the VP4/2 gene sequence", "TEST", 252, 275], ["VP4", "TEST", 285, 288], ["highest divergence", "OBSERVATION", 92, 110]]], ["In addition, the closest relative to R005 is not the same according to VP1 or VP4/2.DiscussionThe polymorphism and genome saturation analyses conducted in this work suggest that HRV viruses might be exposed to two opposite trends: a very high rate of mutations generating genome saturation and a strong negative selective pressure resulting in highly conserved proteins.", [["R005", "GENE_OR_GENE_PRODUCT", 37, 41], ["VP1", "GENE_OR_GENE_PRODUCT", 71, 74], ["VP4/2", "GENE_OR_GENE_PRODUCT", 78, 83], ["HRV viruses", "ORGANISM", 178, 189], ["R005", "DNA", 37, 41], ["VP1", "PROTEIN", 71, 74], ["VP4/2", "PROTEIN", 78, 83], ["VP1", "TEST", 71, 74], ["VP4", "TEST", 78, 81], ["genome saturation analyses", "TEST", 115, 141], ["HRV viruses", "PROBLEM", 178, 189], ["a very high rate of mutations", "PROBLEM", 231, 260], ["genome saturation", "TEST", 272, 289]]], ["It is therefore difficult when in presence of conflicting nucleic-acid and amino-acid distance data to formally assign these viruses to a novel type.", [["nucleic-acid", "CHEMICAL", 58, 70], ["amino-acid", "CHEMICAL", 75, 85], ["amino-acid", "CHEMICAL", 75, 85], ["nucleic-acid", "SIMPLE_CHEMICAL", 58, 70], ["amino", "AMINO_ACID", 75, 80], ["conflicting nucleic", "TREATMENT", 46, 65], ["acid and amino-acid distance data", "TREATMENT", 66, 99]]], ["We suggest that the typology standards developed by McIntyre et al. (2013) should be completed with protein thresholds into order to assign unambiguously these conflicting detections to specific types.DiscussionThe rhinoviruses studied in this work can be clearly discriminated into three genetic distinct taxa, i.e. the already recognised species A, B and C. This is especially true for the VP1 gene which displays indels.", [["rhinoviruses", "ORGANISM", 215, 227], ["B", "GENE_OR_GENE_PRODUCT", 351, 352], ["VP1", "GENE_OR_GENE_PRODUCT", 392, 395], ["VP1 gene", "DNA", 392, 400], ["The rhinoviruses", "PROBLEM", 211, 227], ["the VP1 gene", "PROBLEM", 388, 400]]], ["However, the relative position of the detected viruses within each taxon and their phylogeny cannot be established.", [["the detected viruses", "PROBLEM", 34, 54], ["position", "OBSERVATION_MODIFIER", 22, 30], ["viruses", "OBSERVATION", 47, 54]]], ["Both the high rate of polymorphism and level of saturation observed can easily result in the occurrence of reverse mutations and blurred phylogeny.", [["level of saturation", "PROBLEM", 39, 58], ["reverse mutations", "PROBLEM", 107, 124], ["blurred phylogeny", "PROBLEM", 129, 146], ["high", "OBSERVATION_MODIFIER", 9, 13], ["polymorphism", "OBSERVATION", 22, 34], ["reverse mutations", "OBSERVATION", 107, 124]]], ["The clear genetic clustering and the high negative selective pressure observed on both the VP1 and VP4/2 genes suggest that the three species described might correspond to virus groups having undergone independent evolution and specialisation.DiscussionThis work represents the insights into HRV genetic diversity in South East Asia and provides the first comprehensive view of the HRV genetic diversity and the association between disease severity and infecting genotype in Cambodia during a 3-year period.", [["VP1", "GENE_OR_GENE_PRODUCT", 91, 94], ["VP4/2", "GENE_OR_GENE_PRODUCT", 99, 104], ["VP1 and VP4/2 genes", "DNA", 91, 110], ["the VP1", "TEST", 87, 94], ["the three species", "PROBLEM", 124, 141], ["virus groups", "PROBLEM", 172, 184], ["the HRV genetic diversity", "PROBLEM", 378, 403], ["disease severity", "PROBLEM", 432, 448], ["clear", "OBSERVATION_MODIFIER", 4, 9], ["genetic clustering", "OBSERVATION", 10, 28], ["selective", "OBSERVATION_MODIFIER", 51, 60], ["pressure", "OBSERVATION_MODIFIER", 61, 69]]], ["This work also provides the first demonstration of the very high level of genome saturation and nucleotidic polymorphism of HRV indicating that typing and classification standards should comprise protein distance thresholds.", [["nucleotidic polymorphism of HRV", "PROBLEM", 96, 127], ["protein distance thresholds", "TEST", 196, 223], ["genome saturation", "OBSERVATION", 74, 91]]], ["Finally, it shows that much more research is needed to understand the complex dynamics of this virus.", [["this virus", "PROBLEM", 90, 100]]]], "c1e490929e55f0a26c235cc41786110ef584ef9f": [["INTRODUCTIONhallmark of RNA viruses.", [["RNA viruses", "PROBLEM", 24, 35], ["RNA viruses", "OBSERVATION", 24, 35]]], ["Virus populations in vivo, referred to as quasispecies, are comprised of a heterogeneous mix of related variants that are randomly generated as a result of errors by the viral RNA-dependent RNA polymerase.", [["Virus", "ORGANISM", 0, 5], ["viral RNA", "RNA", 170, 179], ["RNA polymerase", "PROTEIN", 190, 204], ["Virus populations", "PROBLEM", 0, 17], ["a heterogeneous mix of related variants", "PROBLEM", 73, 112], ["the viral RNA-dependent RNA polymerase", "PROBLEM", 166, 204], ["heterogeneous", "OBSERVATION_MODIFIER", 75, 88], ["mix", "OBSERVATION_MODIFIER", 89, 92], ["related variants", "OBSERVATION", 96, 112], ["viral RNA", "OBSERVATION", 170, 179]]], ["This diversity is considered to be an important mechanism of virus persistence and pathogenesis in many virus systems and provides a mechanism to rapidly respond to changes in the host environment.INTRODUCTIONInitially PRRSV genetic variation was studied using consensus genome sequences.", [["PRRSV", "ORGANISM", 219, 224], ["consensus genome sequences", "DNA", 261, 287], ["PRRSV", "SPECIES", 219, 224], ["virus persistence", "PROBLEM", 61, 78], ["pathogenesis in many virus systems", "PROBLEM", 83, 117], ["consensus genome sequences", "TEST", 261, 287], ["considered to be", "UNCERTAINTY", 18, 34], ["virus", "OBSERVATION", 61, 66]]], ["There have been several papers published on PRRSV variation during experimental infection of pigs, 2-5 however only one started with a biologically cloned virus.", [["infection", "DISEASE", 80, 89], ["PRRSV", "ORGANISM", 44, 49], ["pigs", "ORGANISM", 93, 97], ["pigs", "SPECIES", 93, 97], ["PRRSV", "SPECIES", 44, 49], ["pigs", "SPECIES", 93, 97], ["PRRSV variation", "TREATMENT", 44, 59], ["experimental infection of pigs", "PROBLEM", 67, 97], ["a biologically cloned virus", "PROBLEM", 133, 160], ["several", "OBSERVATION_MODIFIER", 16, 23], ["PRRSV variation", "OBSERVATION", 44, 59], ["infection", "OBSERVATION", 80, 89]]], ["4 Our laboratory is currently using a North American infectious clone to investigate the mechanisms of PRRSV persistence and pathogenesis.", [["clone", "CELL", 64, 69], ["PRRSV", "ORGANISM", 103, 108], ["PRRSV", "SPECIES", 103, 108], ["PRRSV persistence", "PROBLEM", 103, 120], ["pathogenesis", "PROBLEM", 125, 137], ["PRRSV persistence", "OBSERVATION", 103, 120]]], ["One purpose of this study was to evaluate the stability of the infectious clone for its manipulation and subsequent use.", [["clone", "CELL", 74, 79], ["this study", "TEST", 15, 25], ["the infectious clone", "PROBLEM", 59, 79], ["infectious", "OBSERVATION", 63, 73]]], ["Use of the infectious clone also allows us to begin with a single DNA sequence, providing a well-defined starting point for studying PRRSV evolution.", [["clone", "CELL", 22, 27], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["PRRSV", "ORGANISM", 133, 138], ["DNA sequence", "DNA", 66, 78], ["PRRSV", "SPECIES", 133, 138], ["the infectious clone", "PROBLEM", 7, 27], ["a single DNA sequence", "TEST", 57, 78]]], ["The other goal of this study was to investigate PRRSV quasispecies evolution in an environment that excludes the immunologic pressure that is present in the previous studies which involved experimental infection in swine.INTRODUCTIONFour regions of the genome were selected for analysis in this study: Nsp2, ORF3, ORF5, and ORF6.", [["infection", "DISEASE", 202, 211], ["PRRSV", "ORGANISM", 48, 53], ["swine", "ORGANISM", 215, 220], ["Nsp2", "GENE_OR_GENE_PRODUCT", 302, 306], ["ORF3", "GENE_OR_GENE_PRODUCT", 308, 312], ["ORF5", "GENE_OR_GENE_PRODUCT", 314, 318], ["ORF6", "GENE_OR_GENE_PRODUCT", 324, 328], ["Nsp2", "DNA", 302, 306], ["ORF3", "DNA", 308, 312], ["ORF5", "DNA", 314, 318], ["ORF6", "DNA", 324, 328], ["swine", "SPECIES", 215, 220], ["PRRSV", "SPECIES", 48, 53], ["swine", "SPECIES", 215, 220], ["this study", "TEST", 18, 28], ["PRRSV quasispecies", "PROBLEM", 48, 66], ["the immunologic pressure", "TEST", 109, 133], ["the previous studies", "TEST", 153, 173], ["experimental infection in swine", "PROBLEM", 189, 220], ["analysis", "TEST", 278, 286], ["this study", "TEST", 290, 300], ["Nsp2", "PROBLEM", 302, 306], ["ORF3", "TEST", 308, 312], ["ORF5", "TREATMENT", 314, 318], ["experimental", "OBSERVATION_MODIFIER", 189, 201], ["infection", "OBSERVATION", 202, 211]]], ["The Nsp2 protein is the most variable region among arteriviruses, 6, 7 and has been implicated in having a role in the humoral immune response.", [["Nsp2", "GENE_OR_GENE_PRODUCT", 4, 8], ["Nsp2 protein", "PROTEIN", 4, 16], ["The Nsp2 protein", "TEST", 0, 16], ["Nsp2 protein", "OBSERVATION", 4, 16], ["most variable", "OBSERVATION_MODIFIER", 24, 37], ["humoral immune response", "OBSERVATION", 119, 142]]], ["8 The ORF3 protein has the greatest percentage of amino acid changes between the modified live vaccine (Ingelvac) and its parent strain, VR-2332, the isolate from which the infectious clone used in this study was derived.", [["amino acid", "CHEMICAL", 50, 60], ["VR-2332", "CHEMICAL", 137, 144], ["amino acid", "CHEMICAL", 50, 60], ["ORF3", "GENE_OR_GENE_PRODUCT", 6, 10], ["amino acid", "AMINO_ACID", 50, 60], ["VR-2332", "CELL", 137, 144], ["clone", "CELL", 184, 189], ["ORF3 protein", "PROTEIN", 6, 18], ["VR-2332", "SPECIES", 137, 144], ["The ORF3 protein", "TEST", 2, 18], ["amino acid changes", "PROBLEM", 50, 68], ["the modified live vaccine", "TREATMENT", 77, 102], ["VR", "TEST", 137, 139], ["the isolate", "PROBLEM", 146, 157], ["the infectious clone", "PROBLEM", 169, 189], ["this study", "TEST", 198, 208], ["greatest", "OBSERVATION_MODIFIER", 27, 35], ["percentage", "OBSERVATION_MODIFIER", 36, 46], ["amino acid", "OBSERVATION", 50, 60], ["infectious", "OBSERVATION", 173, 183]]], ["ORF5 has been the focus of previous quasispecies investigations 2-5 and its corresponding protein has been associated with virus neutralization.", [["ORF5", "CHEMICAL", 0, 4], ["ORF5", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF5", "PROTEIN", 0, 4], ["previous quasispecies investigations", "TEST", 27, 63], ["virus neutralization", "PROBLEM", 123, 143], ["quasispecies", "OBSERVATION", 36, 48], ["associated with", "UNCERTAINTY", 107, 122], ["virus neutralization", "OBSERVATION", 123, 143]]], ["9 The most conserved region of the PRRSV genome across all North * University of Missouri, Columbia, Missouri 65211. respi-Genetic, phenotypic, and antigenic heterogeneity of porcine reproductive and ratory syndrome virus (PRRSV) has been well described.", [["porcine reproductive and ratory syndrome", "DISEASE", 175, 215], ["porcine reproductive and ratory syndrome virus", "ORGANISM", 175, 221], ["PRRSV", "ORGANISM", 223, 228], ["PRRSV genome", "DNA", 35, 47], ["PRRSV", "SPECIES", 35, 40], ["porcine", "SPECIES", 175, 182], ["ratory syndrome virus", "SPECIES", 200, 221], ["PRRSV", "SPECIES", 223, 228], ["PRRSV", "SPECIES", 35, 40], ["ratory syndrome virus", "SPECIES", 200, 221], ["PRRSV", "SPECIES", 223, 228], ["respi-Genetic", "PROBLEM", 117, 130], ["phenotypic", "PROBLEM", 132, 142], ["porcine reproductive and ratory syndrome virus", "PROBLEM", 175, 221], ["most conserved", "OBSERVATION_MODIFIER", 6, 20], ["region", "ANATOMY_MODIFIER", 21, 27], ["PRRSV genome", "OBSERVATION", 35, 47], ["phenotypic", "OBSERVATION_MODIFIER", 132, 142], ["antigenic", "OBSERVATION_MODIFIER", 148, 157], ["heterogeneity", "OBSERVATION_MODIFIER", 158, 171], ["porcine reproductive", "OBSERVATION", 175, 195]]], ["Genetic diversity is aUSE OF A PRRSV INFECTIOUS CLONE TO EVALUATE IN VITRO QUASISPECIES EVOLUTIONAmerican isolates is ORF6 10, 11 and in this study its analysis serves as a basis for comparison in order to safeguard against identifying variation due to errors in methodology or bias as true genetic diversity.MATERIALS AND METHODSThe North American PRRSV infectious clone derived from VR-2332 12 was obtained, used to transform Escherichia coli Top10 strain (Invitrogen), and reisolated 3 times to obtain a pure colony of transformed bacteria.", [["colony", "ANATOMY", 512, 518], ["VR-2332", "CHEMICAL", 385, 392], ["PRRSV", "ORGANISM", 349, 354], ["clone", "CELL", 366, 371], ["VR-2332 12", "CELL", 385, 395], ["Escherichia coli", "ORGANISM", 428, 444], ["Top10 strain", "ORGANISM", 445, 457], ["PRRSV", "SPECIES", 349, 354], ["Escherichia coli", "SPECIES", 428, 444], ["PRRSV", "SPECIES", 31, 36], ["VR-2332 12", "SPECIES", 385, 395], ["Escherichia coli", "SPECIES", 428, 444], ["A PRRSV INFECTIOUS CLONE", "PROBLEM", 29, 53], ["this study", "TEST", 137, 147], ["errors in methodology", "PROBLEM", 253, 274], ["VR", "TEST", 385, 387], ["Escherichia coli Top10 strain (Invitrogen)", "TREATMENT", 428, 470], ["transformed bacteria", "PROBLEM", 522, 542], ["INFECTIOUS", "OBSERVATION", 37, 47], ["Escherichia coli", "OBSERVATION", 428, 444], ["transformed bacteria", "OBSERVATION", 522, 542]]], ["Plasmid DNA was isolated from this clone and linearized using Acl1.", [["Plasmid", "ANATOMY", 0, 7], ["clone", "ANATOMY", 35, 40], ["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["clone", "CELL", 35, 40], ["Acl1", "GENE_OR_GENE_PRODUCT", 62, 66], ["Plasmid DNA", "DNA", 0, 11], ["Acl1", "PROTEIN", 62, 66], ["Plasmid DNA", "PROBLEM", 0, 11], ["this clone", "PROBLEM", 30, 40], ["Acl1", "TREATMENT", 62, 66], ["DNA", "OBSERVATION", 8, 11]]], ["Linearized plasmid was used for in vitro transcription with T7 RNA polymerase (Ambion).", [["plasmid", "ANATOMY", 11, 18], ["Linearized plasmid", "DNA", 0, 18], ["T7 RNA polymerase", "PROTEIN", 60, 77], ["Linearized plasmid", "TREATMENT", 0, 18], ["vitro transcription", "TREATMENT", 35, 54], ["T7 RNA polymerase", "TREATMENT", 60, 77], ["plasmid", "OBSERVATION", 11, 18], ["T7", "ANATOMY", 60, 62]]], ["The in vitro transcribed RNA was DNase-treated and isolated using the RNA Nucleospin II kit (Clontech).", [["DNase", "GENE_OR_GENE_PRODUCT", 33, 38], ["Clontech", "GENE_OR_GENE_PRODUCT", 93, 101], ["in vitro transcribed RNA", "RNA", 4, 28], ["DNase", "PROTEIN", 33, 38], ["RNA Nucleospin II kit", "PROTEIN", 70, 91], ["DNase", "PROBLEM", 33, 38], ["the RNA Nucleospin II kit (Clontech)", "TREATMENT", 66, 102]]], ["BHK-21 cells were transfected with in vitro transcribed RNA and Lipofectamine 2000 (Gibco Life Sciences).", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["BHK-21 cells", "CELL_LINE", 0, 12], ["BHK", "TEST", 0, 3], ["vitro transcribed RNA", "TREATMENT", 38, 59], ["Lipofectamine", "TREATMENT", 64, 77], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["The supernatant RT-PCR was performed directly on RNA extracted from the in vitro transcribed RNA and passages 1 and 3 of wells A and B. These sequences were then compared to a low passage VR-2332 cell culture propagated stock to determine if the use of an infectious clone was able to decrease the quasispecies variation as compared to a viral stock.", [["supernatant", "ANATOMY", 4, 15], ["cell", "ANATOMY", 196, 200], ["VR-2332 cell", "CELL", 188, 200], ["clone", "CELL", 267, 272], ["VR-2332 cell culture", "CELL_LINE", 188, 208], ["The supernatant RT-PCR", "TEST", 0, 22], ["a low passage VR", "TREATMENT", 174, 190], ["an infectious clone", "PROBLEM", 253, 272], ["the quasispecies variation", "PROBLEM", 294, 320], ["infectious", "OBSERVATION", 256, 266], ["quasispecies", "OBSERVATION", 298, 310], ["viral stock", "OBSERVATION", 338, 349]]], ["PCR was performed directly on the plasmid.MATERIALS AND METHODSFour methods of RT-PCR amplification were evaluated for maintenance of sequence fidelity by sequencing the highly conserved ORF6. cDNA synthesis by Invitrogen's SuperScript cDNA synthesis kit followed by PCR with Pfx Platinum Taq was selected based on no identified nucleotide changes in 4650 nucleotides of ORF6 sequence.", [["plasmid", "ANATOMY", 34, 41], ["nucleotide", "CHEMICAL", 329, 339], ["nucleotides", "CHEMICAL", 356, 367], ["ORF6", "GENE_OR_GENE_PRODUCT", 187, 191], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 211, 221], ["Pfx Platinum Taq", "GENE_OR_GENE_PRODUCT", 276, 292], ["ORF6", "GENE_OR_GENE_PRODUCT", 371, 375], ["plasmid", "DNA", 34, 41], ["ORF6", "DNA", 187, 191], ["cDNA", "DNA", 193, 197], ["Invitrogen's SuperScript cDNA", "DNA", 211, 240], ["Pfx Platinum Taq", "DNA", 276, 292], ["ORF6 sequence", "DNA", 371, 384], ["PCR", "TEST", 0, 3], ["the plasmid", "TREATMENT", 30, 41], ["RT-PCR amplification", "TREATMENT", 79, 99], ["cDNA synthesis", "TREATMENT", 193, 207], ["Invitrogen", "TEST", 211, 221], ["cDNA synthesis kit", "TEST", 236, 254], ["PCR", "TEST", 267, 270], ["Pfx Platinum Taq", "TREATMENT", 276, 292], ["nucleotide changes", "PROBLEM", 329, 347], ["ORF6 sequence", "TEST", 371, 384]]], ["A minimum of 2 PCR reactions were combined for each sample then cloned into a Zero Blunt TOPO vector (Invitrogen), with a minimum of 15 clones sequenced for each sample and genetic region.", [["sample", "ANATOMY", 162, 168], ["TOPO", "GENE_OR_GENE_PRODUCT", 89, 93], ["Zero Blunt TOPO vector", "DNA", 78, 100], ["2 PCR reactions", "PROBLEM", 13, 28], ["a Zero Blunt TOPO vector", "TREATMENT", 76, 100]]], ["Each clone was sequenced in both directions at the University of Missouri DNA Core.", [["clone", "ANATOMY", 5, 10], ["clone", "CELL", 5, 10], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["Each clone", "PROBLEM", 0, 10]]], ["The sequence was analyzed using the DNA Star software package.RESULTSA North American infectious cDNA clone, derived from VR-2332, was used to transform bacteria from which a single bacterial colony was reisolated three times.", [["colony", "ANATOMY", 192, 198], ["VR-2332", "CHEMICAL", 122, 129], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["cDNA clone", "CELL", 97, 107], ["VR-2332", "CELL", 122, 129], ["cDNA clone", "DNA", 97, 107], ["VR-2332", "SPECIES", 122, 129], ["VR", "TEST", 122, 124], ["transform bacteria", "PROBLEM", 143, 161], ["a single bacterial colony", "PROBLEM", 173, 198], ["bacterial colony", "OBSERVATION", 182, 198]]], ["This plasmid clone was then used as a template to generate in vitro transcribed RNA which was then transfected into BHK-21 cells.", [["clone", "ANATOMY", 13, 18], ["BHK-21 cells", "ANATOMY", 116, 128], ["BHK-21 cells", "CELL", 116, 128], ["plasmid clone", "DNA", 5, 18], ["BHK-21 cells", "CELL_LINE", 116, 128], ["BHK-21", "SPECIES", 116, 122], ["This plasmid clone", "TREATMENT", 0, 18], ["a template", "TREATMENT", 36, 46]]], ["Two wells (A and B) were CPE positive after one passage on MARC-145 cells and were used for subsequent studies.RESULTSFifteen clones were sequenced and aligned for each sample and genetic region.", [["MARC-145 cells", "ANATOMY", 59, 73], ["clones", "ANATOMY", 126, 132], ["MARC-145", "CHEMICAL", 59, 67], ["MARC-145 cells", "CELL", 59, 73], ["clones", "CELL", 126, 132], ["MARC-145 cells", "CELL_LINE", 59, 73], ["CPE positive", "PROBLEM", 25, 37], ["subsequent studies", "TEST", 92, 110], ["RESULTSFifteen clones", "PROBLEM", 111, 132]]], ["For each infectious clone derived group, the master or dominant sequence was the same as the original plasmid.", [["plasmid", "ANATOMY", 102, 109], ["clone", "CELL", 20, 25], ["master or dominant sequence", "DNA", 45, 72], ["plasmid", "DNA", 102, 109], ["the original plasmid", "TREATMENT", 89, 109], ["infectious", "OBSERVATION_MODIFIER", 9, 19]]], ["Increased passage number generally correlated with a decrease in the percentage of individual clones identical to the master sequence but this was not consistent across all open reading frames analyzed ( Table 1 ).", [["master sequence", "DNA", 118, 133], ["open reading frames", "DNA", 173, 192], ["Increased passage number", "PROBLEM", 0, 24], ["a decrease", "PROBLEM", 51, 61], ["individual clones", "PROBLEM", 83, 100], ["passage", "OBSERVATION_MODIFIER", 10, 17], ["decrease", "OBSERVATION_MODIFIER", 53, 61]]], ["The nucleotide changes from the master sequence were predominantly transitions and nonsynonymous.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["master sequence", "DNA", 32, 47], ["The nucleotide changes", "PROBLEM", 0, 22], ["predominantly", "OBSERVATION_MODIFIER", 53, 66], ["transitions", "OBSERVATION_MODIFIER", 67, 78]]], ["The nucleotide and amino acid changes were randomly distributed within the genes, with no mutation hotspots identified.CONCLUSIONSThe master sequence for each sample derived from the infectious clone was the same as the original plasmid for all genetic regions investigated.", [["sample", "ANATOMY", 159, 165], ["plasmid", "ANATOMY", 229, 236], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["nucleotide", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 19, 29], ["amino acid", "AMINO_ACID", 19, 29], ["clone", "CELL", 194, 199], ["master sequence", "DNA", 134, 149], ["The nucleotide and amino acid changes", "TEST", 0, 37], ["mutation hotspots", "PROBLEM", 90, 107], ["the infectious clone", "PROBLEM", 179, 199], ["the original plasmid", "TREATMENT", 216, 236], ["amino acid", "OBSERVATION", 19, 29], ["no", "UNCERTAINTY", 87, 89], ["infectious", "OBSERVATION", 183, 193]]], ["Analysis of the in vitro transcribed RNA showed that Nsp2, ORF3, and ORF6 all had low levels of genetic variation even though it was prepared directly from a single bacterial colony plasmid preparation.", [["plasmid", "ANATOMY", 182, 189], ["Nsp2", "GENE_OR_GENE_PRODUCT", 53, 57], ["ORF3", "GENE_OR_GENE_PRODUCT", 59, 63], ["ORF6", "GENE_OR_GENE_PRODUCT", 69, 73], ["Nsp2", "PROTEIN", 53, 57], ["ORF3", "DNA", 59, 63], ["ORF6", "DNA", 69, 73], ["Analysis", "TEST", 0, 8], ["the in vitro transcribed RNA", "TEST", 12, 40], ["Nsp2", "PROBLEM", 53, 57], ["ORF3", "TEST", 59, 63], ["ORF6", "TEST", 69, 73], ["low levels of genetic variation", "PROBLEM", 82, 113], ["a single bacterial colony plasmid preparation", "TREATMENT", 156, 201], ["low levels", "OBSERVATION_MODIFIER", 82, 92], ["genetic variation", "OBSERVATION", 96, 113], ["bacterial colony", "OBSERVATION", 165, 181], ["plasmid preparation", "OBSERVATION", 182, 201]]], ["Increased passage number generally correlated with a decrease in the percentage of the master sequence.", [["master sequence", "DNA", 87, 102], ["Increased passage number", "PROBLEM", 0, 24], ["passage", "OBSERVATION_MODIFIER", 10, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["decrease", "OBSERVATION_MODIFIER", 53, 61]]], ["This does not appear to be due to the emergence of more fit viral sequences because the master sequence remains the same and new quasispecies appear and disappear with passage.", [["viral sequences", "DNA", 60, 75], ["master sequence", "DNA", 88, 103], ["fit viral sequences", "TEST", 56, 75], ["the master sequence", "TEST", 84, 103], ["new quasispecies", "PROBLEM", 125, 141], ["new", "OBSERVATION_MODIFIER", 125, 128], ["quasispecies", "OBSERVATION", 129, 141]]], ["There were no cases of a variant present in passage 1 also being present in passage 3 of the same well, although the variants appeared at such low levels that they may not be detected with our sample size.", [["no", "UNCERTAINTY", 11, 13], ["may not be", "UNCERTAINTY", 164, 174], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["It is also unlikely that these changes are a result of error due to the experimental methodology.", [["also unlikely", "UNCERTAINTY", 6, 19]]], ["Minimal error was introduced through the process of PCR, cloning and sequencing as evidenced by the fact that there were no nucleotide changes in ORF6 of the plasmid DNA in 6525 nucleotides of sequence examined.", [["plasmid", "ANATOMY", 158, 165], ["nucleotide", "CHEMICAL", 124, 134], ["nucleotides", "CHEMICAL", 178, 189], ["ORF6", "GENE_OR_GENE_PRODUCT", 146, 150], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["ORF6", "DNA", 146, 150], ["plasmid DNA", "DNA", 158, 169], ["Minimal error", "PROBLEM", 0, 13], ["PCR", "TEST", 52, 55], ["nucleotide changes", "PROBLEM", 124, 142], ["the plasmid DNA", "TREATMENT", 154, 169], ["nucleotides of sequence", "TEST", 178, 201], ["error", "OBSERVATION", 8, 13]]], ["Additionally, analysis of the in vitro RNA ORF6 region found only 1 nucleotide change in 6525 nucleotides. difficult, if not impossible, to create point mutations without accumulating other changes in the genome, especially if multiple in vitro passages are required to obtain sufficient viral titers.", [["nucleotide", "CHEMICAL", 68, 78], ["nucleotides", "CHEMICAL", 94, 105], ["vitro RNA ORF6 region", "DNA", 33, 54], ["analysis", "TEST", 14, 22], ["the in vitro RNA ORF6 region", "TEST", 26, 54], ["1 nucleotide change in 6525 nucleotides", "PROBLEM", 66, 105], ["point mutations", "PROBLEM", 147, 162], ["accumulating other changes in the genome", "PROBLEM", 171, 211], ["multiple in vitro passages", "PROBLEM", 227, 253], ["sufficient viral titers", "PROBLEM", 277, 300]]], ["This will be especially critical when the mutations made are detrimental to the fitness of the virus.", [["the mutations", "PROBLEM", 38, 51], ["the virus", "PROBLEM", 91, 100]]], ["In this experiment, quasispecies changes appear with the first cell culture passage and were readily observed even though our study only looked at 10% of the genome.", [["cell culture", "ANATOMY", 63, 75], ["cell", "CELL", 63, 67], ["quasispecies changes", "PROBLEM", 20, 40], ["the first cell culture passage", "PROBLEM", 53, 83], ["our study", "TEST", 122, 131], ["quasispecies", "OBSERVATION", 20, 32]]], ["Researchers using a PRRSV infectious clone, particularly this one derived from VR-2332, to study the effects of genetic changes on viral phenotype must keep in mind that other unintended mutations may have occurred during the propagation of the virus.437In total, our data suggest that even with the use of an infectious clone it will be", [["VR-2332", "CHEMICAL", 79, 86], ["PRRSV", "ORGANISM", 20, 25], ["clone", "CELL", 37, 42], ["VR-2332", "CELL", 79, 86], ["clone", "CELL", 321, 326], ["PRRSV", "SPECIES", 20, 25], ["a PRRSV infectious clone", "PROBLEM", 18, 42], ["genetic changes", "PROBLEM", 112, 127], ["viral phenotype", "PROBLEM", 131, 146], ["other unintended mutations", "PROBLEM", 170, 196], ["the virus", "PROBLEM", 241, 250], ["an infectious clone", "TREATMENT", 307, 326], ["infectious", "OBSERVATION", 310, 320]]]], "6fc1e467b4f54eafcd50617295364c8391ffd9e2": [["INTRODUCTIONImpact of COVID-19 on healthcare systems.", [["COVID-19", "CHEMICAL", 22, 30], ["COVID", "TREATMENT", 22, 27]]], ["The emergence and rapid spread of novel coronavirus disease (COVID-19) across the world has created massive global disruptions, and its impacts are especially worrisome for healthcare systems, social services, and economic activities within malariaendemic countries.", [["coronavirus disease", "DISEASE", 40, 59], ["COVID-19", "CHEMICAL", 61, 69], ["coronavirus", "ORGANISM", 40, 51], ["novel coronavirus disease", "PROBLEM", 34, 59], ["COVID", "TEST", 61, 66], ["created massive global disruptions", "PROBLEM", 92, 126], ["rapid", "OBSERVATION_MODIFIER", 18, 23], ["spread", "OBSERVATION_MODIFIER", 24, 30], ["coronavirus disease", "OBSERVATION", 40, 59], ["massive", "OBSERVATION_MODIFIER", 100, 107], ["global disruptions", "OBSERVATION", 108, 126]]], ["1 Although COVID-19 containment and mitigation efforts are underway, mobilizing resources can be a daunting task for countries that are resource scarce and have relatively poor healthcare systems, as is the case for most countries where malaria remains a major public health problem.", [["malaria", "DISEASE", 237, 244], ["COVID", "TEST", 11, 16], ["mitigation efforts", "TREATMENT", 36, 54], ["malaria", "PROBLEM", 237, 244]]], ["2 Nearly half of the global population lives in malariaendemic regions, with an estimated 228 million cases and 400,000 deaths in 2018.", [["deaths", "DISEASE", 120, 126], ["global", "OBSERVATION_MODIFIER", 21, 27], ["population", "OBSERVATION", 28, 38]]], ["3 The ongoing malaria struggle, with the backdrop of the COVID-19 pandemic, is creating a public healthcare management dilemma.", [["malaria", "DISEASE", 14, 21], ["The ongoing malaria struggle", "PROBLEM", 2, 30], ["the COVID", "TEST", 53, 62], ["a public healthcare management", "TREATMENT", 88, 118], ["ongoing", "OBSERVATION_MODIFIER", 6, 13], ["malaria", "OBSERVATION", 14, 21]]], ["A significant added burden is the increased risk posed to malaria frontline workers from COVID-19 patients in the community, where antimalarial measures need to be implemented routinely.INTRODUCTIONMalaria in times of COVID-19.", [["malaria", "DISEASE", 58, 65], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["A significant added burden", "PROBLEM", 0, 26], ["antimalarial measures", "TREATMENT", 131, 152], ["COVID", "TEST", 218, 223], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["burden", "OBSERVATION", 20, 26], ["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["Whereas COVID-19 is fittingly distracting for all nations, it is essential that other killer infectious diseases such as malaria are not ignored.", [["infectious diseases", "DISEASE", 93, 112], ["malaria", "DISEASE", 121, 128], ["COVID-19", "GENE_OR_GENE_PRODUCT", 8, 16], ["COVID-19", "DNA", 8, 16], ["other killer infectious diseases", "PROBLEM", 80, 112], ["malaria", "PROBLEM", 121, 128]]], ["In the recent past, Ebola outbreaks in West Africa led to substantial increases in morbidity and mortality due to other diseases, including malaria.", [["Ebola", "DISEASE", 20, 25], ["malaria", "DISEASE", 140, 147], ["Ebola", "ORGANISM", 20, 25], ["substantial increases in morbidity", "PROBLEM", 58, 92], ["other diseases", "PROBLEM", 114, 128], ["malaria", "PROBLEM", 140, 147], ["Ebola", "OBSERVATION", 20, 25], ["substantial", "OBSERVATION_MODIFIER", 58, 69], ["increases", "OBSERVATION_MODIFIER", 70, 79], ["morbidity", "OBSERVATION", 83, 92], ["diseases", "OBSERVATION", 120, 128], ["malaria", "OBSERVATION", 140, 147]]], ["1 This lesson must be borne in mind within malaria-afflicted countries; their redirection of attention to COVID-19 should not come at the expense of efforts to control malaria.", [["malaria-afflicted", "DISEASE", 43, 60], ["malaria", "DISEASE", 168, 175], ["COVID-19", "CHEMICAL", 106, 114], ["malaria", "PROBLEM", 168, 175], ["malaria", "OBSERVATION", 168, 175]]], ["4 Sustained vector control and timely management of malaria cases are the backbone of malaria control and elimination strategies.", [["malaria", "DISEASE", 52, 59], ["malaria", "DISEASE", 86, 93], ["Sustained vector control", "TREATMENT", 2, 26], ["malaria cases", "PROBLEM", 52, 65], ["malaria control", "TREATMENT", 86, 101], ["elimination strategies", "TREATMENT", 106, 128], ["malaria", "OBSERVATION", 52, 59], ["malaria", "OBSERVATION", 86, 93]]], ["Thus, COVID-19 activities can be expected to impact ongoing or planned malaria control activities at multiple levels.INTRODUCTIONThe main malaria interventional tools that could experience disruptions in COVID-19 times are in 1 deployment of insecticide-treated nets (ITNs), 2 indoor residual spraying of insecticides in homes, 3 delivery of larvicides, 4 use of rapid diagnostic test and slide-based diagnostics, 5 appropriate treatment of malaria, 6 malaria chemoprevention programs, and 7 routine malaria surveillance.", [["malaria", "DISEASE", 71, 78], ["malaria", "DISEASE", 138, 145], ["malaria", "DISEASE", 441, 448], ["malaria", "DISEASE", 452, 459], ["malaria", "DISEASE", 500, 507], ["COVID", "TREATMENT", 6, 11], ["malaria control activities at multiple levels", "PROBLEM", 71, 116], ["The main malaria interventional tools", "PROBLEM", 129, 166], ["disruptions in COVID", "PROBLEM", 189, 209], ["larvicides", "TREATMENT", 342, 352], ["rapid diagnostic test", "TEST", 363, 384], ["malaria", "PROBLEM", 441, 448], ["6 malaria chemoprevention programs", "TREATMENT", 450, 484], ["7 routine malaria surveillance", "TREATMENT", 490, 520], ["main", "OBSERVATION_MODIFIER", 133, 137], ["malaria", "OBSERVATION", 138, 145], ["malaria", "OBSERVATION", 441, 448]]], ["4 The lockdown tactic adopted by many countries to contain COVID-19 is also impacting global health product manufacturing and supply chains, potentially derailing distribution of antimalarial drugs, diagnostic kits, insecticides, and ITNs.", [["ITNs", "SIMPLE_CHEMICAL", 234, 238], ["The lockdown tactic", "TREATMENT", 2, 21], ["antimalarial drugs", "TREATMENT", 179, 197], ["insecticides", "TREATMENT", 216, 228], ["ITNs", "PROBLEM", 234, 238], ["antimalarial drugs", "OBSERVATION", 179, 197]]], ["5 A recent modeling analysis by the WHO on the impact of COVID-19 on malaria control in sub-Saharan Africa predicts a > 20% rise in malaria cases and a doubling of malaria deaths, driven by 75% reduction in both routine ITN distribution and access to antimalarials.", [["COVID-19", "CHEMICAL", 57, 65], ["malaria", "DISEASE", 69, 76], ["malaria", "DISEASE", 132, 139], ["malaria", "DISEASE", 164, 171], ["deaths", "DISEASE", 172, 178], ["A recent modeling analysis", "TEST", 2, 28], ["COVID", "TEST", 57, 62], ["malaria control", "TREATMENT", 69, 84], ["malaria cases", "PROBLEM", 132, 145], ["malaria deaths", "PROBLEM", 164, 178], ["antimalarials", "TREATMENT", 251, 264], ["malaria", "OBSERVATION", 132, 139], ["malaria", "OBSERVATION", 164, 171]]], ["Therefore, in many malarious countries, a public health catastrophe due to resurgence of malaria may be of greater magnitude than that directly due to the COVID-19 pandemic.", [["malaria", "DISEASE", 89, 96], ["a public health catastrophe", "PROBLEM", 40, 67], ["malaria", "PROBLEM", 89, 96], ["the COVID", "TEST", 151, 160], ["pandemic", "PROBLEM", 164, 172], ["malaria", "OBSERVATION", 89, 96]]], ["6 Interventional tools used in COVID-19 may be used for malaria.", [["COVID-19", "CHEMICAL", 31, 39], ["malaria", "DISEASE", 56, 63], ["COVID-19", "CHEMICAL", 31, 39], ["COVID-19", "SIMPLE_CHEMICAL", 31, 39], ["malaria", "PROBLEM", 56, 63]]], ["Despite the generally grim world health scenario, several positives are emerging from the COVID-19 crisis.", [["the COVID", "TEST", 86, 95]]], ["Although malaria (an old scourge) and COVID-19 (a newly emergent disease) may compete for public health attention, we feel that the best facets of current COVID-19 management provide lessons that may enable faster control and elimination of malaria.", [["malaria", "DISEASE", 9, 16], ["malaria", "DISEASE", 241, 248], ["malaria", "PROBLEM", 9, 16], ["COVID", "TEST", 38, 43], ["a newly emergent disease", "PROBLEM", 48, 72], ["current COVID-19 management", "TREATMENT", 147, 174], ["malaria", "PROBLEM", 241, 248], ["malaria", "OBSERVATION", 9, 16], ["malaria", "OBSERVATION", 241, 248]]], ["In addition, the new culture of almost daily press briefings in many countries has fostered a sense of accountability, transparency, and trust in national health systems.", [["the new culture", "TEST", 13, 28], ["new", "OBSERVATION_MODIFIER", 17, 20]]], ["A similar display of focused political will, rational approaches, and constant oversight from national leadership toward malaria will boost control and elimination efforts. subject expertise are being resourced as think tanks to devise short-and long-term plans for COVID-19 mitigation.", [["malaria", "DISEASE", 121, 128], ["malaria", "PROBLEM", 121, 128], ["boost control", "TREATMENT", 134, 147], ["COVID", "TREATMENT", 266, 271]]], ["Taking a cue from this, malaria programs need to renew synergies, avoid duplication, and embrace a centralized, multidisciplinary team approach that addresses both the routine management of malaria and plans for progress toward elimination.", [["malaria", "DISEASE", 24, 31], ["malaria", "DISEASE", 190, 197], ["malaria programs", "TREATMENT", 24, 40], ["duplication", "TREATMENT", 72, 83], ["the routine management", "TREATMENT", 164, 186], ["malaria", "PROBLEM", 190, 197], ["malaria", "OBSERVATION", 190, 197]]], ["Thus, the core teams of experts should remain involved for a protracted period of time so as to ensure consistent progress along the trajectories that will lead to malaria elimination.", [["malaria", "DISEASE", 164, 171], ["malaria elimination", "PROBLEM", 164, 183]]], ["Disease dashboards and digital technology: Almost all countries have been transparent in reporting COVID-19 cases in real time.", [["COVID", "TEST", 99, 104]]], ["The data-rich and digitally driven COVID-19 response has provided a new benchmark for sharing disease data, interventional measures, and anonymized clinical profiles and outcomes.", [["The data", "TEST", 0, 8], ["interventional measures", "TREATMENT", 108, 131]]], ["We feel that this digital account of COVID-19 is a game changer in infectious disease epidemiology and should be implemented fully for malaria.", [["infectious disease", "DISEASE", 67, 85], ["malaria", "DISEASE", 135, 142], ["COVID", "TEST", 37, 42], ["malaria", "PROBLEM", 135, 142]]], ["For example, malaria dashboards could include data covering 1) clinical outcomes, 2) diagnostics used, 3) drug and insecticide resistance, 4) intervention measures, 5) malaria cases and deaths, 6) parasite species and prevalence, and 7) vector surveillance.", [["malaria", "DISEASE", 13, 20], ["malaria", "DISEASE", 168, 175], ["deaths", "DISEASE", 186, 192], ["malaria dashboards", "PROBLEM", 13, 31], ["drug and insecticide resistance", "TREATMENT", 106, 137], ["intervention measures", "TREATMENT", 142, 163], ["malaria cases and deaths", "PROBLEM", 168, 192], ["parasite species", "PROBLEM", 197, 213], ["vector surveillance", "TEST", 237, 256], ["malaria", "OBSERVATION", 13, 20]]], ["Implementation of smartphone surveillance apps and establishment of digital chains of information and communication at all levels of health care will be helpful for success in malaria elimination.", [["malaria", "DISEASE", 176, 183], ["smartphone surveillance apps", "TEST", 18, 46], ["malaria elimination", "PROBLEM", 176, 195]]], ["International borders: Countries have implemented rigorous screening to map transitory populations and impose quarantines when required.", [["rigorous screening", "TEST", 50, 68], ["map transitory populations", "TREATMENT", 72, 98]]], ["In malaria, there is a persistent risk of disease importation, and thus focused screening at entry ports might be augmented, using innovative strategies such as interactive malaria networks between countries for prompt data sharing on cases and outbreaks.", [["malaria", "DISEASE", 3, 10], ["malaria", "DISEASE", 173, 180], ["malaria", "PROBLEM", 3, 10], ["disease importation", "PROBLEM", 42, 61], ["focused screening", "TEST", 72, 89], ["innovative strategies", "TREATMENT", 131, 152], ["malaria", "OBSERVATION", 3, 10], ["persistent", "OBSERVATION_MODIFIER", 23, 33], ["disease", "OBSERVATION", 42, 49]]], ["The movement of peoples across borders may entail transfer of drug-resistant parasites, as has been witnessed before in malaria.", [["malaria", "DISEASE", 120, 127], ["resistant parasites", "PROBLEM", 67, 86], ["malaria", "PROBLEM", 120, 127], ["movement", "OBSERVATION_MODIFIER", 4, 12], ["malaria", "OBSERVATION", 120, 127]]], ["National mobile populations: Migratory workers within countries have been tracked, stationed, and quarantined so as to avoid propagation of SARS-CoV-2 infection.", [["SARS", "DISEASE", 140, 144], ["infection", "DISEASE", 151, 160], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV-2", "SPECIES", 140, 150], ["SARS", "PROBLEM", 140, 144], ["CoV-2 infection", "PROBLEM", 145, 160], ["infection", "OBSERVATION", 151, 160]]], ["8 In malaria-endemic countries, labor is often migratory, and frequent movement from villages to cities provides an avenue for migration of malaria parasites.", [["malaria", "DISEASE", 5, 12], ["malaria parasites", "DISEASE", 140, 157], ["malaria", "PROBLEM", 5, 12], ["labor", "PROBLEM", 32, 37], ["malaria parasites", "PROBLEM", 140, 157], ["malaria", "OBSERVATION", 5, 12], ["endemic", "OBSERVATION_MODIFIER", 13, 20], ["malaria", "OBSERVATION", 140, 147]]], ["Be it COVID-19 or established diseases like malaria, the marginalized sections of society who drive development usually lack access to healthcare services.", [["sections", "ANATOMY", 70, 78], ["malaria", "DISEASE", 44, 51], ["established diseases", "PROBLEM", 18, 38], ["malaria", "PROBLEM", 44, 51], ["diseases", "OBSERVATION", 30, 38], ["malaria", "OBSERVATION", 44, 51]]], ["This mobile workforce carries threat of reintroduction of malaria into previously free zones.", [["malaria", "DISEASE", 58, 65], ["malaria into previously free zones", "PROBLEM", 58, 92], ["malaria", "OBSERVATION", 58, 65]]], ["Thus, when relevant, transitory labor may be tracked, tested, and treated for malaria.", [["malaria", "DISEASE", 78, 85], ["transitory labor", "PROBLEM", 21, 37], ["malaria", "PROBLEM", 78, 85]]], ["This awareness can educate and empower the masses about COVID-19, its transmission, and its control measures.", [["masses", "CANCER", 43, 49], ["the masses", "PROBLEM", 39, 49], ["COVID", "TEST", 56, 61], ["masses", "OBSERVATION", 43, 49]]], ["The communication lines between governments, healthcare providers, and communities have been opened up in an unprecedented manner.", [["communication lines", "OBSERVATION", 4, 23]]], ["However, malaria-affected communities are usually poor on literacy, health attitudes, and acceptance of governmental guidelines.", [["malaria", "DISEASE", 9, 16], ["malaria", "PROBLEM", 9, 16], ["malaria", "OBSERVATION", 9, 16]]], ["Often malaria control measures like adherence to treatment or use of vector control methods are simply doled out in communities without effective communication and community engagement, leading to poor compliance.", [["malaria", "DISEASE", 6, 13], ["Often malaria control measures", "TREATMENT", 0, 30], ["treatment", "TREATMENT", 49, 58], ["vector control methods", "TREATMENT", 69, 91], ["malaria", "OBSERVATION", 6, 13]]], ["Channels for healthcare information exchange deployed for COVID-19 should be retained for malaria.", [["malaria", "DISEASE", 90, 97], ["COVID-19", "CHEMICAL", 58, 66], ["COVID", "TREATMENT", 58, 63], ["malaria", "PROBLEM", 90, 97], ["malaria", "OBSERVATION", 90, 97]]], ["Disease hotspots: Identification and containment of infection clusters is being aggressively pursued for COVID-19, as this can facilitate efforts to block SARS-CoV-2 transmission.", [["infection", "DISEASE", 52, 61], ["SARS", "DISEASE", 155, 159], ["SARS-CoV-2", "ORGANISM", 155, 165], ["Disease hotspots", "PROBLEM", 0, 16], ["infection clusters", "PROBLEM", 52, 70], ["COVID", "TEST", 105, 110], ["infection", "OBSERVATION", 52, 61]]], ["Similarly, delineating malaria transmission hotspots will help in stemming outbreaks and eliminating malaria hotspots.", [["malaria", "DISEASE", 23, 30], ["malaria", "DISEASE", 101, 108], ["malaria transmission hotspots", "PROBLEM", 23, 52], ["stemming outbreaks", "PROBLEM", 66, 84], ["malaria hotspots", "PROBLEM", 101, 117], ["malaria", "OBSERVATION", 23, 30]]], ["In this, diagnostics, seroprevalence studies, and tools of digital technology can play key roles.", [["seroprevalence studies", "TEST", 22, 44]]], ["Free testing and treatment: In many countries, public healthcare facilities have been directed to diagnose and treat COVID-19 patients at no charge.", [["COVID", "DISEASE", 117, 122], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Free testing", "TEST", 0, 12], ["COVID", "TEST", 117, 122]]], ["Although malaria care is often offered at no charge, additional provision of free access to private sector health care can be considered, especially in outbreak situations.", [["malaria", "DISEASE", 9, 16], ["malaria care", "TREATMENT", 9, 21], ["malaria", "OBSERVATION", 9, 16]]], ["This will enable stronger public-private linkages and private sector alignment with the national goals of malaria control and elimination.", [["malaria", "DISEASE", 106, 113], ["malaria control", "TREATMENT", 106, 121]]], ["Partnerships with industry: Businesses across the world are contributing to the fight against COVID-19.", [["COVID", "TEST", 94, 99]]], ["This spirit of integration between public and private businesses toward a common enemy needs to be maintained in the context of malaria.", [["malaria", "DISEASE", 128, 135], ["malaria", "PROBLEM", 128, 135], ["malaria", "OBSERVATION", 128, 135]]], ["Businesses may be incentivized via tax breaks to dedicate part of their creative energy toward malaria elimination.", [["malaria", "DISEASE", 95, 102], ["tax", "PROTEIN", 35, 38], ["malaria elimination", "PROBLEM", 95, 114]]], ["Commercial viability is paramount to the private sector, and malaria does not present the best profitmaking opportunities.", [["malaria", "DISEASE", 61, 68], ["malaria", "PROBLEM", 61, 68], ["viability", "OBSERVATION_MODIFIER", 11, 20]]], ["Hence, as for COVID-19, private sector engagement with malaria control and elimination should be projected as a service to the population.", [["malaria", "DISEASE", 55, 62], ["COVID", "TEST", 14, 19], ["malaria control", "TREATMENT", 55, 70]]], ["Reallocation of resources: In most countries, national wealth is being used in a dynamic and flexible manner for COVID-19 mitigation.", [["COVID", "TEST", 113, 118]]], ["The usually bureaucratic, siloed, and inflexible approaches that mark funding for medicine and science have been reshaped into conduits that display integration, fluidity, and urgency.", [["medicine", "TREATMENT", 82, 90], ["urgency", "PROBLEM", 176, 183], ["bureaucratic", "OBSERVATION_MODIFIER", 12, 24], ["fluidity", "OBSERVATION_MODIFIER", 162, 170]]], ["This timely change in public health and science funding should be sustained for malaria control and elimination.", [["malaria", "DISEASE", 80, 87], ["science funding", "TREATMENT", 40, 55], ["malaria control", "TREATMENT", 80, 95], ["change", "OBSERVATION_MODIFIER", 12, 18]]], ["Self-help: Populations are being encouraged via digital technology to take preventive steps to stem SARS-CoV-2 transmission.", [["SARS", "DISEASE", 100, 104], ["CoV-2", "ORGANISM", 105, 110]]], ["Novel coronavirus disease-symptomatic people are being encouraged to self-report for diagnosis in centralized facilities.", [["coronavirus disease", "DISEASE", 6, 25], ["coronavirus", "ORGANISM", 6, 17], ["people", "ORGANISM", 38, 44], ["coronavirus", "SPECIES", 6, 17], ["people", "SPECIES", 38, 44], ["Novel coronavirus disease", "PROBLEM", 0, 25], ["coronavirus disease", "OBSERVATION", 6, 25]]], ["A positive test is followed either by home isolation or hospital admission.", [["A positive test", "TEST", 0, 15]]], ["Although still premature for COVID-19, there is real hope of the availability of rapid diagnostic test (RDT) kits for home use to assess infection with SARS-Cov-2 and/or viral immunity.", [["infection", "DISEASE", 137, 146], ["SARS", "DISEASE", 152, 156], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["COVID", "TEST", 29, 34], ["rapid diagnostic test", "TEST", 81, 102], ["infection", "PROBLEM", 137, 146], ["SARS", "TEST", 152, 156], ["Cov", "TEST", 157, 160]]], ["In addition, the use of masks, sanitizers, and other personal protective equipment is expanding in public life and is even mandatory in many regions.", [["masks", "TREATMENT", 24, 29], ["sanitizers", "TREATMENT", 31, 41], ["other personal protective equipment", "TREATMENT", 47, 82]]], ["In a similar vein, empowering malaria-afflicted communities with readily available longlasting insecticide-impregnated bed nets and RDTs can have a direct impact on malaria control, as it will empower the communities to participate in their own health care.", [["vein", "ANATOMY", 13, 17], ["malaria", "DISEASE", 30, 37], ["malaria", "DISEASE", 165, 172], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["empowering malaria", "PROBLEM", 19, 37], ["longlasting insecticide", "TREATMENT", 83, 106], ["malaria control", "TREATMENT", 165, 180], ["similar vein", "ANATOMY", 5, 17], ["malaria", "OBSERVATION", 30, 37]]], ["Healthcare system preparedness: In view of the COVID-19 crisis, laboratory capacities and medical care facilities have been upgraded or established in record time in many countries.", [["the COVID", "TEST", 43, 52], ["laboratory capacities", "TEST", 64, 85]]], ["This alacrity will be very useful as we approach malaria elimination.", [["malaria", "DISEASE", 49, 56], ["malaria elimination", "PROBLEM", 49, 68]]], ["The expansion of integrated disease surveillance will potentially bring fewer malaria cases to light over time in the elimination phase, but each case will require requisite medical attention for treatment.", [["malaria", "DISEASE", 78, 85], ["integrated disease surveillance", "PROBLEM", 17, 48], ["fewer malaria cases", "PROBLEM", 72, 91], ["treatment", "TREATMENT", 196, 205], ["expansion", "OBSERVATION_MODIFIER", 4, 13], ["integrated", "OBSERVATION_MODIFIER", 17, 27], ["disease", "OBSERVATION", 28, 35]]], ["Hence, just as during the COVID-19 pandemic, laboratory and medical facilities will need to be on high alert for speedy diagnosis and management of patients during elimination phases of malaria.INTRODUCTIONIt is feasible that a dynamic and timely deployment of the intervention tools discussed here will dampen the present COVID-19 pandemic.", [["malaria", "DISEASE", 186, 193], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["management", "TREATMENT", 134, 144], ["malaria", "PROBLEM", 186, 193], ["COVID", "TEST", 323, 328], ["pandemic", "PROBLEM", 332, 340], ["malaria", "OBSERVATION", 186, 193]]], ["Maximal implementation of similar tools adapted in a disease-appropriate manner should also be considered for the control and elimination of other killer diseases such as malaria.", [["killer diseases", "DISEASE", 147, 162], ["malaria", "DISEASE", 171, 178], ["other killer diseases", "PROBLEM", 141, 162], ["malaria", "PROBLEM", 171, 178], ["malaria", "OBSERVATION", 171, 178]]]], "5cc372f3b34e76cd40ac8d089940928770c2cef8": [["AbstractThe emergence of the novel betacoronavirus, recently renamed as severe acute Some variants of CoVs are associated with outbreaks, some others are continuously circulating and cause mostly mild respiratory infections (eg, the common cold).", [["respiratory", "ANATOMY", 201, 212], ["CoVs", "DISEASE", 102, 106], ["respiratory infections", "DISEASE", 201, 223], ["betacoronavirus", "CANCER", 35, 50], ["CoVs", "CANCER", 102, 106], ["the novel betacoronavirus", "PROBLEM", 25, 50], ["CoVs", "PROBLEM", 102, 106], ["outbreaks", "PROBLEM", 127, 136], ["mostly mild respiratory infections", "PROBLEM", 189, 223], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["CoVs", "OBSERVATION", 102, 106], ["mild", "OBSERVATION_MODIFIER", 196, 200], ["respiratory", "OBSERVATION_MODIFIER", 201, 212], ["infections", "OBSERVATION", 213, 223]]], ["The most well known of these CoVs is the SARS-CoV, which between 2002 and 2003 was responsible to cause an outbreak that spread around the world and resulted in over 8000 cases and 774 deaths, with a case fatality rate of around 9% to 11%.", [["SARS", "DISEASE", 41, 45], ["deaths", "DISEASE", 185, 191], ["CoVs", "GENE_OR_GENE_PRODUCT", 29, 33], ["SARS-CoV", "ORGANISM", 41, 49], ["SARS-CoV", "SPECIES", 41, 49], ["these CoVs", "PROBLEM", 23, 33], ["the SARS-CoV", "PROBLEM", 37, 49], ["an outbreak", "PROBLEM", 104, 115], ["a case fatality rate", "TEST", 198, 218], ["CoVs", "OBSERVATION", 29, 33], ["outbreak", "OBSERVATION", 107, 115]]], ["3 In 2012, a novel CoV, MERS-CoV, causing severe respiratory symptoms was identified.", [["respiratory", "ANATOMY", 49, 60], ["respiratory symptoms", "DISEASE", 49, 69], ["CoV", "ORGANISM", 19, 22], ["MERS-CoV", "ORGANISM", 24, 32], ["MERS-CoV", "SPECIES", 24, 32], ["severe respiratory symptoms", "PROBLEM", 42, 69], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["respiratory symptoms", "OBSERVATION", 49, 69]]], ["4 Very recently, in December 2019, a novel beta-CoV, was responsible of a new illness, first detected in Wuhan, China.", [["illness", "DISEASE", 78, 85], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["beta-CoV", "PROTEIN", 43, 51], ["beta-CoV", "SPECIES", 43, 51], ["a new illness", "PROBLEM", 72, 85], ["new", "OBSERVATION_MODIFIER", 74, 77], ["illness", "OBSERVATION", 78, 85]]], ["5 We now know this to be another outbreak of CoV in humans (the 7th), that was recently renamed as SARS-CoV-2.", [["CoV", "ORGANISM", 45, 48], ["humans", "ORGANISM", 52, 58], ["SARS-CoV-2", "ORGANISM", 99, 109], ["humans", "SPECIES", 52, 58], ["humans", "SPECIES", 52, 58], ["SARS-CoV", "SPECIES", 99, 107], ["CoV", "OBSERVATION", 45, 48]]], ["The origin of the virus is still unclear, however, genomic analysis suggests nCoV is most closely related to viruses previously identified in bats.", [["nCoV", "GENE_OR_GENE_PRODUCT", 77, 81], ["bats", "ORGANISM", 142, 146], ["nCoV", "PROTEIN", 77, 81], ["the virus", "PROBLEM", 14, 23], ["genomic analysis", "TEST", 51, 67], ["nCoV", "PROBLEM", 77, 81], ["viruses", "PROBLEM", 109, 116], ["origin", "ANATOMY_MODIFIER", 4, 10], ["virus", "OBSERVATION", 18, 23], ["viruses", "OBSERVATION", 109, 116]]], ["6 In the first week of March 2020, over 98.192 confirmed cases and 3,380 deaths have been reported globally.", [["deaths", "DISEASE", 73, 79]]], ["7 The case counts are dramatically rising in part due to increased surveillance and testing.AbstractWhile the outbreak seems to be centered in Wuhan, which is now under quarantine, the virus has spread throughout China and abroad, including Western and South-Eastern Pacific regions, European regions, Eastern Mediterranean regions as well as many states in the United States of America.", [["The case counts", "TEST", 2, 17], ["increased surveillance and testing", "TEST", 57, 91], ["the virus", "PROBLEM", 181, 190]]], ["8 It comes amid signs of the virus's shift away from its origins in China, with Italy, Iran, and South Korea emerging as the other countries hit hardest by the deadly disease.AbstractItaly is the worst affected country in Europe, with more than 4636 cases, a rise of 778 in a day, and a death toll of 197, an increase of 49.", [["death", "DISEASE", 287, 292], ["the virus", "PROBLEM", 25, 34], ["the deadly disease", "PROBLEM", 156, 174], ["virus", "OBSERVATION", 29, 34]]], ["9 Nevertheless, there is still limited information about the genomic epidemiology of the SARS-CoV-2 circulating in Italy from genomic surveillance studies that impairs our understanding of the virus introduction, establishment, and dissemination in the country.AbstractThus, to better understand the emergence of the recent SARS-CoV-2 epidemic in Italy, we analyzed a larger and updated dataset of recently released data of the COVID-2019 epidemic to improve more effective intervention strategies.| Phylogenetic analysisThe dataset comprised (n = 141) complete genomes sequences from the current (2019-2020) SARS-CoV-2 epidemic retrieved from GISAID (https://www.gisaid.org/) database.", [["SARS", "DISEASE", 89, 93], ["SARS-CoV-2", "ORGANISM", 89, 99], ["SARS-CoV-2", "ORGANISM", 324, 334], ["GISAID", "DNA", 644, 650], ["SARS-CoV", "SPECIES", 89, 97], ["the SARS", "PROBLEM", 85, 93], ["CoV", "TEST", 94, 97], ["genomic surveillance studies", "TEST", 126, 154], ["the virus introduction", "TREATMENT", 189, 211], ["effective intervention strategies", "TREATMENT", 464, 497], ["Phylogenetic analysis", "TEST", 500, 521], ["The dataset", "TEST", 521, 532], ["complete genomes sequences", "TEST", 553, 579], ["SARS", "TEST", 609, 613], ["CoV", "TEST", 614, 617], ["epidemic", "PROBLEM", 620, 628]]], ["10 The complete dataset was assessed for the presence of phylogenetic signal by applying the likelihood mapping analysis implemented in the IQ-TREE 1.6.8 software (http://www.iqtree.org).", [["phylogenetic signal", "PROBLEM", 57, 76], ["the likelihood mapping analysis", "TEST", 89, 120]]], ["11 A maximum likelihood (ML) phylogeny was reconstructed using IQ-TREE 1.6.8 software under the general time-reversible nucleotide substitution model with a proportion of invariant sites (GTR+I) which was inferred in jModelTest (https://github.com/ddarriba/jmodeltest2) as the best fitting model.", [["nucleotide", "CHEMICAL", 120, 130], ["nucleotide", "CHEMICAL", 120, 130], ["IQ", "TEST", 63, 65], ["reversible nucleotide substitution model", "TREATMENT", 109, 149]]], ["12| RESULTSTo better understand the establishment and transmission of the novel SARS-CoV-2 in Italy, the recent Italian genomes available on the GISAID database were added to a dataset of 138 SARS-CoV-2 genomes from the global epidemic.", [["SARS", "DISEASE", 80, 84], ["SARS", "DISEASE", 192, 196], ["SARS-CoV-2", "ORGANISM", 80, 90], ["GISAID database", "DNA", 145, 160], ["SARS-CoV-2 genomes", "DNA", 192, 210], ["SARS-CoV", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 192, 200], ["CoV", "TEST", 85, 88], ["CoV", "TEST", 197, 200]]], ["An ML phylogenetic tree (Figure 1 ) was built to F I G U R E 1 Maximum likelihood phylogeny, estimated from complete and near-complete coronavirus (CoV) genomes using genome data available in GISAID.", [["coronavirus", "ORGANISM", 135, 146], ["CoV", "ORGANISM", 148, 151], ["coronavirus (CoV) genomes", "DNA", 135, 160], ["CoV", "SPECIES", 148, 151], ["Maximum likelihood phylogeny", "TEST", 63, 91], ["genome data", "TEST", 167, 178], ["phylogenetic tree", "OBSERVATION", 6, 23]]], ["Colors represent different locations (panels A and B represent expansions of the clades containing the Italian CoV isolates [green]) in clade 1 closely related with sequence from England, in clade B closely related with sequences from Germany explore the recent Italian genomes relationship with previous worldwide isolates.", [["CoV", "ORGANISM", 111, 114], ["Italian CoV", "SPECIES", 103, 114], ["expansions of the clades", "PROBLEM", 63, 87], ["different", "OBSERVATION_MODIFIER", 17, 26]]], ["ML phylogenies suggested that the three Italian strains, grouped into two different well-supported phylogenetic clades (bootstrap score [BS] 0.80, 0.99, respectively).", [["ML phylogenies", "TEST", 0, 14], ["the three Italian strains", "PROBLEM", 30, 55], ["bootstrap score", "TEST", 120, 135], ["BS", "TEST", 137, 139]]], ["We found that two isolates from Italy (EPI_ISL_410546 a Chinese tourist from Hubei Province, and EPI_ISL_412974 the first Italian case isolate in Rome Italy) fall within a clade (BS = 94%) ( Figure 1A clade 1) including sequences from several countries as China, Japan, Singapore, England, Australia, and Canada.| RESULTSHowever, it is important to note that sequences from China are positioned basally to this first clade, reinforcing the idea that the first introduction event could be mediated, as suspected by China.| RESULTSWe also identified that one Italian strain (EPI_ISL_412973 from the province of Lombardy) isolated in February 2020, grouped separately into a second clade ( Figure 1B lance efforts during epidemics should be undertaken to provide enough data to make reliable inferences on the molecular epidemiology of the rapidly evolving virus.", [["EPI_ISL_410546", "CHEMICAL", 39, 53], ["_ISL_412973", "CHEMICAL", 576, 587], ["BS", "TEST", 179, 181], ["a second clade", "TREATMENT", 670, 684], ["Figure 1B lance efforts", "TREATMENT", 687, 710], ["epidemics", "PROBLEM", 718, 727], ["the rapidly evolving virus", "PROBLEM", 833, 859], ["virus", "OBSERVATION", 854, 859]]], ["Phylogenetic inference robustness will be improved if other genomic sequences will be available to build an even more informative dataset despite the low heterogeneity of the sequenced strains.", [["genomic sequences", "DNA", 60, 77], ["Phylogenetic inference robustness", "PROBLEM", 0, 33], ["other genomic sequences", "PROBLEM", 54, 77], ["the sequenced strains", "PROBLEM", 171, 192], ["low heterogeneity", "OBSERVATION_MODIFIER", 150, 167]]], ["Consequently, this analysis has to be considered as the first preliminary report regarding the SARS-CoV-2 epidemic in Italy that highlights two independent introductions probably mediated by China and Germany, respectively.", [["CoV-2", "ORGANISM", 100, 105], ["this analysis", "TEST", 14, 27], ["the SARS", "TEST", 91, 99], ["CoV", "TEST", 100, 103]]], ["This could reinforce the tight connection within samples that have been isolated all over Europe, indicating that the virus is spreading quite widely in Europe suggesting that it could be likely spreading in the general population.| RESULTSIn conclusion, our study shows that genomic data generated in real-time can be employed to assist public health in monitoring and understanding the outbreak of novel emerging viral 13 pathogens.", [["samples", "ANATOMY", 49, 56], ["samples", "CANCER", 49, 56], ["the virus", "PROBLEM", 114, 123], ["our study", "TEST", 255, 264], ["genomic data", "TEST", 276, 288], ["novel emerging viral 13 pathogens", "PROBLEM", 400, 433], ["tight", "OBSERVATION_MODIFIER", 25, 30], ["virus", "OBSERVATION", 118, 123], ["could be likely", "UNCERTAINTY", 179, 194], ["spreading", "OBSERVATION_MODIFIER", 195, 204]]]], "ccbd9a6f387164eea963a406d9526b36df4ee6e2": [["IntroductionTo combat the SARS-CoV-2 (CoV-2) epidemic once France had gone into lockdown on May 7, 2020, the French Health Minister declared that all persons present in France showing symptoms suggestive of coronavirus disease (COVID-19) should consult their doctor and, if considered necessary, undergo screening (with full national health insurance cover as of May 11, 2020).IntroductionIn the coming weeks and months, French ENT physicians will be prescribing tests in case of symptomatology typically revealing CoV-2 infection (fever, cough, respiratory disorder, taste and/or olfactory disorder), and will also need to interpret the results and explain them to the patient.", [["respiratory", "ANATOMY", 546, 557], ["olfactory", "ANATOMY", 581, 590], ["SARS", "DISEASE", 26, 30], ["coronavirus disease", "DISEASE", 207, 226], ["infection", "DISEASE", 521, 530], ["fever", "DISEASE", 532, 537], ["cough", "DISEASE", 539, 544], ["respiratory disorder", "DISEASE", 546, 566], ["taste and/or olfactory disorder", "DISEASE", 568, 599], ["SARS-CoV-2", "ORGANISM", 26, 36], ["CoV-2", "ORGANISM", 38, 43], ["persons", "ORGANISM", 150, 157], ["coronavirus", "ORGANISM", 207, 218], ["CoV-2", "GENE_OR_GENE_PRODUCT", 515, 520], ["patient", "ORGANISM", 670, 677], ["persons", "SPECIES", 150, 157], ["patient", "SPECIES", 670, 677], ["SARS-CoV", "SPECIES", 26, 34], ["the SARS", "TEST", 22, 30], ["CoV", "TEST", 31, 34], ["symptoms", "PROBLEM", 184, 192], ["coronavirus disease", "PROBLEM", 207, 226], ["prescribing tests", "TEST", 451, 468], ["symptomatology", "PROBLEM", 480, 494], ["CoV-2 infection", "PROBLEM", 515, 530], ["fever", "PROBLEM", 532, 537], ["cough", "PROBLEM", 539, 544], ["respiratory disorder", "PROBLEM", 546, 566], ["olfactory disorder", "PROBLEM", 581, 599], ["suggestive of", "UNCERTAINTY", 193, 206], ["coronavirus disease", "OBSERVATION", 207, 226], ["infection", "OBSERVATION", 521, 530]]], ["The present technical note presents the key points of the tests, stressing test association and combined timely analysis, based on a recent study published in the JAMA [1] .CoV-2 identification testsThe first COVID-19 test is performed on swabs from the nasopharynx or sometimes tracheobronchial tract, oropharynx or sputum.", [["swabs", "ANATOMY", 239, 244], ["nasopharynx", "ANATOMY", 254, 265], ["tracheobronchial tract", "ANATOMY", 279, 301], ["oropharynx", "ANATOMY", 303, 313], ["sputum", "ANATOMY", 317, 323], ["nasopharynx", "ORGAN", 254, 265], ["tracheobronchial tract", "ORGAN", 279, 301], ["oropharynx", "ORGAN", 303, 313], ["the tests", "TEST", 54, 63], ["a recent study", "TEST", 131, 145], ["identification tests", "TEST", 179, 199], ["The first COVID-19 test", "TEST", 199, 222], ["swabs", "TEST", 239, 244], ["sputum", "PROBLEM", 317, 323], ["nasopharynx", "ANATOMY", 254, 265], ["tracheobronchial tract", "ANATOMY", 279, 301], ["oropharynx", "ANATOMY", 303, 313], ["sputum", "OBSERVATION", 317, 323]]], ["It detects coronavirus ribonucleic acid (RNA) on polymerase chain reaction (PCR).CoV-2 identification testsPCR shows almost 100% specificity but variable sensitivity, greatly depending on sample quality, ranging between 60% and 80% in early stages and decreasing over time to just 40-50% at 3-6 months of onset ( Fig. 1) , as viral load rapidly decreases with immune response [1] .", [["ribonucleic acid", "CHEMICAL", 23, 39], ["coronavirus", "ORGANISM", 11, 22], ["CoV-2", "GENE_OR_GENE_PRODUCT", 81, 86], ["coronavirus ribonucleic acid", "RNA", 11, 39], ["CoV-2 identification testsPCR", "DNA", 81, 110], ["coronavirus ribonucleic acid (RNA) on polymerase chain reaction", "PROBLEM", 11, 74], ["PCR", "TEST", 76, 79], ["CoV", "TEST", 81, 84], ["identification testsPCR", "TEST", 87, 110], ["variable sensitivity", "PROBLEM", 145, 165], ["sample quality", "TEST", 188, 202], ["viral load", "TEST", 326, 336], ["coronavirus", "OBSERVATION", 11, 22], ["ribonucleic acid", "OBSERVATION", 23, 39], ["decreasing", "OBSERVATION_MODIFIER", 252, 262]]], ["As well as the problem of sensitivity, PCR, despite its cost advantages, has various drawbacks.", [["sensitivity", "PROBLEM", 26, 37], ["PCR", "TEST", 39, 42], ["its cost advantages", "TREATMENT", 52, 71], ["various drawbacks", "TREATMENT", 77, 94]]], ["Some of its reagents are expensive, and are running out with the exponential * Corresponding author at: Service ORL, HEGP, 20-40, rue Leblanc, 75015 Paris,France.E-mail address: ollivier.laccourreye@aphp.fr (O. Laccourreye).France.growth of testing.", [["HEGP", "TEST", 117, 121], ["testing", "TEST", 241, 248], ["rue Leblanc", "ANATOMY", 130, 141]]], ["Moreover, depending on the degree of automation, the test takes between 3 and 6 hours and results are often not available until 24 hours later or more.France.To facilitate mass screening, various tests are under assessment, by the national reference centre for respiratory infection viruses in France.", [["respiratory infection viruses", "DISEASE", 261, 290], ["automation", "TEST", 37, 47], ["the test", "TEST", 49, 57], ["mass screening", "TEST", 172, 186], ["various tests", "TEST", 188, 201], ["assessment", "TEST", 212, 222], ["respiratory infection viruses", "PROBLEM", 261, 290], ["mass", "OBSERVATION", 172, 176], ["respiratory", "ANATOMY", 261, 272], ["infection", "OBSERVATION", 273, 282]]], ["These rapid screening tests, using saliva, throat or nasal samples, detect either viral RNA (test performed by a clinician in less than 20 minutes) or viral protein on antigen techniques.", [["throat", "ANATOMY", 43, 49], ["nasal samples", "ANATOMY", 53, 66], ["saliva", "ORGANISM_SUBSTANCE", 35, 41], ["throat", "ORGANISM_SUBDIVISION", 43, 49], ["nasal samples", "CANCER", 53, 66], ["viral RNA", "RNA", 82, 91], ["viral protein", "PROTEIN", 151, 164], ["These rapid screening tests", "TEST", 0, 27], ["saliva, throat or nasal samples", "TEST", 35, 66], ["viral protein on antigen techniques", "PROBLEM", 151, 186], ["throat", "ANATOMY", 43, 49], ["nasal", "ANATOMY", 53, 58]]], ["Results are obtained within a matter of minutes, depending on the test, enabling mass implementation, but specificity and, above all, sensitivity remain to be determined.", [["the test", "TEST", 62, 70], ["specificity", "TEST", 106, 117], ["mass", "OBSERVATION", 81, 85]]], ["They also lack a signal amplification phase as strong as in PCR and detect the virus only at high levels of infestation, and are thus probably less sensitive than PCR in identifying an infected individual.", [["a signal amplification phase", "TEST", 15, 43], ["PCR", "TEST", 60, 63], ["the virus", "PROBLEM", 75, 84], ["infestation", "PROBLEM", 108, 119], ["PCR", "TEST", 163, 166], ["an infected individual", "PROBLEM", 182, 204], ["infestation", "OBSERVATION", 108, 119], ["infected", "OBSERVATION", 185, 193]]], ["In case of negative findings in a subject presenting suggestive symptoms, it is probably advisable to complete screening with PCR.Serology testsCompared to diagnostic tests, serology tests provide \"historical\" information on COVID-19, and can identify potentially protected subjects.Serology testsIn response to CoV-2 infection, the immune system produces specific antibodies against viral proteins that can be detected in blood, with inter-individual variations in timing and in level.", [["immune system", "ANATOMY", 333, 346], ["blood", "ANATOMY", 423, 428], ["infection", "DISEASE", 318, 327], ["CoV-2", "ORGANISM", 312, 317], ["blood", "ORGANISM_SUBSTANCE", 423, 428], ["antibodies", "PROTEIN", 365, 375], ["viral proteins", "PROTEIN", 384, 398], ["CoV-2", "SPECIES", 312, 317], ["symptoms", "PROBLEM", 64, 72], ["complete screening", "TEST", 102, 120], ["PCR", "TEST", 126, 129], ["Serology testsCompared", "TEST", 130, 152], ["diagnostic tests", "TEST", 156, 172], ["serology tests", "TEST", 174, 188], ["COVID", "TEST", 225, 230], ["Serology tests", "TEST", 283, 297], ["CoV-2 infection", "PROBLEM", 312, 327], ["the immune system", "TEST", 329, 346], ["specific antibodies", "TEST", 356, 375], ["viral proteins", "PROBLEM", 384, 398], ["inter-individual variations in timing", "PROBLEM", 435, 472], ["negative", "OBSERVATION", 11, 19], ["infection", "OBSERVATION", 318, 327], ["inter-individual variations", "OBSERVATION", 435, 462]]], ["Antibody production begins at a mean 10-20 days after onset of infection ( Fig. 1) [1] .", [["infection", "DISEASE", 63, 72], ["Antibody production", "PROBLEM", 0, 19], ["infection", "PROBLEM", 63, 72], ["infection", "OBSERVATION", 63, 72]]], ["The gold-standard test is ELISA (enzyme-linked immunosorbent assay).", [["ELISA", "TEST", 26, 31], ["enzyme", "TEST", 33, 39], ["immunosorbent assay", "TEST", 47, 66]]], ["Performed in the laboratory on venous blood, this colorimetric reaction includes quantitative spectrometry, specifying IgG and IgM antibody levels.", [["venous blood", "ANATOMY", 31, 43], ["venous blood", "ORGANISM_SUBSTANCE", 31, 43], ["IgG", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 127, 139], ["IgG", "PROTEIN", 119, 122], ["IgM antibody", "PROTEIN", 127, 139], ["venous blood", "TEST", 31, 43], ["this colorimetric reaction", "PROBLEM", 45, 71], ["quantitative spectrometry", "TEST", 81, 106], ["IgG", "TEST", 119, 122], ["IgM antibody levels", "TEST", 127, 146], ["venous blood", "ANATOMY", 31, 43]]], ["Positive findings indicate COVID-19, independently of symptoms.", [["COVID", "TEST", 27, 32], ["symptoms", "PROBLEM", 54, 62]]], ["For care staff, this leads to an application for recognition of COVID-19 as an occu- pational disease.", [["COVID", "TEST", 64, 69], ["pational disease", "PROBLEM", 85, 101]]], ["On April 16, 2020, the French Health Authority (https://www.has-sante.fr/) summarised the state of knowledge on CoV-2 serology dynamics.", [["CoV-2", "GENE_OR_GENE_PRODUCT", 112, 117], ["CoV", "TEST", 112, 115]]], ["IgM production begins at day 5 following symptom onset, becoming detectable in some subjects at day 7 and in all cases during the second week.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "PROTEIN", 0, 3], ["IgM production", "PROBLEM", 0, 14], ["symptom onset", "PROBLEM", 41, 54]]], ["IgG production begins slightly later, but can often be more or less concomitant.", [["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "PROTEIN", 0, 3], ["IgG production", "PROBLEM", 0, 14]]], ["IgM and/or IgG are thus detectable in symptomatic patients at week 2 following symptom onset.", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 11, 14], ["patients", "ORGANISM", 50, 58], ["IgM", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 11, 14], ["patients", "SPECIES", 50, 58], ["IgM", "TEST", 0, 3], ["IgG", "TEST", 11, 14], ["symptom onset", "PROBLEM", 79, 92]]], ["Level seems to be higher in more severe cases.", [["seems to be", "UNCERTAINTY", 6, 17], ["higher", "OBSERVATION_MODIFIER", 18, 24], ["more severe", "OBSERVATION_MODIFIER", 28, 39]]], ["Late production onset has also been reported, beyond 15 days after symptom onset and up to 30 days after infection, notably in asymptomatic or paucisymptomatic cases.", [["infection", "DISEASE", 105, 114], ["symptom onset", "PROBLEM", 67, 80], ["infection", "PROBLEM", 105, 114], ["asymptomatic or paucisymptomatic cases", "PROBLEM", 127, 165], ["infection", "OBSERVATION", 105, 114]]], ["IgM and IgG production kinetics remains unclear in asymptomatic or paucisymptomatic patients.Serology testsThe national reference centre of Lyon found no decrease in antibody production 2 months after symptom onset (current maximum follow-up available in France).Serology testsAbsence of antibodies indicates either absence of infection or infection too recent for antibodies to appear; certain populations (elderly, severely immune-depressed) might not develop antibodies at all, despite infection.", [["infection", "DISEASE", 327, 336], ["infection", "DISEASE", 340, 349], ["depressed", "DISEASE", 433, 442], ["infection", "DISEASE", 489, 498], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 8, 11], ["patients", "ORGANISM", 84, 92], ["IgM", "PROTEIN", 0, 3], ["IgG", "PROTEIN", 8, 11], ["antibodies", "PROTEIN", 288, 298], ["antibodies", "PROTEIN", 365, 375], ["antibodies", "PROTEIN", 462, 472], ["patients", "SPECIES", 84, 92], ["IgM", "TEST", 0, 3], ["IgG production kinetics", "PROBLEM", 8, 31], ["Serology tests", "TEST", 93, 107], ["decrease in antibody production", "PROBLEM", 154, 185], ["symptom onset", "PROBLEM", 201, 214], ["Serology testsAbsence of antibodies", "TEST", 263, 298], ["infection", "PROBLEM", 327, 336], ["infection", "PROBLEM", 340, 349], ["antibodies", "PROBLEM", 365, 375], ["certain populations", "PROBLEM", 387, 406], ["severely immune-depressed", "PROBLEM", 417, 442], ["antibodies", "PROBLEM", 462, 472], ["infection", "PROBLEM", 489, 498], ["IgG production", "OBSERVATION", 8, 22], ["no", "UNCERTAINTY", 151, 153], ["decrease", "OBSERVATION_MODIFIER", 154, 162], ["infection", "OBSERVATION", 327, 336], ["infection", "OBSERVATION", 340, 349], ["infection", "OBSERVATION", 489, 498]]], ["And finally, there is a false-positive rate of less than 5%: positive serology does not rule out contagiousness or guarantee protection, especially in the light of uncertainties as to immunity duration.Serology testsRapid IgM and IgG screening is also possible on the fingerprick test, using less than 20 l of blood, with visual read-out, but without quantification.", [["blood", "ANATOMY", 310, 315], ["IgM", "GENE_OR_GENE_PRODUCT", 222, 225], ["IgG", "GENE_OR_GENE_PRODUCT", 230, 233], ["blood", "ORGANISM_SUBSTANCE", 310, 315], ["IgM", "PROTEIN", 222, 225], ["IgG", "PROTEIN", 230, 233], ["positive serology", "PROBLEM", 61, 78], ["contagiousness", "PROBLEM", 97, 111], ["Serology tests", "TEST", 202, 216], ["Rapid IgM", "TEST", 216, 225], ["IgG screening", "TEST", 230, 243], ["the fingerprick test", "TEST", 264, 284], ["visual read", "TEST", 322, 333], ["false", "OBSERVATION", 24, 29]]], ["Sensitivity and specificity are similar to the previous tests, especially after week 3.ConclusionCombined and interpreted according to the clinical context ( Fig. 1) , diagnostic and serologic COVID-19 tests distinguish 3 groups of subjects.", [["Sensitivity", "TEST", 0, 11], ["the previous tests", "TEST", 43, 61], ["serologic COVID", "TEST", 183, 198], ["tests", "TEST", 202, 207]]], ["Non-infected individuals with neither virus nor immune response are liable to subsequent infection; they should adhere to social distancing or else wear a mask.", [["infection", "DISEASE", 89, 98], ["Non-infected individuals", "PROBLEM", 0, 24], ["neither virus", "PROBLEM", 30, 43], ["subsequent infection", "PROBLEM", 78, 98], ["a mask", "TREATMENT", 153, 159], ["virus", "OBSERVATION", 38, 43], ["infection", "OBSERVATION", 89, 98]]], ["Infected persons, positive for the virus, can spread infection and need to be isolated.", [["infection", "DISEASE", 53, 62], ["persons", "ORGANISM", 9, 16], ["persons", "SPECIES", 9, 16], ["Infected persons", "PROBLEM", 0, 16], ["the virus", "PROBLEM", 31, 40], ["spread infection", "PROBLEM", 46, 62], ["infection", "OBSERVATION", 53, 62]]], ["Individuals who are no longer infected and show antibodies for the virus are presumed to be protected, although there is uncertainty as to the quality and above all to the duration of such protection; it is thus not at present clear whether such persons should be vaccinated or not.Disclosure of interestThe authors declare that they have no competing interest.", [["persons", "ORGANISM", 246, 253], ["antibodies", "PROTEIN", 48, 58], ["persons", "SPECIES", 246, 253], ["longer infected", "PROBLEM", 23, 38], ["antibodies", "PROBLEM", 48, 58], ["the virus", "PROBLEM", 63, 72], ["such protection", "TREATMENT", 184, 199], ["no longer", "UNCERTAINTY", 20, 29]]]], "PMC7384410": [["Being part of a social minority (e.g. migrants, people of color or Asian descent in Western countries) is not itself a risk factor for contracting Coronavirus disease-2019 (COVID-19).", [["Coronavirus disease", "DISEASE", 147, 166], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["contracting Coronavirus disease", "PROBLEM", 135, 166], ["COVID", "TEST", 173, 178]]], ["However, certain groups of people across the world are being targeted by COVID-19 related stigma (COS) and discrimination, what constitutes a growing concern(Bagcchi, 2020).", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["There is an urgent need to better understand it, as it may pose as a barrier for accessing testing and health care and for maintaining treatment adherence(Stangl et al., 2019).", [["accessing testing", "TEST", 81, 98], ["health care", "TREATMENT", 103, 114]]], ["It is very likely that COS is the consequence of multiple socio-ecological drivers (e.g., fear, misinformation) and facilitators (e.g., racism, poverty)(Logie, 2020).", [["very likely", "UNCERTAINTY", 6, 17]]], ["In this letter, we attempt to explore COS related factors based on the real-life experiences of a group of psychiatrists from thirteen countries using the health stigma and discrimination framework (HSDF)(Stangl et al., 2019).", [["COS related factors", "PROBLEM", 38, 57]]]], "bde48d2d7518ea6cdc74f363833e8d98e968852a": [["is a critical need and an ethical obligation for ethics guidelines for decision-making about treatment allocation to be in place before the pandemic reaches the level where tragic choices need to be made.", [["treatment allocation", "TREATMENT", 93, 113]]]], "7d457c3c6b3b43b85285d083a52419a59fc18bd9": [["J o u r n a l P r e -p r o o f 4 complications.", [["complications", "PROBLEM", 33, 46], ["complications", "OBSERVATION", 33, 46]]], ["Moreover, such findings could pave the way to better understanding the mechanisms underlying the established link between body weight and COVID-19 severity.", [["body", "ANATOMY", 122, 126], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["body weight", "TEST", 122, 133], ["COVID", "TEST", 138, 143]]], ["We therefore aimed at investigating the association of VAT deposition with clinical outcomes such as the need of intensive care among patients with COVID-19.Population and study designPatients included in this single center retrospective study were consecutively enrolled among those admitted to the Emergency Department of Sant'Andrea Hospital,Population and study designRome, Italy, who tested positive for SARS-Cov-2 and underwent a chest CT scan in March 2020.", [["SARS", "DISEASE", 409, 413], ["VAT", "TISSUE", 55, 58], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["VAT deposition", "TREATMENT", 55, 69], ["COVID", "TEST", 148, 153], ["SARS", "PROBLEM", 409, 413], ["Cov", "TEST", 414, 417], ["a chest CT scan", "TEST", 434, 449], ["chest", "ANATOMY", 436, 441]]], ["All patients were subjected to two naso-and oro-pharyngeal swabs at a 24-hour interval, and the specimen were tested to confirm SARS-COV2 diagnosis through realtime reverse transcriptase (RT-PCR) (Charit\u00e8, Berlin, Germany).", [["oro-pharyngeal swabs", "ANATOMY", 44, 64], ["specimen", "ANATOMY", 96, 104], ["patients", "ORGANISM", 4, 12], ["reverse transcriptase", "PROTEIN", 165, 186], ["patients", "SPECIES", 4, 12], ["the specimen", "TEST", 92, 104], ["SARS", "PROBLEM", 128, 132], ["realtime reverse transcriptase", "TREATMENT", 156, 186]]], ["Deidentified data about demographic and clinical characteristics were collected, together with laboratory data on presentation.", [["laboratory data", "TEST", 95, 110]]], ["Based on the clinical and radiological assessment, the patients were subsequently addressed from the Emergency Department towards home discharge or admitted to sub-intensive or Intensive Care Unit (ICU), and such clinical outcome was recorded for the purposes of this study.Population and study designAll patients accessing the ICU were intubated and underwent invasive mechanical ventilation, whereas those in subintensive care did not need intubation.Population and study designPatients whose CT could not be evaluated due to severe motion artifact or other technical issues such as restricted field of view for adipose tissue quantification or CT acquired with contrast medium were excluded, as well as those for whom investigated clinical outcomes were unavailable.Population and study designThe study was approved by the local institutional review board (IRB), and written informed consent was obtained from all study participants.", [["adipose tissue", "ANATOMY", 614, 628], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 305, 313], ["adipose tissue", "TISSUE", 614, 628], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 305, 313], ["participants", "SPECIES", 923, 935], ["radiological assessment", "TEST", 26, 49], ["this study", "TEST", 263, 273], ["intubated", "TREATMENT", 337, 346], ["invasive mechanical ventilation", "TREATMENT", 361, 392], ["intubation", "TREATMENT", 442, 452], ["Population and study", "TEST", 453, 473], ["CT", "TEST", 495, 497], ["severe motion artifact", "PROBLEM", 528, 550], ["other technical issues", "PROBLEM", 554, 576], ["adipose tissue quantification", "TEST", 614, 643], ["CT acquired with contrast medium", "TEST", 647, 679], ["The study", "TEST", 796, 805], ["mechanical ventilation", "OBSERVATION", 370, 392]]], ["When patients were unable to provide informed consent, this was received by the next-of-kin or admitting physician.Sample size and study powerJ o u r n a l P r e -p r o o f 5 Based on a preliminary pilot study of 20 patients, the mean \u00b1 SD VAT in the patient population was 14000 \u00b1 8500 mm 2 .", [["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 216, 224], ["patient", "ORGANISM", 251, 258], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 216, 224], ["patient", "SPECIES", 251, 258], ["Sample size", "TEST", 115, 126], ["study", "TEST", 131, 136], ["powerJ", "TEST", 137, 143], ["u", "TEST", 146, 147], ["a preliminary pilot study", "TEST", 184, 209]]], ["Assuming a power of 0.80 and alpha of 0.05, 142 patients were considered appropriate to highlight an expected difference of 2000 mm 2 in the VAT value.", [["VAT", "ANATOMY", 141, 144], ["patients", "ORGANISM", 48, 56], ["VAT", "TISSUE", 141, 144], ["patients", "SPECIES", 48, 56], ["alpha", "TEST", 29, 34], ["the VAT value", "TEST", 137, 150]]], ["The number of subjects was further increased to 150 to prevent possible missing data.", [["missing data", "PROBLEM", 72, 84]]], ["Assuming an alpha of 0.05, the post-hoc power calculated considering the mean \u00b1 SD VAT in the investigated groups with the smaller number of patients (i.e., 23) was 89.2%.Sample size and study power2.3 CT Acquisition Technique and Lung Severity Score evaluation COVID-19 positive patients underwent a chest CT scan to determine the pulmonary involvement.", [["Lung", "ANATOMY", 231, 235], ["pulmonary", "ANATOMY", 332, 341], ["patients", "ORGANISM", 141, 149], ["Lung", "ORGAN", 231, 235], ["patients", "ORGANISM", 280, 288], ["pulmonary", "ORGAN", 332, 341], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 280, 288], ["an alpha", "TEST", 9, 17], ["Sample size", "TEST", 171, 182], ["study power", "TEST", 187, 198], ["CT Acquisition Technique", "TEST", 202, 226], ["Lung Severity Score evaluation", "TEST", 231, 261], ["COVID", "TEST", 262, 267], ["a chest CT scan", "TEST", 299, 314], ["the pulmonary involvement", "PROBLEM", 328, 353], ["alpha", "OBSERVATION_MODIFIER", 12, 17], ["smaller", "OBSERVATION_MODIFIER", 123, 130], ["size", "OBSERVATION_MODIFIER", 178, 182], ["Lung", "ANATOMY", 231, 235], ["chest", "ANATOMY", 301, 306], ["pulmonary", "ANATOMY", 332, 341], ["involvement", "OBSERVATION", 342, 353]]], ["The acquisitions were obtained on a 128-slice CT (GE Revolution EVO, GE Medical Systems, Milwaukee, WI, USA).", [["slice CT", "TEST", 40, 48]]], ["Lung impairment was evaluated through a Lung Severity Score (LSS) calculated through visual assessment by two expert radiologists in consensus (DC and MZ with 10 and 5 years of experience respectively) ranging from 0 to 40 (Figure 1 A-B ) [17] .", [["Lung", "ANATOMY", 0, 4], ["Lung", "ANATOMY", 40, 44], ["DC", "ANATOMY", 144, 146], ["Lung impairment", "DISEASE", 0, 15], ["Lung", "ORGAN", 0, 4], ["Lung", "ORGAN", 40, 44], ["DC", "CELL_TYPE", 144, 146], ["Lung impairment", "PROBLEM", 0, 15], ["a Lung Severity Score", "TEST", 38, 59], ["visual assessment", "TEST", 85, 102], ["impairment", "OBSERVATION", 5, 15], ["Lung", "ANATOMY", 40, 44]]], ["Briefly, each lung was divided in 10 regions as already described [18] , and for each region a visual score of parenchymal involvement was assigned (ground-glass opacities and consolidation), with a score 0 for absence, 1 for < 50% and 2 for > 50% lung involvement.CT Fat deposition assessmentMeasurements were performed by two radiologists in consensus (MP and FP with 6 and 7 years of experience respectively) on a commercially available workstation computer were the chest CTs had been transferred (Advantage Windows Workstation, version 4.7, GE Healthcare).", [["lung", "ANATOMY", 14, 18], ["parenchymal", "ANATOMY", 111, 122], ["lung", "ANATOMY", 248, 252], ["chest", "ANATOMY", 470, 475], ["lung", "ORGAN", 14, 18], ["parenchymal", "MULTI-TISSUE_STRUCTURE", 111, 122], ["lung", "ORGAN", 248, 252], ["parenchymal involvement", "PROBLEM", 111, 134], ["ground-glass opacities", "PROBLEM", 149, 171], ["consolidation", "PROBLEM", 176, 189], ["CT Fat deposition assessment", "TEST", 265, 293], ["the chest CTs", "TEST", 466, 479], ["lung", "ANATOMY", 14, 18], ["parenchymal", "ANATOMY_MODIFIER", 111, 122], ["glass opacities", "OBSERVATION", 156, 171], ["consolidation", "OBSERVATION", 176, 189], ["lung", "ANATOMY", 248, 252], ["involvement", "OBSERVATION", 253, 264], ["chest", "ANATOMY", 470, 475]]], ["To quantify abdominal visceral and subcutaneous fat, the first slice where lung bases were no more visible at the thoracoabdominal level was selected, adapting from a previously described method (Figure 1 C) [19] .", [["abdominal visceral", "ANATOMY", 12, 30], ["subcutaneous fat", "ANATOMY", 35, 51], ["slice", "ANATOMY", 63, 68], ["lung", "ANATOMY", 75, 79], ["thoracoabdominal", "ANATOMY", 114, 130], ["abdominal visceral", "TISSUE", 12, 30], ["subcutaneous fat", "TISSUE", 35, 51], ["lung", "ORGAN", 75, 79], ["thoracoabdominal", "ORGAN", 114, 130], ["abdominal", "ANATOMY_MODIFIER", 12, 21], ["visceral", "ANATOMY", 22, 30], ["subcutaneous fat", "ANATOMY", 35, 51], ["lung", "ANATOMY", 75, 79], ["bases", "ANATOMY_MODIFIER", 80, 85], ["no", "UNCERTAINTY", 91, 93], ["more", "OBSERVATION_MODIFIER", 94, 98], ["visible", "OBSERVATION_MODIFIER", 99, 106], ["thoracoabdominal", "ANATOMY", 114, 130]]], ["A region of interest (ROI) of the body circumference avoiding subcutaneous tissue was identified; then a HU range corresponding to the CT histogram of adipose tissue from -250 to -50 HU was set to automatically calculate the visceral adipose tissue (VAT) area expressed in mm 2 on the J o u r n a l P r e -p r o o f 6 selected slice (Figure 1 D) .", [["body", "ANATOMY", 34, 38], ["subcutaneous tissue", "ANATOMY", 62, 81], ["adipose tissue", "ANATOMY", 151, 165], ["visceral adipose tissue", "ANATOMY", 225, 248], ["VAT) area", "ANATOMY", 250, 259], ["body", "ORGANISM_SUBDIVISION", 34, 38], ["subcutaneous tissue", "TISSUE", 62, 81], ["adipose tissue", "TISSUE", 151, 165], ["visceral adipose tissue", "TISSUE", 225, 248], ["VAT", "TISSUE", 250, 253], ["subcutaneous tissue", "PROBLEM", 62, 81], ["a HU range", "TEST", 103, 113], ["the CT histogram", "TEST", 131, 147], ["adipose tissue", "TEST", 151, 165], ["a l P r e -p r o o f", "TREATMENT", 295, 315], ["body", "ANATOMY", 34, 38], ["subcutaneous tissue", "ANATOMY", 62, 81], ["adipose tissue", "ANATOMY", 151, 165], ["visceral", "ANATOMY_MODIFIER", 225, 233], ["adipose tissue", "ANATOMY", 234, 248]]], ["The procedure was repeated drawing a ROI including the subcutaneous tissue and obtaining the total adipose tissue (TAT) area expressed in mm 2 .CT Fat deposition assessmentSubcutaneous adipose tissue (SAT) area expressed in mm 2 was obtained as the subtraction between TAT and VAT.", [["subcutaneous tissue", "ANATOMY", 55, 74], ["adipose tissue", "ANATOMY", 99, 113], ["Subcutaneous adipose tissue", "ANATOMY", 172, 199], ["SAT) area", "ANATOMY", 201, 210], ["subcutaneous tissue", "TISSUE", 55, 74], ["adipose tissue", "TISSUE", 99, 113], ["Subcutaneous adipose tissue", "TISSUE", 172, 199], ["SAT", "TISSUE", 201, 204], ["TAT", "GENE_OR_GENE_PRODUCT", 269, 272], ["VAT", "TISSUE", 277, 280], ["TAT", "PROTEIN", 269, 272], ["The procedure", "TREATMENT", 0, 13], ["a ROI", "TREATMENT", 35, 40], ["the subcutaneous tissue", "TREATMENT", 51, 74], ["the total adipose tissue (TAT) area", "TREATMENT", 89, 124], ["Fat deposition assessment", "TEST", 147, 172], ["Subcutaneous adipose tissue (SAT) area", "PROBLEM", 172, 210], ["the subtraction between TAT and VAT", "TREATMENT", 245, 280], ["subcutaneous tissue", "ANATOMY", 55, 74], ["adipose tissue", "ANATOMY", 99, 113], ["Subcutaneous adipose", "ANATOMY", 172, 192]]], ["Finally, epicardial fat thickness (EFT) was measured at the level of the right coronary artery origin on the axial plane.", [["epicardial fat", "ANATOMY", 9, 23], ["right coronary artery", "ANATOMY", 73, 94], ["epicardial fat", "TISSUE", 9, 23], ["right coronary artery", "MULTI-TISSUE_STRUCTURE", 73, 94], ["epicardial fat thickness (EFT)", "TREATMENT", 9, 39], ["epicardial", "ANATOMY", 9, 19], ["fat thickness", "OBSERVATION", 20, 33], ["right coronary artery", "ANATOMY", 73, 94], ["origin", "ANATOMY_MODIFIER", 95, 101]]], ["To reduce bias, measurements were assessed three times and a mean of the values was recorded, expressed in millimeters.StatisticsThe Statistical Package for Social Sciences (SPSS), v.20, and R-package (Vienna, Austria) were used for statistical analysis.", [["statistical analysis", "TEST", 233, 253], ["bias", "OBSERVATION", 10, 14]]], ["Normality was assessed with the Kolmogorov-Smirnov test.", [["the Kolmogorov-Smirnov test", "TEST", 28, 55]]], ["Patients were categorized in three groups based on the type of treatment (Home discharge, Sub-intensive Care, and ICU).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The primary endpoint was admission to ICU, which includes requirement for intubation.StatisticsFor continuous variables, a one-way ANCOVA was conducted to compare the distribution of the clinical, biochemical and CT-derived adiposity parameters and LSS among the three different levels of care controlling for age and gender, and a post-hoc multiple comparison LSD adjusted was conducted.", [["intubation", "TREATMENT", 74, 84], ["CT", "TEST", 213, 215], ["LSS", "TREATMENT", 249, 252]]], ["Chi-Square test/Fisher's exact test was used for categorical variables.", [["Chi-Square test", "TEST", 0, 15], ["Fisher's exact test", "TEST", 16, 35]]], ["Pearson's correlation coefficient was used to investigate the level of association between continuous variables.StatisticsTo assess the presence of additive interaction of investigated variables on ICU admission, three indices were calculated [20] using the R-package \"interactionR\": (1) the relative excess risk due to interaction (RERI), (2) the proportion of disease among those with both exposures that is attributable to their interaction (AP), and (3) the synergy index (SI).", [["disease", "PROBLEM", 362, 369], ["disease", "OBSERVATION", 362, 369]]], ["A RERI of greater than one means positive interaction or more than additivity.", [["greater", "OBSERVATION_MODIFIER", 10, 17], ["positive", "OBSERVATION", 33, 41]]], ["A RERI of less than one means negative interaction or less than additivity.", [["less", "OBSERVATION_MODIFIER", 10, 14]]], ["An AP of zero means no interaction or perfect additivity.", [["An AP of zero means", "TEST", 0, 19]]], ["An AP greater than zero means positive J o u r n a l P r e -p r o o f 7 interaction or more than additivity.", [["An AP", "TEST", 0, 5], ["interaction", "PROBLEM", 72, 83]]], ["An AP of less than zero means negative interaction or less than additivity.", [["An AP", "TEST", 0, 5]]], ["AP ranges from -1 to +1.", [["AP ranges", "TEST", 0, 9]]], ["The SI is the ratio of the combined effects and the individual effects.", [["SI", "OBSERVATION_MODIFIER", 4, 6]]], ["An SI of greater than one means positive interaction or more than additivity.", [["SI", "OBSERVATION_MODIFIER", 3, 5], ["greater", "OBSERVATION_MODIFIER", 9, 16], ["positive", "OBSERVATION", 32, 40]]], ["An SI of less than one means negative interaction or less than additivity.", [["SI", "OBSERVATION_MODIFIER", 3, 5]]], ["The ORs represent the mean change in the dependent variable per one unit of change in the independent variable while holding other predictors in the model constant.", [["mean change", "OBSERVATION", 22, 33], ["dependent", "OBSERVATION_MODIFIER", 41, 50], ["variable", "OBSERVATION_MODIFIER", 51, 59], ["one unit", "OBSERVATION_MODIFIER", 64, 72]]], ["Variance inflation factor (VIF) values were lower than 4.0, suggesting the absence of multicollinearity between included variables [22] .", [["VIF", "PROTEIN", 27, 30], ["Variance inflation factor (VIF) values", "TEST", 0, 38]]], ["The results were considered statistically significant when p < 0.05.StatisticsICU admission was used as the gold standard for nonparametric clustered receiver operating characteristic (ROC) analysis to evaluate the predictive utility of the models.", [["ROC) analysis", "TEST", 185, 198]]], ["By comparing observed and calculated ICU admission, sensitivity and specificity were plotted in ROC form.", [["sensitivity", "TEST", 52, 63], ["specificity", "TEST", 68, 79]]], ["When a perfect correlation of predicted versus observed ICU admission was found, the ROC area under curve (AUC) was equal to 1, whereas random assignment of outcome led to an AUC of 0.5.ResultsOne hundred and fifty patients were enrolled, 64.7% male, with a mean \u00b1 SD age of Upon categorization by VAT quartiles, a rise in ICU admission was observed with increasing VAT accumulation (p=0.009; Figure 2A) , and patients belonging to the highest VAT quartile required ICU admission significantly more than those in the second VAT quartile (p=0.026) (Figure 2A) .ResultsStratifying by age, 65 years being the median age of the study population, RERI, AP, and SI, reflecting the interaction between age and VAT accumulation in contributing to ICU admission, consistently indicated a positive interaction on an additive scale, meaning that the combined effect of age and VAT seems to be more than the sum of the effects (1.75, 0.43, and 2.32, respectively, supplementary Table 1 ).", [["patients", "ORGANISM", 215, 223], ["VAT", "TISSUE", 298, 301], ["VAT", "TISSUE", 366, 369], ["patients", "ORGANISM", 410, 418], ["VAT", "TISSUE", 444, 447], ["VAT", "TISSUE", 524, 527], ["VAT", "TISSUE", 703, 706], ["VAT", "TISSUE", 866, 869], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 410, 418], ["the ROC area under curve", "TEST", 81, 105], ["AUC", "TEST", 107, 110], ["an AUC", "TEST", 172, 178], ["increasing VAT accumulation", "PROBLEM", 355, 382], ["the study population", "TEST", 620, 640], ["AP", "TEST", 648, 650], ["VAT accumulation", "PROBLEM", 703, 719], ["an additive scale", "TREATMENT", 803, 820], ["VAT", "TREATMENT", 866, 869], ["rise", "OBSERVATION_MODIFIER", 315, 319], ["positive", "OBSERVATION", 779, 787]]], ["On an exploratory basis, we further performed a subgroup analysis and observed a trend increased need of ICU admission per higher VAT accumulation in the age group >65 years (p=0.084, Figure 2B) ; within this subgroup, a significant difference was observed between the fourth and second VAT quartile (p=0.0394, Figure 2B) .", [["VAT", "TISSUE", 130, 133], ["VAT", "TISSUE", 287, 290], ["a subgroup analysis", "TEST", 46, 65], ["significant", "OBSERVATION_MODIFIER", 221, 232], ["difference", "OBSERVATION", 233, 243]]], ["The exploratory subgroup investigation showed that male subjects confirmed what observed in the general population (p=0.025, Figure 2C) ;Resultsconversely, female subjects did not confirm this finding (p=0.249, Figure 2 C) .", [["The exploratory subgroup investigation", "TEST", 0, 38]]], ["Within the male subgroup, subjects with VAT belonging to the fourth quartile were significantly more in need of ICU admission compared to those in the second quartile (p=0.0126, Figure 2C ).ResultsUpon stratification by LSS, RERI, AP, and SI, suggested a positive interaction on an additive scale between VAT accumulation and LSS (3.67, 0.42, and 1.88, respectively, Supplementary Table 3) , but once again the interaction term was not significant (p=ns, Figure 2D ).", [["VAT", "TISSUE", 40, 43], ["VAT", "TISSUE", 305, 308], ["LSS", "TEST", 220, 223], ["RERI", "TEST", 225, 229], ["AP", "TEST", 231, 233], ["VAT accumulation", "TEST", 305, 321], ["LSS", "TEST", 326, 329], ["positive", "OBSERVATION", 255, 263]]], ["However, the explorative subgroup analysis suggested that patients in the high LSS group (when LSS was higher than the LSS median value) and belonging to the highest quartile of VAT deposition were admitted to ICU more frequently (0.022 for high LSS, Figure 2D ).", [["patients", "ORGANISM", 58, 66], ["VAT", "TISSUE", 178, 181], ["patients", "SPECIES", 58, 66], ["the explorative subgroup analysis", "TEST", 9, 42], ["LSS", "TEST", 95, 98]]], ["Patients in the low LSS group did not confirm this finding (p=0.431, Figure 2D ).DiscussionWe report that visceral deposition of fat within the abdomen is independently associated with worse clinical outcomes upon SARS-CoV-2 infection.", [["visceral", "ANATOMY", 106, 114], ["fat", "ANATOMY", 129, 132], ["abdomen", "ANATOMY", 144, 151], ["infection", "DISEASE", 225, 234], ["Patients", "ORGANISM", 0, 8], ["visceral", "TISSUE", 106, 114], ["fat", "TISSUE", 129, 132], ["abdomen", "ORGAN", 144, 151], ["CoV-2", "ORGANISM", 219, 224], ["Patients", "SPECIES", 0, 8], ["visceral deposition of fat within the abdomen", "PROBLEM", 106, 151], ["SARS", "PROBLEM", 214, 218], ["CoV-2 infection", "PROBLEM", 219, 234], ["visceral", "ANATOMY", 106, 114], ["deposition", "OBSERVATION", 115, 125], ["fat", "OBSERVATION", 129, 132], ["abdomen", "ANATOMY", 144, 151], ["infection", "OBSERVATION", 225, 234]]], ["Interestingly, VAT accumulation seems to have a stronger link with the need of ICU admission and therefore intubation as opposed to other relevant parameters, such as severity of interstitial pneumonia, markers of inflammation, age, gender or comorbidities.", [["VAT", "ANATOMY", 15, 18], ["interstitial", "ANATOMY", 179, 191], ["interstitial pneumonia", "DISEASE", 179, 201], ["inflammation", "DISEASE", 214, 226], ["VAT", "TISSUE", 15, 18], ["VAT accumulation", "PROBLEM", 15, 31], ["intubation", "TREATMENT", 107, 117], ["interstitial pneumonia", "PROBLEM", 179, 201], ["inflammation", "PROBLEM", 214, 226], ["comorbidities", "PROBLEM", 243, 256], ["interstitial", "ANATOMY_MODIFIER", 179, 191], ["pneumonia", "OBSERVATION", 192, 201], ["inflammation", "OBSERVATION", 214, 226]]], ["Upon stratification, it seems that higher VAT is associated with an increased need of intensive care in subjects over 65 and in male gender, and among those with high LSS, having higher VAT is associated with increased ICU admission.", [["VAT", "TISSUE", 42, 45], ["higher VAT", "PROBLEM", 35, 45], ["intensive care", "TREATMENT", 86, 100], ["increased", "OBSERVATION_MODIFIER", 68, 77]]], ["However, it should be noted that the number of patients requiring ICU admission in each subgroup was small leading to non-significant interaction terms between subgroups (gender, age, severity score).", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["Subgroup analysis needs therefore to be considered exploratory and should be taken with caution, but it can lay the path for future studies.J o u r n a l P r e -p r o o fThe pathophysiology underlying the suggested link is likely multi-stranded.", [["Subgroup analysis", "TEST", 0, 17], ["future studies", "TEST", 125, 139], ["The pathophysiology", "TEST", 170, 189], ["multi-stranded", "PROBLEM", 230, 244], ["is likely", "UNCERTAINTY", 220, 229], ["multi-stranded", "OBSERVATION", 230, 244]]], ["First, obesity is associated with complement system hyperactivation, chronic inflammation, and presence of comorbidities such as diabetes and hypertension proposed in turn to be risk factors for COVID-19 poor prognosis [27] .", [["obesity", "DISEASE", 7, 14], ["inflammation", "DISEASE", 77, 89], ["diabetes", "DISEASE", 129, 137], ["hypertension", "DISEASE", 142, 154], ["obesity", "PROBLEM", 7, 14], ["complement system hyperactivation", "PROBLEM", 34, 67], ["chronic inflammation", "PROBLEM", 69, 89], ["comorbidities", "PROBLEM", 107, 120], ["diabetes", "PROBLEM", 129, 137], ["hypertension", "PROBLEM", 142, 154], ["risk factors", "PROBLEM", 178, 190], ["COVID", "TEST", 195, 200], ["poor prognosis", "PROBLEM", 204, 218], ["obesity", "OBSERVATION", 7, 14], ["associated with", "UNCERTAINTY", 18, 33], ["hyperactivation", "OBSERVATION", 52, 67], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["inflammation", "OBSERVATION", 77, 89], ["hypertension", "OBSERVATION", 142, 154]]], ["Furthermore, visceral adipose tissue is capable of secreting Interleukin-6 [28] , whose levels were found to be retrospectively increased in COVID-19 non-survivors [25] .", [["visceral adipose tissue", "ANATOMY", 13, 36], ["visceral adipose tissue", "TISSUE", 13, 36], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 61, 74], ["28", "GENE_OR_GENE_PRODUCT", 76, 78], ["secreting Interleukin", "TEST", 51, 72], ["whose levels", "TEST", 82, 94], ["COVID", "TEST", 141, 146], ["visceral", "ANATOMY_MODIFIER", 13, 21], ["adipose tissue", "ANATOMY", 22, 36]]], ["SARS-CoV-2 seems to infect cells through an Angiotensinconverting enzyme 2 (ACE2)-dependent mechanism, a receptor also expressed by fat, including ectopic reservoirs [29] , and an additional direct proinflammatory role of COVID-19 in the adipose tissue may therefore possibly contribute to the observed results.J o u r n a l P r e -p r o o fAlthough the design of our study does not allow for a causal relationship to be found, our findings led us to hypothesize that VAT accumulation may work behind the scenes to cause some of the conditions currently suggested to be risk factors for poor prognosis.", [["cells", "ANATOMY", 27, 32], ["fat", "ANATOMY", 132, 135], ["adipose tissue", "ANATOMY", 238, 252], ["VAT", "ANATOMY", 468, 471], ["SARS", "DISEASE", 0, 4], ["COVID-19", "CHEMICAL", 222, 230], ["COVID-19", "CHEMICAL", 222, 230], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["cells", "CELL", 27, 32], ["Angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 44, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["fat", "TISSUE", 132, 135], ["COVID-19", "GENE_OR_GENE_PRODUCT", 222, 230], ["adipose tissue", "TISSUE", 238, 252], ["VAT", "TISSUE", 468, 471], ["ACE2", "PROTEIN", 76, 80], ["COVID-19", "PROTEIN", 222, 230], ["SARS", "TEST", 0, 4], ["infect cells", "PROBLEM", 20, 32], ["an Angiotensinconverting enzyme", "TEST", 41, 72], ["ectopic reservoirs", "PROBLEM", 147, 165], ["COVID", "TEST", 222, 227], ["our study", "TEST", 364, 373], ["VAT accumulation", "PROBLEM", 468, 484], ["the conditions", "PROBLEM", 529, 543], ["poor prognosis", "PROBLEM", 587, 601], ["adipose tissue", "ANATOMY", 238, 252]]], ["Noteworthy, our results are in line with a previous report suggesting that ectopic fat deposition within the liver is strongly associated to COVID-19 clinical severity among obese subjects [30] .", [["fat", "ANATOMY", 83, 86], ["liver", "ANATOMY", 109, 114], ["fat", "TISSUE", 83, 86], ["liver", "ORGAN", 109, 114], ["ectopic fat deposition within the liver", "PROBLEM", 75, 114], ["COVID", "TEST", 141, 146], ["obese subjects", "PROBLEM", 174, 188], ["ectopic", "OBSERVATION", 75, 82], ["fat deposition", "OBSERVATION", 83, 97], ["liver", "ANATOMY", 109, 114]]], ["However, Non-Alcoholic Fatty Liver Disease is hard to be diagnosed as a chest CT scan only is performed in COVID-19 patients, and our findings are therefore more likely to produce an immediate clinical impact.J o u r n a l P r e -p r o o fAmong the great variety of ectopic fat deposition sites, epicardial fat represents a marker of systemic inflammation [31] , and a role has been hypothesized in the worse evolution of patients with COVID-19 and obesity [32, 33] .", [["Liver", "ANATOMY", 29, 34], ["fat deposition sites", "ANATOMY", 274, 294], ["epicardial fat", "ANATOMY", 296, 310], ["Fatty Liver Disease", "DISEASE", 23, 42], ["inflammation", "DISEASE", 343, 355], ["obesity", "DISEASE", 449, 456], ["Liver", "ORGAN", 29, 34], ["patients", "ORGANISM", 116, 124], ["fat", "TISSUE", 274, 277], ["epicardial fat", "TISSUE", 296, 310], ["patients", "ORGANISM", 422, 430], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 422, 430], ["Non-Alcoholic Fatty Liver Disease", "PROBLEM", 9, 42], ["a chest CT scan", "TEST", 70, 85], ["an immediate clinical impact", "PROBLEM", 180, 208], ["fAmong", "TREATMENT", 238, 244], ["ectopic fat deposition sites", "PROBLEM", 266, 294], ["systemic inflammation", "PROBLEM", 334, 355], ["COVID", "TEST", 436, 441], ["obesity", "PROBLEM", 449, 456], ["Non-Alcoholic", "OBSERVATION_MODIFIER", 9, 22], ["Fatty", "OBSERVATION", 23, 28], ["Liver", "ANATOMY", 29, 34], ["Disease", "OBSERVATION", 35, 42], ["chest", "ANATOMY", 72, 77], ["more likely", "UNCERTAINTY", 157, 168], ["ectopic fat deposition", "OBSERVATION", 266, 288], ["epicardial fat", "OBSERVATION", 296, 310], ["systemic", "OBSERVATION_MODIFIER", 334, 342], ["inflammation", "OBSERVATION", 343, 355]]], ["Interestingly, no correlation was observed with pulmonary disease severity, hinting that this specific reservoir may have no role in the increased need of intubation correlated with obesity, possibly retaining one in cardiac manifestations related to COVID-19, which were not investigated in the present study.J o u r n a l P r e -p r o o fOur study has several limitations.", [["pulmonary", "ANATOMY", 48, 57], ["cardiac", "ANATOMY", 217, 224], ["pulmonary disease", "DISEASE", 48, 65], ["obesity", "DISEASE", 182, 189], ["COVID-19", "CHEMICAL", 251, 259], ["pulmonary", "ORGAN", 48, 57], ["cardiac", "ORGAN", 217, 224], ["pulmonary disease severity", "PROBLEM", 48, 74], ["intubation", "TREATMENT", 155, 165], ["obesity", "PROBLEM", 182, 189], ["COVID", "TEST", 251, 256], ["the present study", "TEST", 292, 309], ["fOur study", "TEST", 339, 349], ["pulmonary", "ANATOMY", 48, 57], ["disease", "OBSERVATION", 58, 65], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["obesity", "OBSERVATION", 182, 189], ["cardiac", "ANATOMY", 217, 224], ["manifestations", "OBSERVATION", 225, 239]]], ["First, the sample size was relatively small, leading to small subgroup sizes upon stratification analysis by age or gender.", [["the sample size", "TEST", 7, 22], ["small subgroup sizes", "PROBLEM", 56, 76], ["stratification analysis", "TEST", 82, 105], ["size", "OBSERVATION_MODIFIER", 18, 22], ["relatively", "OBSERVATION_MODIFIER", 27, 37], ["small", "OBSERVATION_MODIFIER", 38, 43], ["small", "OBSERVATION_MODIFIER", 56, 61], ["subgroup", "OBSERVATION_MODIFIER", 62, 70], ["sizes", "OBSERVATION_MODIFIER", 71, 76]]], ["However, the sample size exceeded that calculated based on a preliminary pilot study, and the posthoc power was 89.2%.", [["the sample size", "TEST", 9, 24], ["a preliminary pilot study", "TEST", 59, 84], ["the posthoc power", "TEST", 90, 107], ["size", "OBSERVATION_MODIFIER", 20, 24]]], ["The nature of this study was retrospective, and only selected biochemical and clinical parameters were available, together with a partial clinical history, J o u r n a l P r e -p r o o f 13 making correction for some possible confounders not possible.", [["this study", "TEST", 14, 24], ["a l P r e -p r o o f", "TREATMENT", 166, 186]]], ["Also, other hard outcomes such as mortality could not be retrieved in the study population, as many patients were transferred to other COVID centers due to governmental directives.", [["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108]]], ["Moreover, anthropometric parameters (i.e. BMI) were unavailable, and a comparison in outcomes prediction was therefore not performed.", [["anthropometric parameters", "TEST", 10, 35], ["BMI", "TEST", 42, 45]]], ["Furthermore, this was not a mechanistic study, and the pathophysiology underlying the findings, possibly involving the inflammatory role of visceral adipocytes, could not be clarified.J o u r n a l P r e -p r o o fSome strengths should also be acknowledged.", [["visceral adipocytes", "ANATOMY", 140, 159], ["visceral adipocytes", "TISSUE", 140, 159], ["visceral adipocytes", "CELL_TYPE", 140, 159], ["a mechanistic study", "TEST", 26, 45], ["visceral adipocytes", "PROBLEM", 140, 159], ["fSome strengths", "PROBLEM", 213, 228], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131], ["visceral adipocytes", "ANATOMY", 140, 159]]], ["The age distribution of our study population was wider than that of many reports.", [["our study population", "TEST", 24, 44]]], ["Moreover, not only the need of intubation was available, but also a categorization between patients in need of subintensive care as opposed to those whose clinical conditions were good enough to be discharged for home monitoring could be retrieved.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["intubation", "TREATMENT", 31, 41], ["subintensive care", "TREATMENT", 111, 128], ["home monitoring", "TEST", 213, 228]]], ["Finally, to the best of our knowledge, this is the first study investigating fat deposition, thus indirectly body composition, in patients with COVID-19, and the assessed markers did not require additional instrumental tests, leading to a possible immediate clinical applicability.J o u r n a l P r e -p r o o fIn conclusion, our preliminary findings suggesting that increased visceral accumulation of fat is associated with worse COVID-19 severity might aid in further confirmatory studies, on the one hand investigating VAT as a useful clinical marker, and on the other hand elucidating the underlying pathophysiology.", [["fat", "ANATOMY", 77, 80], ["body", "ANATOMY", 109, 113], ["visceral", "ANATOMY", 377, 385], ["fat", "ANATOMY", 402, 405], ["VAT", "ANATOMY", 522, 525], ["fat", "TISSUE", 77, 80], ["body", "ORGANISM_SUBDIVISION", 109, 113], ["patients", "ORGANISM", 130, 138], ["visceral", "ORGANISM_SUBDIVISION", 377, 385], ["fat", "TISSUE", 402, 405], ["VAT", "TISSUE", 522, 525], ["patients", "SPECIES", 130, 138], ["fat deposition", "PROBLEM", 77, 91], ["COVID", "TEST", 144, 149], ["additional instrumental tests", "TEST", 195, 224], ["a l P r e -p r o o fIn conclusion", "TEST", 291, 324], ["increased visceral accumulation of fat", "PROBLEM", 367, 405], ["further confirmatory studies", "TEST", 462, 490], ["increased", "OBSERVATION_MODIFIER", 367, 376], ["visceral", "ANATOMY", 377, 385], ["accumulation", "OBSERVATION", 386, 398], ["fat", "OBSERVATION", 402, 405]]]], "2cc33f427a4ab5cad8a56bbb51bb2d661091b1fb": [["The Permeability of the Endothelial BarrierUntil recently, our understanding of endothelial barrier regulation was limited to ADO, which plays an essential role in resealing the gate after the transmigration of inflammatory cells (review: [2] ).", [["Endothelial", "ANATOMY", 24, 35], ["endothelial barrier", "ANATOMY", 80, 99], ["inflammatory cells", "ANATOMY", 211, 229], ["ADO", "CHEMICAL", 126, 129], ["ADO", "CHEMICAL", 126, 129], ["Endothelial", "CELL", 24, 35], ["endothelial barrier", "TISSUE", 80, 99], ["ADO", "SIMPLE_CHEMICAL", 126, 129], ["cells", "CELL", 224, 229], ["inflammatory cells", "CELL_TYPE", 211, 229], ["the Endothelial BarrierUntil", "TREATMENT", 20, 48], ["endothelial barrier regulation", "TREATMENT", 80, 110], ["Permeability", "OBSERVATION_MODIFIER", 4, 16], ["Endothelial", "ANATOMY", 24, 35], ["inflammatory cells", "OBSERVATION", 211, 229]]], ["Then again, we have learned through the first seven chapters of this book that purinergic signaling generally initiates an ATPmediated pro-inflammatory response, which is followed by an ADO-mediated antiinflammatory response.", [["ADO", "CHEMICAL", 186, 189], ["purinergic", "CELL", 79, 89], ["ADO", "SIMPLE_CHEMICAL", 186, 189], ["purinergic signaling", "PROBLEM", 79, 99], ["an ADO-mediated antiinflammatory response", "TREATMENT", 183, 224], ["pro-inflammatory response", "OBSERVATION", 135, 160]]], ["Therefore, several groups tested the impact of P2 receptor agonists on the regulation of endothelial barrier permeability.", [["endothelial barrier", "ANATOMY", 89, 108], ["P2 receptor", "GENE_OR_GENE_PRODUCT", 47, 58], ["endothelial barrier", "TISSUE", 89, 108], ["P2 receptor", "PROTEIN", 47, 58], ["P2 receptor agonists", "TREATMENT", 47, 67], ["endothelial barrier permeability", "TREATMENT", 89, 121], ["endothelial", "ANATOMY", 89, 100], ["barrier permeability", "OBSERVATION", 101, 121]]], ["While the use of stable analogues and P2 receptor antagonists clearly demonstrated the sensitivity of the barrier to ATP, these studies provided contradictory conclusions (review: [1] ).", [["ATP", "CHEMICAL", 117, 120], ["ATP", "CHEMICAL", 117, 120], ["P2 receptor antagonists", "GENE_OR_GENE_PRODUCT", 38, 61], ["ATP", "SIMPLE_CHEMICAL", 117, 120], ["stable analogues and P2 receptor antagonists", "TREATMENT", 17, 61], ["these studies", "TEST", 122, 135]]], ["In this section, we provide a thorough analysis of all data which reconciles the literature under a unifying concept: opposing regulations of barrier permeability by P2Y 1 Rs (ADP) and P2Y 2 Rs (ATP), depending on local ATP/ADP concentrations.", [["ADP", "CHEMICAL", 176, 179], ["ATP", "CHEMICAL", 195, 198], ["ATP", "CHEMICAL", 220, 223], ["ADP", "CHEMICAL", 224, 227], ["ADP", "CHEMICAL", 176, 179], ["ATP", "CHEMICAL", 195, 198], ["ATP", "CHEMICAL", 220, 223], ["ADP", "CHEMICAL", 224, 227], ["barrier", "TISSUE", 142, 149], ["P2Y 1 Rs", "GENE_OR_GENE_PRODUCT", 166, 174], ["ADP", "SIMPLE_CHEMICAL", 176, 179], ["P2Y 2 Rs", "SIMPLE_CHEMICAL", 185, 193], ["ATP", "SIMPLE_CHEMICAL", 195, 198], ["ATP", "SIMPLE_CHEMICAL", 220, 223], ["ADP", "SIMPLE_CHEMICAL", 224, 227], ["a thorough analysis", "TEST", 28, 47], ["all data", "TEST", 51, 59], ["barrier permeability", "TREATMENT", 142, 162], ["ADP", "TEST", 176, 179], ["P2Y", "TEST", 185, 188], ["ATP", "TEST", 195, 198], ["local ATP/ADP concentrations", "TREATMENT", 214, 242], ["barrier permeability", "OBSERVATION_MODIFIER", 142, 162]]], ["While these studies were conducted on various endothelia, these receptors are co-localized on pulmonary endothelial cells [3] .The Permeability of the Endothelial BarrierIn human pulmonary artery and lung microvascular endothelial cultures, the low micromolar ATP concentrations induced a dose-dependent increase in transendothelial electrical resistance (TER) [4] .", [["endothelia", "ANATOMY", 46, 56], ["pulmonary endothelial cells", "ANATOMY", 94, 121], ["Endothelial", "ANATOMY", 151, 162], ["pulmonary artery", "ANATOMY", 179, 195], ["lung microvascular endothelial cultures", "ANATOMY", 200, 239], ["transendothelial", "ANATOMY", 316, 332], ["ATP", "CHEMICAL", 260, 263], ["ATP", "CHEMICAL", 260, 263], ["endothelia", "TISSUE", 46, 56], ["pulmonary endothelial cells", "CELL", 94, 121], ["Endothelial", "CELL", 151, 162], ["human", "ORGANISM", 173, 178], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 179, 195], ["lung microvascular endothelial cultures", "CELL", 200, 239], ["ATP", "SIMPLE_CHEMICAL", 260, 263], ["pulmonary endothelial cells", "CELL_TYPE", 94, 121], ["Endothelial BarrierIn human pulmonary artery and lung microvascular endothelial cultures", "CELL_LINE", 151, 239], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["these studies", "TEST", 6, 19], ["the Endothelial BarrierIn human pulmonary artery", "TREATMENT", 147, 195], ["lung microvascular endothelial cultures", "TEST", 200, 239], ["the low micromolar ATP concentrations", "PROBLEM", 241, 278], ["transendothelial electrical resistance", "TREATMENT", 316, 354], ["pulmonary", "ANATOMY", 94, 103], ["endothelial cells", "OBSERVATION", 104, 121], ["Endothelial", "ANATOMY_MODIFIER", 151, 162], ["pulmonary artery", "ANATOMY", 179, 195], ["lung", "ANATOMY", 200, 204], ["microvascular", "ANATOMY_MODIFIER", 205, 218], ["endothelial", "ANATOMY", 219, 230], ["low micromolar", "OBSERVATION_MODIFIER", 245, 259], ["ATP concentrations", "OBSERVATION", 260, 278], ["dependent", "OBSERVATION_MODIFIER", 294, 303], ["increase", "OBSERVATION_MODIFIER", 304, 312], ["transendothelial electrical resistance", "OBSERVATION", 316, 354]]], ["Likewise, 10 mM ATP reduced the thrombin-mediated barrier permeability of cultured human umbilical vein endothelial cells [5] .", [["barrier", "ANATOMY", 50, 57], ["human umbilical vein endothelial cells", "ANATOMY", 83, 121], ["ATP", "CHEMICAL", 16, 19], ["ATP", "CHEMICAL", 16, 19], ["ATP", "SIMPLE_CHEMICAL", 16, 19], ["thrombin", "GENE_OR_GENE_PRODUCT", 32, 40], ["barrier", "TISSUE", 50, 57], ["human umbilical vein endothelial cells", "CELL", 83, 121], ["thrombin", "PROTEIN", 32, 40], ["cultured human umbilical vein endothelial cells", "CELL_LINE", 74, 121], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["the thrombin-mediated barrier permeability", "TREATMENT", 28, 70], ["10 mM", "OBSERVATION_MODIFIER", 10, 15], ["thrombin", "OBSERVATION", 32, 40], ["umbilical vein", "ANATOMY", 89, 103], ["endothelial cells", "OBSERVATION", 104, 121]]], ["Similar data were obtained with non-hydrolysable ATP analogs known to interact with P2Y receptors, ruling out the possibility that these effects were mediated by ADO after ATP metabolism by the CD39-CD73 tandem [4] .", [["ATP", "CHEMICAL", 49, 52], ["ADO", "CHEMICAL", 162, 165], ["ATP", "CHEMICAL", 172, 175], ["ATP", "CHEMICAL", 49, 52], ["ADO", "CHEMICAL", 162, 165], ["ATP", "CHEMICAL", 172, 175], ["ATP", "SIMPLE_CHEMICAL", 49, 52], ["P2Y receptors", "GENE_OR_GENE_PRODUCT", 84, 97], ["ADO", "SIMPLE_CHEMICAL", 162, 165], ["ATP", "SIMPLE_CHEMICAL", 172, 175], ["CD39", "GENE_OR_GENE_PRODUCT", 194, 198], ["CD73", "GENE_OR_GENE_PRODUCT", 199, 203], ["P2Y receptors", "PROTEIN", 84, 97], ["CD39", "PROTEIN", 194, 198], ["CD73", "PROTEIN", 199, 203], ["non-hydrolysable ATP analogs", "PROBLEM", 32, 60], ["P2Y receptors", "TREATMENT", 84, 97], ["ATP metabolism", "TEST", 172, 186], ["the CD39", "TEST", 190, 198]]], ["This ATP concentration also inhibited the passage of macromolecules across endothelial monolayers, thus labeling this nucleotide as barrier protective [6] .", [["endothelial monolayers", "ANATOMY", 75, 97], ["ATP", "CHEMICAL", 5, 8], ["nucleotide", "CHEMICAL", 118, 128], ["ATP", "CHEMICAL", 5, 8], ["nucleotide", "CHEMICAL", 118, 128], ["ATP", "SIMPLE_CHEMICAL", 5, 8], ["endothelial monolayers", "CELL", 75, 97], ["endothelial monolayers", "CELL_TYPE", 75, 97], ["This ATP concentration", "PROBLEM", 0, 22], ["macromolecules across endothelial monolayers", "PROBLEM", 53, 97], ["labeling this nucleotide as barrier protective", "TREATMENT", 104, 150], ["endothelial monolayers", "OBSERVATION", 75, 97]]], ["Pharmacological analysis ascribed this response to P2Y 2 Rs which initiates a signaling cascade involving the activation of phospholipase C (PLC), but not PKC or Ca 2+ mobilization.", [["Ca", "CHEMICAL", 162, 164], ["Ca 2+", "CHEMICAL", 162, 167], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 51, 59], ["phospholipase C", "GENE_OR_GENE_PRODUCT", 124, 139], ["PLC", "GENE_OR_GENE_PRODUCT", 141, 144], ["PKC", "GENE_OR_GENE_PRODUCT", 155, 158], ["Ca 2+", "SIMPLE_CHEMICAL", 162, 167], ["P2Y 2 Rs", "PROTEIN", 51, 59], ["phospholipase C", "PROTEIN", 124, 139], ["PLC", "PROTEIN", 141, 144], ["PKC", "PROTEIN", 155, 158], ["Pharmacological analysis", "TEST", 0, 24], ["P2Y 2 Rs", "TEST", 51, 59], ["a signaling cascade", "PROBLEM", 76, 95], ["phospholipase C (PLC)", "PROBLEM", 124, 145]]], ["Incidentally, Kolosova et al. demonstrated that the enhancement of barrier integrity by low micromolar ATP involves reorganization of the intercellular tight junctions, which occurs independently of Ca 2+ mobilization or ERK1/2 [4] ( Fig. 8.1 ).", [["barrier", "ANATOMY", 67, 74], ["intercellular tight junctions", "ANATOMY", 138, 167], ["ATP", "CHEMICAL", 103, 106], ["Ca", "CHEMICAL", 199, 201], ["ATP", "CHEMICAL", 103, 106], ["Ca 2+", "CHEMICAL", 199, 204], ["barrier", "TISSUE", 67, 74], ["ATP", "SIMPLE_CHEMICAL", 103, 106], ["intercellular", "CELLULAR_COMPONENT", 138, 151], ["tight junctions", "CELLULAR_COMPONENT", 152, 167], ["Ca 2+", "SIMPLE_CHEMICAL", 199, 204], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 221, 227], ["barrier integrity", "TREATMENT", 67, 84], ["low micromolar ATP", "PROBLEM", 88, 106], ["Ca", "TEST", 199, 201], ["ERK1/2", "TEST", 221, 227], ["Fig.", "TEST", 234, 238], ["enhancement", "OBSERVATION_MODIFIER", 52, 63], ["barrier integrity", "OBSERVATION_MODIFIER", 67, 84], ["low micromolar", "OBSERVATION_MODIFIER", 88, 102], ["intercellular", "ANATOMY_MODIFIER", 138, 151], ["tight junctions", "OBSERVATION", 152, 167]]], ["The signaling cascade is reminiscent of P2Y 2 R-mediated induction of cell migration during epithelial repair (see Chap 6 for details).", [["cell", "ANATOMY", 70, 74], ["epithelial", "ANATOMY", 92, 102], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 40, 47], ["cell", "CELL", 70, 74], ["epithelial", "TISSUE", 92, 102], ["P2Y 2 R", "PROTEIN", 40, 47], ["The signaling cascade", "PROBLEM", 0, 21], ["P2Y", "PROBLEM", 40, 43], ["cell migration", "TREATMENT", 70, 84], ["epithelial repair", "TREATMENT", 92, 109], ["signaling cascade", "OBSERVATION", 4, 21], ["cell migration", "OBSERVATION", 70, 84], ["epithelial repair", "OBSERVATION", 92, 109]]], ["The P2Y 2 Rs located near tight junctions are coupled to G proteins G q or G i2 (not G 12 or G 13 ), which induce protein kinase A (PKA) activation, leading to the dephosphorylation of myosin light chain, and phosphorylation of vasodilator-stimulated phosphoprotein (VASP).", [["tight junctions", "ANATOMY", 26, 41], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 4, 12], ["tight junctions", "CELLULAR_COMPONENT", 26, 41], ["G proteins G q", "GENE_OR_GENE_PRODUCT", 57, 71], ["G i2", "GENE_OR_GENE_PRODUCT", 75, 79], ["G 12", "GENE_OR_GENE_PRODUCT", 85, 89], ["G 13", "GENE_OR_GENE_PRODUCT", 93, 97], ["protein kinase A", "GENE_OR_GENE_PRODUCT", 114, 130], ["PKA", "GENE_OR_GENE_PRODUCT", 132, 135], ["myosin light chain", "GENE_OR_GENE_PRODUCT", 185, 203], ["vasodilator-stimulated phosphoprotein", "GENE_OR_GENE_PRODUCT", 228, 265], ["VASP", "GENE_OR_GENE_PRODUCT", 267, 271], ["P2Y 2 Rs", "PROTEIN", 4, 12], ["G proteins", "PROTEIN", 57, 67], ["G q", "PROTEIN", 68, 71], ["G i2", "PROTEIN", 75, 79], ["G 12", "PROTEIN", 85, 89], ["G 13", "PROTEIN", 93, 97], ["protein kinase A", "PROTEIN", 114, 130], ["PKA", "PROTEIN", 132, 135], ["myosin light chain", "PROTEIN", 185, 203], ["vasodilator-stimulated phosphoprotein", "PROTEIN", 228, 265], ["VASP", "PROTEIN", 267, 271], ["G proteins", "TEST", 57, 67], ["G i2", "TEST", 75, 79], ["G", "TEST", 85, 86], ["G", "TEST", 93, 94], ["protein kinase A (PKA) activation", "PROBLEM", 114, 147], ["myosin light chain", "TREATMENT", 185, 203], ["phosphorylation of vasodilator", "TREATMENT", 209, 239], ["tight junctions", "OBSERVATION", 26, 41]]], ["When phosphorylated, VASP inhibits actin polymerization and the formation of stress fibers that would disrupt the barrier.", [["stress fibers", "ANATOMY", 77, 90], ["VASP", "GENE_OR_GENE_PRODUCT", 21, 25], ["actin", "GENE_OR_GENE_PRODUCT", 35, 40], ["stress fibers", "CELLULAR_COMPONENT", 77, 90], ["VASP", "PROTEIN", 21, 25], ["actin", "PROTEIN", 35, 40], ["actin polymerization", "TREATMENT", 35, 55], ["stress fibers", "PROBLEM", 77, 90], ["actin polymerization", "OBSERVATION", 35, 55], ["stress fibers", "OBSERVATION", 77, 90]]], ["A second barrier protects the airways against excess fluid accumulation: the epithelial barrier.", [["airways", "ANATOMY", 30, 37], ["fluid", "ANATOMY", 53, 58], ["epithelial barrier", "ANATOMY", 77, 95], ["airways", "MULTI-TISSUE_STRUCTURE", 30, 37], ["fluid", "ORGANISM_SUBSTANCE", 53, 58], ["epithelial barrier", "TISSUE", 77, 95], ["A second barrier", "TREATMENT", 0, 16], ["excess fluid accumulation", "PROBLEM", 46, 71], ["the epithelial barrier", "TREATMENT", 73, 95], ["airways", "ANATOMY", 30, 37], ["fluid accumulation", "OBSERVATION", 53, 71], ["epithelial barrier", "OBSERVATION", 77, 95]]], ["Alveolar cells express A 1 Rs and A 2A Rs which regulate fluid fluxes in and out of the airspace along ion gradients generated by the CFTR chloride (Cl -) channel and the ENaC sodium (Na + ) channel.", [["Alveolar cells", "ANATOMY", 0, 14], ["fluid", "ANATOMY", 57, 62], ["airspace", "ANATOMY", 88, 96], ["chloride", "CHEMICAL", 139, 147], ["Cl", "CHEMICAL", 149, 151], ["sodium", "CHEMICAL", 176, 182], ["Na", "CHEMICAL", 184, 186], ["chloride", "CHEMICAL", 139, 147], ["Cl", "CHEMICAL", 149, 151], ["sodium", "CHEMICAL", 176, 182], ["Na + )", "CHEMICAL", 184, 190], ["Alveolar cells", "CELL", 0, 14], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 23, 29], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 34, 41], ["airspace", "MULTI-TISSUE_STRUCTURE", 88, 96], ["CFTR", "GENE_OR_GENE_PRODUCT", 134, 138], ["chloride", "SIMPLE_CHEMICAL", 139, 147], ["ENaC sodium", "SIMPLE_CHEMICAL", 171, 182], ["Na +", "SIMPLE_CHEMICAL", 184, 188], ["Alveolar cells", "CELL_TYPE", 0, 14], ["A 1 Rs and A 2A Rs", "PROTEIN", 23, 41], ["CFTR chloride (Cl -) channel", "PROTEIN", 134, 162], ["ENaC sodium (Na + ) channel", "PROTEIN", 171, 198], ["Alveolar cells", "TEST", 0, 14], ["A 2A Rs", "TEST", 34, 41], ["fluid fluxes", "TEST", 57, 69], ["the CFTR chloride", "TEST", 130, 147], ["the ENaC sodium", "TEST", 167, 182], ["fluid fluxes", "OBSERVATION", 57, 69], ["airspace", "OBSERVATION", 88, 96]]], ["During viral infection, pulmonary edema is caused by the production, release and conversion of UTP into UDP, which activates P2Y 6 Rs to inhibit Na + and fluid absorption via ENaCThe Permeability of the Endothelial BarrierThe barrier resistance of human umbilical vein endothelial cells is reduced by selective agonists of P2Y 1 Rs [7] .", [["pulmonary edema", "ANATOMY", 24, 39], ["Endothelial Barrier", "ANATOMY", 203, 222], ["human umbilical vein endothelial cells", "ANATOMY", 248, 286], ["viral infection", "DISEASE", 7, 22], ["pulmonary edema", "DISEASE", 24, 39], ["UTP", "CHEMICAL", 95, 98], ["UDP", "CHEMICAL", 104, 107], ["Na", "CHEMICAL", 145, 147], ["UTP", "CHEMICAL", 95, 98], ["UDP", "CHEMICAL", 104, 107], ["Na +", "CHEMICAL", 145, 149], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 24, 39], ["UTP", "SIMPLE_CHEMICAL", 95, 98], ["UDP", "SIMPLE_CHEMICAL", 104, 107], ["P2Y 6 Rs", "GENE_OR_GENE_PRODUCT", 125, 133], ["Na +", "SIMPLE_CHEMICAL", 145, 149], ["Endothelial Barrier", "TISSUE", 203, 222], ["human umbilical vein endothelial cells", "CELL", 248, 286], ["P2Y 1 Rs", "GENE_OR_GENE_PRODUCT", 323, 331], ["P2Y 6 Rs", "PROTEIN", 125, 133], ["human umbilical vein endothelial cells", "CELL_TYPE", 248, 286], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 248, 253], ["viral infection", "PROBLEM", 7, 22], ["pulmonary edema", "PROBLEM", 24, 39], ["UTP into UDP", "PROBLEM", 95, 107], ["P2Y", "TEST", 125, 128], ["Na", "TEST", 145, 147], ["fluid absorption", "TEST", 154, 170], ["ENaCThe Permeability", "TREATMENT", 175, 195], ["the Endothelial Barrier", "TREATMENT", 199, 222], ["The barrier resistance of human umbilical vein endothelial cells", "TREATMENT", 222, 286], ["P2Y", "TEST", 323, 326], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["pulmonary", "ANATOMY", 24, 33], ["edema", "OBSERVATION", 34, 39], ["fluid absorption", "OBSERVATION", 154, 170], ["Endothelial", "ANATOMY", 203, 214], ["barrier resistance", "OBSERVATION", 226, 244], ["umbilical vein", "ANATOMY", 254, 268], ["endothelial cells", "OBSERVATION", 269, 286]]], ["Contrary to P2Y 2 Rs, the signaling mechanism is Ca 2+ -dependent [7] and requires myosin light chain phosphorylation [8] .", [["Ca", "CHEMICAL", 49, 51], ["Ca 2+", "CHEMICAL", 49, 54], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 12, 20], ["Ca 2+", "SIMPLE_CHEMICAL", 49, 54], ["myosin light chain", "GENE_OR_GENE_PRODUCT", 83, 101], ["P2Y 2 Rs", "PROTEIN", 12, 20], ["myosin light chain", "PROTEIN", 83, 101], ["P2Y", "TEST", 12, 15], ["Ca", "TEST", 49, 51], ["myosin light chain phosphorylation", "TREATMENT", 83, 117]]], ["Incidentally, the use of ionomycin to trigger Ca 2+ entry into the cells facilitated the passage of albumin across aortic endothelial monolayers [6] .", [["cells", "ANATOMY", 67, 72], ["aortic endothelial monolayers", "ANATOMY", 115, 144], ["ionomycin", "CHEMICAL", 25, 34], ["Ca", "CHEMICAL", 46, 48], ["ionomycin", "CHEMICAL", 25, 34], ["Ca 2+", "CHEMICAL", 46, 51], ["ionomycin", "SIMPLE_CHEMICAL", 25, 34], ["Ca 2+", "SIMPLE_CHEMICAL", 46, 51], ["cells", "CELL", 67, 72], ["albumin", "GENE_OR_GENE_PRODUCT", 100, 107], ["aortic endothelial monolayers", "CELL", 115, 144], ["albumin", "PROTEIN", 100, 107], ["ionomycin", "TREATMENT", 25, 34], ["Ca", "TEST", 46, 48], ["albumin across aortic endothelial monolayers", "TREATMENT", 100, 144], ["aortic endothelial", "ANATOMY", 115, 133]]], ["On the other hand, this receptor is only activated by ADP, released at high micromolar concentrations by platelets and red blood cells.", [["platelets", "ANATOMY", 105, 114], ["red blood cells", "ANATOMY", 119, 134], ["ADP", "CHEMICAL", 54, 57], ["ADP", "CHEMICAL", 54, 57], ["ADP", "SIMPLE_CHEMICAL", 54, 57], ["platelets", "CELL", 105, 114], ["red blood cells", "CELL", 119, 134], ["platelets", "CELL_TYPE", 105, 114], ["red blood cells", "CELL_TYPE", 119, 134], ["ADP", "TEST", 54, 57], ["platelets", "TEST", 105, 114], ["red blood cells", "TEST", 119, 134], ["blood cells", "OBSERVATION", 123, 134]]], ["While CD39 expressed on the endothelial surface generates ADP from ATP, the enzyme does not allow this product to accumulate significantly before further dephosphorylation into AMP.", [["endothelial surface", "ANATOMY", 28, 47], ["ADP", "CHEMICAL", 58, 61], ["ATP", "CHEMICAL", 67, 70], ["AMP", "CHEMICAL", 177, 180], ["ADP", "CHEMICAL", 58, 61], ["ATP", "CHEMICAL", 67, 70], ["AMP", "CHEMICAL", 177, 180], ["CD39", "GENE_OR_GENE_PRODUCT", 6, 10], ["endothelial surface", "CELLULAR_COMPONENT", 28, 47], ["ADP", "SIMPLE_CHEMICAL", 58, 61], ["ATP", "SIMPLE_CHEMICAL", 67, 70], ["AMP", "SIMPLE_CHEMICAL", 177, 180], ["CD39", "PROTEIN", 6, 10], ["ATP", "PROBLEM", 67, 70], ["the enzyme", "TEST", 72, 82], ["further dephosphorylation into AMP", "TREATMENT", 146, 180]]], ["This is an important point, since the affinity of P2Y 1 Rs for ADP (EC 50 \u00bc 8 mM) is considerably lower than P2Y 2 Rs for ATP (EC 50 \u00bc 0.2 mM) (review: [9] ).", [["ADP", "CHEMICAL", 63, 66], ["ATP", "CHEMICAL", 122, 125], ["ADP", "CHEMICAL", 63, 66], ["ATP", "CHEMICAL", 122, 125], ["P2Y 1 Rs", "GENE_OR_GENE_PRODUCT", 50, 58], ["ADP", "SIMPLE_CHEMICAL", 63, 66], ["P2Y 2 Rs", "SIMPLE_CHEMICAL", 109, 117], ["ATP", "SIMPLE_CHEMICAL", 122, 125], ["ADP", "TEST", 63, 66], ["EC", "TEST", 68, 70], ["P2Y", "TEST", 109, 112], ["ATP", "TEST", 122, 125], ["EC", "TEST", 127, 129]]], ["Under normal conditions, low micromolar ATP would prevent pulmonary edema primarily via P2Y 2 Rs.", [["pulmonary", "ANATOMY", 58, 67], ["ATP", "CHEMICAL", 40, 43], ["pulmonary edema", "DISEASE", 58, 73], ["ATP", "CHEMICAL", 40, 43], ["ATP", "SIMPLE_CHEMICAL", 40, 43], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 58, 73], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 88, 96], ["P2Y 2 Rs", "PROTEIN", 88, 96], ["low micromolar ATP", "PROBLEM", 25, 43], ["pulmonary edema", "PROBLEM", 58, 73], ["normal conditions", "OBSERVATION", 6, 23], ["low micromolar", "OBSERVATION_MODIFIER", 25, 39], ["pulmonary", "ANATOMY", 58, 67], ["edema", "OBSERVATION", 68, 73]]], ["On the other hand, massive local ADP release from platelets or red blood cells squeezing into the pulmonary vascular bed would transiently raise barrier permeability via P2Y 1 Rs, before the nucleotide is dephosphorylated by CD39.", [["platelets", "ANATOMY", 50, 59], ["red blood cells", "ANATOMY", 63, 78], ["pulmonary vascular bed", "ANATOMY", 98, 120], ["barrier", "ANATOMY", 145, 152], ["ADP", "CHEMICAL", 33, 36], ["nucleotide", "CHEMICAL", 191, 201], ["ADP", "CHEMICAL", 33, 36], ["nucleotide", "CHEMICAL", 191, 201], ["ADP", "SIMPLE_CHEMICAL", 33, 36], ["platelets", "CELL", 50, 59], ["red blood cells", "CELL", 63, 78], ["pulmonary vascular bed", "MULTI-TISSUE_STRUCTURE", 98, 120], ["barrier", "TISSUE", 145, 152], ["P2Y 1 Rs", "GENE_OR_GENE_PRODUCT", 170, 178], ["CD39", "GENE_OR_GENE_PRODUCT", 225, 229], ["platelets", "CELL_TYPE", 50, 59], ["red blood cells", "CELL_TYPE", 63, 78], ["P2Y 1 Rs", "PROTEIN", 170, 178], ["CD39", "PROTEIN", 225, 229], ["massive local ADP release", "TREATMENT", 19, 44], ["platelets", "PROBLEM", 50, 59], ["red blood cells", "TREATMENT", 63, 78], ["massive", "OBSERVATION_MODIFIER", 19, 26], ["pulmonary vascular", "ANATOMY", 98, 116]]], ["In vascular beds, P2Y 1 Rs have been shown to facilitate the passage of circulating cells through the narrow vessels by inducing nitric oxide-mediated vasodilatation [10] .", [["vascular beds", "ANATOMY", 3, 16], ["cells", "ANATOMY", 84, 89], ["vessels", "ANATOMY", 109, 116], ["nitric oxide", "CHEMICAL", 129, 141], ["nitric oxide", "CHEMICAL", 129, 141], ["vascular", "MULTI-TISSUE_STRUCTURE", 3, 11], ["P2Y 1 Rs", "GENE_OR_GENE_PRODUCT", 18, 26], ["cells", "CELL", 84, 89], ["vessels", "MULTI-TISSUE_STRUCTURE", 109, 116], ["nitric oxide", "SIMPLE_CHEMICAL", 129, 141], ["P2Y 1 Rs", "PROTEIN", 18, 26], ["circulating cells", "CELL_TYPE", 72, 89], ["P2Y 1 Rs", "TEST", 18, 26], ["nitric oxide-mediated vasodilatation", "TREATMENT", 129, 165], ["vascular beds", "ANATOMY", 3, 16], ["narrow", "OBSERVATION_MODIFIER", 102, 108], ["vessels", "ANATOMY", 109, 116]]], ["However, conditions reducing CD39 activity, such as hypoxia/oxidative stress (see Chap.", [["hypoxia", "DISEASE", 52, 59], ["CD39", "GENE_OR_GENE_PRODUCT", 29, 33], ["CD39", "PROTEIN", 29, 33], ["hypoxia", "PROBLEM", 52, 59], ["oxidative stress", "PROBLEM", 60, 76]]], ["4), may overwhelm the protective effects of P2Y 2 Rs and cause pulmonary edema.The Permeability of the Endothelial BarrierThe highly efficient surface conversion of ATP and ADP into ADO generates a secondary wave of purinergic signaling for the regulation of endothelial barrier integrity.", [["pulmonary", "ANATOMY", 63, 72], ["Endothelial Barrier", "ANATOMY", 103, 122], ["surface", "ANATOMY", 143, 150], ["endothelial barrier", "ANATOMY", 259, 278], ["P2Y 2 Rs", "CHEMICAL", 44, 52], ["pulmonary edema", "DISEASE", 63, 78], ["ATP", "CHEMICAL", 165, 168], ["ADP", "CHEMICAL", 173, 176], ["ADO", "CHEMICAL", 182, 185], ["ATP", "CHEMICAL", 165, 168], ["ADP", "CHEMICAL", 173, 176], ["ADO", "CHEMICAL", 182, 185], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 44, 52], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 63, 78], ["Endothelial Barrier", "TISSUE", 103, 122], ["surface", "CELLULAR_COMPONENT", 143, 150], ["ATP", "SIMPLE_CHEMICAL", 165, 168], ["ADP", "SIMPLE_CHEMICAL", 173, 176], ["ADO", "SIMPLE_CHEMICAL", 182, 185], ["purinergic", "SIMPLE_CHEMICAL", 216, 226], ["endothelial barrier", "TISSUE", 259, 278], ["P2Y 2 Rs", "TREATMENT", 44, 52], ["pulmonary edema", "PROBLEM", 63, 78], ["the Endothelial Barrier", "TREATMENT", 99, 122], ["ATP and ADP into ADO", "TREATMENT", 165, 185], ["purinergic signaling", "PROBLEM", 216, 236], ["endothelial barrier integrity", "TREATMENT", 259, 288], ["pulmonary", "ANATOMY", 63, 72], ["edema", "OBSERVATION", 73, 78], ["Permeability", "OBSERVATION_MODIFIER", 83, 95], ["Endothelial", "ANATOMY", 103, 114], ["purinergic signaling", "OBSERVATION", 216, 236], ["endothelial", "ANATOMY", 259, 270]]], ["An in vivo study comparing the extent of hypoxia-induced vascular leakage among the knockout mice for each ADO receptor revealed that only the A 2B R \u00c0/\u00c0 mice respond to hypoxia by significantly worse lung edema than wildtype mice, which was prevented by the A 2B R agonist, BAY60-6583 [11] .", [["vascular", "ANATOMY", 57, 65], ["lung", "ANATOMY", 201, 205], ["hypoxia", "DISEASE", 41, 48], ["ADO", "CHEMICAL", 107, 110], ["hypoxia", "DISEASE", 170, 177], ["lung edema", "DISEASE", 201, 211], ["BAY60-6583", "CHEMICAL", 275, 285], ["BAY60-6583", "CHEMICAL", 275, 285], ["vascular", "MULTI-TISSUE_STRUCTURE", 57, 65], ["mice", "ORGANISM", 93, 97], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 107, 119], ["A 2B", "ORGANISM", 143, 147], ["R", "GENE_OR_GENE_PRODUCT", 148, 149], ["lung", "ORGAN", 201, 205], ["edema", "PATHOLOGICAL_FORMATION", 206, 211], ["mice", "ORGANISM", 226, 230], ["A 2B R", "GENE_OR_GENE_PRODUCT", 259, 265], ["BAY60-6583", "SIMPLE_CHEMICAL", 275, 285], ["ADO receptor", "PROTEIN", 107, 119], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 226, 230], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 226, 230], ["An in vivo study", "TEST", 0, 16], ["hypoxia", "PROBLEM", 41, 48], ["induced vascular leakage", "PROBLEM", 49, 73], ["each ADO receptor", "TEST", 102, 119], ["hypoxia", "PROBLEM", 170, 177], ["significantly worse lung edema", "PROBLEM", 181, 211], ["BAY60", "TEST", 275, 280], ["hypoxia", "OBSERVATION", 41, 48], ["vascular", "ANATOMY", 57, 65], ["leakage", "OBSERVATION", 66, 73], ["hypoxia", "OBSERVATION", 170, 177], ["significantly", "OBSERVATION_MODIFIER", 181, 194], ["worse", "OBSERVATION_MODIFIER", 195, 200], ["lung", "ANATOMY", 201, 205], ["edema", "OBSERVATION", 206, 211]]], ["The capacity of A 2B R activation to raise endothelial TER was confirmed on human microvascular endothelial cultures using an antagonist (PSB 1115) and by RNA silencing technique [11] .", [["endothelial", "ANATOMY", 43, 54], ["microvascular endothelial cultures", "ANATOMY", 82, 116], ["PSB 1115", "CHEMICAL", 138, 146], ["PSB 1115", "CHEMICAL", 138, 146], ["A 2B R", "GENE_OR_GENE_PRODUCT", 16, 22], ["endothelial", "CELL", 43, 54], ["human", "ORGANISM", 76, 81], ["microvascular endothelial cultures", "CELL", 82, 116], ["human microvascular endothelial cultures", "CELL_LINE", 76, 116], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["A 2B R activation", "TREATMENT", 16, 33], ["endothelial TER", "PROBLEM", 43, 58], ["human microvascular endothelial cultures", "TEST", 76, 116], ["an antagonist (PSB", "TREATMENT", 123, 141], ["microvascular endothelial", "ANATOMY", 82, 107]]], ["In fact, Rounds et al. recently showed that A 2A Rs, A 2B Rs and ADO transporters work in concert to prevent pulmonary edema through endothelial barrier enhancement [12] .", [["pulmonary", "ANATOMY", 109, 118], ["endothelial barrier", "ANATOMY", 133, 152], ["ADO", "CHEMICAL", 65, 68], ["pulmonary edema", "DISEASE", 109, 124], ["ADO", "CHEMICAL", 65, 68], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 44, 51], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 53, 60], ["ADO transporters", "GENE_OR_GENE_PRODUCT", 65, 81], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 109, 124], ["endothelial barrier", "TISSUE", 133, 152], ["A 2A Rs, A 2B Rs", "PROTEIN", 44, 60], ["A 2B Rs", "TREATMENT", 53, 60], ["ADO transporters work", "TREATMENT", 65, 86], ["pulmonary edema", "PROBLEM", 109, 124], ["endothelial barrier enhancement", "TREATMENT", 133, 164], ["pulmonary", "ANATOMY", 109, 118], ["edema", "OBSERVATION", 119, 124], ["endothelial", "ANATOMY", 133, 144]]], ["The adenosine deaminase inhibitor, pentostatin, raised surface ADO levels by tenfold, which enhanced the formation of endothelial adherens junction and focal adhesion through Rac1 GTPase activation.", [["surface", "ANATOMY", 55, 62], ["endothelial adherens junction", "ANATOMY", 118, 147], ["adenosine", "CHEMICAL", 4, 13], ["pentostatin", "CHEMICAL", 35, 46], ["ADO", "CHEMICAL", 63, 66], ["adenosine", "CHEMICAL", 4, 13], ["pentostatin", "CHEMICAL", 35, 46], ["ADO", "CHEMICAL", 63, 66], ["adenosine deaminase", "GENE_OR_GENE_PRODUCT", 4, 23], ["pentostatin", "SIMPLE_CHEMICAL", 35, 46], ["ADO", "SIMPLE_CHEMICAL", 63, 66], ["endothelial adherens junction", "CELLULAR_COMPONENT", 118, 147], ["focal adhesion", "CELLULAR_COMPONENT", 152, 166], ["Rac1", "GENE_OR_GENE_PRODUCT", 175, 179], ["Rac1", "PROTEIN", 175, 179], ["GTPase", "PROTEIN", 180, 186], ["The adenosine deaminase inhibitor", "TREATMENT", 0, 33], ["pentostatin", "TREATMENT", 35, 46], ["raised surface ADO levels", "TEST", 48, 73], ["endothelial adherens junction", "TREATMENT", 118, 147], ["focal adhesion through Rac1 GTPase activation", "PROBLEM", 152, 197], ["adenosine deaminase", "OBSERVATION", 4, 23], ["endothelial", "ANATOMY", 118, 129], ["adherens junction", "OBSERVATION", 130, 147], ["focal", "OBSERVATION_MODIFIER", 152, 157], ["adhesion", "OBSERVATION_MODIFIER", 158, 166], ["Rac1 GTPase activation", "OBSERVATION", 175, 197]]], ["The fact that A 1 Rs and A 3 Rs were ineffective at regulating endothelial barrier permeability supports the well-established notion that barrier resistance is cyclic AMP (cAMP)-dependent (review: [2] ).", [["endothelial barrier", "ANATOMY", 63, 82], ["AMP", "CHEMICAL", 167, 170], ["cAMP", "CHEMICAL", 172, 176], ["cyclic AMP", "CHEMICAL", 160, 170], ["cAMP", "CHEMICAL", 172, 176], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 14, 20], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 25, 31], ["endothelial barrier", "TISSUE", 63, 82], ["barrier", "TISSUE", 138, 145], ["AMP", "SIMPLE_CHEMICAL", 167, 170], ["cAMP", "SIMPLE_CHEMICAL", 172, 176], ["A 3 Rs", "TREATMENT", 25, 31], ["endothelial barrier permeability", "TREATMENT", 63, 95]]], ["Under baseline conditions, ADO-mediated TER would be maintained by the high-affinity A 2A Rs (EC 50 \u00bc 0.56\u00c00.95 mM) (review: [9] ), whereas crisis situations raising circulating ADO levels (i.e. hypoxia or infection) would recruit the low-affinity A 2B Rs (EC 50 \u00bc 16.2\u00c064.1 mM) (review: [9] ) for additional protection against vascular leakage.The Permeability of the Endothelial BarrierThe therapeutic potential of A 2B R agonists for lung edema was demonstrated in a study conducted with endotoxemic pigs [13] .", [["vascular", "ANATOMY", 328, 336], ["Endothelial", "ANATOMY", 369, 380], ["lung edema", "ANATOMY", 437, 447], ["ADO", "CHEMICAL", 27, 30], ["ADO", "CHEMICAL", 178, 181], ["hypoxia", "DISEASE", 195, 202], ["infection", "DISEASE", 206, 215], ["vascular leakage", "DISEASE", 328, 344], ["lung edema", "DISEASE", 437, 447], ["ADO", "CHEMICAL", 27, 30], ["ADO", "CHEMICAL", 178, 181], ["ADO", "SIMPLE_CHEMICAL", 27, 30], ["TER", "SIMPLE_CHEMICAL", 40, 43], ["EC", "CELL", 94, 96], ["ADO", "SIMPLE_CHEMICAL", 178, 181], ["EC", "CELL", 257, 259], ["vascular", "MULTI-TISSUE_STRUCTURE", 328, 336], ["Endothelial Barrier", "TISSUE", 369, 388], ["A 2B R agonists", "GENE_OR_GENE_PRODUCT", 417, 432], ["lung", "ORGAN", 437, 441], ["pigs", "ORGANISM", 503, 507], ["pigs", "SPECIES", 503, 507], ["ADO-mediated TER", "TREATMENT", 27, 43], ["whereas crisis situations", "PROBLEM", 132, 157], ["circulating ADO levels", "PROBLEM", 166, 188], ["hypoxia", "PROBLEM", 195, 202], ["infection", "PROBLEM", 206, 215], ["EC", "TEST", 257, 259], ["vascular leakage", "PROBLEM", 328, 344], ["the Endothelial Barrier", "TREATMENT", 365, 388], ["A 2B R agonists", "TREATMENT", 417, 432], ["lung edema", "PROBLEM", 437, 447], ["a study", "TEST", 468, 475], ["endotoxemic pigs", "TREATMENT", 491, 507], ["infection", "OBSERVATION", 206, 215], ["vascular", "ANATOMY", 328, 336], ["leakage", "OBSERVATION", 337, 344], ["Permeability", "OBSERVATION_MODIFIER", 349, 361], ["Endothelial", "ANATOMY", 369, 380], ["lung", "ANATOMY", 437, 441], ["edema", "OBSERVATION", 442, 447]]], ["Endotoxin-induced acute lung injury and increase in lung extravascular water were, both, reduced by intravenously infused ADO.", [["lung", "ANATOMY", 24, 28], ["lung extravascular", "ANATOMY", 52, 70], ["intravenously", "ANATOMY", 100, 113], ["Endotoxin", "CHEMICAL", 0, 9], ["acute lung injury", "DISEASE", 18, 35], ["ADO", "CHEMICAL", 122, 125], ["ADO", "CHEMICAL", 122, 125], ["Endotoxin", "SIMPLE_CHEMICAL", 0, 9], ["lung", "ORGAN", 24, 28], ["lung", "ORGAN", 52, 56], ["extravascular water", "ORGANISM_SUBSTANCE", 57, 76], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 100, 113], ["ADO", "SIMPLE_CHEMICAL", 122, 125], ["Endotoxin", "TREATMENT", 0, 9], ["acute lung injury", "PROBLEM", 18, 35], ["increase in lung extravascular water", "PROBLEM", 40, 76], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["lung", "ANATOMY", 24, 28], ["injury", "OBSERVATION", 29, 35], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["lung", "ANATOMY", 52, 56], ["extravascular water", "OBSERVATION", 57, 76]]], ["A similar response was obtained with the ADO receptor agonist, 2-chloroadenosine, in endotoxemic guinea-pigs [14] .", [["ADO", "CHEMICAL", 41, 44], ["2-chloroadenosine", "CHEMICAL", 63, 80], ["ADO", "CHEMICAL", 41, 44], ["2-chloroadenosine", "CHEMICAL", 63, 80], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 41, 53], ["2-chloroadenosine", "SIMPLE_CHEMICAL", 63, 80], ["guinea-pigs", "ORGANISM", 97, 108], ["guinea-pigs", "SPECIES", 97, 108], ["the ADO receptor agonist", "TREATMENT", 37, 61], ["chloroadenosine", "TREATMENT", 65, 80], ["endotoxemic guinea", "TREATMENT", 85, 103]]], ["Interestingly, the microvascular endothelial cells express predominantly ADO receptors causing an increase in cyclic AMP (cAMP) production (A 2A Rs and A 2 BRs), which leads to PKA-dependent VASP phosphorylation, like for the abovementioned P2Y 2 Rs [15] .", [["microvascular endothelial cells", "ANATOMY", 19, 50], ["ADO", "CHEMICAL", 73, 76], ["AMP", "CHEMICAL", 117, 120], ["cAMP", "CHEMICAL", 122, 126], ["cyclic AMP", "CHEMICAL", 110, 120], ["cAMP", "CHEMICAL", 122, 126], ["microvascular endothelial cells", "CELL", 19, 50], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 73, 86], ["cyclic AMP", "GENE_OR_GENE_PRODUCT", 110, 120], ["cAMP", "SIMPLE_CHEMICAL", 122, 126], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 140, 147], ["A 2 BRs", "GENE_OR_GENE_PRODUCT", 152, 159], ["PKA", "GENE_OR_GENE_PRODUCT", 177, 180], ["VASP", "GENE_OR_GENE_PRODUCT", 191, 195], ["microvascular endothelial cells", "CELL_TYPE", 19, 50], ["ADO receptors", "PROTEIN", 73, 86], ["PKA", "PROTEIN", 177, 180], ["VASP", "PROTEIN", 191, 195], ["the microvascular endothelial cells", "PROBLEM", 15, 50], ["ADO receptors", "PROBLEM", 73, 86], ["an increase in cyclic AMP (cAMP) production", "PROBLEM", 95, 138], ["PKA", "TEST", 177, 180], ["dependent VASP phosphorylation", "PROBLEM", 181, 211], ["microvascular", "ANATOMY", 19, 32], ["endothelial cells", "OBSERVATION", 33, 50], ["predominantly", "OBSERVATION_MODIFIER", 59, 72], ["ADO receptors", "OBSERVATION", 73, 86], ["increase", "OBSERVATION_MODIFIER", 98, 106], ["cyclic AMP", "OBSERVATION", 110, 120], ["VASP phosphorylation", "OBSERVATION", 191, 211]]], ["These data suggest that circulating nucleotides normally maintain TER by successive waves of ATP-and ADO-mediated signals, which by the same token, would regulate leukocyte migration induced by inflammatory mediators.Fluid Clearance on Alveolar EpitheliaThe respiratory tract is frequently subjected to mechanical stress and infections, which stimulate the release of nucleotides into the airways.", [["leukocyte", "ANATOMY", 163, 172], ["Alveolar Epithelia", "ANATOMY", 236, 254], ["respiratory tract", "ANATOMY", 258, 275], ["airways", "ANATOMY", 389, 396], ["ATP", "CHEMICAL", 93, 96], ["ADO", "CHEMICAL", 101, 104], ["respiratory tract", "DISEASE", 258, 275], ["infections", "DISEASE", 325, 335], ["nucleotides", "CHEMICAL", 36, 47], ["ATP", "CHEMICAL", 93, 96], ["ADO", "CHEMICAL", 101, 104], ["nucleotides", "CHEMICAL", 368, 379], ["TER", "GENE_OR_GENE_PRODUCT", 66, 69], ["ATP", "SIMPLE_CHEMICAL", 93, 96], ["ADO", "SIMPLE_CHEMICAL", 101, 104], ["leukocyte", "CELL", 163, 172], ["respiratory tract", "ORGANISM_SUBDIVISION", 258, 275], ["airways", "MULTI-TISSUE_STRUCTURE", 389, 396], ["inflammatory mediators", "PROTEIN", 194, 216], ["These data", "TEST", 0, 10], ["circulating nucleotides", "PROBLEM", 24, 47], ["ATP", "TEST", 93, 96], ["ADO-mediated signals", "PROBLEM", 101, 121], ["leukocyte migration", "PROBLEM", 163, 182], ["Fluid Clearance", "TEST", 217, 232], ["Alveolar Epithelia", "PROBLEM", 236, 254], ["The respiratory tract", "PROBLEM", 254, 275], ["mechanical stress", "PROBLEM", 303, 320], ["infections", "PROBLEM", 325, 335], ["leukocyte migration", "OBSERVATION", 163, 182], ["inflammatory", "OBSERVATION_MODIFIER", 194, 206], ["Alveolar", "ANATOMY_MODIFIER", 236, 244], ["Epithelia", "ANATOMY_MODIFIER", 245, 254], ["respiratory tract", "ANATOMY", 258, 275], ["infections", "OBSERVATION", 325, 335], ["airways", "ANATOMY", 389, 396]]], ["Decades of research clearly established that extracellular nucleotides are the major regulators of airway hydration (review: [16] ).", [["extracellular", "ANATOMY", 45, 58], ["airway", "ANATOMY", 99, 105], ["nucleotides", "CHEMICAL", 59, 70], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["airway", "MULTI-TISSUE_STRUCTURE", 99, 105], ["extracellular nucleotides", "TREATMENT", 45, 70], ["airway", "ANATOMY", 99, 105]]], ["More importantly, they showed that the epithelial barrier regulates fluid fluxes by purinergic regulation of ion channels.", [["epithelial barrier", "ANATOMY", 39, 57], ["fluid", "ANATOMY", 68, 73], ["epithelial barrier", "TISSUE", 39, 57], ["fluid", "ORGANISM_SUBSTANCE", 68, 73], ["purinergic", "SIMPLE_CHEMICAL", 84, 94], ["ion channels", "PROTEIN", 109, 121], ["the epithelial barrier regulates fluid fluxes", "TREATMENT", 35, 80], ["epithelial", "ANATOMY_MODIFIER", 39, 49], ["fluid fluxes", "OBSERVATION", 68, 80], ["ion channels", "OBSERVATION", 109, 121]]], ["The vectorial movements of Na + and Clions across the barrier create an osmotic gradient for water to follow.", [["Na", "CHEMICAL", 27, 29], ["Na +", "CHEMICAL", 27, 31], ["Clions", "CHEMICAL", 36, 42], ["Na +", "SIMPLE_CHEMICAL", 27, 31], ["Na", "TEST", 27, 29], ["Clions", "TREATMENT", 36, 42], ["an osmotic gradient", "TREATMENT", 69, 88], ["vectorial", "OBSERVATION_MODIFIER", 4, 13], ["movements", "OBSERVATION_MODIFIER", 14, 23], ["osmotic gradient", "OBSERVATION", 72, 88]]], ["The absorption of Na + by the epithelial sodium channel (ENaC) mediates fluid clearance, and Cl \u00c0 secretion by the Ca 2+ -dependent Clchannels (CaCC) and cystic fibrosis transmembrane regulator (CFTR) hydrates airway surfaces.", [["epithelial", "ANATOMY", 30, 40], ["fluid", "ANATOMY", 72, 77], ["airway", "ANATOMY", 210, 216], ["Na", "CHEMICAL", 18, 20], ["sodium", "CHEMICAL", 41, 47], ["Cl", "CHEMICAL", 93, 95], ["Ca", "CHEMICAL", 115, 117], ["fibrosis", "DISEASE", 161, 169], ["Na +", "CHEMICAL", 18, 22], ["sodium", "CHEMICAL", 41, 47], ["Cl", "CHEMICAL", 93, 95], ["Ca 2+", "CHEMICAL", 115, 120], ["Na +", "SIMPLE_CHEMICAL", 18, 22], ["epithelial sodium channel", "GENE_OR_GENE_PRODUCT", 30, 55], ["ENaC", "GENE_OR_GENE_PRODUCT", 57, 61], ["fluid", "ORGANISM_SUBSTANCE", 72, 77], ["Cl \u00c0", "SIMPLE_CHEMICAL", 93, 97], ["Ca 2+", "SIMPLE_CHEMICAL", 115, 120], ["Clchannels", "SIMPLE_CHEMICAL", 132, 142], ["CaCC", "SIMPLE_CHEMICAL", 144, 148], ["cystic fibrosis transmembrane regulator", "GENE_OR_GENE_PRODUCT", 154, 193], ["CFTR", "GENE_OR_GENE_PRODUCT", 195, 199], ["epithelial sodium channel", "PROTEIN", 30, 55], ["ENaC", "PROTEIN", 57, 61], ["Ca 2+ -dependent Clchannels", "PROTEIN", 115, 142], ["CaCC", "PROTEIN", 144, 148], ["cystic fibrosis transmembrane regulator", "PROTEIN", 154, 193], ["CFTR", "PROTEIN", 195, 199], ["Na", "TEST", 18, 20], ["the epithelial sodium channel", "TEST", 26, 55], ["fluid clearance", "TEST", 72, 87], ["Cl \u00c0 secretion", "PROBLEM", 93, 107], ["the Ca", "TEST", 111, 117], ["dependent Clchannels (CaCC", "PROBLEM", 122, 148], ["cystic fibrosis transmembrane regulator (CFTR) hydrates airway surfaces", "PROBLEM", 154, 225], ["cystic", "OBSERVATION_MODIFIER", 154, 160], ["fibrosis", "OBSERVATION", 161, 169], ["airway", "ANATOMY", 210, 216], ["surfaces", "OBSERVATION_MODIFIER", 217, 225]]], ["5 for the large airways, where nucleotides are identified as stimulators of fluid accumulation into the airspace.", [["airways", "ANATOMY", 16, 23], ["fluid", "ANATOMY", 76, 81], ["airspace", "ANATOMY", 104, 112], ["nucleotides", "CHEMICAL", 31, 42], ["airways", "MULTI-TISSUE_STRUCTURE", 16, 23], ["fluid", "ORGANISM_SUBSTANCE", 76, 81], ["airspace", "MULTI-TISSUE_STRUCTURE", 104, 112], ["nucleotides", "TREATMENT", 31, 42], ["fluid accumulation into the airspace", "PROBLEM", 76, 112], ["large", "OBSERVATION_MODIFIER", 10, 15], ["airways", "ANATOMY", 16, 23], ["fluid accumulation", "OBSERVATION", 76, 94], ["airspace", "ANATOMY", 104, 112]]], ["This concept seems to apply to the regulation of alveolar fluid clearance (AFC), as intra-tracheal instillation of ATP caused lung edema in mice [17] .", [["alveolar fluid", "ANATOMY", 49, 63], ["intra-tracheal", "ANATOMY", 84, 98], ["lung", "ANATOMY", 126, 130], ["ATP", "CHEMICAL", 115, 118], ["lung edema", "DISEASE", 126, 136], ["ATP", "CHEMICAL", 115, 118], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 49, 63], ["ATP", "SIMPLE_CHEMICAL", 115, 118], ["lung", "ORGAN", 126, 130], ["edema", "PATHOLOGICAL_FORMATION", 131, 136], ["mice", "ORGANISM", 140, 144], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 140, 144], ["alveolar fluid clearance", "TEST", 49, 73], ["intra-tracheal instillation of ATP", "TREATMENT", 84, 118], ["lung edema", "PROBLEM", 126, 136], ["alveolar", "ANATOMY", 49, 57], ["fluid clearance", "OBSERVATION", 58, 73], ["lung", "ANATOMY", 126, 130], ["edema", "OBSERVATION", 131, 136]]], ["This initial observation launched various initiatives to clarify the involvement of purinergic signaling in the impaired epithelial fluid clearance observed during pulmonary edema.Fluid Clearance on Alveolar EpitheliaIn mice, the respiratory syncytial virus (RSV) causes a transient reduction in AFC, likely to promote clearance by the mucociliary escalator [18] .", [["epithelial fluid", "ANATOMY", 121, 137], ["pulmonary", "ANATOMY", 164, 173], ["mucociliary", "ANATOMY", 336, 347], ["pulmonary edema", "DISEASE", 164, 179], ["respiratory syncytial virus", "DISEASE", 230, 257], ["purinergic", "SIMPLE_CHEMICAL", 84, 94], ["epithelial fluid", "TISSUE", 121, 137], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 164, 179], ["Alveolar EpitheliaIn mice", "ORGANISM", 199, 224], ["respiratory syncytial virus", "ORGANISM", 230, 257], ["RSV", "ORGANISM", 259, 262], ["AFC", "SIMPLE_CHEMICAL", 296, 299], ["mice", "SPECIES", 220, 224], ["respiratory syncytial virus", "SPECIES", 230, 257], ["mice", "SPECIES", 220, 224], ["respiratory syncytial virus", "SPECIES", 230, 257], ["RSV", "SPECIES", 259, 262], ["purinergic signaling", "PROBLEM", 84, 104], ["the impaired epithelial fluid clearance", "PROBLEM", 108, 147], ["pulmonary edema", "PROBLEM", 164, 179], ["Fluid Clearance", "TEST", 180, 195], ["Alveolar EpitheliaIn mice", "TREATMENT", 199, 224], ["the respiratory syncytial virus", "PROBLEM", 226, 257], ["a transient reduction in AFC", "PROBLEM", 271, 299], ["purinergic signaling", "OBSERVATION", 84, 104], ["impaired", "OBSERVATION_MODIFIER", 112, 120], ["epithelial", "ANATOMY_MODIFIER", 121, 131], ["fluid clearance", "OBSERVATION", 132, 147], ["pulmonary", "ANATOMY", 164, 173], ["edema", "OBSERVATION", 174, 179], ["Alveolar", "ANATOMY_MODIFIER", 199, 207], ["respiratory syncytial", "ANATOMY", 230, 251], ["transient", "OBSERVATION_MODIFIER", 273, 282], ["reduction", "OBSERVATION_MODIFIER", 283, 292]]], ["Using in vivo and in vitro studies, Matalon et al. showed that RSV impairs Na + -driven AFC through ENaC in distal lung and upper airway epithelia [19] [20] [21] .", [["distal lung", "ANATOMY", 108, 119], ["upper airway epithelia", "ANATOMY", 124, 146], ["Na", "CHEMICAL", 75, 77], ["Na +", "CHEMICAL", 75, 79], ["RSV", "ORGANISM", 63, 66], ["Na + -driven AFC", "GENE_OR_GENE_PRODUCT", 75, 91], ["ENaC", "GENE_OR_GENE_PRODUCT", 100, 104], ["lung", "ORGAN", 115, 119], ["upper airway epithelia", "TISSUE", 124, 146], ["Na + -driven AFC", "PROTEIN", 75, 91], ["ENaC", "PROTEIN", 100, 104], ["RSV", "SPECIES", 63, 66], ["vitro studies", "TEST", 21, 34], ["RSV impairs", "PROBLEM", 63, 74], ["Na", "TEST", 75, 77], ["upper airway epithelia", "PROBLEM", 124, 146], ["RSV", "OBSERVATION", 63, 66], ["distal", "ANATOMY_MODIFIER", 108, 114], ["lung", "ANATOMY", 115, 119], ["upper", "ANATOMY_MODIFIER", 124, 129], ["airway", "ANATOMY", 130, 136], ["epithelia", "ANATOMY_MODIFIER", 137, 146]]], ["In the H441 Clara cells, RSV-mediated ENaC inhibition was partially prevented by blockers of nitric oxide production (1,400 W), or de novo UTP synthesis (A77-1726).", [["H441 Clara cells", "ANATOMY", 7, 23], ["nitric oxide", "CHEMICAL", 93, 105], ["UTP", "CHEMICAL", 139, 142], ["A77-1726", "CHEMICAL", 154, 162], ["nitric oxide", "CHEMICAL", 93, 105], ["UTP", "CHEMICAL", 139, 142], ["A77-1726", "CHEMICAL", 154, 162], ["H441 Clara cells", "CELL", 7, 23], ["RSV", "ORGANISM", 25, 28], ["ENaC", "GENE_OR_GENE_PRODUCT", 38, 42], ["nitric oxide", "SIMPLE_CHEMICAL", 93, 105], ["UTP", "SIMPLE_CHEMICAL", 139, 142], ["H441 Clara cells", "CELL_LINE", 7, 23], ["ENaC", "PROTEIN", 38, 42], ["RSV", "SPECIES", 25, 28], ["RSV", "TEST", 25, 28], ["ENaC inhibition", "TREATMENT", 38, 53], ["nitric oxide production", "TREATMENT", 93, 116], ["H441", "ANATOMY", 7, 11], ["Clara cells", "OBSERVATION", 12, 23]]], ["During RSV infection, the accumulation of both purines (ATP, ADP) and pyrimidines (UTP, UDP) in the alveolar space [20] , and the prevention of fluid accumulation by P2Y receptor antagonists [19] , support a role for UTP synthesis and release in the purinergic regulation of AFC.Fluid Clearance on Alveolar EpitheliaThe predominant P2Y receptor capable of mediating pyrimidinergic signals in the respiratory tract is the P2Y 2 R, which is activated by ATP and UTP, not by ADP or UDP (Chap.", [["alveolar space", "ANATOMY", 100, 114], ["fluid", "ANATOMY", 144, 149], ["Alveolar Epithelia", "ANATOMY", 298, 316], ["respiratory tract", "ANATOMY", 396, 413], ["RSV infection", "DISEASE", 7, 20], ["purines", "CHEMICAL", 47, 54], ["ATP", "CHEMICAL", 56, 59], ["ADP", "CHEMICAL", 61, 64], ["pyrimidines", "CHEMICAL", 70, 81], ["UTP", "CHEMICAL", 83, 86], ["UDP", "CHEMICAL", 88, 91], ["UTP", "CHEMICAL", 217, 220], ["ATP", "CHEMICAL", 452, 455], ["UTP", "CHEMICAL", 460, 463], ["ADP", "CHEMICAL", 472, 475], ["UDP", "CHEMICAL", 479, 482], ["purines", "CHEMICAL", 47, 54], ["ATP", "CHEMICAL", 56, 59], ["ADP", "CHEMICAL", 61, 64], ["pyrimidines", "CHEMICAL", 70, 81], ["UTP", "CHEMICAL", 83, 86], ["UDP", "CHEMICAL", 88, 91], ["UTP", "CHEMICAL", 217, 220], ["ATP", "CHEMICAL", 452, 455], ["UTP", "CHEMICAL", 460, 463], ["ADP", "CHEMICAL", 472, 475], ["UDP", "CHEMICAL", 479, 482], ["RSV", "ORGANISM", 7, 10], ["purines", "SIMPLE_CHEMICAL", 47, 54], ["ATP", "SIMPLE_CHEMICAL", 56, 59], ["ADP", "SIMPLE_CHEMICAL", 61, 64], ["pyrimidines", "SIMPLE_CHEMICAL", 70, 81], ["UTP", "SIMPLE_CHEMICAL", 83, 86], ["UDP", "SIMPLE_CHEMICAL", 88, 91], ["fluid", "ORGANISM_SUBSTANCE", 144, 149], ["P2Y receptor", "GENE_OR_GENE_PRODUCT", 166, 178], ["UTP", "SIMPLE_CHEMICAL", 217, 220], ["AFC", "GENE_OR_GENE_PRODUCT", 275, 278], ["P2Y receptor", "GENE_OR_GENE_PRODUCT", 332, 344], ["respiratory tract", "ORGANISM_SUBDIVISION", 396, 413], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 421, 428], ["ATP", "SIMPLE_CHEMICAL", 452, 455], ["UTP", "SIMPLE_CHEMICAL", 460, 463], ["ADP", "SIMPLE_CHEMICAL", 472, 475], ["UDP", "SIMPLE_CHEMICAL", 479, 482], ["AFC", "PROTEIN", 275, 278], ["P2Y receptor", "PROTEIN", 332, 344], ["P2Y 2 R", "PROTEIN", 421, 428], ["RSV", "SPECIES", 7, 10], ["RSV infection", "PROBLEM", 7, 20], ["both purines (ATP, ADP) and pyrimidines (UTP, UDP) in the alveolar space", "TEST", 42, 114], ["fluid accumulation", "PROBLEM", 144, 162], ["P2Y receptor antagonists", "TREATMENT", 166, 190], ["UTP synthesis", "TREATMENT", 217, 230], ["AFC", "PROBLEM", 275, 278], ["Fluid Clearance", "TEST", 279, 294], ["Alveolar Epithelia", "PROBLEM", 298, 316], ["mediating pyrimidinergic signals in the respiratory tract", "PROBLEM", 356, 413], ["UTP", "TEST", 460, 463], ["RSV", "ANATOMY", 7, 10], ["infection", "OBSERVATION", 11, 20], ["alveolar", "ANATOMY_MODIFIER", 100, 108], ["fluid accumulation", "OBSERVATION", 144, 162], ["Alveolar", "ANATOMY_MODIFIER", 298, 306], ["Epithelia", "ANATOMY_MODIFIER", 307, 316], ["predominant", "OBSERVATION_MODIFIER", 320, 331], ["P2Y receptor", "OBSERVATION", 332, 344], ["pyrimidinergic signals", "OBSERVATION", 366, 388], ["respiratory tract", "ANATOMY", 396, 413]]], ["On the other hand, only soluble enzymes degrading pyrimidines (UDP-glucose pyrophosphorylase or apyrase) prevented RSV-induced edema [19] .", [["edema", "ANATOMY", 127, 132], ["pyrimidines", "CHEMICAL", 50, 61], ["UDP-glucose", "CHEMICAL", 63, 74], ["apyrase", "CHEMICAL", 96, 103], ["edema", "DISEASE", 127, 132], ["pyrimidines", "CHEMICAL", 50, 61], ["UDP", "CHEMICAL", 63, 66], ["glucose", "CHEMICAL", 67, 74], ["pyrimidines", "SIMPLE_CHEMICAL", 50, 61], ["UDP-glucose pyrophosphorylase", "GENE_OR_GENE_PRODUCT", 63, 92], ["apyrase", "SIMPLE_CHEMICAL", 96, 103], ["RSV", "ORGANISM", 115, 118], ["edema", "PATHOLOGICAL_FORMATION", 127, 132], ["soluble enzymes", "PROTEIN", 24, 39], ["UDP-glucose pyrophosphorylase", "PROTEIN", 63, 92], ["RSV", "SPECIES", 115, 118], ["soluble enzymes", "TEST", 24, 39], ["pyrimidines", "TEST", 50, 61], ["UDP", "TEST", 63, 66], ["glucose pyrophosphorylase", "TEST", 67, 92], ["apyrase", "TEST", 96, 103], ["RSV", "PROBLEM", 115, 118], ["edema", "PROBLEM", 127, 132], ["edema", "OBSERVATION", 127, 132]]], ["In addition, intratracheal UTP and UDP, both, reproduced RSVmediated AFC reduction [18] .", [["UTP", "CHEMICAL", 27, 30], ["UDP", "CHEMICAL", 35, 38], ["UTP", "CHEMICAL", 27, 30], ["UDP", "CHEMICAL", 35, 38], ["UTP", "SIMPLE_CHEMICAL", 27, 30], ["UDP", "SIMPLE_CHEMICAL", 35, 38], ["intratracheal UTP and UDP", "TEST", 13, 38], ["RSVmediated AFC reduction", "TREATMENT", 57, 82], ["intratracheal", "ANATOMY", 13, 26], ["UTP", "OBSERVATION", 27, 30], ["UDP", "ANATOMY_MODIFIER", 35, 38]]], ["And, UTP is readily dephosphorylated into UDP by ectonucleotidases on airway surfaces [22, 23] .", [["airway", "ANATOMY", 70, 76], ["UTP", "CHEMICAL", 5, 8], ["UDP", "CHEMICAL", 42, 45], ["UTP", "CHEMICAL", 5, 8], ["UDP", "CHEMICAL", 42, 45], ["UTP", "SIMPLE_CHEMICAL", 5, 8], ["UDP", "SIMPLE_CHEMICAL", 42, 45], ["ectonucleotidases", "SIMPLE_CHEMICAL", 49, 66], ["airway", "PATHOLOGICAL_FORMATION", 70, 76], ["ectonucleotidases", "PROTEIN", 49, 66], ["UTP", "TEST", 5, 8], ["ectonucleotidases on airway surfaces", "TEST", 49, 85], ["airway", "ANATOMY", 70, 76]]], ["Contrary to the endothelial surface, the ectonucleotidase population of the epithelial cells allows for significant accumulation of UDP before it is dephosphorylated further into UMP and uridine (see Chap.", [["endothelial surface", "ANATOMY", 16, 35], ["epithelial cells", "ANATOMY", 76, 92], ["UDP", "CHEMICAL", 132, 135], ["UMP", "CHEMICAL", 179, 182], ["uridine", "CHEMICAL", 187, 194], ["UDP", "CHEMICAL", 132, 135], ["UMP", "CHEMICAL", 179, 182], ["uridine", "CHEMICAL", 187, 194], ["endothelial surface", "CELLULAR_COMPONENT", 16, 35], ["ectonucleotidase", "GENE_OR_GENE_PRODUCT", 41, 57], ["epithelial cells", "CELL", 76, 92], ["UDP", "SIMPLE_CHEMICAL", 132, 135], ["UMP", "SIMPLE_CHEMICAL", 179, 182], ["uridine", "SIMPLE_CHEMICAL", 187, 194], ["epithelial cells", "CELL_TYPE", 76, 92], ["significant accumulation of UDP", "PROBLEM", 104, 135], ["UMP and uridine", "TREATMENT", 179, 194], ["endothelial", "ANATOMY", 16, 27], ["surface", "ANATOMY_MODIFIER", 28, 35], ["epithelial cells", "OBSERVATION", 76, 92], ["UDP", "ANATOMY_MODIFIER", 132, 135]]], ["These results raised the possibility that UTP and UDP, both, mediated their effects through P2Y 6 R activation.", [["UTP", "CHEMICAL", 42, 45], ["UDP", "CHEMICAL", 50, 53], ["UTP", "CHEMICAL", 42, 45], ["UDP", "CHEMICAL", 50, 53], ["UTP", "SIMPLE_CHEMICAL", 42, 45], ["UDP", "SIMPLE_CHEMICAL", 50, 53], ["P2Y 6 R", "GENE_OR_GENE_PRODUCT", 92, 99], ["P2Y 6 R", "PROTEIN", 92, 99], ["UTP and UDP", "TEST", 42, 53], ["P2Y 6 R activation", "TREATMENT", 92, 110]]], ["This receptor is functionally expressed on the apical surface of airway and alveolar epithelial cells (review: [24] ).", [["apical surface", "ANATOMY", 47, 61], ["airway", "ANATOMY", 65, 71], ["alveolar epithelial cells", "ANATOMY", 76, 101], ["apical surface", "CELLULAR_COMPONENT", 47, 61], ["airway", "CELL", 65, 71], ["alveolar epithelial cells", "CELL", 76, 101], ["airway and alveolar epithelial cells", "CELL_TYPE", 65, 101], ["apical", "ANATOMY_MODIFIER", 47, 53], ["surface", "ANATOMY_MODIFIER", 54, 61], ["airway", "ANATOMY", 65, 71], ["alveolar epithelial cells", "OBSERVATION", 76, 101]]], ["In A549 human alveolar Type 2 cells, P2Y 6 Rs activation accounts for the majority of Ca 2+ -dependent ATP secretion [25] .", [["A549", "ANATOMY", 3, 7], ["alveolar Type 2 cells", "ANATOMY", 14, 35], ["Ca", "CHEMICAL", 86, 88], ["ATP", "CHEMICAL", 103, 106], ["Ca 2+", "CHEMICAL", 86, 91], ["ATP", "CHEMICAL", 103, 106], ["A549", "CELL", 3, 7], ["human", "ORGANISM", 8, 13], ["alveolar Type 2 cells", "CELL", 14, 35], ["P2Y 6 Rs", "GENE_OR_GENE_PRODUCT", 37, 45], ["Ca 2+", "SIMPLE_CHEMICAL", 86, 91], ["ATP", "SIMPLE_CHEMICAL", 103, 106], ["A549 human alveolar Type 2 cells", "CELL_LINE", 3, 35], ["P2Y 6 Rs", "PROTEIN", 37, 45], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["P2Y", "TEST", 37, 40], ["Rs activation", "TEST", 43, 56], ["Ca", "TEST", 86, 88], ["dependent ATP secretion", "PROBLEM", 93, 116], ["alveolar", "ANATOMY", 14, 22]]], ["The identity of this receptor was later confirmed using mice infected with the influenza A virus [26] .", [["influenza A", "DISEASE", 79, 90], ["mice", "ORGANISM", 56, 60], ["influenza A virus", "ORGANISM", 79, 96], ["mice", "SPECIES", 56, 60], ["influenza A virus", "SPECIES", 79, 96], ["mice", "SPECIES", 56, 60], ["influenza A virus", "SPECIES", 79, 96], ["this receptor", "TREATMENT", 16, 29], ["the influenza A virus", "PROBLEM", 75, 96]]], ["Like RSV, this virus induced hypoxemia and inhibited AFC, and was associated with a rapid increase in ATP and UTP concentrations in the BAL fluid.", [["BAL fluid", "ANATOMY", 136, 145], ["hypoxemia", "DISEASE", 29, 38], ["ATP", "CHEMICAL", 102, 105], ["UTP", "CHEMICAL", 110, 113], ["ATP", "CHEMICAL", 102, 105], ["UTP", "CHEMICAL", 110, 113], ["RSV", "ORGANISM", 5, 8], ["ATP", "SIMPLE_CHEMICAL", 102, 105], ["UTP", "SIMPLE_CHEMICAL", 110, 113], ["BAL fluid", "ORGANISM_SUBSTANCE", 136, 145], ["RSV", "SPECIES", 5, 8], ["RSV", "PROBLEM", 5, 8], ["this virus induced hypoxemia", "PROBLEM", 10, 38], ["inhibited AFC", "PROBLEM", 43, 56], ["a rapid increase in ATP", "PROBLEM", 82, 105], ["UTP concentrations in the BAL fluid", "PROBLEM", 110, 145], ["RSV", "OBSERVATION", 5, 8], ["hypoxemia", "OBSERVATION", 29, 38], ["rapid", "OBSERVATION_MODIFIER", 84, 89], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["UTP concentrations", "OBSERVATION", 110, 128], ["BAL", "ANATOMY", 136, 139], ["fluid", "OBSERVATION", 140, 145]]], ["The use of various ion channel blockers and P2Y receptor antagonists confirmed that viral infections induce de novo UTP synthesis and secretion, followed by UTP dephosphorylation into UDP and P2Y 6 R activation.", [["viral infections", "DISEASE", 84, 100], ["UTP", "CHEMICAL", 116, 119], ["UTP", "CHEMICAL", 157, 160], ["UDP", "CHEMICAL", 184, 187], ["UTP", "CHEMICAL", 116, 119], ["UTP", "CHEMICAL", 157, 160], ["UDP", "CHEMICAL", 184, 187], ["P2Y receptor", "GENE_OR_GENE_PRODUCT", 44, 56], ["UTP", "SIMPLE_CHEMICAL", 116, 119], ["UTP", "SIMPLE_CHEMICAL", 157, 160], ["UDP", "SIMPLE_CHEMICAL", 184, 187], ["P2Y 6 R", "GENE_OR_GENE_PRODUCT", 192, 199], ["various ion channel blockers", "TREATMENT", 11, 39], ["P2Y receptor antagonists", "TREATMENT", 44, 68], ["viral infections", "PROBLEM", 84, 100], ["novo UTP synthesis", "PROBLEM", 111, 129], ["UTP dephosphorylation into UDP", "TEST", 157, 187], ["P2Y", "TEST", 192, 195]]], ["This signaling cascade inhibits Na + absorption by ENaC, allowing fluid to accumulate into the alveolar space.Fluid Clearance on Alveolar EpitheliaThis purinergic receptor does not support the ATP-mediated pulmonary edema observed in mice during mechanical ventilation [17] .", [["fluid", "ANATOMY", 66, 71], ["alveolar space", "ANATOMY", 95, 109], ["Alveolar", "ANATOMY", 129, 137], ["pulmonary", "ANATOMY", 206, 215], ["Na", "CHEMICAL", 32, 34], ["ATP", "CHEMICAL", 193, 196], ["pulmonary edema", "DISEASE", 206, 221], ["Na +", "CHEMICAL", 32, 36], ["ATP", "CHEMICAL", 193, 196], ["Na +", "SIMPLE_CHEMICAL", 32, 36], ["ENaC", "GENE_OR_GENE_PRODUCT", 51, 55], ["fluid", "ORGANISM_SUBSTANCE", 66, 71], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 95, 109], ["ATP", "SIMPLE_CHEMICAL", 193, 196], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 206, 221], ["mice", "ORGANISM", 234, 238], ["ENaC", "PROTEIN", 51, 55], ["Alveolar EpitheliaThis purinergic receptor", "PROTEIN", 129, 171], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 234, 238], ["This signaling cascade", "PROBLEM", 0, 22], ["Fluid Clearance", "TEST", 110, 125], ["Alveolar EpitheliaThis purinergic receptor", "TREATMENT", 129, 171], ["the ATP", "PROBLEM", 189, 196], ["pulmonary edema", "PROBLEM", 206, 221], ["mechanical ventilation", "TREATMENT", 246, 268], ["fluid", "OBSERVATION", 66, 71], ["alveolar space", "ANATOMY", 95, 109], ["Alveolar", "ANATOMY_MODIFIER", 129, 137], ["pulmonary", "ANATOMY", 206, 215], ["edema", "OBSERVATION", 216, 221]]], ["On the other hand, most purinergic networks accommodate a dual regulation of cellular functions mediated by the balancing effects of nucleotide (P2) receptors and ADO (P1) receptors.", [["cellular", "ANATOMY", 77, 85], ["nucleotide", "CHEMICAL", 133, 143], ["ADO", "CHEMICAL", 163, 166], ["nucleotide", "CHEMICAL", 133, 143], ["purinergic networks", "MULTI-TISSUE_STRUCTURE", 24, 43], ["cellular", "CELL", 77, 85], ["nucleotide (P2) receptors", "GENE_OR_GENE_PRODUCT", 133, 158], ["ADO (P1) receptors", "GENE_OR_GENE_PRODUCT", 163, 181], ["nucleotide (P2) receptors", "PROTEIN", 133, 158], ["ADO (P1) receptors", "PROTEIN", 163, 181], ["nucleotide (P2) receptors", "TREATMENT", 133, 158], ["ADO (P1) receptors", "TREATMENT", 163, 181], ["cellular functions", "OBSERVATION", 77, 95]]], ["Davis et al. demonstrated that CFTR inhibitors, or agents preventing the formation of ADO from ATP metabolism, improved AFC during viral infection [26] .", [["ADO", "CHEMICAL", 86, 89], ["ATP", "CHEMICAL", 95, 98], ["viral infection", "DISEASE", 131, 146], ["ADO", "CHEMICAL", 86, 89], ["ATP", "CHEMICAL", 95, 98], ["CFTR", "GENE_OR_GENE_PRODUCT", 31, 35], ["ADO", "SIMPLE_CHEMICAL", 86, 89], ["ATP", "SIMPLE_CHEMICAL", 95, 98], ["CFTR inhibitors", "TREATMENT", 31, 46], ["agents", "TREATMENT", 51, 57], ["ATP metabolism", "PROBLEM", 95, 109], ["viral infection", "PROBLEM", 131, 146]]], ["The use of selective P1 receptor antagonists identified the A 1 R as the culprit responsible for the CFTR-mediated reduction of AFC in infected mice.", [["A 1 R", "GENE_OR_GENE_PRODUCT", 60, 65], ["CFTR", "GENE_OR_GENE_PRODUCT", 101, 105], ["AFC", "GENE_OR_GENE_PRODUCT", 128, 131], ["mice", "ORGANISM", 144, 148], ["CFTR", "PROTEIN", 101, 105], ["AFC", "PROTEIN", 128, 131], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["selective P1 receptor antagonists", "TREATMENT", 11, 44], ["the CFTR", "PROBLEM", 97, 105], ["AFC", "PROBLEM", 128, 131], ["AFC", "OBSERVATION", 128, 131], ["infected mice", "OBSERVATION", 135, 148]]], ["These findings were quite surprising considering the well established role of A 2B Rs in the stimulation of fluid secretion by CFTR in human airways (see Chap.", [["fluid", "ANATOMY", 108, 113], ["airways", "ANATOMY", 141, 148], ["Rs", "GENE_OR_GENE_PRODUCT", 83, 85], ["fluid", "ORGANISM_SUBSTANCE", 108, 113], ["CFTR", "GENE_OR_GENE_PRODUCT", 127, 131], ["human", "ORGANISM", 135, 140], ["airways", "MULTI-TISSUE_STRUCTURE", 141, 148], ["Rs", "PROTEIN", 83, 85], ["CFTR", "PROTEIN", 127, 131], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["fluid secretion", "PROBLEM", 108, 123], ["CFTR in human airways", "PROBLEM", 127, 148], ["fluid secretion", "OBSERVATION", 108, 123], ["airways", "ANATOMY", 141, 148]]], ["As will be described below, the purinergic network of the alveolar wall differs from the airways in terms of ectonucleotidases (see Chap.", [["alveolar wall", "ANATOMY", 58, 71], ["airways", "ANATOMY", 89, 96], ["alveolar wall", "MULTI-TISSUE_STRUCTURE", 58, 71], ["airways", "MULTI-TISSUE_STRUCTURE", 89, 96], ["ectonucleotidases", "GENE_OR_GENE_PRODUCT", 109, 126], ["ectonucleotidases", "PROTEIN", 109, 126], ["Chap", "PROTEIN", 132, 136], ["ectonucleotidases", "PROBLEM", 109, 126], ["alveolar wall", "ANATOMY", 58, 71], ["airways", "ANATOMY", 89, 96]]], ["2), as well as purinoceptors.Fluid Clearance on Alveolar EpitheliaWe are grateful for Factor et al., who meticulously determined the identity and polarity of the ADO receptors on alveolar epithelial cells [27] .", [["alveolar epithelial cells", "ANATOMY", 179, 204], ["ADO", "CHEMICAL", 162, 165], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 162, 175], ["alveolar epithelial cells", "CELL", 179, 204], ["ADO receptors", "PROTEIN", 162, 175], ["alveolar epithelial cells", "CELL_TYPE", 179, 204], ["alveolar epithelial cells", "PROBLEM", 179, 204], ["Alveolar", "ANATOMY", 48, 56], ["alveolar epithelial", "ANATOMY", 179, 198]]], ["Based on laser capture microdissection and quantitative PCR, they showed that all four receptors are detected on the murine epithelial barrier.", [["epithelial barrier", "ANATOMY", 124, 142], ["murine", "ORGANISM", 117, 123], ["epithelial barrier", "TISSUE", 124, 142], ["murine", "SPECIES", 117, 123], ["laser capture microdissection", "TEST", 9, 38], ["quantitative PCR", "TEST", 43, 59], ["the murine epithelial barrier", "TREATMENT", 113, 142], ["capture microdissection", "OBSERVATION", 15, 38], ["epithelial barrier", "OBSERVATION", 124, 142]]], ["Contrary to the upper airways, alveolar cells predominantly express the A 2A R, with an mRNA level at least fivefold higher than for the other receptors.", [["upper airways", "ANATOMY", 16, 29], ["alveolar cells", "ANATOMY", 31, 45], ["upper airways", "MULTI-TISSUE_STRUCTURE", 16, 29], ["alveolar cells", "CELL", 31, 45], ["A 2A R", "GENE_OR_GENE_PRODUCT", 72, 78], ["alveolar cells", "CELL_TYPE", 31, 45], ["A 2A R", "PROTEIN", 72, 78], ["an mRNA level", "PROBLEM", 85, 98], ["upper", "ANATOMY_MODIFIER", 16, 21], ["airways", "ANATOMY", 22, 29], ["alveolar cells", "ANATOMY", 31, 45]]], ["Membrane fractionation indicated that A 1 Rs and A 2A Rs are concentrated on the apical surface, whereas A 2B Rs and A 3 Rs were undetected by Western blot.", [["Membrane", "ANATOMY", 0, 8], ["apical surface", "ANATOMY", 81, 95], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 38, 44], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 49, 56], ["apical surface", "CELLULAR_COMPONENT", 81, 95], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 105, 112], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 117, 123], ["2A Rs", "PROTEIN", 51, 56], ["Rs", "PROTEIN", 110, 112], ["A 3 Rs", "PROTEIN", 117, 123], ["Membrane fractionation", "TEST", 0, 22], ["A 2B Rs", "TEST", 105, 112], ["apical", "ANATOMY_MODIFIER", 81, 87], ["surface", "ANATOMY_MODIFIER", 88, 95]]], ["However, one must keep in mind that in vivo measurements of AFC will include the A 2B R-mediated CFTR activation and fluid secretion taking place in the airways.", [["fluid", "ANATOMY", 117, 122], ["airways", "ANATOMY", 153, 160], ["AFC", "SIMPLE_CHEMICAL", 60, 63], ["A 2B R", "GENE_OR_GENE_PRODUCT", 81, 87], ["CFTR", "GENE_OR_GENE_PRODUCT", 97, 101], ["fluid", "ORGANISM_SUBSTANCE", 117, 122], ["airways", "MULTI-TISSUE_STRUCTURE", 153, 160], ["CFTR", "PROTEIN", 97, 101], ["A 2B R-mediated CFTR activation", "TREATMENT", 81, 112], ["fluid secretion", "PROBLEM", 117, 132], ["fluid secretion", "OBSERVATION", 117, 132], ["airways", "ANATOMY", 153, 160]]], ["Incidentally, the lung edema induced, in mice, by mechanical ventilation was significantly reduced by intratracheal instillation of an A 2B R antagonist (PSB1115) [28] .", [["lung edema", "ANATOMY", 18, 28], ["lung edema", "DISEASE", 18, 28], ["PSB1115", "CHEMICAL", 154, 161], ["PSB1115", "CHEMICAL", 154, 161], ["lung", "ORGAN", 18, 22], ["mice", "ORGANISM", 41, 45], ["A 2B R antagonist", "SIMPLE_CHEMICAL", 135, 152], ["PSB1115", "SIMPLE_CHEMICAL", 154, 161], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["the lung edema", "PROBLEM", 14, 28], ["mechanical ventilation", "TREATMENT", 50, 72], ["intratracheal instillation", "TREATMENT", 102, 128], ["an A 2B R antagonist", "TREATMENT", 132, 152], ["lung", "ANATOMY", 18, 22], ["edema", "OBSERVATION", 23, 28], ["mechanical ventilation", "OBSERVATION", 50, 72]]], ["To specifically study the purinergic regulation of alveolar ion channels, Factor et al. used two approaches: the alveolar cell monolayers and the isolated perfused lungs [27] .", [["alveolar", "ANATOMY", 51, 59], ["alveolar cell monolayers", "ANATOMY", 113, 137], ["lungs", "ANATOMY", 164, 169], ["alveolar", "MULTI-TISSUE_STRUCTURE", 51, 59], ["alveolar cell monolayers", "CELL", 113, 137], ["lungs", "ORGAN", 164, 169], ["alveolar ion channels", "PROTEIN", 51, 72], ["alveolar cell monolayers", "CELL_TYPE", 113, 137], ["the alveolar cell monolayers", "TEST", 109, 137], ["alveolar", "ANATOMY_MODIFIER", 51, 59], ["alveolar cell monolayers", "OBSERVATION", 113, 137], ["perfused", "ANATOMY_MODIFIER", 155, 163], ["lungs", "ANATOMY", 164, 169]]], ["Both models revealed that low ADO concentrations (0.01\u00c010 nM) and A 2A R agonists (CGS 21680) stimulate AFC via ENaC activation.", [["ADO", "CHEMICAL", 30, 33], ["CGS 21680", "CHEMICAL", 83, 92], ["ADO", "CHEMICAL", 30, 33], ["CGS 21680", "CHEMICAL", 83, 92], ["ADO", "SIMPLE_CHEMICAL", 30, 33], ["A 2A R", "GENE_OR_GENE_PRODUCT", 66, 72], ["CGS 21680", "SIMPLE_CHEMICAL", 83, 92], ["AFC", "GENE_OR_GENE_PRODUCT", 104, 107], ["ENaC", "GENE_OR_GENE_PRODUCT", 112, 116], ["ENaC", "PROTEIN", 112, 116], ["low ADO concentrations", "PROBLEM", 26, 48], ["A 2A R agonists", "TREATMENT", 66, 81], ["CGS", "TEST", 83, 86], ["low ADO", "OBSERVATION_MODIFIER", 26, 33]]], ["In contrast, low micromolar ADO (!1 mM) and A 1 R agonists (CCPA) reduce AFC via CFTR activation [27] , as reported during viral infection [26] .", [["ADO", "CHEMICAL", 28, 31], ["viral infection", "DISEASE", 123, 138], ["ADO", "CHEMICAL", 28, 31], ["ADO", "SIMPLE_CHEMICAL", 28, 31], ["A 1 R agonists", "GENE_OR_GENE_PRODUCT", 44, 58], ["CCPA", "SIMPLE_CHEMICAL", 60, 64], ["AFC", "GENE_OR_GENE_PRODUCT", 73, 76], ["CFTR", "GENE_OR_GENE_PRODUCT", 81, 85], ["AFC", "PROTEIN", 73, 76], ["CFTR", "PROTEIN", 81, 85], ["A 1 R agonists (CCPA", "TREATMENT", 44, 64], ["AFC via CFTR activation", "TREATMENT", 73, 96], ["viral infection", "PROBLEM", 123, 138], ["low micromolar", "OBSERVATION_MODIFIER", 13, 27], ["infection", "OBSERVATION", 129, 138]]], ["Since both ADO receptors enhance opposing fluid fluxes across the epithelial barrier, the net directionality will depend on the local fluctuations in alveolar ADO concentrations.Fluid Clearance on Alveolar EpitheliaCollectively, these studies support a complex purinergic regulation of AFC which involves P2Y 6 Rs (UDP), A 2A Rs (ADO) and A 1 Rs (ADO) (Fig. 8.1 ).", [["fluid", "ANATOMY", 42, 47], ["epithelial barrier", "ANATOMY", 66, 84], ["alveolar", "ANATOMY", 150, 158], ["Alveolar", "ANATOMY", 197, 205], ["ADO", "CHEMICAL", 11, 14], ["ADO", "CHEMICAL", 159, 162], ["UDP", "CHEMICAL", 315, 318], ["ADO", "CHEMICAL", 159, 162], ["UDP", "CHEMICAL", 315, 318], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 11, 24], ["epithelial barrier", "TISSUE", 66, 84], ["alveolar", "MULTI-TISSUE_STRUCTURE", 150, 158], ["ADO", "SIMPLE_CHEMICAL", 159, 162], ["AFC", "GENE_OR_GENE_PRODUCT", 286, 289], ["P2Y 6 Rs", "GENE_OR_GENE_PRODUCT", 305, 313], ["UDP", "SIMPLE_CHEMICAL", 315, 318], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 321, 328], ["ADO", "SIMPLE_CHEMICAL", 330, 333], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 339, 345], ["ADO", "SIMPLE_CHEMICAL", 347, 350], ["ADO receptors", "PROTEIN", 11, 24], ["opposing fluid fluxes", "PROBLEM", 33, 54], ["the epithelial barrier", "TREATMENT", 62, 84], ["alveolar ADO concentrations", "PROBLEM", 150, 177], ["Fluid Clearance", "TEST", 178, 193], ["these studies", "TEST", 229, 242], ["a complex purinergic regulation of AFC", "PROBLEM", 251, 289], ["P2Y", "TEST", 305, 308], ["opposing", "OBSERVATION_MODIFIER", 33, 41], ["fluid fluxes", "OBSERVATION", 42, 54], ["epithelial barrier", "OBSERVATION", 66, 84], ["net directionality", "OBSERVATION", 90, 108], ["alveolar ADO concentrations", "OBSERVATION", 150, 177], ["Alveolar", "ANATOMY", 197, 205]]], ["In healthy lungs, the mechanical stress induced by normal rhythmic breathing induces the release of purines and pyrimidines into the airspace.", [["lungs", "ANATOMY", 11, 16], ["airspace", "ANATOMY", 133, 141], ["purines", "CHEMICAL", 100, 107], ["pyrimidines", "CHEMICAL", 112, 123], ["purines", "CHEMICAL", 100, 107], ["pyrimidines", "CHEMICAL", 112, 123], ["lungs", "ORGAN", 11, 16], ["purines", "SIMPLE_CHEMICAL", 100, 107], ["pyrimidines", "SIMPLE_CHEMICAL", 112, 123], ["airspace", "MULTI-TISSUE_STRUCTURE", 133, 141], ["the mechanical stress", "PROBLEM", 18, 39], ["the release of purines", "TREATMENT", 85, 107], ["pyrimidines into the airspace", "PROBLEM", 112, 141], ["lungs", "ANATOMY", 11, 16], ["mechanical stress", "OBSERVATION", 22, 39], ["rhythmic breathing", "OBSERVATION", 58, 76], ["airspace", "ANATOMY", 133, 141]]], ["Under these conditions, only the ADO concentration maintained by ATP release/metabolism reaches the activation thresholds of purinergic receptors, which mediates a balanced ENaC/CFTR activation to optimize AFC.", [["ADO", "CHEMICAL", 33, 36], ["ATP", "CHEMICAL", 65, 68], ["ADO", "CHEMICAL", 33, 36], ["ATP", "CHEMICAL", 65, 68], ["ADO", "SIMPLE_CHEMICAL", 33, 36], ["ATP", "SIMPLE_CHEMICAL", 65, 68], ["ENaC", "GENE_OR_GENE_PRODUCT", 173, 177], ["CFTR", "GENE_OR_GENE_PRODUCT", 178, 182], ["AFC", "GENE_OR_GENE_PRODUCT", 206, 209], ["purinergic receptors", "PROTEIN", 125, 145], ["ENaC", "PROTEIN", 173, 177], ["CFTR", "PROTEIN", 178, 182], ["AFC", "PROTEIN", 206, 209], ["the ADO concentration", "TREATMENT", 29, 50], ["ATP release", "TREATMENT", 65, 76], ["purinergic receptors", "TREATMENT", 125, 145], ["a balanced ENaC/CFTR activation", "TREATMENT", 162, 193], ["AFC", "TEST", 206, 209]]], ["During mechanical ventilation, the excessive ATP release raises ADO levels, tilting the balance toward the CFTR-mediated fluid accumulation into the lung.", [["fluid", "ANATOMY", 121, 126], ["lung", "ANATOMY", 149, 153], ["ATP", "CHEMICAL", 45, 48], ["ADO", "CHEMICAL", 64, 67], ["ATP", "CHEMICAL", 45, 48], ["ADO", "CHEMICAL", 64, 67], ["ATP", "SIMPLE_CHEMICAL", 45, 48], ["ADO", "SIMPLE_CHEMICAL", 64, 67], ["CFTR", "GENE_OR_GENE_PRODUCT", 107, 111], ["fluid", "ORGANISM_SUBSTANCE", 121, 126], ["lung", "ORGAN", 149, 153], ["CFTR", "PROTEIN", 107, 111], ["mechanical ventilation", "TREATMENT", 7, 29], ["the excessive ATP release", "TREATMENT", 31, 56], ["ADO levels", "TEST", 64, 74], ["the CFTR", "TEST", 103, 111], ["fluid accumulation into the lung", "PROBLEM", 121, 153], ["mechanical ventilation", "OBSERVATION", 7, 29], ["fluid accumulation", "OBSERVATION", 121, 139], ["lung", "ANATOMY", 149, 153]]], ["In addition, mechanical ventilation activates lung phosphoinositides 3-kinase gamma, which degrades cAMP [29] , thereby weakening the protective effects of the ADO-A 2A R-cAMP pathway against lung edema.", [["lung", "ANATOMY", 46, 50], ["lung edema", "ANATOMY", 192, 202], ["cAMP", "CHEMICAL", 100, 104], ["ADO", "CHEMICAL", 160, 163], ["cAMP", "CHEMICAL", 171, 175], ["lung edema", "DISEASE", 192, 202], ["cAMP", "CHEMICAL", 100, 104], ["cAMP", "CHEMICAL", 171, 175], ["lung", "ORGAN", 46, 50], ["phosphoinositides 3-kinase gamma", "GENE_OR_GENE_PRODUCT", 51, 83], ["cAMP [29]", "SIMPLE_CHEMICAL", 100, 109], ["ADO-A 2A R", "GENE_OR_GENE_PRODUCT", 160, 170], ["cAMP", "SIMPLE_CHEMICAL", 171, 175], ["lung edema", "PATHOLOGICAL_FORMATION", 192, 202], ["lung phosphoinositides 3-kinase gamma", "PROTEIN", 46, 83], ["mechanical ventilation", "TREATMENT", 13, 35], ["lung phosphoinositides", "TEST", 46, 68], ["kinase gamma", "TEST", 71, 83], ["the ADO", "TREATMENT", 156, 163], ["A 2A R-cAMP pathway", "TREATMENT", 164, 183], ["lung edema", "PROBLEM", 192, 202], ["mechanical ventilation", "OBSERVATION", 13, 35], ["lung", "ANATOMY", 46, 50], ["lung", "ANATOMY", 192, 196], ["edema", "OBSERVATION", 197, 202]]], ["Consequently, patients with chronic illnesses associated with high airway ADO levels would be particularly at risk of developing pulmonary edema during mechanical ventilation, combining a dominant A 1 R-mediated flooding and a weak A 2A Rmediated AFC.", [["airway", "ANATOMY", 67, 73], ["pulmonary", "ANATOMY", 129, 138], ["chronic illnesses", "DISEASE", 28, 45], ["ADO", "CHEMICAL", 74, 77], ["pulmonary edema", "DISEASE", 129, 144], ["patients", "ORGANISM", 14, 22], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["pulmonary", "ORGAN", 129, 138], ["edema", "PATHOLOGICAL_FORMATION", 139, 144], ["A 1 R", "GENE_OR_GENE_PRODUCT", 197, 202], ["patients", "SPECIES", 14, 22], ["chronic illnesses", "PROBLEM", 28, 45], ["high airway ADO levels", "PROBLEM", 62, 84], ["developing pulmonary edema", "PROBLEM", 118, 144], ["mechanical ventilation", "TREATMENT", 152, 174], ["mediated flooding", "PROBLEM", 203, 220], ["a weak A 2A Rmediated AFC", "PROBLEM", 225, 250], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["illnesses", "OBSERVATION", 36, 45], ["pulmonary", "ANATOMY", 129, 138], ["edema", "OBSERVATION", 139, 144], ["mechanical ventilation", "OBSERVATION", 152, 174], ["dominant", "OBSERVATION_MODIFIER", 188, 196]]], ["Likewise, bacterial infection causes ATP release from alveolar epithelial cells [30, 31] , and thus initiates the same A 1 R/A 2A R imbalance toward flooding.", [["alveolar epithelial cells", "ANATOMY", 54, 79], ["infection", "DISEASE", 20, 29], ["ATP", "CHEMICAL", 37, 40], ["ATP", "CHEMICAL", 37, 40], ["ATP", "SIMPLE_CHEMICAL", 37, 40], ["alveolar epithelial cells", "CELL", 54, 79], ["A 2A R", "GENE_OR_GENE_PRODUCT", 125, 131], ["alveolar epithelial cells", "CELL_TYPE", 54, 79], ["bacterial infection", "PROBLEM", 10, 29], ["ATP release", "PROBLEM", 37, 48], ["alveolar epithelial cells", "TEST", 54, 79], ["flooding", "PROBLEM", 149, 157], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infection", "OBSERVATION", 20, 29], ["alveolar epithelial cells", "OBSERVATION", 54, 79]]], ["In the case of viral infection, the de novo synthesis and secretion of UTP provides additional UDP for P2Y 6 R activation, which causes alveolar flooding via ENaC inhibition.Fluid Clearance on Alveolar EpitheliaIn terms of therapeutic application, simultaneous inhibition of CFTR (CFTR inh\u00c0172 ), and prevention of ENaC inhibition using a blocker of UTP de novo synthesis (A77-1726), restored normal AFC in infected mice [26] .", [["alveolar", "ANATOMY", 136, 144], ["viral infection", "DISEASE", 15, 30], ["UTP", "CHEMICAL", 71, 74], ["UDP", "CHEMICAL", 95, 98], ["UTP", "CHEMICAL", 350, 353], ["A77-1726", "CHEMICAL", 373, 381], ["UTP", "CHEMICAL", 71, 74], ["UDP", "CHEMICAL", 95, 98], ["UTP", "CHEMICAL", 350, 353], ["A77-1726", "CHEMICAL", 373, 381], ["UTP", "SIMPLE_CHEMICAL", 71, 74], ["UDP", "SIMPLE_CHEMICAL", 95, 98], ["P2Y 6 R", "GENE_OR_GENE_PRODUCT", 103, 110], ["alveolar", "MULTI-TISSUE_STRUCTURE", 136, 144], ["ENaC", "GENE_OR_GENE_PRODUCT", 158, 162], ["CFTR", "GENE_OR_GENE_PRODUCT", 275, 279], ["CFTR", "GENE_OR_GENE_PRODUCT", 281, 285], ["ENaC", "GENE_OR_GENE_PRODUCT", 315, 319], ["UTP", "SIMPLE_CHEMICAL", 350, 353], ["A77-1726", "SIMPLE_CHEMICAL", 373, 381], ["AFC", "GENE_OR_GENE_PRODUCT", 400, 403], ["mice", "ORGANISM", 416, 420], ["ENaC", "PROTEIN", 158, 162], ["CFTR", "PROTEIN", 275, 279], ["CFTR inh\u00c0172", "PROTEIN", 281, 293], ["ENaC", "PROTEIN", 315, 319], ["mice", "SPECIES", 416, 420], ["mice", "SPECIES", 416, 420], ["viral infection", "PROBLEM", 15, 30], ["the de novo synthesis", "TREATMENT", 32, 53], ["UTP", "TEST", 71, 74], ["P2Y 6 R activation", "TREATMENT", 103, 121], ["alveolar flooding", "PROBLEM", 136, 153], ["ENaC inhibition", "TREATMENT", 158, 173], ["Fluid Clearance", "TEST", 174, 189], ["Alveolar EpitheliaIn terms", "TREATMENT", 193, 219], ["therapeutic application", "TREATMENT", 223, 246], ["CFTR (CFTR", "TREATMENT", 275, 285], ["ENaC inhibition", "TREATMENT", 315, 330], ["a blocker of UTP", "TREATMENT", 337, 353], ["novo synthesis", "PROBLEM", 357, 371], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["alveolar flooding", "OBSERVATION", 136, 153], ["ENaC inhibition", "OBSERVATION", 158, 173], ["Alveolar EpitheliaIn", "OBSERVATION", 193, 213]]], ["While this approach seem attractive for the treatment of pulmonary edema, clinical studies reported considerable side-effects during treatments involving A77-1726, or its prodrug leflunomide (review: [32] ).", [["pulmonary edema", "ANATOMY", 57, 72], ["pulmonary edema", "DISEASE", 57, 72], ["A77-1726", "CHEMICAL", 154, 162], ["leflunomide", "CHEMICAL", 179, 190], ["A77-1726", "CHEMICAL", 154, 162], ["leflunomide", "CHEMICAL", 179, 190], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 57, 72], ["A77-1726", "SIMPLE_CHEMICAL", 154, 162], ["leflunomide", "SIMPLE_CHEMICAL", 179, 190], ["pulmonary edema", "PROBLEM", 57, 72], ["clinical studies", "TEST", 74, 90], ["pulmonary", "ANATOMY", 57, 66], ["edema", "OBSERVATION", 67, 72]]], ["Inhibition of UTP synthesis within the cells is expected to impair critical functions, including DNA synthesis.", [["cells", "ANATOMY", 39, 44], ["UTP", "CHEMICAL", 14, 17], ["UTP", "CHEMICAL", 14, 17], ["UTP", "SIMPLE_CHEMICAL", 14, 17], ["cells", "CELL", 39, 44], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["UTP synthesis within the cells", "PROBLEM", 14, 44], ["DNA synthesis", "PROBLEM", 97, 110], ["UTP synthesis", "OBSERVATION", 14, 27]]], ["Instead, the development of drugs targeting A 1 Rs, A 2A Rs or P2Y 6 Rs would allow more flexibility in dose optimization with minimal side-effects.", [["A 1 Rs", "SIMPLE_CHEMICAL", 44, 50], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 52, 59], ["P2Y 6 Rs", "GENE_OR_GENE_PRODUCT", 63, 71], ["drugs", "TREATMENT", 28, 33], ["P2Y 6 Rs", "TREATMENT", 63, 71], ["flexibility in dose optimization", "TREATMENT", 89, 121]]], ["Since CFTR and ENaC are primarily regulated by P2Y 2 Rs and A 2B Rs in the large airways, targeting these receptors would not compromise the clearance of pathogens by the mucociliary escalator.Fluid Clearance on Alveolar EpitheliaThis section emphasizes the distinct purinergic regulations of barrier permeability on the endothelial and epithelial barriers separating the bloodstream from the alveolar space.", [["airways", "ANATOMY", 81, 88], ["mucociliary", "ANATOMY", 171, 182], ["barrier", "ANATOMY", 293, 300], ["endothelial", "ANATOMY", 321, 332], ["epithelial", "ANATOMY", 337, 347], ["bloodstream", "ANATOMY", 372, 383], ["alveolar space", "ANATOMY", 393, 407], ["CFTR", "GENE_OR_GENE_PRODUCT", 6, 10], ["ENaC", "GENE_OR_GENE_PRODUCT", 15, 19], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 47, 55], ["A 2B", "GENE_OR_GENE_PRODUCT", 60, 64], ["Rs", "GENE_OR_GENE_PRODUCT", 65, 67], ["airways", "MULTI-TISSUE_STRUCTURE", 81, 88], ["barrier", "TISSUE", 293, 300], ["endothelial", "CELL", 321, 332], ["epithelial barriers", "TISSUE", 337, 356], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 393, 407], ["CFTR", "PROTEIN", 6, 10], ["ENaC", "PROTEIN", 15, 19], ["pathogens", "PROBLEM", 154, 163], ["Fluid Clearance", "TEST", 193, 208], ["Alveolar EpitheliaThis section", "TREATMENT", 212, 242], ["barrier permeability", "TREATMENT", 293, 313], ["epithelial barriers", "TREATMENT", 337, 356], ["large", "OBSERVATION_MODIFIER", 75, 80], ["airways", "ANATOMY", 81, 88], ["Clearance", "OBSERVATION_MODIFIER", 199, 208], ["Alveolar EpitheliaThis", "OBSERVATION", 212, 234], ["distinct", "OBSERVATION_MODIFIER", 258, 266], ["purinergic regulations", "OBSERVATION", 267, 289], ["barrier permeability", "OBSERVATION_MODIFIER", 293, 313], ["endothelial", "ANATOMY", 321, 332], ["epithelial", "ANATOMY_MODIFIER", 337, 347], ["bloodstream", "OBSERVATION_MODIFIER", 372, 383], ["alveolar space", "ANATOMY", 393, 407]]], ["Armed with this information, we will begin our description of the murine models which were developed to appreciate the contribution of impaired ATP and ADO regulation in the development of acute and chronic disorders, with a critical eye on the therapeutic strategies proposed to restore lung homeostasis.Murine Models of Aberrant Purine RegulationMurine models were developed to determine the contribution of aberrant ATP and/ or ADO concentrations to the development and progression of complex disorders, including respiratory diseases.", [["eye", "ANATOMY", 234, 237], ["lung", "ANATOMY", 288, 292], ["respiratory", "ANATOMY", 517, 528], ["ATP", "CHEMICAL", 144, 147], ["ADO", "CHEMICAL", 152, 155], ["Purine", "CHEMICAL", 331, 337], ["ATP", "CHEMICAL", 419, 422], ["ADO", "CHEMICAL", 431, 434], ["respiratory diseases", "DISEASE", 517, 537], ["ATP", "CHEMICAL", 144, 147], ["ADO", "CHEMICAL", 152, 155], ["Purine", "CHEMICAL", 331, 337], ["ATP", "CHEMICAL", 419, 422], ["ADO", "CHEMICAL", 431, 434], ["murine", "ORGANISM", 66, 72], ["ATP", "SIMPLE_CHEMICAL", 144, 147], ["ADO", "SIMPLE_CHEMICAL", 152, 155], ["eye", "ORGAN", 234, 237], ["lung", "ORGAN", 288, 292], ["Murine", "ORGANISM", 305, 311], ["ATP", "SIMPLE_CHEMICAL", 419, 422], ["ADO", "SIMPLE_CHEMICAL", 431, 434], ["murine", "SPECIES", 66, 72], ["Murine", "SPECIES", 305, 311], ["impaired ATP", "PROBLEM", 135, 147], ["ADO regulation", "PROBLEM", 152, 166], ["acute and chronic disorders", "PROBLEM", 189, 216], ["the therapeutic strategies", "TREATMENT", 241, 267], ["restore lung homeostasis", "PROBLEM", 280, 304], ["Aberrant Purine RegulationMurine models", "PROBLEM", 322, 361], ["aberrant ATP", "PROBLEM", 410, 422], ["ADO concentrations", "TREATMENT", 431, 449], ["complex disorders", "PROBLEM", 488, 505], ["respiratory diseases", "PROBLEM", 517, 537], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["chronic", "OBSERVATION_MODIFIER", 199, 206], ["disorders", "OBSERVATION", 207, 216], ["eye", "ANATOMY", 234, 237], ["lung", "ANATOMY", 288, 292], ["homeostasis", "OBSERVATION", 293, 304], ["Aberrant", "OBSERVATION_MODIFIER", 322, 330], ["Purine RegulationMurine", "OBSERVATION", 331, 354], ["aberrant ATP", "OBSERVATION", 410, 422], ["progression", "OBSERVATION_MODIFIER", 473, 484], ["complex", "OBSERVATION_MODIFIER", 488, 495], ["disorders", "OBSERVATION", 496, 505], ["respiratory diseases", "OBSERVATION", 517, 537]]], ["Most mammalian cells regulate surface ATP and ADO by the sequential activities of CD39, CD73 and ADA.", [["cells", "ANATOMY", 15, 20], ["surface", "ANATOMY", 30, 37], ["ATP", "CHEMICAL", 38, 41], ["ADO", "CHEMICAL", 46, 49], ["ATP", "CHEMICAL", 38, 41], ["ADO", "CHEMICAL", 46, 49], ["mammalian cells", "CELL", 5, 20], ["surface", "CELLULAR_COMPONENT", 30, 37], ["ATP", "SIMPLE_CHEMICAL", 38, 41], ["ADO", "SIMPLE_CHEMICAL", 46, 49], ["CD39", "GENE_OR_GENE_PRODUCT", 82, 86], ["CD73", "GENE_OR_GENE_PRODUCT", 88, 92], ["ADA", "GENE_OR_GENE_PRODUCT", 97, 100], ["mammalian cells", "CELL_TYPE", 5, 20], ["CD39", "PROTEIN", 82, 86], ["CD73", "PROTEIN", 88, 92], ["ADA", "PROTEIN", 97, 100], ["ATP", "TEST", 38, 41], ["ADO", "TREATMENT", 46, 49], ["CD39", "TEST", 82, 86], ["CD73", "TEST", 88, 92], ["surface", "OBSERVATION_MODIFIER", 30, 37]]], ["First, CD39 dephosphorylates ATP and ADP into AMP, and then CD73 converts AMP into ADO.Murine Models of Aberrant Purine RegulationFinally, cell surface ADA converts a fraction of the extracellular ADO into inosine, whereas the remaining portion is transported back into the cells through concentrative transporters (see Chap.", [["cell surface", "ANATOMY", 139, 151], ["extracellular", "ANATOMY", 183, 196], ["cells", "ANATOMY", 274, 279], ["ATP", "CHEMICAL", 29, 32], ["ADP", "CHEMICAL", 37, 40], ["AMP", "CHEMICAL", 46, 49], ["AMP", "CHEMICAL", 74, 77], ["ADO", "CHEMICAL", 83, 86], ["Purine", "CHEMICAL", 113, 119], ["ADO", "CHEMICAL", 197, 200], ["inosine", "CHEMICAL", 206, 213], ["ATP", "CHEMICAL", 29, 32], ["ADP", "CHEMICAL", 37, 40], ["AMP", "CHEMICAL", 46, 49], ["AMP", "CHEMICAL", 74, 77], ["ADO", "CHEMICAL", 83, 86], ["Purine", "CHEMICAL", 113, 119], ["ADO", "CHEMICAL", 197, 200], ["inosine", "CHEMICAL", 206, 213], ["CD39", "GENE_OR_GENE_PRODUCT", 7, 11], ["ATP", "SIMPLE_CHEMICAL", 29, 32], ["ADP", "SIMPLE_CHEMICAL", 37, 40], ["AMP", "SIMPLE_CHEMICAL", 46, 49], ["CD73", "GENE_OR_GENE_PRODUCT", 60, 64], ["AMP", "SIMPLE_CHEMICAL", 74, 77], ["ADO", "SIMPLE_CHEMICAL", 83, 86], ["Murine", "ORGANISM", 87, 93], ["Purine", "SIMPLE_CHEMICAL", 113, 119], ["cell", "CELL", 139, 143], ["ADA", "SIMPLE_CHEMICAL", 152, 155], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 196], ["ADO", "SIMPLE_CHEMICAL", 197, 200], ["inosine", "SIMPLE_CHEMICAL", 206, 213], ["cells", "CELL", 274, 279], ["CD39", "PROTEIN", 7, 11], ["CD73", "PROTEIN", 60, 64], ["ADA", "PROTEIN", 152, 155], ["concentrative transporters", "PROTEIN", 288, 314], ["Chap", "PROTEIN", 320, 324], ["Murine", "SPECIES", 87, 93], ["CD39 dephosphorylates ATP", "TREATMENT", 7, 32], ["ADP into AMP", "TEST", 37, 49], ["AMP into ADO", "TREATMENT", 74, 86], ["Aberrant Purine RegulationFinally", "PROBLEM", 104, 137], ["the extracellular ADO into inosine", "TREATMENT", 179, 213], ["Aberrant", "OBSERVATION_MODIFIER", 104, 112], ["Purine RegulationFinally", "OBSERVATION", 113, 137]]], ["Consequently, animal models were designed to target each of these ectonucleotidases.", [["ectonucleotidases", "GENE_OR_GENE_PRODUCT", 66, 83], ["ectonucleotidases", "PROTEIN", 66, 83], ["these ectonucleotidases", "PROBLEM", 60, 83]]], ["In the following section, we compare the phenotype of these mice to chronic respiratory diseases bearing the same metabolic disorders, to gain an appreciation of their role in the lung complications, and determine the potential of purinergic-based therapeutic approaches.Too Much Adenosine in ADA-Deficient MiceHumans with mutations in the ada gene resulting in a lack of enzyme activity suffer from severe combined immunodeficiency (ADA-SCID) [33] .", [["respiratory", "ANATOMY", 76, 87], ["lung", "ANATOMY", 180, 184], ["respiratory diseases", "DISEASE", 76, 96], ["metabolic disorders", "DISEASE", 114, 133], ["lung complications", "DISEASE", 180, 198], ["Adenosine", "CHEMICAL", 280, 289], ["immunodeficiency", "DISEASE", 416, 432], ["SCID", "DISEASE", 438, 442], ["Adenosine", "CHEMICAL", 280, 289], ["mice", "ORGANISM", 60, 64], ["lung", "ORGAN", 180, 184], ["purinergic", "SIMPLE_CHEMICAL", 231, 241], ["Adenosine", "SIMPLE_CHEMICAL", 280, 289], ["ADA", "GENE_OR_GENE_PRODUCT", 293, 296], ["ada", "GENE_OR_GENE_PRODUCT", 340, 343], ["ADA", "PROTEIN", 293, 296], ["ada gene", "DNA", 340, 348], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["chronic respiratory diseases", "PROBLEM", 68, 96], ["the same metabolic disorders", "PROBLEM", 105, 133], ["the lung complications", "PROBLEM", 176, 198], ["Adenosine in ADA", "TREATMENT", 280, 296], ["mutations in the ada gene", "PROBLEM", 323, 348], ["a lack of enzyme activity", "PROBLEM", 362, 387], ["severe combined immunodeficiency", "PROBLEM", 400, 432], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["respiratory diseases", "OBSERVATION", 76, 96], ["lung", "ANATOMY", 180, 184], ["complications", "OBSERVATION", 185, 198], ["severe", "OBSERVATION_MODIFIER", 400, 406]]], ["Because ADA-deficient patients are extremely rare, considerable effort was expended in the generation of ada gene-targeted mice to better understand this genetic disease.", [["ADA", "GENE_OR_GENE_PRODUCT", 8, 11], ["patients", "ORGANISM", 22, 30], ["ada", "GENE_OR_GENE_PRODUCT", 105, 108], ["mice", "ORGANISM", 123, 127], ["ADA", "PROTEIN", 8, 11], ["ada gene", "DNA", 105, 113], ["patients", "SPECIES", 22, 30], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 123, 127], ["this genetic disease", "PROBLEM", 149, 169]]], ["Unfortunately, mice in which the ada gene was deleted in all tissues suffered from perinatal lethality [34, 35] .", [["tissues", "ANATOMY", 61, 68], ["mice", "ORGANISM", 15, 19], ["ada", "GENE_OR_GENE_PRODUCT", 33, 36], ["tissues", "TISSUE", 61, 68], ["ada gene", "DNA", 33, 41], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["perinatal lethality", "PROBLEM", 83, 102]]], ["Surprisingly, the cause of death was not immunodeficiency, as they survive quite well in a clean animal facility, but rather hepatotoxicity.", [["death", "DISEASE", 27, 32], ["immunodeficiency", "DISEASE", 41, 57], ["hepatotoxicity", "DISEASE", 125, 139], ["death", "PROBLEM", 27, 32], ["immunodeficiency", "PROBLEM", 41, 57], ["rather hepatotoxicity", "PROBLEM", 118, 139], ["hepatotoxicity", "OBSERVATION", 125, 139]]], ["In an attempt to create viable ada \u00c0/\u00c0 mice, Blackburn et al. engineered an ada \u00c0/\u00c0 mouse strain that expressed an ada mini-gene in the placenta using trophoblast-specific controlling elements in the ada promoter [36] .", [["placenta", "ANATOMY", 136, 144], ["trophoblast", "ANATOMY", 151, 162], ["mice", "ORGANISM", 39, 43], ["ada", "GENE_OR_GENE_PRODUCT", 76, 79], ["mouse", "ORGANISM", 84, 89], ["ada", "GENE_OR_GENE_PRODUCT", 115, 118], ["placenta", "ORGAN", 136, 144], ["trophoblast", "CELL", 151, 162], ["ada", "GENE_OR_GENE_PRODUCT", 200, 203], ["ada mini-gene", "DNA", 115, 128], ["trophoblast-specific controlling elements", "DNA", 151, 192], ["ada promoter", "DNA", 200, 212], ["mice", "SPECIES", 39, 43], ["mouse", "SPECIES", 84, 89], ["mouse", "SPECIES", 84, 89], ["mouse strain", "PROBLEM", 84, 96], ["placenta", "ANATOMY", 136, 144]]], ["These mice were viable and had normal liver function.", [["liver", "ANATOMY", 38, 43], ["mice", "ORGANISM", 6, 10], ["liver", "ORGAN", 38, 43], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["normal", "OBSERVATION", 31, 37], ["liver", "ANATOMY", 38, 43]]], ["However, they died at about 3 weeks of age from respiratory distress, characterized by severe inflammation, rapid and labored breathing.", [["respiratory", "ANATOMY", 48, 59], ["respiratory distress", "DISEASE", 48, 68], ["inflammation", "DISEASE", 94, 106], ["respiratory distress", "PROBLEM", 48, 68], ["severe inflammation", "PROBLEM", 87, 106], ["rapid and labored breathing", "PROBLEM", 108, 135], ["respiratory distress", "OBSERVATION", 48, 68], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["inflammation", "OBSERVATION", 94, 106], ["rapid", "OBSERVATION_MODIFIER", 108, 113], ["labored breathing", "OBSERVATION", 118, 135]]], ["Their lifespan was extended by treatment with polyethylene glycol-conjugated bovine ADA (PEG-ADA) [37] , the same material used for enzyme replacement therapy in ADA-deficient patients [38] .", [["polyethylene glycol", "CHEMICAL", 46, 65], ["PEG-ADA", "CHEMICAL", 89, 96], ["polyethylene glycol", "CHEMICAL", 46, 65], ["PEG-ADA", "CHEMICAL", 89, 96], ["polyethylene glycol", "SIMPLE_CHEMICAL", 46, 65], ["bovine", "ORGANISM", 77, 83], ["ADA", "SIMPLE_CHEMICAL", 84, 87], ["PEG-ADA", "SIMPLE_CHEMICAL", 89, 96], ["ADA", "SIMPLE_CHEMICAL", 162, 165], ["patients", "ORGANISM", 176, 184], ["ADA", "PROTEIN", 162, 165], ["bovine", "SPECIES", 77, 83], ["patients", "SPECIES", 176, 184], ["polyethylene glycol-conjugated bovine ADA (PEG-ADA)", "TREATMENT", 46, 97], ["the same material", "TREATMENT", 105, 122], ["enzyme replacement therapy", "TREATMENT", 132, 158]]], ["These mice received PEG-ADA intramuscularly every 4 days after birth, which partially suppressed the ADO-mediated lung inflammation.", [["lung", "ANATOMY", 114, 118], ["PEG-ADA", "CHEMICAL", 20, 27], ["ADO", "CHEMICAL", 101, 104], ["lung inflammation", "DISEASE", 114, 131], ["PEG-ADA", "CHEMICAL", 20, 27], ["ADO", "CHEMICAL", 101, 104], ["mice", "ORGANISM", 6, 10], ["PEG-ADA", "SIMPLE_CHEMICAL", 20, 27], ["ADO", "SIMPLE_CHEMICAL", 101, 104], ["lung", "ORGAN", 114, 118], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["PEG-ADA intramuscularly", "TREATMENT", 20, 43], ["the ADO-mediated lung inflammation", "PROBLEM", 97, 131], ["lung", "ANATOMY", 114, 118], ["inflammation", "OBSERVATION", 119, 131]]], ["Contrary to intranasal instillation, intramuscular injection of PEG-ADA suppresses early events in the development of lung inflammation, like leukocyte and dendritic cell migration (see Chap.", [["intramuscular", "ANATOMY", 37, 50], ["lung", "ANATOMY", 118, 122], ["leukocyte", "ANATOMY", 142, 151], ["dendritic cell", "ANATOMY", 156, 170], ["PEG-ADA", "CHEMICAL", 64, 71], ["lung inflammation", "DISEASE", 118, 135], ["PEG-ADA", "CHEMICAL", 64, 71], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["PEG-ADA", "SIMPLE_CHEMICAL", 64, 71], ["lung", "ORGAN", 118, 122], ["leukocyte", "CELL", 142, 151], ["dendritic cell", "CELL", 156, 170], ["ADA", "PROTEIN", 68, 71], ["intranasal instillation", "TREATMENT", 12, 35], ["PEG", "TREATMENT", 64, 67], ["ADA suppresses", "TREATMENT", 68, 82], ["lung inflammation", "PROBLEM", 118, 135], ["leukocyte", "PROBLEM", 142, 151], ["dendritic cell migration", "PROBLEM", 156, 180], ["lung", "ANATOMY", 118, 122], ["inflammation", "OBSERVATION", 123, 135], ["leukocyte", "ANATOMY", 142, 151], ["dendritic cell migration", "OBSERVATION", 156, 180]]], ["For the purpose of this review, these mice will be referred to as \"ADA-deficient mice\".", [["mice", "ORGANISM", 38, 42], ["ADA", "GENE_OR_GENE_PRODUCT", 67, 70], ["mice", "ORGANISM", 81, 85], ["ADA", "PROTEIN", 67, 70], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 81, 85]]], ["A second strain with partial ADA activity was generated by ectopic expression of a minigene in the gastrointestinal tract of ADA-deficient mice [39] .", [["gastrointestinal tract", "ANATOMY", 99, 121], ["ADA", "GENE_OR_GENE_PRODUCT", 29, 32], ["gastrointestinal tract", "ORGAN", 99, 121], ["ADA", "GENE_OR_GENE_PRODUCT", 125, 128], ["mice", "ORGANISM", 139, 143], ["ADA", "PROTEIN", 29, 32], ["minigene", "DNA", 83, 91], ["ADA", "PROTEIN", 125, 128], ["mice", "SPECIES", 139, 143], ["A second strain", "PROBLEM", 0, 15], ["partial ADA activity", "PROBLEM", 21, 41], ["a minigene", "TREATMENT", 81, 91], ["gastrointestinal tract", "ANATOMY", 99, 121]]], ["They developed a milder pulmonary disease and had a lifespan of about 5 months.", [["pulmonary", "ANATOMY", 24, 33], ["pulmonary disease", "DISEASE", 24, 41], ["pulmonary", "ORGAN", 24, 33], ["a milder pulmonary disease", "PROBLEM", 15, 41], ["milder", "OBSERVATION_MODIFIER", 17, 23], ["pulmonary", "ANATOMY", 24, 33], ["disease", "OBSERVATION", 34, 41]]], ["They will be referred to as \"partially ADA-deficient\" mice.Too Much Adenosine in ADA-Deficient MiceThe ADA-deficient mice appeared normal at birth, but their lungs exhibited larger alveolar spaces by day 5 [36, 37] .", [["lungs", "ANATOMY", 158, 163], ["alveolar", "ANATOMY", 181, 189], ["Adenosine", "CHEMICAL", 68, 77], ["Adenosine", "CHEMICAL", 68, 77], ["ADA", "GENE_OR_GENE_PRODUCT", 39, 42], ["mice", "ORGANISM", 54, 58], ["Adenosine", "SIMPLE_CHEMICAL", 68, 77], ["ADA", "GENE_OR_GENE_PRODUCT", 81, 84], ["ADA", "GENE_OR_GENE_PRODUCT", 103, 106], ["mice", "ORGANISM", 117, 121], ["lungs", "ORGAN", 158, 163], ["alveolar spaces", "MULTI-TISSUE_STRUCTURE", 181, 196], ["ADA", "PROTEIN", 39, 42], ["ADA", "PROTEIN", 81, 84], ["ADA", "PROTEIN", 103, 106], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 117, 121], ["Much Adenosine", "TREATMENT", 63, 77], ["ADA", "TEST", 81, 84], ["normal", "OBSERVATION", 131, 137], ["lungs", "ANATOMY", 158, 163], ["larger", "OBSERVATION_MODIFIER", 174, 180], ["alveolar", "ANATOMY_MODIFIER", 181, 189]]], ["There was no inflammatory cell in the lungs at that time, so the defect in alveogenesis preceded the onset of inflammation, which occurred around day 10.", [["inflammatory cell", "ANATOMY", 13, 30], ["lungs", "ANATOMY", 38, 43], ["alveogenesis", "DISEASE", 75, 87], ["inflammation", "DISEASE", 110, 122], ["cell", "CELL", 26, 30], ["lungs", "ORGAN", 38, 43], ["inflammatory cell in the lungs", "PROBLEM", 13, 43], ["the defect in alveogenesis", "PROBLEM", 61, 87], ["inflammation", "PROBLEM", 110, 122], ["no", "UNCERTAINTY", 10, 12], ["inflammatory cell", "OBSERVATION", 13, 30], ["lungs", "ANATOMY", 38, 43], ["defect", "OBSERVATION", 65, 71], ["onset", "OBSERVATION_MODIFIER", 101, 106], ["inflammation", "OBSERVATION", 110, 122]]], ["By day 18, abnormal alveogenesis was obvious, and was characterized by thickened vascular smooth muscles and marked enlargement of the alveolar spaces.", [["vascular smooth muscles", "ANATOMY", 81, 104], ["alveolar spaces", "ANATOMY", 135, 150], ["vascular smooth muscles", "TISSUE", 81, 104], ["alveolar", "MULTI-TISSUE_STRUCTURE", 135, 143], ["abnormal alveogenesis", "PROBLEM", 11, 32], ["thickened vascular smooth muscles", "PROBLEM", 71, 104], ["marked enlargement of the alveolar spaces", "PROBLEM", 109, 150], ["thickened", "OBSERVATION", 71, 80], ["vascular", "ANATOMY_MODIFIER", 81, 89], ["smooth muscles", "ANATOMY", 90, 104], ["marked", "OBSERVATION_MODIFIER", 109, 115], ["enlargement", "OBSERVATION", 116, 127], ["alveolar", "ANATOMY_MODIFIER", 135, 143]]], ["There was also hypertrophy of bronchial epithelia with increased mucus production, and cell debris accumulated in the airways.", [["bronchial epithelia", "ANATOMY", 30, 49], ["mucus", "ANATOMY", 65, 70], ["cell", "ANATOMY", 87, 91], ["airways", "ANATOMY", 118, 125], ["bronchial epithelia", "TISSUE", 30, 49], ["mucus", "ORGANISM_SUBSTANCE", 65, 70], ["cell", "CELL", 87, 91], ["airways", "MULTI-TISSUE_STRUCTURE", 118, 125], ["hypertrophy of bronchial epithelia", "PROBLEM", 15, 49], ["increased mucus production", "PROBLEM", 55, 81], ["cell debris", "PROBLEM", 87, 98], ["hypertrophy", "OBSERVATION", 15, 26], ["bronchial", "ANATOMY", 30, 39], ["epithelia", "ANATOMY_MODIFIER", 40, 49], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["mucus production", "OBSERVATION", 65, 81], ["cell debris", "OBSERVATION", 87, 98], ["airways", "ANATOMY", 118, 125]]], ["Most inflammatory cells in bronchoalveolar (BAL) fluid were macrophages, in the form of enlarged and foamy multinucleated giant cells, clustered around bronchioles and pulmonary vessels.", [["inflammatory cells", "ANATOMY", 5, 23], ["bronchoalveolar (BAL) fluid", "ANATOMY", 27, 54], ["macrophages", "ANATOMY", 60, 71], ["multinucleated giant cells", "ANATOMY", 107, 133], ["bronchioles", "ANATOMY", 152, 163], ["pulmonary vessels", "ANATOMY", 168, 185], ["inflammatory cells", "CELL", 5, 23], ["bronchoalveolar", "MULTI-TISSUE_STRUCTURE", 27, 42], ["macrophages", "CELL", 60, 71], ["foamy multinucleated giant cells", "CELL", 101, 133], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 152, 163], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 168, 185], ["inflammatory cells", "CELL_TYPE", 5, 23], ["macrophages", "CELL_TYPE", 60, 71], ["foamy multinucleated giant cells", "CELL_TYPE", 101, 133], ["Most inflammatory cells", "PROBLEM", 0, 23], ["bronchoalveolar (BAL) fluid", "TEST", 27, 54], ["macrophages", "PROBLEM", 60, 71], ["enlarged and foamy multinucleated giant cells", "PROBLEM", 88, 133], ["inflammatory cells", "OBSERVATION", 5, 23], ["bronchoalveolar", "ANATOMY", 27, 42], ["BAL", "ANATOMY", 44, 47], ["fluid", "OBSERVATION_MODIFIER", 49, 54], ["macrophages", "OBSERVATION_MODIFIER", 60, 71], ["enlarged", "OBSERVATION_MODIFIER", 88, 96], ["foamy", "OBSERVATION_MODIFIER", 101, 106], ["multinucleated", "OBSERVATION_MODIFIER", 107, 121], ["giant cells", "OBSERVATION", 122, 133], ["bronchioles", "ANATOMY_MODIFIER", 152, 163], ["pulmonary vessels", "ANATOMY", 168, 185]]], ["Few eosinophils accumulated in the interstitium and the luminal space.", [["eosinophils", "ANATOMY", 4, 15], ["interstitium", "ANATOMY", 35, 47], ["luminal space", "ANATOMY", 56, 69], ["luminal", "CHEMICAL", 56, 63], ["eosinophils", "CELL", 4, 15], ["interstitium", "TISSUE", 35, 47], ["luminal space", "CELLULAR_COMPONENT", 56, 69], ["eosinophils", "CELL_TYPE", 4, 15], ["Few eosinophils", "PROBLEM", 0, 15], ["eosinophils", "OBSERVATION", 4, 15], ["interstitium", "ANATOMY_MODIFIER", 35, 47], ["luminal space", "ANATOMY", 56, 69]]], ["It was suspected that these structural changes and inflammatory responses were caused by the excess ADO measured in the total lung tissue of ADA-deficient mice.", [["lung tissue", "ANATOMY", 126, 137], ["ADO", "CHEMICAL", 100, 103], ["ADO", "CHEMICAL", 100, 103], ["ADO", "SIMPLE_CHEMICAL", 100, 103], ["lung tissue", "TISSUE", 126, 137], ["ADA", "GENE_OR_GENE_PRODUCT", 141, 144], ["mice", "ORGANISM", 155, 159], ["ADA", "PROTEIN", 141, 144], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 155, 159], ["these structural changes", "PROBLEM", 22, 46], ["inflammatory responses", "PROBLEM", 51, 73], ["the excess ADO", "PROBLEM", 89, 103], ["inflammatory", "OBSERVATION_MODIFIER", 51, 63], ["lung tissue", "ANATOMY", 126, 137]]], ["Whereas lung ADO levels were barely detectable in wild-type mice, they rose about 20-fold in ADA-deficient mice, reaching a concentration of 4 nmol\u00c1mg \u00c01 protein.", [["lung", "ANATOMY", 8, 12], ["ADO", "CHEMICAL", 13, 16], ["ADO", "CHEMICAL", 13, 16], ["lung", "ORGAN", 8, 12], ["ADO", "GENE_OR_GENE_PRODUCT", 13, 16], ["mice", "ORGANISM", 60, 64], ["ADA", "GENE_OR_GENE_PRODUCT", 93, 96], ["mice", "ORGANISM", 107, 111], ["ADA", "PROTEIN", 93, 96], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 107, 111], ["lung ADO levels", "TEST", 8, 23], ["lung", "ANATOMY", 8, 12]]], ["The concentration of the other ADA substrate, deoxyADO was also elevated, but to a lesser extent (<0.05 nmol\u00c1mg \u00c01 protein), suggesting that the toxicity of this molecule for DNA synthesis played a minor role in lung pathology.", [["lung", "ANATOMY", 212, 216], ["deoxyADO", "CHEMICAL", 46, 54], ["toxicity", "DISEASE", 145, 153], ["deoxyADO", "CHEMICAL", 46, 54], ["ADA", "SIMPLE_CHEMICAL", 31, 34], ["deoxyADO", "SIMPLE_CHEMICAL", 46, 54], ["DNA", "CELLULAR_COMPONENT", 175, 178], ["lung", "ORGAN", 212, 216], ["ADA substrate", "PROTEIN", 31, 44], ["deoxyADO", "TEST", 46, 54], ["the toxicity of this molecule", "PROBLEM", 141, 170], ["DNA synthesis", "PROBLEM", 175, 188], ["lung pathology", "PROBLEM", 212, 226], ["lung", "ANATOMY", 212, 216], ["pathology", "OBSERVATION", 217, 226]]], ["The critical role of ADO was clearly demonstrated by the fact that ADA-deficient mice were essentially \"cured\" by PEG-ADA treatments.", [["ADO", "CHEMICAL", 21, 24], ["PEG-ADA", "CHEMICAL", 114, 121], ["ADO", "CHEMICAL", 21, 24], ["PEG", "CHEMICAL", 114, 117], ["ADO", "SIMPLE_CHEMICAL", 21, 24], ["ADA", "GENE_OR_GENE_PRODUCT", 67, 70], ["mice", "ORGANISM", 81, 85], ["PEG-ADA", "SIMPLE_CHEMICAL", 114, 121], ["ADA", "PROTEIN", 67, 70], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["ADA-deficient mice", "TREATMENT", 67, 85], ["PEG-ADA treatments", "TREATMENT", 114, 132]]], ["The improvements in lung physiology and histology correlated with the decrease in lung ADO concentrations.Too Much Adenosine in ADA-Deficient MiceExtensive gene profiling was conducted to gain insight into the lung pathology of the ADA-deficient mice.", [["lung", "ANATOMY", 20, 24], ["lung", "ANATOMY", 82, 86], ["lung", "ANATOMY", 210, 214], ["ADO", "CHEMICAL", 87, 90], ["Adenosine", "CHEMICAL", 115, 124], ["ADO", "CHEMICAL", 87, 90], ["Adenosine", "CHEMICAL", 115, 124], ["lung", "ORGAN", 20, 24], ["lung", "ORGAN", 82, 86], ["ADO", "SIMPLE_CHEMICAL", 87, 90], ["Adenosine", "SIMPLE_CHEMICAL", 115, 124], ["ADA", "SIMPLE_CHEMICAL", 128, 131], ["lung", "ORGAN", 210, 214], ["ADA", "GENE_OR_GENE_PRODUCT", 232, 235], ["mice", "ORGANISM", 246, 250], ["ADA", "PROTEIN", 128, 131], ["ADA", "PROTEIN", 232, 235], ["mice", "SPECIES", 246, 250], ["lung physiology", "TEST", 20, 35], ["histology", "TEST", 40, 49], ["the decrease in lung ADO concentrations", "PROBLEM", 66, 105], ["Adenosine in ADA", "TREATMENT", 115, 131], ["Deficient MiceExtensive gene profiling", "TREATMENT", 132, 170], ["improvements", "OBSERVATION_MODIFIER", 4, 16], ["lung", "ANATOMY", 20, 24], ["physiology", "OBSERVATION", 25, 35], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["lung", "ANATOMY", 82, 86], ["ADO concentrations", "OBSERVATION", 87, 105], ["lung", "ANATOMY", 210, 214]]], ["In the initial report [40] , data were generated with Atlas mouse cDNA expression arrays containing 1,176 known genes and RNA isolated at day 18 of life, when the mice were near death.", [["death", "DISEASE", 178, 183], ["mouse", "ORGANISM", 60, 65], ["mice", "ORGANISM", 163, 167], ["Atlas mouse cDNA expression arrays", "DNA", 54, 88], ["mouse", "SPECIES", 60, 65], ["mice", "SPECIES", 163, 167], ["mouse", "SPECIES", 60, 65], ["mice", "SPECIES", 163, 167], ["Atlas mouse cDNA expression arrays", "TREATMENT", 54, 88], ["known genes and RNA", "PROBLEM", 106, 125]]], ["The two genes, whose expression levels were most altered in ADA-deficient mice, were vascular endothelial growth factor (VEGF) which was down-regulated by about 50%, and monocyte chemoattractant protein-3 (MCP-3) which was up-regulated about tenfold.", [["ADA", "GENE_OR_GENE_PRODUCT", 60, 63], ["mice", "ORGANISM", 74, 78], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 85, 119], ["VEGF", "GENE_OR_GENE_PRODUCT", 121, 125], ["monocyte chemoattractant protein-3", "GENE_OR_GENE_PRODUCT", 170, 204], ["MCP-3", "GENE_OR_GENE_PRODUCT", 206, 211], ["ADA", "PROTEIN", 60, 63], ["vascular endothelial growth factor", "PROTEIN", 85, 119], ["VEGF", "PROTEIN", 121, 125], ["monocyte chemoattractant protein-3", "PROTEIN", 170, 204], ["MCP", "PROTEIN", 206, 209], ["mice", "SPECIES", 74, 78], ["vascular endothelial growth factor", "PROBLEM", 85, 119], ["monocyte chemoattractant protein", "TEST", 170, 202], ["MCP", "TEST", 206, 209], ["vascular endothelial", "ANATOMY", 85, 105]]], ["These data are consistent with the inhibitory effect of ADO on the secretion of VEGF from neutrophils, a potent inducer of endothelial barrier permeability [41] .", [["neutrophils", "ANATOMY", 90, 101], ["endothelial barrier", "ANATOMY", 123, 142], ["ADO", "CHEMICAL", 56, 59], ["ADO", "CHEMICAL", 56, 59], ["ADO", "SIMPLE_CHEMICAL", 56, 59], ["VEGF", "GENE_OR_GENE_PRODUCT", 80, 84], ["neutrophils", "CELL", 90, 101], ["endothelial barrier", "TISSUE", 123, 142], ["VEGF", "PROTEIN", 80, 84], ["neutrophils", "CELL_TYPE", 90, 101], ["neutrophils", "PROBLEM", 90, 101], ["endothelial barrier permeability", "TREATMENT", 123, 155], ["consistent with", "UNCERTAINTY", 15, 30]]], ["Therefore, these mice are not expected to develop vascular leakage or excessive leukocyte infiltration, as indicated by the vast majority of resident macrophages in the BAL fluid [36, 37] .", [["vascular", "ANATOMY", 50, 58], ["leukocyte", "ANATOMY", 80, 89], ["macrophages", "ANATOMY", 150, 161], ["BAL fluid", "ANATOMY", 169, 178], ["mice", "ORGANISM", 17, 21], ["vascular", "MULTI-TISSUE_STRUCTURE", 50, 58], ["leukocyte", "CELL", 80, 89], ["macrophages", "CELL", 150, 161], ["BAL fluid", "ORGANISM_SUBSTANCE", 169, 178], ["resident macrophages", "CELL_TYPE", 141, 161], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["vascular leakage", "PROBLEM", 50, 66], ["excessive leukocyte infiltration", "PROBLEM", 70, 102], ["the BAL fluid", "TEST", 165, 178], ["vascular", "ANATOMY", 50, 58], ["leakage", "OBSERVATION", 59, 66], ["excessive", "OBSERVATION_MODIFIER", 70, 79], ["leukocyte infiltration", "OBSERVATION", 80, 102], ["macrophages", "OBSERVATION", 150, 161], ["BAL", "ANATOMY", 169, 172]]], ["Other genes related to eosinophil trafficking, cell adhesion, inflammation and fibrosis were also significantly up-regulated in the lungs of the ADA-deficient mice.", [["eosinophil", "ANATOMY", 23, 33], ["cell", "ANATOMY", 47, 51], ["lungs", "ANATOMY", 132, 137], ["inflammation", "DISEASE", 62, 74], ["fibrosis", "DISEASE", 79, 87], ["eosinophil", "CELL", 23, 33], ["cell", "CELL", 47, 51], ["lungs", "ORGAN", 132, 137], ["ADA", "GENE_OR_GENE_PRODUCT", 145, 148], ["mice", "ORGANISM", 159, 163], ["ADA", "PROTEIN", 145, 148], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 159, 163], ["eosinophil trafficking", "PROBLEM", 23, 45], ["cell adhesion", "PROBLEM", 47, 60], ["inflammation", "PROBLEM", 62, 74], ["fibrosis", "PROBLEM", 79, 87], ["eosinophil trafficking", "OBSERVATION", 23, 45], ["cell adhesion", "OBSERVATION", 47, 60], ["inflammation", "OBSERVATION", 62, 74], ["fibrosis", "OBSERVATION", 79, 87], ["lungs", "ANATOMY", 132, 137]]], ["Importantly, the expression of all these genes was largely normalized by treating the mice with PEG-ADA under dosing conditions that prevented lung pathology.", [["lung", "ANATOMY", 143, 147], ["PEG-ADA", "CHEMICAL", 96, 103], ["PEG-ADA", "CHEMICAL", 96, 103], ["mice", "ORGANISM", 86, 90], ["PEG-ADA", "SIMPLE_CHEMICAL", 96, 103], ["lung", "ORGAN", 143, 147], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["PEG", "TREATMENT", 96, 99], ["ADA under dosing conditions", "TREATMENT", 100, 127], ["lung pathology", "PROBLEM", 143, 157], ["lung", "ANATOMY", 143, 147], ["pathology", "OBSERVATION", 148, 157]]], ["The second study was more extensive and used arrays containing 7,056 oligonucleotides (70-mers) that were produced at the UCSF Sandler Center of Basic Research in Asthma [42] .", [["Asthma", "DISEASE", 163, 169], ["The second study", "TEST", 0, 16], ["arrays containing 7,056 oligonucleotides", "TREATMENT", 45, 85], ["Asthma", "PROBLEM", 163, 169]]], ["The aim of this study was to identify the pathways causing abnormal alveogenesis in ADA-deficient mice.", [["abnormal alveogenesis", "DISEASE", 59, 80], ["ADA", "GENE_OR_GENE_PRODUCT", 84, 87], ["mice", "ORGANISM", 98, 102], ["ADA", "PROTEIN", 84, 87], ["mice", "SPECIES", 98, 102], ["this study", "TEST", 11, 21], ["abnormal alveogenesis in ADA-deficient mice", "PROBLEM", 59, 102]]], ["Therefore, RNA samples were collected at earlier time points: at birth and at 5 and 10 days of life.", [["samples", "ANATOMY", 15, 22], ["RNA samples", "TEST", 11, 22]]], ["This study showed that ADA deficiency up-regulates genes involved in apoptosis, but down-regulates genes coding growth factors and their receptors, as well as surfactant proteins and angiogenic factors.", [["ADA", "GENE_OR_GENE_PRODUCT", 23, 26], ["ADA", "PROTEIN", 23, 26], ["growth factors", "PROTEIN", 112, 126], ["surfactant proteins", "PROTEIN", 159, 178], ["angiogenic factors", "PROTEIN", 183, 201], ["This study", "TEST", 0, 10], ["ADA deficiency", "PROBLEM", 23, 37], ["apoptosis", "PROBLEM", 69, 78], ["coding growth factors", "PROBLEM", 105, 126], ["surfactant proteins", "TREATMENT", 159, 178], ["angiogenic factors", "PROBLEM", 183, 201], ["ADA deficiency", "OBSERVATION", 23, 37], ["apoptosis", "OBSERVATION_MODIFIER", 69, 78]]], ["As for the first study, these changes in gene expression were largely reversed by treatment with PEG-ADA.", [["PEG-ADA", "CHEMICAL", 97, 104], ["PEG-ADA", "CHEMICAL", 97, 104], ["PEG-ADA", "SIMPLE_CHEMICAL", 97, 104], ["ADA", "PROTEIN", 101, 104], ["the first study", "TEST", 7, 22], ["these changes in gene expression", "PROBLEM", 24, 56], ["PEG", "TREATMENT", 97, 100]]], ["These data suggest that excess ADO, reported in the airways of patients with asthma and COPD [43, 44] impacts the developing lung via multiple pathways including apoptosis, proliferation and migration, which would promote the development of airway remodeling and sub-epithelial fibrosis.", [["airways", "ANATOMY", 52, 59], ["lung", "ANATOMY", 125, 129], ["airway", "ANATOMY", 241, 247], ["epithelial", "ANATOMY", 267, 277], ["ADO", "CHEMICAL", 31, 34], ["asthma", "DISEASE", 77, 83], ["COPD", "DISEASE", 88, 92], ["fibrosis", "DISEASE", 278, 286], ["ADO", "CHEMICAL", 31, 34], ["ADO", "SIMPLE_CHEMICAL", 31, 34], ["airways", "MULTI-TISSUE_STRUCTURE", 52, 59], ["patients", "ORGANISM", 63, 71], ["lung", "ORGAN", 125, 129], ["airway", "MULTI-TISSUE_STRUCTURE", 241, 247], ["epithelial", "TISSUE", 267, 277], ["patients", "SPECIES", 63, 71], ["These data", "TEST", 0, 10], ["excess ADO", "PROBLEM", 24, 34], ["asthma", "PROBLEM", 77, 83], ["COPD", "PROBLEM", 88, 92], ["the developing lung via multiple pathways", "PROBLEM", 110, 151], ["apoptosis", "PROBLEM", 162, 171], ["proliferation", "PROBLEM", 173, 186], ["migration", "PROBLEM", 191, 200], ["airway remodeling", "PROBLEM", 241, 258], ["sub-epithelial fibrosis", "PROBLEM", 263, 286], ["excess ADO", "OBSERVATION", 24, 34], ["airways", "ANATOMY", 52, 59], ["asthma", "OBSERVATION", 77, 83], ["COPD", "OBSERVATION", 88, 92], ["lung", "ANATOMY", 125, 129], ["multiple", "OBSERVATION_MODIFIER", 134, 142], ["apoptosis", "OBSERVATION", 162, 171], ["proliferation", "OBSERVATION_MODIFIER", 173, 186], ["migration", "OBSERVATION_MODIFIER", 191, 200], ["airway", "ANATOMY", 241, 247], ["remodeling", "OBSERVATION", 248, 258], ["sub-", "OBSERVATION_MODIFIER", 263, 267], ["epithelial", "ANATOMY_MODIFIER", 267, 277], ["fibrosis", "OBSERVATION", 278, 286]]], ["Yet, the short lifespan of the ADAdeficient mice did not allow for adequate documentation of these manifestations.Too Much Adenosine in ADA-Deficient MiceThe long-term consequences of high lung ADO concentrations were investigated using two different approaches: untreated partially-deficient ADA mice [39] and ADA-deficient mice treated with low doses of PEG-ADA over the course of 16 weeks [45] .", [["lung", "ANATOMY", 189, 193], ["Adenosine", "CHEMICAL", 123, 132], ["ADO", "CHEMICAL", 194, 197], ["PEG-ADA", "CHEMICAL", 356, 363], ["Adenosine", "CHEMICAL", 123, 132], ["ADO", "CHEMICAL", 194, 197], ["PEG", "CHEMICAL", 356, 359], ["mice", "ORGANISM", 44, 48], ["Adenosine", "SIMPLE_CHEMICAL", 123, 132], ["ADA", "SIMPLE_CHEMICAL", 136, 139], ["Mice", "ORGANISM", 150, 154], ["lung", "ORGAN", 189, 193], ["ADO", "SIMPLE_CHEMICAL", 194, 197], ["ADA", "ORGANISM", 293, 296], ["mice", "ORGANISM", 297, 301], ["ADA", "GENE_OR_GENE_PRODUCT", 311, 314], ["mice", "ORGANISM", 325, 329], ["PEG-ADA", "SIMPLE_CHEMICAL", 356, 363], ["ADA", "PROTEIN", 136, 139], ["ADA", "PROTEIN", 311, 314], ["mice", "SPECIES", 44, 48], ["Mice", "SPECIES", 150, 154], ["mice", "SPECIES", 297, 301], ["mice", "SPECIES", 325, 329], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 325, 329], ["these manifestations", "PROBLEM", 93, 113], ["Adenosine in ADA", "TREATMENT", 123, 139], ["high lung ADO concentrations", "PROBLEM", 184, 212], ["untreated partially-deficient ADA mice", "TREATMENT", 263, 301], ["ADA-deficient mice", "TREATMENT", 311, 329], ["PEG", "TREATMENT", 356, 359], ["ADA", "TREATMENT", 360, 363], ["long-term", "OBSERVATION_MODIFIER", 158, 167], ["lung", "ANATOMY", 189, 193]]], ["Under these conditions, both cohorts eventually maintained comparable lung ADO levels ( 1.0 nmol\u00c1mg \u00c01 protein), which were at least fourfold lower than untreated ADA-deficient mice.", [["lung", "ANATOMY", 70, 74], ["ADO", "CHEMICAL", 75, 78], ["ADO", "CHEMICAL", 75, 78], ["lung", "ORGAN", 70, 74], ["ADO", "SIMPLE_CHEMICAL", 75, 78], ["ADA", "GENE_OR_GENE_PRODUCT", 163, 166], ["mice", "ORGANISM", 177, 181], ["ADA", "PROTEIN", 163, 166], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 177, 181], ["comparable lung ADO levels", "TEST", 59, 85], ["lung", "ANATOMY", 70, 74]]], ["As a consequence, both cohorts developed severe lung pathology and died from respiratory distress at about 5 months of age.", [["lung", "ANATOMY", 48, 52], ["respiratory", "ANATOMY", 77, 88], ["respiratory distress", "DISEASE", 77, 97], ["lung", "ORGAN", 48, 52], ["severe lung pathology", "PROBLEM", 41, 62], ["respiratory distress", "PROBLEM", 77, 97], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["lung", "ANATOMY", 48, 52], ["pathology", "OBSERVATION", 53, 62], ["respiratory distress", "OBSERVATION", 77, 97]]], ["These models allowed the authors to analyze the long-term impact of high ADO concentrations on the respiratory system to better understand the implications for chronic airway diseases.", [["airway", "ANATOMY", 168, 174], ["ADO", "CHEMICAL", 73, 76], ["chronic airway diseases", "DISEASE", 160, 183], ["ADO", "CHEMICAL", 73, 76], ["ADO", "SIMPLE_CHEMICAL", 73, 76], ["airway", "MULTI-TISSUE_STRUCTURE", 168, 174], ["the respiratory system", "TREATMENT", 95, 117], ["chronic airway diseases", "PROBLEM", 160, 183], ["airway", "ANATOMY", 168, 174], ["diseases", "OBSERVATION", 175, 183]]], ["After completion of the 16 weeks of treatment, the ADA-deficient mice exhibited lung complications comparable to untreated partially ADA-deficient mice [45] .", [["lung", "ANATOMY", 80, 84], ["lung complications", "DISEASE", 80, 98], ["ADA", "GENE_OR_GENE_PRODUCT", 51, 54], ["mice", "ORGANISM", 65, 69], ["lung", "ORGAN", 80, 84], ["ADA", "GENE_OR_GENE_PRODUCT", 133, 136], ["mice", "ORGANISM", 147, 151], ["ADA", "PROTEIN", 51, 54], ["ADA", "PROTEIN", 133, 136], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 65, 69], ["treatment", "TREATMENT", 36, 45], ["the ADA-deficient mice", "TREATMENT", 47, 69], ["lung complications", "PROBLEM", 80, 98], ["lung", "ANATOMY", 80, 84], ["complications", "OBSERVATION", 85, 98]]], ["While the inflammatory response was still dominated by multinucleated macrophages, BAL fluid also accumulated lymphocytes, neutrophils and eosinophils.", [["multinucleated macrophages", "ANATOMY", 55, 81], ["BAL fluid", "ANATOMY", 83, 92], ["lymphocytes", "ANATOMY", 110, 121], ["neutrophils", "ANATOMY", 123, 134], ["eosinophils", "ANATOMY", 139, 150], ["multinucleated macrophages", "CELL", 55, 81], ["BAL fluid", "ORGANISM_SUBSTANCE", 83, 92], ["lymphocytes", "CELL", 110, 121], ["neutrophils", "CELL", 123, 134], ["eosinophils", "CELL", 139, 150], ["multinucleated macrophages", "CELL_TYPE", 55, 81], ["lymphocytes", "CELL_TYPE", 110, 121], ["neutrophils", "CELL_TYPE", 123, 134], ["eosinophils", "CELL_TYPE", 139, 150], ["the inflammatory response", "TEST", 6, 31], ["multinucleated macrophages", "PROBLEM", 55, 81], ["BAL fluid", "TEST", 83, 92], ["lymphocytes", "TEST", 110, 121], ["neutrophils", "TEST", 123, 134], ["eosinophils", "TEST", 139, 150], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["multinucleated macrophages", "OBSERVATION", 55, 81], ["BAL fluid", "OBSERVATION", 83, 92], ["accumulated lymphocytes", "OBSERVATION", 98, 121], ["neutrophils", "OBSERVATION_MODIFIER", 123, 134]]], ["The histology revealed extensive remodeling, characterized by epithelial cell hyperplasia and hypertrophy, pulmonary fibrosis, matrix deposition and smooth muscle cell thickening.", [["epithelial cell", "ANATOMY", 62, 77], ["pulmonary", "ANATOMY", 107, 116], ["matrix", "ANATOMY", 127, 133], ["smooth muscle cell", "ANATOMY", 149, 167], ["hypertrophy", "DISEASE", 94, 105], ["fibrosis", "DISEASE", 117, 125], ["epithelial cell", "CELL", 62, 77], ["pulmonary", "ORGAN", 107, 116], ["matrix", "CELLULAR_COMPONENT", 127, 133], ["smooth muscle cell", "CELL", 149, 167], ["The histology", "TEST", 0, 13], ["extensive remodeling", "PROBLEM", 23, 43], ["epithelial cell hyperplasia", "PROBLEM", 62, 89], ["hypertrophy", "PROBLEM", 94, 105], ["pulmonary fibrosis", "PROBLEM", 107, 125], ["matrix deposition", "PROBLEM", 127, 144], ["smooth muscle cell thickening", "PROBLEM", 149, 178], ["extensive", "OBSERVATION_MODIFIER", 23, 32], ["remodeling", "OBSERVATION", 33, 43], ["epithelial cell hyperplasia", "OBSERVATION", 62, 89], ["hypertrophy", "OBSERVATION", 94, 105], ["pulmonary", "ANATOMY", 107, 116], ["fibrosis", "OBSERVATION", 117, 125], ["matrix deposition", "OBSERVATION", 127, 144], ["smooth", "OBSERVATION_MODIFIER", 149, 155], ["muscle cell thickening", "OBSERVATION", 156, 178]]], ["These observations were confirmed by real-time PCR analysis of the lung tissue, which showed that chronically-elevated ADO up-regulates several pro-fibrotic factors (TGFb1, osteopontin, plasminogen activator inhibitor-1 and matrix metalloproteinase-2) and pro-inflammatory Th2 cytokines (IL-1b and IL-13) [45] .", [["lung tissue", "ANATOMY", 67, 78], ["ADO", "CHEMICAL", 119, 122], ["ADO", "CHEMICAL", 119, 122], ["lung tissue", "TISSUE", 67, 78], ["ADO", "SIMPLE_CHEMICAL", 119, 122], ["TGFb1", "GENE_OR_GENE_PRODUCT", 166, 171], ["osteopontin", "GENE_OR_GENE_PRODUCT", 173, 184], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 186, 219], ["matrix metalloproteinase-2", "GENE_OR_GENE_PRODUCT", 224, 250], ["IL-1b", "GENE_OR_GENE_PRODUCT", 288, 293], ["IL-13", "GENE_OR_GENE_PRODUCT", 298, 303], ["pro-fibrotic factors", "PROTEIN", 144, 164], ["TGFb1", "PROTEIN", 166, 171], ["osteopontin", "PROTEIN", 173, 184], ["plasminogen activator inhibitor-1", "PROTEIN", 186, 219], ["matrix metalloproteinase-2", "PROTEIN", 224, 250], ["pro-inflammatory Th2 cytokines", "PROTEIN", 256, 286], ["IL-1b and IL-13", "PROTEIN", 288, 303], ["real-time PCR analysis", "TEST", 37, 59], ["elevated ADO", "PROBLEM", 110, 122], ["several pro-fibrotic factors", "PROBLEM", 136, 164], ["TGFb1", "TEST", 166, 171], ["osteopontin", "TEST", 173, 184], ["plasminogen activator inhibitor", "TREATMENT", 186, 217], ["matrix metalloproteinase", "TEST", 224, 248], ["pro-inflammatory Th2 cytokines", "TEST", 256, 286], ["IL", "TEST", 288, 290], ["IL", "TEST", 298, 300], ["lung tissue", "ANATOMY", 67, 78]]], ["Functional experiments conducted on dendritic cells showed that chronic exposure to excess ADO reduces the capacity to initiate and amplify a Th1 immune response [46] .", [["dendritic cells", "ANATOMY", 36, 51], ["ADO", "CHEMICAL", 91, 94], ["ADO", "CHEMICAL", 91, 94], ["dendritic cells", "CELL", 36, 51], ["ADO", "SIMPLE_CHEMICAL", 91, 94], ["dendritic cells", "CELL_TYPE", 36, 51], ["dendritic cells", "PROBLEM", 36, 51], ["chronic exposure", "PROBLEM", 64, 80], ["excess ADO", "PROBLEM", 84, 94], ["the capacity", "PROBLEM", 103, 115], ["chronic", "OBSERVATION_MODIFIER", 64, 71]]], ["These complications were largely reversed by 5 weeks of high-dose PEG-ADA in ADA-deficient mice initially treated 13 weeks with low-dose PEG-ADA [45] .Too Much Adenosine in ADA-Deficient MiceThe partially ADA-deficient mice also adopted Th2-skewed lung inflammatory responses typical of pulmonary fibrosis and asthma [47] [48] [49] .", [["lung", "ANATOMY", 248, 252], ["pulmonary", "ANATOMY", 287, 296], ["PEG-ADA", "CHEMICAL", 66, 73], ["PEG-ADA", "CHEMICAL", 137, 144], ["Adenosine", "CHEMICAL", 160, 169], ["pulmonary fibrosis", "DISEASE", 287, 305], ["asthma", "DISEASE", 310, 316], ["PEG", "CHEMICAL", 66, 69], ["PEG", "CHEMICAL", 137, 140], ["Adenosine", "CHEMICAL", 160, 169], ["PEG-ADA", "SIMPLE_CHEMICAL", 66, 73], ["ADA", "SIMPLE_CHEMICAL", 77, 80], ["mice", "ORGANISM", 91, 95], ["PEG-ADA", "SIMPLE_CHEMICAL", 137, 144], ["Adenosine", "SIMPLE_CHEMICAL", 160, 169], ["ADA-Deficient MiceThe", "SIMPLE_CHEMICAL", 173, 194], ["ADA", "GENE_OR_GENE_PRODUCT", 205, 208], ["mice", "ORGANISM", 219, 223], ["lung", "ORGAN", 248, 252], ["pulmonary", "ORGAN", 287, 296], ["ADA", "PROTEIN", 70, 73], ["ADA", "PROTEIN", 77, 80], ["ADA", "PROTEIN", 205, 208], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 219, 223], ["high-dose PEG", "TREATMENT", 56, 69], ["ADA in ADA-deficient mice", "TREATMENT", 70, 95], ["low-dose PEG-ADA", "TREATMENT", 128, 144], ["Adenosine in ADA", "TREATMENT", 160, 176], ["skewed lung inflammatory responses", "PROBLEM", 241, 275], ["pulmonary fibrosis", "PROBLEM", 287, 305], ["asthma", "PROBLEM", 310, 316], ["lung", "ANATOMY", 248, 252], ["inflammatory", "OBSERVATION", 253, 265], ["pulmonary", "ANATOMY", 287, 296], ["fibrosis", "OBSERVATION", 297, 305]]], ["The transcript of IL-13 was undetected in the lung tissue of wild-type animals, but easily measured in partially ADA-deficient mice [50] .", [["lung tissue", "ANATOMY", 46, 57], ["IL-13", "GENE_OR_GENE_PRODUCT", 18, 23], ["lung tissue", "TISSUE", 46, 57], ["animals", "ORGANISM", 71, 78], ["ADA", "GENE_OR_GENE_PRODUCT", 113, 116], ["mice", "ORGANISM", 127, 131], ["IL-13", "PROTEIN", 18, 23], ["ADA", "PROTEIN", 113, 116], ["mice", "SPECIES", 127, 131], ["The transcript of IL", "TREATMENT", 0, 20], ["lung", "ANATOMY", 46, 50], ["tissue", "ANATOMY_MODIFIER", 51, 57]]], ["Other Th2 cytokines were up-regulated (IL-4 and IL-5), whereas the Th1 cytokine, IFNg, was down-regulated, compared to wildtype mice [50] .", [["Th2", "GENE_OR_GENE_PRODUCT", 6, 9], ["IL-4", "GENE_OR_GENE_PRODUCT", 39, 43], ["IL-5", "GENE_OR_GENE_PRODUCT", 48, 52], ["Th1", "GENE_OR_GENE_PRODUCT", 67, 70], ["IFNg", "GENE_OR_GENE_PRODUCT", 81, 85], ["mice", "ORGANISM", 128, 132], ["Th2 cytokines", "PROTEIN", 6, 19], ["Th1 cytokine", "PROTEIN", 67, 79], ["IFNg", "PROTEIN", 81, 85], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["Other Th2 cytokines", "TEST", 0, 19], ["IL", "TEST", 39, 41]]], ["Interestingly, IL-13 transgenic mice share many lung complications with partially ADA-deficient mice [51, 52].", [["lung", "ANATOMY", 48, 52], ["lung complications", "DISEASE", 48, 66], ["IL-13", "GENE_OR_GENE_PRODUCT", 15, 20], ["mice", "ORGANISM", 32, 36], ["lung", "ORGAN", 48, 52], ["ADA", "GENE_OR_GENE_PRODUCT", 82, 85], ["mice", "ORGANISM", 96, 100], ["IL-13", "PROTEIN", 15, 20], ["ADA", "PROTEIN", 82, 85], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 32, 36], ["many lung complications", "PROBLEM", 43, 66], ["lung", "ANATOMY", 48, 52], ["complications", "OBSERVATION", 53, 66]]], ["They develop inflammatory infiltrates enriched in macrophages and eosinophils, airway epithelial cell hypertrophy and fibrosis, mucus cell metaplasia and hypersecretion.", [["macrophages", "ANATOMY", 50, 61], ["eosinophils", "ANATOMY", 66, 77], ["airway epithelial cell", "ANATOMY", 79, 101], ["mucus cell metaplasia", "ANATOMY", 128, 149], ["fibrosis", "DISEASE", 118, 126], ["macrophages", "CELL", 50, 61], ["eosinophils", "CELL", 66, 77], ["airway epithelial cell", "CELL", 79, 101], ["mucus cell metaplasia", "CANCER", 128, 149], ["macrophages", "CELL_TYPE", 50, 61], ["eosinophils", "CELL_TYPE", 66, 77], ["inflammatory infiltrates", "PROBLEM", 13, 37], ["macrophages", "PROBLEM", 50, 61], ["eosinophils", "TEST", 66, 77], ["airway epithelial cell hypertrophy", "PROBLEM", 79, 113], ["fibrosis", "PROBLEM", 118, 126], ["mucus cell metaplasia", "PROBLEM", 128, 149], ["hypersecretion", "PROBLEM", 154, 168], ["inflammatory", "OBSERVATION_MODIFIER", 13, 25], ["infiltrates", "OBSERVATION", 26, 37], ["macrophages", "ANATOMY", 50, 61], ["eosinophils", "OBSERVATION_MODIFIER", 66, 77], ["airway", "ANATOMY", 79, 85], ["epithelial cell hypertrophy", "OBSERVATION", 86, 113], ["fibrosis", "OBSERVATION", 118, 126], ["mucus cell metaplasia", "OBSERVATION", 128, 149], ["hypersecretion", "OBSERVATION", 154, 168]]], ["Furthermore, IL-13 transgenic mice exhibit high lung ADO levels and a reduced ADA expression.", [["lung", "ANATOMY", 48, 52], ["ADO", "CHEMICAL", 53, 56], ["IL-13", "GENE_OR_GENE_PRODUCT", 13, 18], ["mice", "ORGANISM", 30, 34], ["lung", "ORGAN", 48, 52], ["ADO", "SIMPLE_CHEMICAL", 53, 56], ["ADA", "GENE_OR_GENE_PRODUCT", 78, 81], ["IL", "PROTEIN", 13, 15], ["ADA", "PROTEIN", 78, 81], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["IL", "TEST", 13, 15], ["high lung ADO levels", "PROBLEM", 43, 63], ["a reduced ADA expression", "PROBLEM", 68, 92], ["lung", "ANATOMY", 48, 52], ["ADO levels", "OBSERVATION", 53, 63], ["reduced", "OBSERVATION_MODIFIER", 70, 77], ["ADA expression", "OBSERVATION", 78, 92]]], ["The fact that most lung complications of IL-13 transgenic mice and partially-deficient ADA mice were resolved by PEG-ADA treatment supports the existence of a positive amplification pathway for IL-13 and ADO accumulation in the lungs.", [["lung", "ANATOMY", 19, 23], ["lungs", "ANATOMY", 228, 233], ["PEG-ADA", "CHEMICAL", 113, 120], ["ADO", "CHEMICAL", 204, 207], ["PEG-ADA", "CHEMICAL", 113, 120], ["ADO", "CHEMICAL", 204, 207], ["lung", "ORGAN", 19, 23], ["IL-13", "GENE_OR_GENE_PRODUCT", 41, 46], ["mice", "ORGANISM", 58, 62], ["ADA mice", "ORGANISM", 87, 95], ["PEG-ADA", "SIMPLE_CHEMICAL", 113, 120], ["IL-13", "GENE_OR_GENE_PRODUCT", 194, 199], ["ADO", "SIMPLE_CHEMICAL", 204, 207], ["lungs", "ORGAN", 228, 233], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["IL-13 transgenic mice", "TREATMENT", 41, 62], ["partially-deficient ADA mice", "PROBLEM", 67, 95], ["PEG-ADA treatment", "TREATMENT", 113, 130], ["a positive amplification pathway", "TREATMENT", 157, 189], ["IL", "TEST", 194, 196], ["ADO accumulation in the lungs", "PROBLEM", 204, 233], ["most", "OBSERVATION_MODIFIER", 14, 18], ["lung", "ANATOMY", 19, 23], ["complications", "OBSERVATION", 24, 37], ["lungs", "ANATOMY", 228, 233]]], ["Whereas high ADO levels upregulate IL-13, the overexpression of this cytokine promotes ADO accumulation by a reduction in ADA activity.", [["ADO", "CHEMICAL", 13, 16], ["ADO", "CHEMICAL", 87, 90], ["ADO", "CHEMICAL", 13, 16], ["ADO", "CHEMICAL", 87, 90], ["ADO", "SIMPLE_CHEMICAL", 13, 16], ["IL-13", "GENE_OR_GENE_PRODUCT", 35, 40], ["ADO", "SIMPLE_CHEMICAL", 87, 90], ["ADA", "SIMPLE_CHEMICAL", 122, 125], ["IL-13", "PROTEIN", 35, 40], ["cytokine", "PROTEIN", 69, 77], ["ADA", "PROTEIN", 122, 125], ["high ADO levels upregulate", "PROBLEM", 8, 34], ["IL", "TEST", 35, 37], ["ADO accumulation", "PROBLEM", 87, 103], ["a reduction in ADA activity", "TREATMENT", 107, 134], ["ADO accumulation", "OBSERVATION", 87, 103], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["ADA activity", "OBSERVATION", 122, 134]]], ["These findings are consistent with an in vitro study conducted on cultures of human bronchial epithelia cells, whereby chronic exposure to excess ADO raised IL-13 mRNA levels by sixfold [53] .", [["bronchial epithelia cells", "ANATOMY", 84, 109], ["ADO", "CHEMICAL", 146, 149], ["ADO", "CHEMICAL", 146, 149], ["human", "ORGANISM", 78, 83], ["bronchial epithelia cells", "CELL", 84, 109], ["ADO", "SIMPLE_CHEMICAL", 146, 149], ["IL-13", "GENE_OR_GENE_PRODUCT", 157, 162], ["human bronchial epithelia cells", "CELL_TYPE", 78, 109], ["IL-13 mRNA", "RNA", 157, 167], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["an in vitro study", "TEST", 35, 52], ["cultures", "TEST", 66, 74], ["human bronchial epithelia cells", "PROBLEM", 78, 109], ["chronic exposure", "PROBLEM", 119, 135], ["excess ADO raised IL", "PROBLEM", 139, 159], ["mRNA levels", "TEST", 163, 174], ["consistent with", "UNCERTAINTY", 19, 34], ["bronchial", "ANATOMY", 84, 93], ["epithelia cells", "OBSERVATION", 94, 109], ["chronic", "OBSERVATION_MODIFIER", 119, 126]]], ["This Th2 cytokine, which promotes eosinophilia, remodeling and fibrosis (review: [54]), likely plays a major role in the development of lung complications associated with excess airway ADO.Too Much Adenosine in ADA-Deficient MiceNeovascularization is a major complication of chronic inflammatory disorders, including asthma (review: [55] ).", [["lung", "ANATOMY", 136, 140], ["airway", "ANATOMY", 178, 184], ["eosinophilia", "DISEASE", 34, 46], ["fibrosis", "DISEASE", 63, 71], ["lung complications", "DISEASE", 136, 154], ["ADO", "CHEMICAL", 185, 188], ["Adenosine", "CHEMICAL", 198, 207], ["MiceNeovascularization", "DISEASE", 225, 247], ["inflammatory disorders", "DISEASE", 283, 305], ["asthma", "DISEASE", 317, 323], ["Adenosine", "CHEMICAL", 198, 207], ["Th2", "GENE_OR_GENE_PRODUCT", 5, 8], ["lung", "ORGAN", 136, 140], ["airway", "MULTI-TISSUE_STRUCTURE", 178, 184], ["Adenosine", "SIMPLE_CHEMICAL", 198, 207], ["ADA", "SIMPLE_CHEMICAL", 211, 214], ["Th2 cytokine", "PROTEIN", 5, 17], ["eosinophilia", "PROBLEM", 34, 46], ["remodeling and fibrosis", "PROBLEM", 48, 71], ["lung complications", "PROBLEM", 136, 154], ["excess airway ADO", "PROBLEM", 171, 188], ["Adenosine in ADA", "TREATMENT", 198, 214], ["Deficient MiceNeovascularization", "PROBLEM", 215, 247], ["chronic inflammatory disorders", "PROBLEM", 275, 305], ["asthma", "PROBLEM", 317, 323], ["eosinophilia", "OBSERVATION", 34, 46], ["fibrosis", "OBSERVATION", 63, 71], ["lung", "ANATOMY", 136, 140], ["complications", "OBSERVATION", 141, 154], ["airway", "ANATOMY", 178, 184], ["chronic", "OBSERVATION_MODIFIER", 275, 282], ["inflammatory", "OBSERVATION", 283, 295]]], ["Inflammation stimulates the growth of new blood vessels, which enhances inflammatory cell recruitment, airway obstruction and hyper-responsiveness.", [["blood vessels", "ANATOMY", 42, 55], ["inflammatory cell", "ANATOMY", 72, 89], ["airway", "ANATOMY", 103, 109], ["Inflammation", "DISEASE", 0, 12], ["airway obstruction", "DISEASE", 103, 121], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 42, 55], ["cell", "CELL", 85, 89], ["airway", "MULTI-TISSUE_STRUCTURE", 103, 109], ["Inflammation", "PROBLEM", 0, 12], ["new blood vessels", "PROBLEM", 38, 55], ["inflammatory cell recruitment", "TREATMENT", 72, 101], ["airway obstruction", "PROBLEM", 103, 121], ["hyper-responsiveness", "PROBLEM", 126, 146], ["growth", "OBSERVATION_MODIFIER", 28, 34], ["new", "OBSERVATION_MODIFIER", 38, 41], ["blood vessels", "ANATOMY", 42, 55], ["inflammatory cell recruitment", "OBSERVATION", 72, 101], ["airway", "ANATOMY", 103, 109], ["obstruction", "OBSERVATION", 110, 121], ["hyper", "OBSERVATION_MODIFIER", 126, 131]]], ["The ADA-deficient mice exhibited significantly enhanced vascularity in the trachea than wild-type mice as early as 18 days after birth, which was quantified by immunolocalization of the endothelial cell marker CD31 [56].", [["trachea", "ANATOMY", 75, 82], ["endothelial cell", "ANATOMY", 186, 202], ["ADA", "GENE_OR_GENE_PRODUCT", 4, 7], ["mice", "ORGANISM", 18, 22], ["trachea", "ORGAN", 75, 82], ["mice", "ORGANISM", 98, 102], ["endothelial cell", "CELL", 186, 202], ["CD31", "GENE_OR_GENE_PRODUCT", 210, 214], ["ADA", "PROTEIN", 4, 7], ["CD31", "PROTEIN", 210, 214], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 98, 102], ["The ADA", "TEST", 0, 7], ["significantly enhanced vascularity in the trachea", "PROBLEM", 33, 82], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["enhanced", "OBSERVATION_MODIFIER", 47, 55], ["vascularity", "OBSERVATION", 56, 67], ["trachea", "ANATOMY", 75, 82], ["endothelial", "ANATOMY", 186, 197]]], ["This complication was prevented by PEG-ADA treatment, and was attributed to the up-regulation of the pro-angiogenic chemokine, CXCL1, and its receptor CXCR2.", [["PEG-ADA", "CHEMICAL", 35, 42], ["PEG", "CHEMICAL", 35, 38], ["PEG-ADA", "SIMPLE_CHEMICAL", 35, 42], ["CXCL1", "GENE_OR_GENE_PRODUCT", 127, 132], ["CXCR2", "GENE_OR_GENE_PRODUCT", 151, 156], ["pro-angiogenic chemokine", "PROTEIN", 101, 125], ["CXCL1", "PROTEIN", 127, 132], ["CXCR2", "PROTEIN", 151, 156], ["This complication", "PROBLEM", 0, 17], ["PEG-ADA treatment", "TREATMENT", 35, 52], ["the pro-angiogenic chemokine", "TREATMENT", 97, 125], ["CXCL1", "TEST", 127, 132], ["its receptor CXCR2", "TEST", 138, 156]]], ["These findings are consistent with the corneal micropocket assay of angiogenesis using lung extracts from wild-type and ADA-deficient mice.", [["corneal", "ANATOMY", 39, 46], ["lung extracts", "ANATOMY", 87, 100], ["corneal", "TISSUE", 39, 46], ["lung extracts", "ORGANISM_SUBSTANCE", 87, 100], ["ADA", "GENE_OR_GENE_PRODUCT", 120, 123], ["mice", "ORGANISM", 134, 138], ["ADA", "PROTEIN", 120, 123], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["the corneal micropocket assay", "TEST", 35, 64], ["angiogenesis", "PROBLEM", 68, 80], ["lung extracts", "TREATMENT", 87, 100], ["ADA-deficient mice", "TREATMENT", 120, 138], ["consistent with", "UNCERTAINTY", 19, 34], ["corneal", "ANATOMY", 39, 46], ["angiogenesis", "OBSERVATION", 68, 80], ["lung", "ANATOMY", 87, 91]]], ["The angiogenic activity of lungs extract from ADA-deficient mice was inhibited by pre-treatment with PEG-ADA, or neutralizing antibodies to either CXCL1 or CXCR2.", [["lungs extract", "ANATOMY", 27, 40], ["PEG-ADA", "CHEMICAL", 101, 108], ["PEG", "CHEMICAL", 101, 104], ["lungs", "ORGAN", 27, 32], ["extract", "ORGANISM_SUBSTANCE", 33, 40], ["ADA", "GENE_OR_GENE_PRODUCT", 46, 49], ["mice", "ORGANISM", 60, 64], ["PEG-ADA", "SIMPLE_CHEMICAL", 101, 108], ["CXCL1", "GENE_OR_GENE_PRODUCT", 147, 152], ["CXCR2", "GENE_OR_GENE_PRODUCT", 156, 161], ["ADA", "PROTEIN", 46, 49], ["ADA", "PROTEIN", 105, 108], ["neutralizing antibodies", "PROTEIN", 113, 136], ["CXCL1", "PROTEIN", 147, 152], ["CXCR2", "PROTEIN", 156, 161], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["ADA-deficient mice", "TREATMENT", 46, 64], ["PEG-ADA", "TREATMENT", 101, 108], ["neutralizing antibodies", "TREATMENT", 113, 136], ["CXCR2", "TEST", 156, 161], ["angiogenic", "OBSERVATION_MODIFIER", 4, 14], ["activity", "OBSERVATION_MODIFIER", 15, 23], ["lungs", "ANATOMY", 27, 32]]], ["The source of CXCL1 appears to be macrophages, which accumulate in high numbers in the lung of ADA-deficient mice.", [["macrophages", "ANATOMY", 34, 45], ["lung", "ANATOMY", 87, 91], ["CXCL1", "GENE_OR_GENE_PRODUCT", 14, 19], ["macrophages", "CELL", 34, 45], ["lung", "ORGAN", 87, 91], ["ADA", "GENE_OR_GENE_PRODUCT", 95, 98], ["mice", "ORGANISM", 109, 113], ["CXCL1", "PROTEIN", 14, 19], ["macrophages", "CELL_TYPE", 34, 45], ["ADA", "PROTEIN", 95, 98], ["mice", "SPECIES", 109, 113], ["CXCL1", "TEST", 14, 19], ["macrophages", "PROBLEM", 34, 45], ["CXCL1", "OBSERVATION", 14, 19], ["appears to be", "UNCERTAINTY", 20, 33], ["macrophages", "OBSERVATION", 34, 45], ["high", "OBSERVATION_MODIFIER", 67, 71], ["numbers", "OBSERVATION_MODIFIER", 72, 79], ["lung", "ANATOMY", 87, 91]]], ["While the gene expression surveys support an increased resistance against leukocyte transmigration into the airspace of the ADA-deficient mice, the longer lifespan of partially-deficient ADA mice and PEG-ADA treated ADA-deficient mice allows sufficient time to develop intense neovascularization as zones of vulnerability for leukocyte infiltration.", [["leukocyte", "ANATOMY", 74, 83], ["airspace", "ANATOMY", 108, 116], ["leukocyte", "ANATOMY", 326, 335], ["PEG-ADA", "CHEMICAL", 200, 207], ["neovascularization", "DISEASE", 277, 295], ["PEG-ADA", "CHEMICAL", 200, 207], ["leukocyte", "CELL", 74, 83], ["airspace", "MULTI-TISSUE_STRUCTURE", 108, 116], ["ADA", "GENE_OR_GENE_PRODUCT", 124, 127], ["mice", "ORGANISM", 138, 142], ["ADA mice", "ORGANISM", 187, 195], ["PEG-ADA", "GENE_OR_GENE_PRODUCT", 200, 207], ["ADA", "GENE_OR_GENE_PRODUCT", 216, 219], ["mice", "ORGANISM", 230, 234], ["leukocyte", "CELL", 326, 335], ["ADA", "PROTEIN", 124, 127], ["ADA", "PROTEIN", 216, 219], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 230, 234], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 191, 195], ["an increased resistance", "PROBLEM", 42, 65], ["leukocyte transmigration", "PROBLEM", 74, 98], ["partially-deficient ADA mice", "TREATMENT", 167, 195], ["PEG", "TREATMENT", 200, 203], ["ADA treated ADA-deficient mice", "TREATMENT", 204, 234], ["intense neovascularization", "PROBLEM", 269, 295], ["leukocyte infiltration", "PROBLEM", 326, 348], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["resistance", "OBSERVATION", 55, 65], ["leukocyte transmigration", "OBSERVATION", 74, 98], ["airspace", "ANATOMY_MODIFIER", 108, 116], ["intense", "OBSERVATION_MODIFIER", 269, 276], ["neovascularization", "OBSERVATION", 277, 295], ["zones", "OBSERVATION_MODIFIER", 299, 304], ["leukocyte infiltration", "OBSERVATION", 326, 348]]], ["Interestingly, genetic inactivation of A 2A Rs attenuated the pathological, but not developmental, angiogenesis in mouse retina [57] .", [["retina", "ANATOMY", 121, 127], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 39, 46], ["mouse", "ORGANISM", 115, 120], ["retina", "MULTI-TISSUE_STRUCTURE", 121, 127], ["A 2A Rs", "PROTEIN", 39, 46], ["mouse", "SPECIES", 115, 120], ["mouse", "SPECIES", 115, 120], ["angiogenesis", "OBSERVATION", 99, 111]]], ["Understanding the mechanisms by which excess ADO enhances neovascularization may lead to preventive therapies for airway remodeling and chronic inflammation.Too Little Adenosine in CD73 \u00c0/\u00c0 MiceMost chronic respiratory diseases are associated with aberrances in extracellular nucleotide metabolism which maintain excess ADO in airway secretions (see Chap.", [["airway", "ANATOMY", 114, 120], ["respiratory", "ANATOMY", 207, 218], ["extracellular", "ANATOMY", 262, 275], ["airway secretions", "ANATOMY", 327, 344], ["ADO", "CHEMICAL", 45, 48], ["neovascularization", "DISEASE", 58, 76], ["inflammation", "DISEASE", 144, 156], ["Adenosine", "CHEMICAL", 168, 177], ["respiratory diseases", "DISEASE", 207, 227], ["nucleotide", "CHEMICAL", 276, 286], ["ADO", "CHEMICAL", 320, 323], ["ADO", "CHEMICAL", 45, 48], ["Adenosine", "CHEMICAL", 168, 177], ["nucleotide", "CHEMICAL", 276, 286], ["ADO", "CHEMICAL", 320, 323], ["ADO", "SIMPLE_CHEMICAL", 45, 48], ["airway", "MULTI-TISSUE_STRUCTURE", 114, 120], ["Adenosine", "SIMPLE_CHEMICAL", 168, 177], ["CD73", "GENE_OR_GENE_PRODUCT", 181, 185], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 262, 275], ["nucleotide", "SIMPLE_CHEMICAL", 276, 286], ["ADO", "SIMPLE_CHEMICAL", 320, 323], ["airway secretions", "MULTI-TISSUE_STRUCTURE", 327, 344], ["CD73", "PROTEIN", 181, 185], ["Mice", "SPECIES", 190, 194], ["excess ADO enhances neovascularization", "PROBLEM", 38, 76], ["preventive therapies", "TREATMENT", 89, 109], ["airway remodeling", "PROBLEM", 114, 131], ["chronic inflammation", "PROBLEM", 136, 156], ["Most chronic respiratory diseases", "PROBLEM", 194, 227], ["aberrances", "PROBLEM", 248, 258], ["extracellular nucleotide metabolism", "PROBLEM", 262, 297], ["excess ADO in airway secretions", "PROBLEM", 313, 344], ["neovascularization", "OBSERVATION", 58, 76], ["airway", "ANATOMY", 114, 120], ["remodeling", "OBSERVATION", 121, 131], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["inflammation", "OBSERVATION", 144, 156], ["chronic", "OBSERVATION_MODIFIER", 199, 206], ["respiratory diseases", "OBSERVATION", 207, 227], ["nucleotide metabolism", "OBSERVATION", 276, 297], ["airway", "ANATOMY", 327, 333], ["secretions", "OBSERVATION", 334, 344]]], ["Given the devastating consequences predicted from the ADA-deficient mice, therapeutic strategies are being formulated to restore normal airway ADO levels in these patients.", [["airway", "ANATOMY", 136, 142], ["ADO", "CHEMICAL", 143, 146], ["ADA", "GENE_OR_GENE_PRODUCT", 54, 57], ["mice", "ORGANISM", 68, 72], ["airway", "MULTI-TISSUE_STRUCTURE", 136, 142], ["ADO", "SIMPLE_CHEMICAL", 143, 146], ["patients", "ORGANISM", 163, 171], ["ADA", "PROTEIN", 54, 57], ["mice", "SPECIES", 68, 72], ["patients", "SPECIES", 163, 171], ["mice", "SPECIES", 68, 72], ["the ADA-deficient mice", "TREATMENT", 50, 72], ["therapeutic strategies", "TREATMENT", 74, 96], ["airway", "ANATOMY", 136, 142]]], ["The importance of careful dosing the pharmacological agents is emphasized by an animal model which restricts the production of this receptor agonist.", [["careful dosing the pharmacological agents", "TREATMENT", 18, 59], ["this receptor agonist", "TREATMENT", 127, 148]]], ["Studies were conducted with Cd73 \u00c0/\u00c0 mice to determine the impact of too little ADO on the overall health of the subject, as well as airway responses to acute insults and chronic conditions.", [["airway", "ANATOMY", 133, 139], ["ADO", "CHEMICAL", 80, 83], ["acute insults", "DISEASE", 153, 166], ["ADO", "CHEMICAL", 80, 83], ["Cd73 \u00c0/\u00c0 mice", "ORGANISM", 28, 41], ["ADO", "SIMPLE_CHEMICAL", 80, 83], ["airway", "MULTI-TISSUE_STRUCTURE", 133, 139], ["mice", "SPECIES", 37, 41], ["Studies", "TEST", 0, 7], ["Cd73", "TEST", 28, 32], ["acute insults", "PROBLEM", 153, 166], ["chronic conditions", "PROBLEM", 171, 189], ["airway", "ANATOMY", 133, 139], ["chronic", "OBSERVATION_MODIFIER", 171, 178]]], ["Pulmonary hypoxia/ischemia initiates the translocation of inflammatory cells from the bloodstream into the interstitium as a pathological healing response (review: [58]).", [["Pulmonary", "ANATOMY", 0, 9], ["inflammatory cells", "ANATOMY", 58, 76], ["bloodstream", "ANATOMY", 86, 97], ["interstitium", "ANATOMY", 107, 119], ["hypoxia", "DISEASE", 10, 17], ["ischemia", "DISEASE", 18, 26], ["Pulmonary", "ORGAN", 0, 9], ["inflammatory cells", "CELL", 58, 76], ["interstitium", "TISSUE", 107, 119], ["inflammatory cells", "CELL_TYPE", 58, 76], ["Pulmonary hypoxia", "PROBLEM", 0, 17], ["ischemia", "PROBLEM", 18, 26], ["inflammatory cells", "PROBLEM", 58, 76], ["hypoxia", "OBSERVATION", 10, 17], ["ischemia", "OBSERVATION", 18, 26], ["inflammatory cells", "OBSERVATION", 58, 76], ["bloodstream", "OBSERVATION_MODIFIER", 86, 97], ["interstitium", "ANATOMY", 107, 119]]], ["Hypoxic tissue releases ATP, which constitutes a powerful neutrophil chemoattractant to eliminate apoptotic cells as part of the repair process (see Chap.", [["tissue", "ANATOMY", 8, 14], ["neutrophil", "ANATOMY", 58, 68], ["cells", "ANATOMY", 108, 113], ["ATP", "CHEMICAL", 24, 27], ["ATP", "CHEMICAL", 24, 27], ["Hypoxic tissue", "TISSUE", 0, 14], ["ATP", "SIMPLE_CHEMICAL", 24, 27], ["neutrophil", "CELL", 58, 68], ["cells", "CELL", 108, 113], ["neutrophil chemoattractant", "PROTEIN", 58, 84], ["apoptotic cells", "CELL_TYPE", 98, 113], ["Hypoxic tissue releases ATP", "PROBLEM", 0, 27], ["a powerful neutrophil chemoattractant", "TREATMENT", 47, 84], ["apoptotic cells", "PROBLEM", 98, 113], ["the repair process", "TREATMENT", 125, 143], ["apoptotic cells", "OBSERVATION", 98, 113], ["repair", "OBSERVATION", 129, 135]]], ["Without the existence of an efficient feedback mechanism, the excess recruitment of inflammatory cells would cause extensive tissue injury.", [["inflammatory cells", "ANATOMY", 84, 102], ["tissue", "ANATOMY", 125, 131], ["cells", "CELL", 97, 102], ["tissue", "TISSUE", 125, 131], ["inflammatory cells", "CELL_TYPE", 84, 102], ["an efficient feedback mechanism", "PROBLEM", 25, 56], ["inflammatory cells", "PROBLEM", 84, 102], ["extensive tissue injury", "PROBLEM", 115, 138], ["recruitment", "OBSERVATION_MODIFIER", 69, 80], ["inflammatory cells", "OBSERVATION", 84, 102], ["extensive", "OBSERVATION_MODIFIER", 115, 124], ["tissue", "OBSERVATION_MODIFIER", 125, 131], ["injury", "OBSERVATION", 132, 138]]], ["Purinergic signaling provides a critical defense mechanism by terminating neutrophil transmigration across the endothelial barrier.", [["neutrophil", "ANATOMY", 74, 84], ["endothelial barrier", "ANATOMY", 111, 130], ["Purinergic", "GENE_OR_GENE_PRODUCT", 0, 10], ["neutrophil", "CELL", 74, 84], ["endothelial barrier", "TISSUE", 111, 130], ["Purinergic signaling", "PROBLEM", 0, 20], ["terminating neutrophil transmigration", "PROBLEM", 62, 99], ["the endothelial barrier", "TREATMENT", 107, 130], ["neutrophil transmigration", "OBSERVATION", 74, 99], ["endothelial", "ANATOMY", 111, 122]]], ["The sequential activities of CD39 and CD73 on endothelial cells convert circulating ATP into ADO, which raises barrier resistance via A 2A Rs/A 2B Rs ( Fig. 8.1 ).", [["endothelial cells", "ANATOMY", 46, 63], ["ATP", "CHEMICAL", 84, 87], ["ADO", "CHEMICAL", 93, 96], ["ATP", "CHEMICAL", 84, 87], ["ADO", "CHEMICAL", 93, 96], ["CD39", "GENE_OR_GENE_PRODUCT", 29, 33], ["CD73", "GENE_OR_GENE_PRODUCT", 38, 42], ["endothelial cells", "CELL", 46, 63], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["ADO", "SIMPLE_CHEMICAL", 93, 96], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 142, 149], ["CD39", "PROTEIN", 29, 33], ["CD73", "PROTEIN", 38, 42], ["endothelial cells", "CELL_TYPE", 46, 63], ["CD39", "TEST", 29, 33], ["endothelial cells", "TEST", 46, 63], ["circulating ATP into ADO", "PROBLEM", 72, 96], ["barrier resistance", "OBSERVATION", 111, 129]]], ["Although ADO induces the production of VEGF, a potent inducer of endothelial barrier permeability, in many circumstances, it can also block its secretion from neutrophils [41] .", [["endothelial barrier", "ANATOMY", 65, 84], ["neutrophils", "ANATOMY", 159, 170], ["ADO", "CHEMICAL", 9, 12], ["ADO", "CHEMICAL", 9, 12], ["ADO", "SIMPLE_CHEMICAL", 9, 12], ["VEGF", "GENE_OR_GENE_PRODUCT", 39, 43], ["endothelial barrier", "TISSUE", 65, 84], ["neutrophils", "CELL", 159, 170], ["VEGF", "PROTEIN", 39, 43], ["neutrophils", "CELL_TYPE", 159, 170], ["VEGF", "PROBLEM", 39, 43], ["endothelial barrier permeability", "TREATMENT", 65, 97], ["VEGF", "OBSERVATION", 39, 43], ["endothelial", "ANATOMY", 65, 76], ["barrier permeability", "OBSERVATION", 77, 97]]], ["Incidentally, adherent neutrophils were shown to facilitate their transmigration by inhibiting CD73 activity on endothelial cells [59] , which may explain the lack of CD73 on these inflammatory cells [60] .", [["neutrophils", "ANATOMY", 23, 34], ["endothelial cells", "ANATOMY", 112, 129], ["inflammatory cells", "ANATOMY", 181, 199], ["neutrophils", "CELL", 23, 34], ["CD73", "GENE_OR_GENE_PRODUCT", 95, 99], ["endothelial cells", "CELL", 112, 129], ["CD73", "GENE_OR_GENE_PRODUCT", 167, 171], ["inflammatory cells", "CELL", 181, 199], ["adherent neutrophils", "CELL_TYPE", 14, 34], ["CD73", "PROTEIN", 95, 99], ["endothelial cells", "CELL_TYPE", 112, 129], ["CD73", "PROTEIN", 167, 171], ["inflammatory cells", "CELL_TYPE", 181, 199], ["adherent neutrophils", "PROBLEM", 14, 34], ["endothelial cells", "TEST", 112, 129], ["these inflammatory cells", "PROBLEM", 175, 199], ["adherent", "OBSERVATION_MODIFIER", 14, 22], ["neutrophils", "OBSERVATION", 23, 34]]], ["For all these reasons, ADO formation by the CD39-CD73 tandem is essential for the prevention of excessive inflammation and acute lung injury during hypoxia.Too Little Adenosine in CD73 \u00c0/\u00c0 MiceHypoxia triggers the up-regulation of CD39, CD73 and A 2B Rs [11, 61, 62] .", [["lung", "ANATOMY", 129, 133], ["ADO", "CHEMICAL", 23, 26], ["inflammation", "DISEASE", 106, 118], ["acute lung injury", "DISEASE", 123, 140], ["hypoxia", "DISEASE", 148, 155], ["Adenosine", "CHEMICAL", 167, 176], ["ADO", "CHEMICAL", 23, 26], ["Adenosine", "CHEMICAL", 167, 176], ["ADO", "SIMPLE_CHEMICAL", 23, 26], ["CD39", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD73", "GENE_OR_GENE_PRODUCT", 49, 53], ["lung", "ORGAN", 129, 133], ["Adenosine", "SIMPLE_CHEMICAL", 167, 176], ["CD73", "GENE_OR_GENE_PRODUCT", 180, 184], ["CD39", "GENE_OR_GENE_PRODUCT", 231, 235], ["CD73", "GENE_OR_GENE_PRODUCT", 237, 241], ["A 2B", "GENE_OR_GENE_PRODUCT", 246, 250], ["CD39", "PROTEIN", 44, 48], ["CD73", "PROTEIN", 49, 53], ["CD73", "PROTEIN", 180, 184], ["CD39", "PROTEIN", 231, 235], ["CD73", "PROTEIN", 237, 241], ["ADO formation", "PROBLEM", 23, 36], ["the CD39", "TEST", 40, 48], ["CD73 tandem", "TREATMENT", 49, 60], ["excessive inflammation", "PROBLEM", 96, 118], ["acute lung injury", "PROBLEM", 123, 140], ["hypoxia", "PROBLEM", 148, 155], ["CD39", "TEST", 231, 235], ["CD73", "TEST", 237, 241], ["A 2B Rs", "TEST", 246, 253], ["excessive", "OBSERVATION_MODIFIER", 96, 105], ["inflammation", "OBSERVATION", 106, 118], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140], ["hypoxia", "OBSERVATION", 148, 155]]], ["While CD39 up-regulation is mediated by the Sp1 transcription factor [61] , CD73 and A 2B R up-regulation require binding of the hypoxia inducible factor-1a (HIF-1a) to their promoter site [11, 62] .", [["CD39", "GENE_OR_GENE_PRODUCT", 6, 10], ["Sp1", "GENE_OR_GENE_PRODUCT", 44, 47], ["CD73", "GENE_OR_GENE_PRODUCT", 76, 80], ["A 2B R", "GENE_OR_GENE_PRODUCT", 85, 91], ["hypoxia inducible factor-1a", "GENE_OR_GENE_PRODUCT", 129, 156], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 158, 164], ["CD39", "PROTEIN", 6, 10], ["Sp1 transcription factor", "PROTEIN", 44, 68], ["CD73", "PROTEIN", 76, 80], ["hypoxia inducible factor-1a (HIF-1a", "PROTEIN", 129, 164], ["promoter site", "DNA", 175, 188], ["the Sp1 transcription factor", "TEST", 40, 68], ["CD73", "TEST", 76, 80], ["A 2B", "TEST", 85, 89], ["the hypoxia inducible factor", "PROBLEM", 125, 153], ["hypoxia", "OBSERVATION", 129, 136]]], ["The higher CD39-CD73 efficiency is expected to raise the circulating ADO concentration above the activation threshold of the A 2B Rs to enhance barrier resistance against vascular leakage and leukocyte transmigration (review: [2] ).", [["barrier", "ANATOMY", 144, 151], ["vascular", "ANATOMY", 171, 179], ["leukocyte", "ANATOMY", 192, 201], ["ADO", "CHEMICAL", 69, 72], ["ADO", "CHEMICAL", 69, 72], ["CD39", "GENE_OR_GENE_PRODUCT", 11, 15], ["CD73", "GENE_OR_GENE_PRODUCT", 16, 20], ["ADO", "SIMPLE_CHEMICAL", 69, 72], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 125, 132], ["barrier", "TISSUE", 144, 151], ["vascular", "MULTI-TISSUE_STRUCTURE", 171, 179], ["leukocyte", "CELL", 192, 201], ["CD39", "PROTEIN", 11, 15], ["CD73", "PROTEIN", 16, 20], ["A 2B Rs", "PROTEIN", 125, 132], ["the circulating ADO concentration", "TREATMENT", 53, 86], ["the A 2B Rs", "TREATMENT", 121, 132], ["barrier resistance", "TREATMENT", 144, 162], ["vascular leakage", "PROBLEM", 171, 187], ["CD73 efficiency", "OBSERVATION", 16, 31], ["vascular", "ANATOMY", 171, 179], ["leakage", "OBSERVATION", 180, 187], ["leukocyte transmigration", "OBSERVATION", 192, 216]]], ["The importance of this purinergic regulation is demonstrated in mice denied CD73.", [["mice", "ORGANISM", 64, 68], ["CD73", "GENE_OR_GENE_PRODUCT", 76, 80], ["CD73", "PROTEIN", 76, 80], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["this purinergic regulation", "TEST", 18, 44]]], ["The Cd73 \u00c0/\u00c0 mice exhibit significant vascular leakage in multiple organs, including the lung [63] .", [["vascular", "ANATOMY", 38, 46], ["organs", "ANATOMY", 67, 73], ["lung", "ANATOMY", 89, 93], ["Cd73", "GENE_OR_GENE_PRODUCT", 4, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 38, 46], ["organs", "ORGAN", 67, 73], ["lung", "ORGAN", 89, 93], ["Cd73", "PROTEIN", 4, 8], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["The Cd73", "TEST", 0, 8], ["significant vascular leakage in multiple organs", "PROBLEM", 26, 73], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["vascular", "ANATOMY", 38, 46], ["leakage", "OBSERVATION", 47, 54], ["multiple", "OBSERVATION_MODIFIER", 58, 66], ["organs", "ANATOMY", 67, 73], ["lung", "ANATOMY", 89, 93]]], ["Acute hypoxia (8% O 2; 4 h) causes more severe vascular leakage in Cd73 \u00c0/\u00c0 mice than in wild-type mice, characterized by perivascular edema and inflammatory infiltrates.", [["vascular", "ANATOMY", 47, 55], ["perivascular edema", "ANATOMY", 122, 140], ["hypoxia", "DISEASE", 6, 13], ["edema", "DISEASE", 135, 140], ["O 2", "CHEMICAL", 18, 21], ["vascular", "MULTI-TISSUE_STRUCTURE", 47, 55], ["Cd73", "GENE_OR_GENE_PRODUCT", 67, 71], ["mice", "ORGANISM", 99, 103], ["perivascular edema", "PATHOLOGICAL_FORMATION", 122, 140], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["Acute hypoxia", "PROBLEM", 0, 13], ["more severe vascular leakage", "PROBLEM", 35, 63], ["Cd73", "TEST", 67, 71], ["perivascular edema", "PROBLEM", 122, 140], ["inflammatory infiltrates", "PROBLEM", 145, 169], ["hypoxia", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["vascular", "ANATOMY", 47, 55], ["leakage", "OBSERVATION", 56, 63], ["Cd73", "ANATOMY", 67, 71], ["perivascular", "ANATOMY_MODIFIER", 122, 134], ["edema", "OBSERVATION", 135, 140], ["inflammatory", "OBSERVATION_MODIFIER", 145, 157], ["infiltrates", "OBSERVATION", 158, 169]]], ["These complications are partially reversed by the intraperitoneal injection of P1 receptor agonists, or soluble 5 0 -nucleotidase to replace CD73 [63, 64] .", [["intraperitoneal", "ANATOMY", 50, 65], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 65], ["5 0 -nucleotidase", "GENE_OR_GENE_PRODUCT", 112, 129], ["CD73", "GENE_OR_GENE_PRODUCT", 141, 145], ["soluble 5 0 -nucleotidase", "PROTEIN", 104, 129], ["CD73", "PROTEIN", 141, 145], ["These complications", "PROBLEM", 0, 19], ["the intraperitoneal injection of P1 receptor agonists", "TREATMENT", 46, 99], ["CD73", "TEST", 141, 145]]], ["These results are consistent with the relative affinities of A 2A Rs and A 2B Rs, both involved in barrier protection ( Fig. 8.1 ).", [["A 2A Rs", "GENE_OR_GENE_PRODUCT", 61, 68], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 73, 80], ["barrier", "TISSUE", 99, 106], ["A 2B Rs", "PROTEIN", 73, 80], ["barrier protection", "TREATMENT", 99, 117], ["consistent with", "UNCERTAINTY", 18, 33]]], ["While high-affinity A 2A Rs maintain baseline barrier resistance, the dramatic rise in circulating ADO level caused by hypoxia recruits the activities of low-affinity A 2B Rs.", [["ADO", "CHEMICAL", 99, 102], ["hypoxia", "DISEASE", 119, 126], ["ADO", "CHEMICAL", 99, 102], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 20, 27], ["ADO", "SIMPLE_CHEMICAL", 99, 102], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 167, 174], ["high-affinity A 2A Rs", "PROTEIN", 6, 27], ["low-affinity A 2B Rs", "PROTEIN", 154, 174], ["baseline barrier resistance", "PROBLEM", 37, 64], ["the dramatic rise", "PROBLEM", 66, 83], ["circulating ADO level", "PROBLEM", 87, 108], ["hypoxia", "PROBLEM", 119, 126], ["barrier resistance", "OBSERVATION", 46, 64], ["dramatic", "OBSERVATION_MODIFIER", 70, 78], ["rise", "OBSERVATION_MODIFIER", 79, 83], ["hypoxia", "OBSERVATION", 119, 126]]], ["This study suggests that therapies aiming to suppress ADO production in chronic respiratory diseases could leave the patients vulnerable to hypoxia-induced pulmonary edema, and even aggravate lung inflammation, if the suppression of CD73 activity is not carefully optimized and restricted to the airways.Too Little Adenosine in CD73 \u00c0/\u00c0 MiceAnimal models are currently available to assess the potential of new therapies for acute lung injury (review: [65] ).", [["respiratory", "ANATOMY", 80, 91], ["pulmonary", "ANATOMY", 156, 165], ["lung", "ANATOMY", 192, 196], ["airways", "ANATOMY", 296, 303], ["lung", "ANATOMY", 430, 434], ["ADO", "CHEMICAL", 54, 57], ["respiratory diseases", "DISEASE", 80, 100], ["hypoxia", "DISEASE", 140, 147], ["pulmonary edema", "DISEASE", 156, 171], ["lung inflammation", "DISEASE", 192, 209], ["Adenosine", "CHEMICAL", 315, 324], ["acute lung injury", "DISEASE", 424, 441], ["ADO", "CHEMICAL", 54, 57], ["Adenosine", "CHEMICAL", 315, 324], ["ADO", "SIMPLE_CHEMICAL", 54, 57], ["patients", "ORGANISM", 117, 125], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 156, 171], ["lung", "ORGAN", 192, 196], ["CD73", "GENE_OR_GENE_PRODUCT", 233, 237], ["airways", "MULTI-TISSUE_STRUCTURE", 296, 303], ["Adenosine", "SIMPLE_CHEMICAL", 315, 324], ["CD73", "GENE_OR_GENE_PRODUCT", 328, 332], ["lung", "ORGAN", 430, 434], ["CD73", "PROTEIN", 233, 237], ["CD73", "PROTEIN", 328, 332], ["patients", "SPECIES", 117, 125], ["This study", "TEST", 0, 10], ["therapies", "TREATMENT", 25, 34], ["ADO production", "PROBLEM", 54, 68], ["chronic respiratory diseases", "PROBLEM", 72, 100], ["hypoxia", "PROBLEM", 140, 147], ["pulmonary edema", "PROBLEM", 156, 171], ["aggravate lung inflammation", "PROBLEM", 182, 209], ["CD73 activity", "PROBLEM", 233, 246], ["MiceAnimal models", "TREATMENT", 337, 354], ["new therapies", "TREATMENT", 406, 419], ["acute lung injury", "PROBLEM", 424, 441], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["respiratory diseases", "OBSERVATION", 80, 100], ["hypoxia", "OBSERVATION", 140, 147], ["pulmonary", "ANATOMY", 156, 165], ["edema", "OBSERVATION", 166, 171], ["lung", "ANATOMY", 192, 196], ["inflammation", "OBSERVATION", 197, 209], ["airways", "ANATOMY", 296, 303], ["acute", "OBSERVATION_MODIFIER", 424, 429], ["lung", "ANATOMY", 430, 434], ["injury", "OBSERVATION", 435, 441]]], ["The intratracheal instillation of bleomycin ranks among the five most popular models, as it recapitulates most features: neutrophilic alveolitis, damage to alveolar epithelia and endothelia, hyaline membrane formation, and thrombus accumulation in the microvasculature.", [["intratracheal", "ANATOMY", 4, 17], ["alveolar epithelia", "ANATOMY", 156, 174], ["endothelia", "ANATOMY", 179, 189], ["hyaline membrane", "ANATOMY", 191, 207], ["thrombus", "ANATOMY", 223, 231], ["microvasculature", "ANATOMY", 252, 268], ["bleomycin", "CHEMICAL", 34, 43], ["alveolitis", "DISEASE", 134, 144], ["thrombus", "DISEASE", 223, 231], ["bleomycin", "CHEMICAL", 34, 43], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["bleomycin", "SIMPLE_CHEMICAL", 34, 43], ["alveolar epithelia", "TISSUE", 156, 174], ["endothelia", "TISSUE", 179, 189], ["hyaline membrane", "TISSUE", 191, 207], ["thrombus", "PATHOLOGICAL_FORMATION", 223, 231], ["microvasculature", "TISSUE", 252, 268], ["The intratracheal instillation of bleomycin ranks", "TREATMENT", 0, 49], ["neutrophilic alveolitis", "PROBLEM", 121, 144], ["damage to alveolar epithelia and endothelia", "PROBLEM", 146, 189], ["hyaline membrane formation", "PROBLEM", 191, 217], ["thrombus accumulation in the microvasculature", "PROBLEM", 223, 268], ["intratracheal", "ANATOMY", 4, 17], ["instillation", "OBSERVATION", 18, 30], ["neutrophilic alveolitis", "OBSERVATION", 121, 144], ["alveolar", "ANATOMY_MODIFIER", 156, 164], ["epithelia", "ANATOMY_MODIFIER", 165, 174], ["endothelia", "ANATOMY", 179, 189], ["hyaline membrane formation", "OBSERVATION", 191, 217], ["thrombus", "OBSERVATION", 223, 231], ["microvasculature", "ANATOMY", 252, 268]]], ["This antibiotic is isolated from Streptomyces verticillus and complexes with oxygen and metals, leading to the production of oxygen radicals, DNA breaks and ultimately cell death.", [["cell", "ANATOMY", 168, 172], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 125, 131], ["death", "DISEASE", 173, 178], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 125, 131], ["Streptomyces verticillus", "ORGANISM", 33, 57], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["metals", "SIMPLE_CHEMICAL", 88, 94], ["oxygen radicals", "SIMPLE_CHEMICAL", 125, 140], ["DNA", "CELLULAR_COMPONENT", 142, 145], ["cell", "CELL", 168, 172], ["Streptomyces verticillus", "SPECIES", 33, 57], ["Streptomyces verticillus", "SPECIES", 33, 57], ["This antibiotic", "TREATMENT", 0, 15], ["Streptomyces verticillus", "TREATMENT", 33, 57], ["oxygen and metals", "TREATMENT", 77, 94], ["oxygen radicals", "TREATMENT", 125, 140], ["DNA breaks", "PROBLEM", 142, 152], ["ultimately cell death", "PROBLEM", 157, 178], ["oxygen radicals", "OBSERVATION", 125, 140], ["ultimately cell death", "OBSERVATION", 157, 178]]], ["Within 24 h, mice develop inflammation, depicted by the accumulation of macrophages, lymphocytes and neutrophils in the BAL fluid, which lasts about 11 days [66] .", [["macrophages", "ANATOMY", 72, 83], ["lymphocytes", "ANATOMY", 85, 96], ["neutrophils", "ANATOMY", 101, 112], ["BAL fluid", "ANATOMY", 120, 129], ["inflammation", "DISEASE", 26, 38], ["mice", "ORGANISM", 13, 17], ["macrophages", "CELL", 72, 83], ["lymphocytes", "CELL", 85, 96], ["neutrophils", "CELL", 101, 112], ["BAL fluid", "ORGANISM_SUBSTANCE", 120, 129], ["macrophages", "CELL_TYPE", 72, 83], ["lymphocytes", "CELL_TYPE", 85, 96], ["neutrophils", "CELL_TYPE", 101, 112], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["inflammation", "PROBLEM", 26, 38], ["macrophages", "PROBLEM", 72, 83], ["lymphocytes", "PROBLEM", 85, 96], ["neutrophils", "TEST", 101, 112], ["the BAL fluid", "TEST", 116, 129], ["inflammation", "OBSERVATION", 26, 38], ["accumulation", "OBSERVATION_MODIFIER", 56, 68], ["macrophages", "OBSERVATION", 72, 83], ["lymphocytes", "ANATOMY", 85, 96], ["neutrophils", "OBSERVATION_MODIFIER", 101, 112], ["BAL fluid", "OBSERVATION", 120, 129]]], ["Lung tissue contains higher mRNA levels of pro-inflammatory cytokines (IL-1b and TNFa) and many pro-fibrotic factors (osteopontin, plasminogen activator inhibitor-1, TGFb1 and tissue inhibitor of metalloproteinase-1), as well as excess collagen.", [["Lung tissue", "ANATOMY", 0, 11], ["Lung tissue", "TISSUE", 0, 11], ["IL-1b", "GENE_OR_GENE_PRODUCT", 71, 76], ["TNFa", "GENE_OR_GENE_PRODUCT", 81, 85], ["osteopontin", "GENE_OR_GENE_PRODUCT", 118, 129], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 131, 164], ["TGFb1", "GENE_OR_GENE_PRODUCT", 166, 171], ["tissue inhibitor of metalloproteinase-1", "GENE_OR_GENE_PRODUCT", 176, 215], ["collagen", "GENE_OR_GENE_PRODUCT", 236, 244], ["pro-inflammatory cytokines", "PROTEIN", 43, 69], ["IL-1b", "PROTEIN", 71, 76], ["TNFa", "PROTEIN", 81, 85], ["pro-fibrotic factors", "PROTEIN", 96, 116], ["osteopontin", "PROTEIN", 118, 129], ["plasminogen activator inhibitor-1", "PROTEIN", 131, 164], ["TGFb1", "PROTEIN", 166, 171], ["tissue inhibitor of metalloproteinase-1", "PROTEIN", 176, 215], ["collagen", "PROTEIN", 236, 244], ["Lung tissue", "TEST", 0, 11], ["pro-inflammatory cytokines", "TEST", 43, 69], ["IL", "TEST", 71, 73], ["TNFa", "TEST", 81, 85], ["many pro-fibrotic factors", "PROBLEM", 91, 116], ["osteopontin, plasminogen activator inhibitor", "TREATMENT", 118, 162], ["TGFb1 and tissue inhibitor of metalloproteinase", "TREATMENT", 166, 213], ["tissue", "OBSERVATION", 5, 11], ["higher mRNA", "OBSERVATION", 21, 32], ["pro-inflammatory cytokines", "OBSERVATION", 43, 69], ["pro-fibrotic", "OBSERVATION_MODIFIER", 96, 108]]], ["Fibrosis appears around day 11, and is reversed within 10 days.Too Little Adenosine in CD73 \u00c0/\u00c0 MiceAcute lung injury reproduces the high airway ADO concentrations reported in asthmatic and COPD patients [43, 44] .", [["lung", "ANATOMY", 106, 110], ["airway", "ANATOMY", 138, 144], ["Fibrosis", "DISEASE", 0, 8], ["Adenosine", "CHEMICAL", 74, 83], ["lung injury", "DISEASE", 106, 117], ["ADO", "CHEMICAL", 145, 148], ["asthmatic", "DISEASE", 176, 185], ["COPD", "DISEASE", 190, 194], ["Adenosine", "CHEMICAL", 74, 83], ["ADO", "CHEMICAL", 145, 148], ["Adenosine", "SIMPLE_CHEMICAL", 74, 83], ["CD73", "GENE_OR_GENE_PRODUCT", 87, 91], ["lung", "ORGAN", 106, 110], ["airway", "MULTI-TISSUE_STRUCTURE", 138, 144], ["ADO", "SIMPLE_CHEMICAL", 145, 148], ["patients", "ORGANISM", 195, 203], ["CD73", "PROTEIN", 87, 91], ["patients", "SPECIES", 195, 203], ["Fibrosis", "PROBLEM", 0, 8], ["MiceAcute lung injury", "PROBLEM", 96, 117], ["the high airway ADO concentrations", "PROBLEM", 129, 163], ["asthmatic and COPD patients", "PROBLEM", 176, 203], ["lung", "ANATOMY", 106, 110], ["injury", "OBSERVATION", 111, 117], ["high airway", "OBSERVATION", 133, 144], ["ADO concentrations", "OBSERVATION", 145, 163], ["COPD", "OBSERVATION", 190, 194]]], ["The bleomycin-challenged mice maintain threefold higher total lung ADO levels, and a proportional increase in CD73 activity, during 14 days [66] .", [["lung", "ANATOMY", 62, 66], ["bleomycin", "CHEMICAL", 4, 13], ["ADO", "CHEMICAL", 67, 70], ["bleomycin", "CHEMICAL", 4, 13], ["ADO", "CHEMICAL", 67, 70], ["bleomycin", "SIMPLE_CHEMICAL", 4, 13], ["mice", "ORGANISM", 25, 29], ["lung", "ORGAN", 62, 66], ["ADO", "SIMPLE_CHEMICAL", 67, 70], ["CD73", "GENE_OR_GENE_PRODUCT", 110, 114], ["CD73", "PROTEIN", 110, 114], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["The bleomycin", "TREATMENT", 0, 13], ["a proportional increase in CD73 activity", "PROBLEM", 83, 123], ["lung", "ANATOMY", 62, 66], ["increase", "OBSERVATION_MODIFIER", 98, 106], ["CD73 activity", "OBSERVATION", 110, 123]]], ["To determine whether this metabolic imbalance promotes or suppresses the pulmonary complications, Cd73 \u00c0/\u00c0 mice were subjected to the bleomycin challenge [66] .", [["pulmonary", "ANATOMY", 73, 82], ["bleomycin", "CHEMICAL", 134, 143], ["bleomycin", "CHEMICAL", 134, 143], ["pulmonary", "ORGAN", 73, 82], ["Cd73", "GENE_OR_GENE_PRODUCT", 98, 102], ["bleomycin", "SIMPLE_CHEMICAL", 134, 143], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["the pulmonary complications", "PROBLEM", 69, 96], ["Cd73", "TEST", 98, 102], ["the bleomycin challenge", "TREATMENT", 130, 153], ["pulmonary", "ANATOMY", 73, 82], ["complications", "OBSERVATION", 83, 96]]], ["These mice developed more severe complications to bleomycin, and died within 18 days.", [["bleomycin", "CHEMICAL", 50, 59], ["bleomycin", "CHEMICAL", 50, 59], ["mice", "ORGANISM", 6, 10], ["bleomycin", "SIMPLE_CHEMICAL", 50, 59], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["more severe complications", "PROBLEM", 21, 46], ["bleomycin", "TREATMENT", 50, 59], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["complications", "OBSERVATION", 33, 46]]], ["However, their lung ADO levels remained normal, identifying AMP dephosphorylation as the source of the agonist.", [["lung", "ANATOMY", 15, 19], ["ADO", "CHEMICAL", 20, 23], ["AMP", "CHEMICAL", 60, 63], ["AMP", "CHEMICAL", 60, 63], ["lung", "ORGAN", 15, 19], ["ADO", "SIMPLE_CHEMICAL", 20, 23], ["AMP", "SIMPLE_CHEMICAL", 60, 63], ["their lung ADO levels", "TEST", 9, 30], ["AMP dephosphorylation", "TREATMENT", 60, 81], ["lung", "ANATOMY", 15, 19], ["normal", "OBSERVATION", 40, 46]]], ["These data suggest that a transient increase in airway ADO production is a defense mechanism to suppress acute lung injury.", [["airway", "ANATOMY", 48, 54], ["lung", "ANATOMY", 111, 115], ["ADO", "CHEMICAL", 55, 58], ["acute lung injury", "DISEASE", 105, 122], ["ADO", "CHEMICAL", 55, 58], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["ADO", "SIMPLE_CHEMICAL", 55, 58], ["lung", "ORGAN", 111, 115], ["These data", "TEST", 0, 10], ["a transient increase in airway ADO production", "PROBLEM", 24, 69], ["acute lung injury", "PROBLEM", 105, 122], ["transient", "OBSERVATION_MODIFIER", 26, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["airway", "ANATOMY", 48, 54], ["ADO production", "OBSERVATION", 55, 69], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["lung", "ANATOMY", 111, 115], ["injury", "OBSERVATION", 116, 122]]], ["Incidentally, enzyme replacement therapy by intranasal instillation of 5 0 -nucleotidase restored the ability of Cd73 \u00c0/\u00c0 mice to accumulate lung ADO, which reduced all symptoms of inflammation and fibrosis.", [["lung", "ANATOMY", 141, 145], ["ADO", "CHEMICAL", 146, 149], ["inflammation", "DISEASE", 181, 193], ["fibrosis", "DISEASE", 198, 206], ["ADO", "CHEMICAL", 146, 149], ["5 0 -nucleotidase", "GENE_OR_GENE_PRODUCT", 71, 88], ["Cd73", "GENE_OR_GENE_PRODUCT", 113, 117], ["mice", "ORGANISM", 122, 126], ["lung", "ORGAN", 141, 145], ["ADO", "SIMPLE_CHEMICAL", 146, 149], ["5 0 -nucleotidase", "PROTEIN", 71, 88], ["Cd73", "PROTEIN", 113, 117], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["enzyme replacement therapy", "TREATMENT", 14, 40], ["intranasal instillation", "TREATMENT", 44, 67], ["Cd73 \u00c0/\u00c0 mice", "TREATMENT", 113, 126], ["lung ADO", "TREATMENT", 141, 149], ["inflammation", "PROBLEM", 181, 193], ["fibrosis", "PROBLEM", 198, 206], ["replacement therapy", "OBSERVATION", 21, 40], ["lung", "ANATOMY", 141, 145], ["ADO", "OBSERVATION", 146, 149], ["inflammation", "OBSERVATION", 181, 193], ["fibrosis", "OBSERVATION", 198, 206]]], ["The fact that 5 0 -nucleotidase, given intranasally, was able to reduce the number of inflammatory cells in BAL fluid suggests that airway ADO can reach the interstitium to suppress leukocyte migration, or regulates epithelial permeability.", [["intranasally", "ANATOMY", 39, 51], ["inflammatory cells", "ANATOMY", 86, 104], ["BAL fluid", "ANATOMY", 108, 117], ["airway", "ANATOMY", 132, 138], ["interstitium", "ANATOMY", 157, 169], ["leukocyte", "ANATOMY", 182, 191], ["epithelial", "ANATOMY", 216, 226], ["ADO", "CHEMICAL", 139, 142], ["ADO", "CHEMICAL", 139, 142], ["5 0 -nucleotidase", "GENE_OR_GENE_PRODUCT", 14, 31], ["cells", "CELL", 99, 104], ["BAL fluid", "ORGANISM_SUBSTANCE", 108, 117], ["airway", "MULTI-TISSUE_STRUCTURE", 132, 138], ["ADO", "SIMPLE_CHEMICAL", 139, 142], ["interstitium", "MULTI-TISSUE_STRUCTURE", 157, 169], ["leukocyte", "CELL", 182, 191], ["epithelial", "TISSUE", 216, 226], ["5 0 -nucleotidase", "PROTEIN", 14, 31], ["inflammatory cells", "CELL_TYPE", 86, 104], ["nucleotidase", "TREATMENT", 19, 31], ["inflammatory cells", "PROBLEM", 86, 104], ["BAL fluid", "TEST", 108, 117], ["airway ADO", "TREATMENT", 132, 142], ["leukocyte migration", "PROBLEM", 182, 201], ["inflammatory cells", "OBSERVATION", 86, 104], ["BAL fluid", "OBSERVATION", 108, 117], ["airway", "ANATOMY", 132, 138], ["leukocyte migration", "OBSERVATION", 182, 201], ["epithelial permeability", "OBSERVATION", 216, 239]]], ["Our current knowledge does not support a role for ADO in the regulation of neutrophil epithelial transmigration ( Fig. 8.1 ).", [["neutrophil epithelial", "ANATOMY", 75, 96], ["ADO", "CHEMICAL", 50, 53], ["ADO", "SIMPLE_CHEMICAL", 50, 53], ["neutrophil epithelial", "CELL", 75, 96], ["ADO", "TREATMENT", 50, 53], ["neutrophil epithelial transmigration", "TREATMENT", 75, 111], ["neutrophil epithelial transmigration", "OBSERVATION", 75, 111]]], ["However, Hirsh et al. demonstrated that polarized bronchial epithelia support the vectorial transport of airway ADO into the interstitial tissue via apical concentrative, and basolateral equilibrative, nucleoside transporters [53] .", [["bronchial epithelia", "ANATOMY", 50, 69], ["airway", "ANATOMY", 105, 111], ["interstitial tissue", "ANATOMY", 125, 144], ["apical", "ANATOMY", 149, 155], ["basolateral", "ANATOMY", 175, 186], ["ADO", "CHEMICAL", 112, 115], ["nucleoside", "CHEMICAL", 202, 212], ["ADO", "CHEMICAL", 112, 115], ["nucleoside", "CHEMICAL", 202, 212], ["bronchial epithelia", "TISSUE", 50, 69], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["ADO", "SIMPLE_CHEMICAL", 112, 115], ["interstitial tissue", "TISSUE", 125, 144], ["polarized bronchial epithelia", "PROBLEM", 40, 69], ["polarized", "OBSERVATION_MODIFIER", 40, 49], ["bronchial epithelia", "OBSERVATION", 50, 69], ["airway", "ANATOMY", 105, 111], ["interstitial tissue", "ANATOMY", 125, 144], ["apical", "ANATOMY_MODIFIER", 149, 155], ["concentrative", "OBSERVATION_MODIFIER", 156, 169]]], ["Hence, the benefits of aerosolized drugs, given to acutely raise ADO levels during acute lung injury, may extend beyond the airways.Too Little Adenosine in CD73 \u00c0/\u00c0 MiceThe chronic model of allergic asthma supports the detrimental effects of chronic excess ADO in the airways.", [["lung", "ANATOMY", 89, 93], ["airways", "ANATOMY", 124, 131], ["airways", "ANATOMY", 268, 275], ["ADO", "CHEMICAL", 65, 68], ["acute lung injury", "DISEASE", 83, 100], ["Adenosine", "CHEMICAL", 143, 152], ["allergic asthma", "DISEASE", 190, 205], ["ADO", "CHEMICAL", 257, 260], ["ADO", "CHEMICAL", 65, 68], ["Adenosine", "CHEMICAL", 143, 152], ["ADO", "CHEMICAL", 257, 260], ["ADO", "SIMPLE_CHEMICAL", 65, 68], ["lung", "ORGAN", 89, 93], ["airways", "MULTI-TISSUE_STRUCTURE", 124, 131], ["Adenosine", "SIMPLE_CHEMICAL", 143, 152], ["CD73", "GENE_OR_GENE_PRODUCT", 156, 160], ["ADO", "SIMPLE_CHEMICAL", 257, 260], ["airways", "MULTI-TISSUE_STRUCTURE", 268, 275], ["CD73", "PROTEIN", 156, 160], ["Mice", "SPECIES", 165, 169], ["aerosolized drugs", "TREATMENT", 23, 40], ["ADO levels", "TEST", 65, 75], ["acute lung injury", "PROBLEM", 83, 100], ["allergic asthma", "PROBLEM", 190, 205], ["chronic excess ADO in the airways", "PROBLEM", 242, 275], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100], ["airways", "ANATOMY", 124, 131], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["allergic asthma", "OBSERVATION", 190, 205], ["chronic", "OBSERVATION_MODIFIER", 242, 249], ["excess ADO", "OBSERVATION", 250, 260], ["airways", "ANATOMY", 268, 275]]], ["Mice are generally sensitized with ovalbumin (OVA) by intraperitoneal injections taking place over 14 days, followed by four challenges with nebulized OVA over an additional week [67] .", [["intraperitoneal", "ANATOMY", 54, 69], ["Mice", "ORGANISM", 0, 4], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 69], ["Mice", "SPECIES", 0, 4], ["ovalbumin (OVA)", "TREATMENT", 35, 50], ["intraperitoneal injections", "TREATMENT", 54, 80], ["nebulized OVA", "TREATMENT", 141, 154]]], ["Within 24 h after the last challenge, their lungs develop features of allergic asthma, including eosinophilic inflammation, goblet cell metaplasia and hyperresponsiveness to methacholine [68] .", [["lungs", "ANATOMY", 44, 49], ["goblet cell metaplasia", "ANATOMY", 124, 146], ["allergic asthma", "DISEASE", 70, 85], ["eosinophilic inflammation", "DISEASE", 97, 122], ["methacholine", "CHEMICAL", 174, 186], ["methacholine", "CHEMICAL", 174, 186], ["lungs", "ORGAN", 44, 49], ["goblet cell metaplasia", "CANCER", 124, 146], ["allergic asthma", "PROBLEM", 70, 85], ["eosinophilic inflammation", "PROBLEM", 97, 122], ["goblet cell metaplasia", "PROBLEM", 124, 146], ["hyperresponsiveness", "PROBLEM", 151, 170], ["methacholine", "TEST", 174, 186], ["lungs", "ANATOMY", 44, 49], ["allergic asthma", "OBSERVATION", 70, 85], ["eosinophilic inflammation", "OBSERVATION", 97, 122], ["goblet cell metaplasia", "OBSERVATION", 124, 146]]], ["Furthermore, the BAL fluid of OVA-challenged mice contains eightfold higher ATP concentrations than in saline-challenged control mice, as reported for asthmatic patients following an allergen challenge [68] .", [["BAL fluid", "ANATOMY", 17, 26], ["ATP", "CHEMICAL", 76, 79], ["asthmatic", "DISEASE", 151, 160], ["ATP", "CHEMICAL", 76, 79], ["BAL fluid", "ORGANISM_SUBSTANCE", 17, 26], ["OVA", "SIMPLE_CHEMICAL", 30, 33], ["mice", "ORGANISM", 45, 49], ["ATP", "SIMPLE_CHEMICAL", 76, 79], ["saline", "SIMPLE_CHEMICAL", 103, 109], ["mice", "ORGANISM", 129, 133], ["patients", "ORGANISM", 161, 169], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 129, 133], ["patients", "SPECIES", 161, 169], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 129, 133], ["the BAL fluid", "TEST", 13, 26], ["OVA", "PROBLEM", 30, 33], ["eightfold higher ATP concentrations", "TREATMENT", 59, 94], ["saline", "TREATMENT", 103, 109], ["an allergen challenge", "TREATMENT", 180, 201], ["BAL", "ANATOMY", 17, 20], ["fluid", "OBSERVATION", 21, 26]]], ["Schreiber et al. tested the impact of preventing ADO production, from this excess nucleotide, in this model of allergic asthma [69] .", [["ADO", "CHEMICAL", 49, 52], ["nucleotide", "CHEMICAL", 82, 92], ["allergic asthma", "DISEASE", 111, 126], ["ADO", "CHEMICAL", 49, 52], ["nucleotide", "CHEMICAL", 82, 92], ["ADO", "SIMPLE_CHEMICAL", 49, 52], ["ADO production", "PROBLEM", 49, 63], ["this excess nucleotide", "PROBLEM", 70, 92], ["allergic asthma", "PROBLEM", 111, 126], ["ADO production", "OBSERVATION", 49, 63], ["allergic asthma", "OBSERVATION", 111, 126]]], ["The Cd73 \u00c0/\u00c0 mice exhibited no baseline allergen-induced inflammation, and failed to develop hyperresponsiveness to methacholine following OVA treatment.", [["inflammation", "DISEASE", 57, 69], ["hyperresponsiveness", "DISEASE", 93, 112], ["methacholine", "CHEMICAL", 116, 128], ["methacholine", "CHEMICAL", 116, 128], ["Cd73", "GENE_OR_GENE_PRODUCT", 4, 8], ["methacholine", "SIMPLE_CHEMICAL", 116, 128], ["Cd73", "PROTEIN", 4, 8], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["The Cd73", "TEST", 0, 8], ["baseline allergen", "PROBLEM", 31, 48], ["induced inflammation", "PROBLEM", 49, 69], ["hyperresponsiveness", "PROBLEM", 93, 112], ["methacholine", "TREATMENT", 116, 128], ["OVA treatment", "TREATMENT", 139, 152], ["no", "UNCERTAINTY", 28, 30], ["inflammation", "OBSERVATION", 57, 69]]], ["These data demonstrate that the airway ADO produced by CD73, and not excess ATP, is responsible for the hyperresponsiveness of OVAchallenged mice.", [["airway", "ANATOMY", 32, 38], ["ADO", "CHEMICAL", 39, 42], ["ATP", "CHEMICAL", 76, 79], ["ADO", "CHEMICAL", 39, 42], ["ATP", "CHEMICAL", 76, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 32, 38], ["CD73", "GENE_OR_GENE_PRODUCT", 55, 59], ["ATP", "SIMPLE_CHEMICAL", 76, 79], ["mice", "ORGANISM", 141, 145], ["CD73", "PROTEIN", 55, 59], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 141, 145], ["These data", "TEST", 0, 10], ["CD73", "TEST", 55, 59], ["excess ATP", "PROBLEM", 69, 79], ["the hyperresponsiveness of OVAchallenged mice", "PROBLEM", 100, 145], ["airway", "ANATOMY", 32, 38], ["hyperresponsiveness", "OBSERVATION", 104, 123]]], ["Aerosolized PEG-ADA may constitute a potential therapeutic intervention for airway hyperresponsiveness in asthmatic patients.How Informative Are CD39 \u00c0/\u00c0 Mice?The impact of chronically-high airway ATP concentrations has been investigated by genetic deletion of the ATP/ADP-hydrolyzing ectonucleotidase, CD39.", [["airway", "ANATOMY", 76, 82], ["airway", "ANATOMY", 190, 196], ["PEG-ADA", "CHEMICAL", 12, 19], ["airway hyperresponsiveness", "DISEASE", 76, 102], ["asthmatic", "DISEASE", 106, 115], ["ATP", "CHEMICAL", 197, 200], ["ATP", "CHEMICAL", 265, 268], ["ADP", "CHEMICAL", 269, 272], ["PEG-ADA", "CHEMICAL", 12, 19], ["ATP", "CHEMICAL", 197, 200], ["ATP", "CHEMICAL", 265, 268], ["ADP", "CHEMICAL", 269, 272], ["PEG-ADA", "SIMPLE_CHEMICAL", 12, 19], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["patients", "ORGANISM", 116, 124], ["CD39", "GENE_OR_GENE_PRODUCT", 145, 149], ["airway", "MULTI-TISSUE_STRUCTURE", 190, 196], ["ATP", "SIMPLE_CHEMICAL", 197, 200], ["ATP", "SIMPLE_CHEMICAL", 265, 268], ["ADP", "SIMPLE_CHEMICAL", 269, 272], ["ectonucleotidase", "GENE_OR_GENE_PRODUCT", 285, 301], ["CD39", "GENE_OR_GENE_PRODUCT", 303, 307], ["CD39", "PROTEIN", 145, 149], ["ATP/ADP-hydrolyzing ectonucleotidase", "PROTEIN", 265, 301], ["CD39", "PROTEIN", 303, 307], ["patients", "SPECIES", 116, 124], ["Mice", "SPECIES", 154, 158], ["Aerosolized PEG", "TREATMENT", 0, 15], ["a potential therapeutic intervention", "TREATMENT", 35, 71], ["airway hyperresponsiveness", "PROBLEM", 76, 102], ["asthmatic patients", "PROBLEM", 106, 124], ["high airway ATP concentrations", "PROBLEM", 185, 215], ["the ATP", "TEST", 261, 268], ["ADP", "TEST", 269, 272], ["CD39", "PROBLEM", 303, 307], ["PEG", "OBSERVATION", 12, 15], ["airway", "ANATOMY", 76, 82], ["hyperresponsiveness", "OBSERVATION", 83, 102], ["chronically", "OBSERVATION_MODIFIER", 173, 184], ["high airway", "OBSERVATION", 185, 196], ["ATP concentrations", "OBSERVATION", 197, 215]]], ["This choice was originally based on the predominant role of endothelial CD39 in the prevention of ADP-mediated thrombus formation (review: [70] ).", [["endothelial", "ANATOMY", 60, 71], ["thrombus", "ANATOMY", 111, 119], ["ADP", "CHEMICAL", 98, 101], ["thrombus", "DISEASE", 111, 119], ["ADP", "CHEMICAL", 98, 101], ["endothelial CD39", "GENE_OR_GENE_PRODUCT", 60, 76], ["ADP", "SIMPLE_CHEMICAL", 98, 101], ["thrombus", "PATHOLOGICAL_FORMATION", 111, 119], ["endothelial CD39", "PROTEIN", 60, 76], ["endothelial CD39", "TREATMENT", 60, 76], ["ADP-mediated thrombus formation", "PROBLEM", 98, 129], ["endothelial CD39", "OBSERVATION", 60, 76], ["thrombus", "OBSERVATION", 111, 119]]], ["Consequently, it was quite surprising to find that Cd39 \u00c0/\u00c0 mice exhibit no symptom of pulmonary complication, unless they are subjected to an insult.", [["pulmonary", "ANATOMY", 87, 96], ["pulmonary complication", "DISEASE", 87, 109], ["Cd39", "GENE_OR_GENE_PRODUCT", 51, 55], ["pulmonary", "ORGAN", 87, 96], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["Cd39", "TEST", 51, 55], ["symptom", "PROBLEM", 76, 83], ["pulmonary complication", "PROBLEM", 87, 109], ["an insult", "PROBLEM", 140, 149], ["no", "UNCERTAINTY", 73, 75], ["pulmonary", "ANATOMY", 87, 96], ["complication", "OBSERVATION", 97, 109]]], ["For instance, mechanical ventilation has been used as a model of acute lung injury in over 500 publications (review: [65] ).", [["lung", "ANATOMY", 71, 75], ["acute lung injury", "DISEASE", 65, 82], ["lung", "ORGAN", 71, 75], ["mechanical ventilation", "TREATMENT", 14, 36], ["acute lung injury", "PROBLEM", 65, 82], ["mechanical ventilation", "OBSERVATION", 14, 36], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["lung", "ANATOMY", 71, 75], ["injury", "OBSERVATION", 76, 82]]], ["Patients kept on a ventilator for less than 3 days usually recover from an acute inflammatory response, but prolonged intubation initiates tissue fibrosis and loss of lung function.", [["tissue", "ANATOMY", 139, 145], ["lung", "ANATOMY", 167, 171], ["fibrosis", "DISEASE", 146, 154], ["loss of lung function", "DISEASE", 159, 180], ["Patients", "ORGANISM", 0, 8], ["tissue", "TISSUE", 139, 145], ["lung", "ORGAN", 167, 171], ["Patients", "SPECIES", 0, 8], ["a ventilator", "TREATMENT", 17, 29], ["an acute inflammatory response", "PROBLEM", 72, 102], ["prolonged intubation", "TREATMENT", 108, 128], ["tissue fibrosis", "PROBLEM", 139, 154], ["loss of lung function", "PROBLEM", 159, 180], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["inflammatory", "OBSERVATION", 81, 93], ["fibrosis", "OBSERVATION", 146, 154], ["lung", "ANATOMY", 167, 171]]], ["For this reason, mechanical ventilation remains the focus of most animal studies on acute lung injury.How Informative Are CD39 \u00c0/\u00c0 Mice?Eckle et al. demonstrated that mice subjected 90 min to high-pressure mechanical ventilation develop typical manifestations of acute lung injury, characterized by vascular leakage, pulmonary edema, neutrophil infiltration and hemorrhage [71] .How Informative Are CD39 \u00c0/\u00c0 Mice?Interestingly, as in the case of hypoxia, this insult up-regulated both CD39 and CD73 by threefold within 2 h, resulting in a fourfold increase in total lung ADO concentration [71] .", [["lung", "ANATOMY", 90, 94], ["lung", "ANATOMY", 269, 273], ["vascular", "ANATOMY", 299, 307], ["pulmonary", "ANATOMY", 317, 326], ["neutrophil", "ANATOMY", 334, 344], ["lung", "ANATOMY", 566, 570], ["acute lung injury", "DISEASE", 84, 101], ["acute lung injury", "DISEASE", 263, 280], ["pulmonary edema", "DISEASE", 317, 332], ["hemorrhage", "DISEASE", 362, 372], ["hypoxia", "DISEASE", 446, 453], ["ADO", "CHEMICAL", 571, 574], ["ADO", "CHEMICAL", 571, 574], ["lung", "ORGAN", 90, 94], ["CD39", "GENE_OR_GENE_PRODUCT", 122, 126], ["mice", "ORGANISM", 167, 171], ["lung", "ORGAN", 269, 273], ["vascular", "MULTI-TISSUE_STRUCTURE", 299, 307], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 317, 332], ["neutrophil", "CELL", 334, 344], ["CD39", "GENE_OR_GENE_PRODUCT", 399, 403], ["CD39", "GENE_OR_GENE_PRODUCT", 485, 489], ["CD73", "GENE_OR_GENE_PRODUCT", 494, 498], ["lung", "ORGAN", 566, 570], ["ADO", "SIMPLE_CHEMICAL", 571, 574], ["CD39", "PROTEIN", 122, 126], ["CD39", "PROTEIN", 399, 403], ["CD39", "PROTEIN", 485, 489], ["CD73", "PROTEIN", 494, 498], ["Mice", "SPECIES", 131, 135], ["mice", "SPECIES", 167, 171], ["Mice", "SPECIES", 408, 412], ["mice", "SPECIES", 167, 171], ["mechanical ventilation", "TREATMENT", 17, 39], ["most animal studies", "TEST", 61, 80], ["acute lung injury", "PROBLEM", 84, 101], ["high-pressure mechanical ventilation", "TREATMENT", 192, 228], ["acute lung injury", "PROBLEM", 263, 280], ["vascular leakage", "PROBLEM", 299, 315], ["pulmonary edema", "PROBLEM", 317, 332], ["neutrophil infiltration", "PROBLEM", 334, 357], ["hemorrhage", "PROBLEM", 362, 372], ["hypoxia", "PROBLEM", 446, 453], ["this insult", "TEST", 455, 466], ["total lung ADO concentration", "TREATMENT", 560, 588], ["mechanical ventilation", "OBSERVATION", 17, 39], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["lung", "ANATOMY", 90, 94], ["injury", "OBSERVATION", 95, 101], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["lung", "ANATOMY", 269, 273], ["injury", "OBSERVATION", 274, 280], ["vascular", "ANATOMY", 299, 307], ["leakage", "OBSERVATION", 308, 315], ["pulmonary", "ANATOMY", 317, 326], ["edema", "OBSERVATION", 327, 332], ["neutrophil infiltration", "OBSERVATION", 334, 357], ["hemorrhage", "OBSERVATION", 362, 372], ["hypoxia", "OBSERVATION", 446, 453], ["fourfold", "OBSERVATION_MODIFIER", 539, 547], ["increase", "OBSERVATION_MODIFIER", 548, 556], ["lung", "ANATOMY", 566, 570], ["ADO concentration", "OBSERVATION", 571, 588]]], ["To test whether these metabolic disruptions constitute a defense mechanism, or promote the lung damage, Cd39 \u00c0/\u00c0 and Cd73 \u00c0/\u00c0 mice were subjected to the same insult.", [["lung", "ANATOMY", 91, 95], ["lung damage", "DISEASE", 91, 102], ["lung", "ORGAN", 91, 95], ["Cd39", "GENE_OR_GENE_PRODUCT", 104, 108], ["\u00c0", "GENE_OR_GENE_PRODUCT", 111, 112], ["Cd73", "GENE_OR_GENE_PRODUCT", 117, 121], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["these metabolic disruptions", "PROBLEM", 16, 43], ["the lung damage", "PROBLEM", 87, 102], ["Cd39", "TEST", 104, 108], ["Cd73", "TEST", 117, 121], ["lung", "ANATOMY", 91, 95], ["damage", "OBSERVATION", 96, 102]]], ["These knockout mice developed the same symptoms, but they were dramatically more severe than in the wild-type mice [71] .", [["mice", "ORGANISM", 15, 19], ["mice", "ORGANISM", 110, 114], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 15, 19], ["the same symptoms", "PROBLEM", 30, 47]]], ["Surprisingly, similar BAL albumin level and neutrophil myeloperoxidase activity, as well as lung water content, were detected in the ventilated Cd39 \u00c0/\u00c0 and Cd73 \u00c0/\u00c0 mice.", [["BAL", "ANATOMY", 22, 25], ["neutrophil", "ANATOMY", 44, 54], ["lung", "ANATOMY", 92, 96], ["BAL", "ORGANISM_SUBSTANCE", 22, 25], ["albumin", "GENE_OR_GENE_PRODUCT", 26, 33], ["neutrophil", "CELL", 44, 54], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 55, 70], ["lung", "ORGAN", 92, 96], ["Cd39", "GENE_OR_GENE_PRODUCT", 144, 148], ["\u00c0", "GENE_OR_GENE_PRODUCT", 151, 152], ["Cd73", "GENE_OR_GENE_PRODUCT", 157, 161], ["BAL albumin", "PROTEIN", 22, 33], ["neutrophil", "CELL_TYPE", 44, 54], ["myeloperoxidase", "PROTEIN", 55, 70], ["mice", "SPECIES", 166, 170], ["similar BAL albumin level", "TEST", 14, 39], ["neutrophil myeloperoxidase activity", "TEST", 44, 79], ["lung water content", "TEST", 92, 110], ["Cd73", "TEST", 157, 161], ["BAL albumin", "OBSERVATION", 22, 33], ["neutrophil myeloperoxidase activity", "OBSERVATION", 44, 79], ["lung", "ANATOMY", 92, 96], ["water content", "OBSERVATION", 97, 110], ["ventilated Cd39", "ANATOMY", 133, 148]]], ["During acute insults, it is widely accepted that ATP mediates predominantly proinflammatory effects, whereas ADO generally provides a feedback anti-inflammatory response (review: [72] ).", [["acute insults", "DISEASE", 7, 20], ["ATP", "CHEMICAL", 49, 52], ["ADO", "CHEMICAL", 109, 112], ["ATP", "CHEMICAL", 49, 52], ["ADO", "CHEMICAL", 109, 112], ["ATP", "SIMPLE_CHEMICAL", 49, 52], ["ADO", "SIMPLE_CHEMICAL", 109, 112], ["acute insults", "PROBLEM", 7, 20], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["insults", "OBSERVATION", 13, 20], ["predominantly", "OBSERVATION_MODIFIER", 62, 75], ["proinflammatory", "OBSERVATION_MODIFIER", 76, 91]]], ["Since Cd39 \u00c0/\u00c0 mice allow ATP to accumulate and prevent ADO formation, we would have expected a more severe lung inflammation than in the Cd73 \u00c0/\u00c0 mice, which simply deny ADO formation.", [["lung", "ANATOMY", 108, 112], ["ATP", "CHEMICAL", 26, 29], ["ADO", "CHEMICAL", 56, 59], ["lung inflammation", "DISEASE", 108, 125], ["ADO", "CHEMICAL", 171, 174], ["ATP", "CHEMICAL", 26, 29], ["ADO", "CHEMICAL", 56, 59], ["ADO", "CHEMICAL", 171, 174], ["Cd39", "GENE_OR_GENE_PRODUCT", 6, 10], ["ATP", "SIMPLE_CHEMICAL", 26, 29], ["ADO", "SIMPLE_CHEMICAL", 56, 59], ["lung", "ORGAN", 108, 112], ["Cd73", "GENE_OR_GENE_PRODUCT", 138, 142], ["ADO", "SIMPLE_CHEMICAL", 171, 174], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 15, 19], ["Cd39", "TEST", 6, 10], ["ATP", "PROBLEM", 26, 29], ["ADO formation", "PROBLEM", 56, 69], ["a more severe lung inflammation", "PROBLEM", 94, 125], ["ADO formation", "PROBLEM", 171, 184], ["more", "OBSERVATION_MODIFIER", 96, 100], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["lung", "ANATOMY", 108, 112], ["inflammation", "OBSERVATION", 113, 125]]], ["This study highlights the critical protective role of excess ADO production during an acute insult, which outweighs any short-term detrimental effect of ATP accumulation.", [["ADO", "CHEMICAL", 61, 64], ["ATP", "CHEMICAL", 153, 156], ["ADO", "CHEMICAL", 61, 64], ["ATP", "CHEMICAL", 153, 156], ["ADO", "SIMPLE_CHEMICAL", 61, 64], ["ATP", "SIMPLE_CHEMICAL", 153, 156], ["This study", "TEST", 0, 10], ["excess ADO production", "PROBLEM", 54, 75], ["an acute insult", "PROBLEM", 83, 98], ["ATP accumulation", "PROBLEM", 153, 169], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["insult", "OBSERVATION", 92, 98], ["short-term", "OBSERVATION_MODIFIER", 120, 130], ["ATP accumulation", "OBSERVATION", 153, 169]]], ["The significance of this purinergic protection was confirmed by the beneficial effects of enzyme replacement therapy on the ventilated wild-type mice.", [["mice", "ORGANISM", 145, 149], ["mice", "SPECIES", 145, 149], ["mice", "SPECIES", 145, 149], ["this purinergic protection", "TREATMENT", 20, 46], ["enzyme replacement therapy", "TREATMENT", 90, 116], ["enzyme replacement", "OBSERVATION", 90, 108]]], ["The intraperitoneal administration of apyrase (commercial form of CD39) or 5 0 -nucleotidase (commercial form of CD73), significantly reduced the accumulation of BAL albumin during mechanical ventilation.", [["intraperitoneal", "ANATOMY", 4, 19], ["BAL", "ANATOMY", 162, 165], ["apyrase", "CHEMICAL", 38, 45], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 19], ["apyrase", "SIMPLE_CHEMICAL", 38, 45], ["CD39", "GENE_OR_GENE_PRODUCT", 66, 70], ["5 0 -nucleotidase", "GENE_OR_GENE_PRODUCT", 75, 92], ["CD73", "GENE_OR_GENE_PRODUCT", 113, 117], ["BAL albumin", "GENE_OR_GENE_PRODUCT", 162, 173], ["apyrase", "PROTEIN", 38, 45], ["CD39", "PROTEIN", 66, 70], ["5 0 -nucleotidase", "PROTEIN", 75, 92], ["CD73", "PROTEIN", 113, 117], ["The intraperitoneal administration of apyrase", "TREATMENT", 0, 45], ["CD39)", "TREATMENT", 66, 71], ["BAL albumin", "TREATMENT", 162, 173], ["mechanical ventilation", "TREATMENT", 181, 203], ["intraperitoneal", "ANATOMY", 4, 19], ["accumulation of", "OBSERVATION", 146, 161], ["BAL albumin", "OBSERVATION", 162, 173], ["mechanical ventilation", "OBSERVATION", 181, 203]]], ["The excess circulating ADO, likely, provided additional endothelial barrier protection against vascular leakage via the low-affinity A 2B Rs ( Fig. 8.1 ).", [["endothelial", "ANATOMY", 56, 67], ["vascular", "ANATOMY", 95, 103], ["ADO", "CHEMICAL", 23, 26], ["ADO", "CHEMICAL", 23, 26], ["ADO", "SIMPLE_CHEMICAL", 23, 26], ["endothelial barrier", "TISSUE", 56, 75], ["vascular", "MULTI-TISSUE_STRUCTURE", 95, 103], ["The excess circulating ADO", "PROBLEM", 0, 26], ["additional endothelial barrier protection", "TREATMENT", 45, 86], ["vascular leakage", "PROBLEM", 95, 111], ["circulating ADO", "OBSERVATION", 11, 26], ["vascular", "ANATOMY", 95, 103], ["leakage", "OBSERVATION", 104, 111]]], ["Incidentally, this study also showed that intraperitoneal injection of an antagonist of A 2B Rs, not A 2A Rs, before the onset of mechanical ventilation reproduced the severity of the lung edema observed in the knockout mice.", [["intraperitoneal", "ANATOMY", 42, 57], ["lung", "ANATOMY", 184, 188], ["lung edema", "DISEASE", 184, 194], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 57], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 88, 95], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 101, 108], ["lung edema", "PATHOLOGICAL_FORMATION", 184, 194], ["mice", "ORGANISM", 220, 224], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 220, 224], ["this study", "TEST", 14, 24], ["intraperitoneal injection", "TREATMENT", 42, 67], ["mechanical ventilation", "TREATMENT", 130, 152], ["the lung edema", "PROBLEM", 180, 194], ["mechanical ventilation", "OBSERVATION", 130, 152], ["severity", "OBSERVATION_MODIFIER", 168, 176], ["lung", "ANATOMY", 184, 188], ["edema", "OBSERVATION", 189, 194]]], ["Consequently, this study confirms the protective role of excessive ADO against pulmonary edema during acute lung injury.", [["pulmonary", "ANATOMY", 79, 88], ["lung", "ANATOMY", 108, 112], ["ADO", "CHEMICAL", 67, 70], ["pulmonary edema", "DISEASE", 79, 94], ["acute lung injury", "DISEASE", 102, 119], ["ADO", "CHEMICAL", 67, 70], ["ADO", "SIMPLE_CHEMICAL", 67, 70], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 79, 94], ["lung", "ORGAN", 108, 112], ["this study", "TEST", 14, 24], ["excessive ADO", "TREATMENT", 57, 70], ["pulmonary edema", "PROBLEM", 79, 94], ["acute lung injury", "PROBLEM", 102, 119], ["pulmonary", "ANATOMY", 79, 88], ["edema", "OBSERVATION", 89, 94], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["lung", "ANATOMY", 108, 112], ["injury", "OBSERVATION", 113, 119]]], ["Endothelial A 2B Rs should be targeted at the first manifestations of acute lung injury.How Informative Are CD39 \u00c0/\u00c0 Mice?Most animal models of acute lung injury are based on clinical disorders, including mechanical ventilation, gastric aspiration and sepsis (review: [65] ).", [["Endothelial", "ANATOMY", 0, 11], ["lung", "ANATOMY", 76, 80], ["lung", "ANATOMY", 150, 154], ["gastric", "ANATOMY", 229, 236], ["acute lung injury", "DISEASE", 70, 87], ["acute lung injury", "DISEASE", 144, 161], ["sepsis", "DISEASE", 252, 258], ["Endothelial A 2B", "CELL", 0, 16], ["Rs", "GENE_OR_GENE_PRODUCT", 17, 19], ["lung", "ORGAN", 76, 80], ["CD39", "GENE_OR_GENE_PRODUCT", 108, 112], ["lung", "ORGAN", 150, 154], ["gastric", "ORGAN", 229, 236], ["CD39", "PROTEIN", 108, 112], ["Mice", "SPECIES", 117, 121], ["acute lung injury", "PROBLEM", 70, 87], ["acute lung injury", "PROBLEM", 144, 161], ["clinical disorders", "PROBLEM", 175, 193], ["mechanical ventilation", "TREATMENT", 205, 227], ["gastric aspiration", "PROBLEM", 229, 247], ["sepsis", "PROBLEM", 252, 258], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["lung", "ANATOMY", 76, 80], ["injury", "OBSERVATION", 81, 87], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["lung", "ANATOMY", 150, 154], ["injury", "OBSERVATION", 155, 161], ["mechanical ventilation", "OBSERVATION", 205, 227], ["gastric", "ANATOMY", 229, 236], ["aspiration", "OBSERVATION", 237, 247], ["sepsis", "OBSERVATION", 252, 258]]], ["The intratracheal administration of bacterial lipopolysaccharide (LPS) is particularly suited to investigate the impact of purinergic signaling on neutrophil migration into the airways.", [["intratracheal", "ANATOMY", 4, 17], ["neutrophil", "ANATOMY", 147, 157], ["airways", "ANATOMY", 177, 184], ["lipopolysaccharide", "CHEMICAL", 46, 64], ["LPS", "CHEMICAL", 66, 69], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 46, 64], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["purinergic", "SIMPLE_CHEMICAL", 123, 133], ["neutrophil", "CELL", 147, 157], ["airways", "MULTI-TISSUE_STRUCTURE", 177, 184], ["neutrophil", "CELL_TYPE", 147, 157], ["The intratracheal administration", "TREATMENT", 0, 32], ["bacterial lipopolysaccharide (LPS)", "TREATMENT", 36, 70], ["neutrophil migration", "TREATMENT", 147, 167], ["intratracheal", "ANATOMY", 4, 17], ["bacterial lipopolysaccharide", "OBSERVATION", 36, 64], ["neutrophil migration", "OBSERVATION", 147, 167], ["airways", "ANATOMY", 177, 184]]], ["Aside from the usual BAL fluid cytokines, vascular leakage and disruption of the lung architecture, the mice accumulate neutrophils in all compartments of the respiratory system.", [["BAL fluid", "ANATOMY", 21, 30], ["vascular", "ANATOMY", 42, 50], ["lung", "ANATOMY", 81, 85], ["neutrophils", "ANATOMY", 120, 131], ["respiratory system", "ANATOMY", 159, 177], ["vascular", "MULTI-TISSUE_STRUCTURE", 42, 50], ["lung architecture", "MULTI-TISSUE_STRUCTURE", 81, 98], ["mice", "ORGANISM", 104, 108], ["neutrophils", "CELL", 120, 131], ["BAL fluid cytokines", "PROTEIN", 21, 40], ["neutrophils", "CELL_TYPE", 120, 131], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["the usual BAL fluid cytokines", "TEST", 11, 40], ["vascular leakage", "PROBLEM", 42, 58], ["disruption of the lung architecture", "PROBLEM", 63, 98], ["fluid cytokines", "OBSERVATION", 25, 40], ["vascular", "ANATOMY", 42, 50], ["leakage", "OBSERVATION", 51, 58], ["lung", "ANATOMY", 81, 85], ["architecture", "ANATOMY_MODIFIER", 86, 98], ["neutrophils", "OBSERVATION_MODIFIER", 120, 131], ["all compartments", "ANATOMY_MODIFIER", 135, 151], ["respiratory system", "ANATOMY", 159, 177]]], ["This LPS challenge also induced a coordinated up-regulation of CD39 and CD73 [73] , as described above for hypoxia [74] and mechanical ventilation [71] .", [["LPS", "CHEMICAL", 5, 8], ["hypoxia", "DISEASE", 107, 114], ["LPS", "SIMPLE_CHEMICAL", 5, 8], ["CD39", "GENE_OR_GENE_PRODUCT", 63, 67], ["CD73", "GENE_OR_GENE_PRODUCT", 72, 76], ["CD39", "PROTEIN", 63, 67], ["CD73", "PROTEIN", 72, 76], ["This LPS challenge", "TEST", 0, 18], ["CD39", "TEST", 63, 67], ["CD73", "TEST", 72, 76], ["hypoxia", "PROBLEM", 107, 114], ["mechanical ventilation", "TREATMENT", 124, 146]]], ["The exposure of Cd39 \u00c0/\u00c0 mice and Cd73 \u00c0/\u00c0 mice to intratracheal LPS generated more severe accumulation of neutrophils in the pulmonary tissue than in LPS-treated wild-type mice.", [["neutrophils", "ANATOMY", 107, 118], ["pulmonary tissue", "ANATOMY", 126, 142], ["LPS", "CHEMICAL", 65, 68], ["LPS", "CHEMICAL", 151, 154], ["Cd39", "GENE_OR_GENE_PRODUCT", 16, 20], ["Cd73", "GENE_OR_GENE_PRODUCT", 34, 38], ["LPS", "SIMPLE_CHEMICAL", 65, 68], ["neutrophils", "CELL", 107, 118], ["pulmonary tissue", "TISSUE", 126, 142], ["LPS", "SIMPLE_CHEMICAL", 151, 154], ["mice", "ORGANISM", 173, 177], ["neutrophils", "CELL_TYPE", 107, 118], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 173, 177], ["mice", "SPECIES", 43, 47], ["Cd39", "TEST", 16, 20], ["Cd73", "TEST", 34, 38], ["intratracheal LPS", "TEST", 51, 68], ["more severe accumulation of neutrophils in the pulmonary tissue", "PROBLEM", 79, 142], ["intratracheal LPS", "ANATOMY", 51, 68], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["accumulation", "OBSERVATION_MODIFIER", 91, 103], ["neutrophils", "OBSERVATION", 107, 118], ["pulmonary tissue", "ANATOMY", 126, 142]]], ["To determine which step of neutrophil migration was affected in the knockout mice, Reutershan et al. labeled their neutrophils by intravenous injection of Alexa 633-labelled Gr-1 [73] .", [["neutrophil", "ANATOMY", 27, 37], ["neutrophils", "ANATOMY", 115, 126], ["intravenous", "ANATOMY", 130, 141], ["Alexa 633", "CHEMICAL", 155, 164], ["Alexa 633", "CHEMICAL", 155, 164], ["neutrophil", "CELL", 27, 37], ["mice", "ORGANISM", 77, 81], ["neutrophils", "CELL", 115, 126], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 130, 141], ["Alexa 633", "SIMPLE_CHEMICAL", 155, 164], ["Gr-1", "GENE_OR_GENE_PRODUCT", 174, 178], ["neutrophil", "CELL_TYPE", 27, 37], ["neutrophils", "CELL_TYPE", 115, 126], ["Alexa 633", "PROTEIN", 155, 164], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["neutrophil migration", "PROBLEM", 27, 47], ["Alexa", "TEST", 155, 160], ["neutrophil migration", "OBSERVATION", 27, 47]]], ["They showed that the absence of CD39 or CD73 raised neutrophil numbers in the interstitium and the airspace, but not in the bloodstream.", [["neutrophil", "ANATOMY", 52, 62], ["interstitium", "ANATOMY", 78, 90], ["airspace", "ANATOMY", 99, 107], ["bloodstream", "ANATOMY", 124, 135], ["CD39", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD73", "GENE_OR_GENE_PRODUCT", 40, 44], ["neutrophil", "CELL", 52, 62], ["interstitium", "TISSUE", 78, 90], ["airspace", "MULTI-TISSUE_STRUCTURE", 99, 107], ["CD39", "PROTEIN", 32, 36], ["CD73", "PROTEIN", 40, 44], ["CD39", "PROBLEM", 32, 36], ["neutrophil numbers", "TEST", 52, 70], ["neutrophil numbers", "OBSERVATION", 52, 70], ["interstitium", "ANATOMY_MODIFIER", 78, 90], ["airspace", "ANATOMY", 99, 107], ["bloodstream", "OBSERVATION", 124, 135]]], ["Since both knockout mice respond similarly to the LPS challenge, this study suggests that the prevention of ADO formation in the Cd39 \u00c0/\u00c0 mice and Cd73 \u00c0/\u00c0 mice was responsible for the exaggerated lung neutrophilia.", [["lung", "ANATOMY", 197, 201], ["LPS", "CHEMICAL", 50, 53], ["ADO", "CHEMICAL", 108, 111], ["lung neutrophilia", "DISEASE", 197, 214], ["ADO", "CHEMICAL", 108, 111], ["mice", "ORGANISM", 20, 24], ["LPS", "SIMPLE_CHEMICAL", 50, 53], ["ADO", "SIMPLE_CHEMICAL", 108, 111], ["Cd39 \u00c0/\u00c0 mice", "ORGANISM", 129, 142], ["Cd73", "GENE_OR_GENE_PRODUCT", 147, 151], ["lung", "ORGAN", 197, 201], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 156, 160], ["the LPS challenge", "TREATMENT", 46, 63], ["this study", "TEST", 65, 75], ["ADO formation", "PROBLEM", 108, 121], ["the Cd39", "TEST", 125, 133], ["Cd73", "TEST", 147, 151], ["the exaggerated lung neutrophilia", "PROBLEM", 181, 214], ["exaggerated", "OBSERVATION_MODIFIER", 185, 196], ["lung", "ANATOMY", 197, 201], ["neutrophilia", "OBSERVATION", 202, 214]]], ["The fact that ADO deficiency allowed neutrophils to accumulate to greater extent, both, in the interstitium and BAL fluid, suggest that this P1 receptor agonist normally restrict their transmigration across the endothelial and alveolar epithelial barriers.", [["neutrophils", "ANATOMY", 37, 48], ["interstitium", "ANATOMY", 95, 107], ["BAL fluid", "ANATOMY", 112, 121], ["endothelial", "ANATOMY", 211, 222], ["alveolar epithelial", "ANATOMY", 227, 246], ["ADO", "CHEMICAL", 14, 17], ["ADO", "CHEMICAL", 14, 17], ["ADO", "SIMPLE_CHEMICAL", 14, 17], ["neutrophils", "CELL", 37, 48], ["interstitium", "TISSUE", 95, 107], ["BAL fluid", "ORGANISM_SUBSTANCE", 112, 121], ["P1 receptor", "GENE_OR_GENE_PRODUCT", 141, 152], ["endothelial", "CELL", 211, 222], ["alveolar epithelial", "TISSUE", 227, 246], ["neutrophils", "CELL_TYPE", 37, 48], ["P1 receptor", "PROTEIN", 141, 152], ["ADO deficiency", "PROBLEM", 14, 28], ["neutrophils", "PROBLEM", 37, 48], ["BAL fluid", "TEST", 112, 121], ["this P1 receptor agonist", "TREATMENT", 136, 160], ["ADO deficiency", "OBSERVATION", 14, 28], ["greater extent", "OBSERVATION_MODIFIER", 66, 80], ["interstitium", "ANATOMY", 95, 107], ["BAL fluid", "OBSERVATION", 112, 121], ["endothelial", "ANATOMY", 211, 222], ["alveolar", "ANATOMY_MODIFIER", 227, 235], ["epithelial", "ANATOMY_MODIFIER", 236, 246]]], ["As in the other models of acute lung injury described above, the low circulating ADO levels of Cd39 \u00c0/\u00c0 mice and Cd73 \u00c0/\u00c0 mice were associated with a loss of endothelial barrier resistance, as determined by extravasation of Evans blue dye.", [["lung", "ANATOMY", 32, 36], ["endothelial barrier", "ANATOMY", 158, 177], ["acute lung injury", "DISEASE", 26, 43], ["ADO", "CHEMICAL", 81, 84], ["Evans blue", "CHEMICAL", 224, 234], ["ADO", "CHEMICAL", 81, 84], ["Evans blue", "CHEMICAL", 224, 234], ["lung", "ORGAN", 32, 36], ["ADO", "SIMPLE_CHEMICAL", 81, 84], ["Cd39 \u00c0/\u00c0 mice", "ORGANISM", 95, 108], ["Cd73", "GENE_OR_GENE_PRODUCT", 113, 117], ["endothelial barrier", "TISSUE", 158, 177], ["Evans blue dye", "SIMPLE_CHEMICAL", 224, 238], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 122, 126], ["acute lung injury", "PROBLEM", 26, 43], ["Cd39", "TEST", 95, 99], ["Cd73", "TEST", 113, 117], ["a loss of endothelial barrier resistance", "PROBLEM", 148, 188], ["Evans blue dye", "TREATMENT", 224, 238], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["lung", "ANATOMY", 32, 36], ["injury", "OBSERVATION", 37, 43], ["loss", "OBSERVATION", 150, 154], ["endothelial barrier resistance", "OBSERVATION", 158, 188], ["extravasation", "OBSERVATION", 207, 220]]], ["On the other hand, this study provides the first evidence of a purinergic regulation of leukocyte migration across airway epithelia.How Informative Are CD39 \u00c0/\u00c0 Mice?A common pattern emerges from studies conducted with mouse models of aberrant purine regulation.", [["leukocyte", "ANATOMY", 88, 97], ["airway epithelia", "ANATOMY", 115, 131], ["purine", "CHEMICAL", 244, 250], ["purine", "CHEMICAL", 244, 250], ["leukocyte", "CELL", 88, 97], ["airway epithelia", "TISSUE", 115, 131], ["CD39", "GENE_OR_GENE_PRODUCT", 152, 156], ["mouse", "ORGANISM", 219, 224], ["purine", "SIMPLE_CHEMICAL", 244, 250], ["CD39", "PROTEIN", 152, 156], ["Mice", "SPECIES", 161, 165], ["mouse", "SPECIES", 219, 224], ["mouse", "SPECIES", 219, 224], ["this study", "TEST", 19, 29], ["leukocyte migration across airway epithelia", "PROBLEM", 88, 131], ["aberrant purine regulation", "PROBLEM", 235, 261], ["leukocyte migration", "OBSERVATION", 88, 107], ["airway epithelia", "OBSERVATION", 115, 131], ["purine regulation", "OBSERVATION", 244, 261]]], ["The fact that Cd39 \u00c0/\u00c0 mice and Cd73 \u00c0/\u00c0 mice respond similarly to acute insults indicates that circulating/airway ADO, not ATP, significantly influences the short term and reversible inflammatory responses.", [["airway", "ANATOMY", 108, 114], ["ADO", "CHEMICAL", 115, 118], ["ATP", "CHEMICAL", 124, 127], ["ADO", "CHEMICAL", 115, 118], ["ATP", "CHEMICAL", 124, 127], ["Cd39", "GENE_OR_GENE_PRODUCT", 14, 18], ["\u00c0", "GENE_OR_GENE_PRODUCT", 21, 22], ["Cd73", "GENE_OR_GENE_PRODUCT", 32, 36], ["airway", "MULTI-TISSUE_STRUCTURE", 108, 114], ["ADO", "SIMPLE_CHEMICAL", 115, 118], ["ATP", "SIMPLE_CHEMICAL", 124, 127], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 41, 45], ["Cd39", "TEST", 14, 18], ["Cd73", "TEST", 32, 36], ["acute insults", "PROBLEM", 67, 80], ["circulating/airway ADO", "TREATMENT", 96, 118], ["ATP", "PROBLEM", 124, 127], ["the short term and reversible inflammatory responses", "PROBLEM", 154, 206], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["insults", "OBSERVATION", 73, 80], ["airway", "ANATOMY", 108, 114], ["short term", "OBSERVATION_MODIFIER", 158, 168], ["reversible", "OBSERVATION_MODIFIER", 173, 183], ["inflammatory", "OBSERVATION", 184, 196]]], ["In these situations, a robust and transient increase in circulating ADO appears essential to raise endothelial barrier integrity, which restricts pulmonary edema and the infiltration of inflammatory cells.", [["endothelial barrier", "ANATOMY", 99, 118], ["pulmonary", "ANATOMY", 146, 155], ["inflammatory cells", "ANATOMY", 186, 204], ["ADO", "CHEMICAL", 68, 71], ["pulmonary edema", "DISEASE", 146, 161], ["ADO", "CHEMICAL", 68, 71], ["ADO", "SIMPLE_CHEMICAL", 68, 71], ["endothelial barrier", "TISSUE", 99, 118], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 146, 161], ["cells", "CELL", 199, 204], ["inflammatory cells", "CELL_TYPE", 186, 204], ["a robust and transient increase", "PROBLEM", 21, 52], ["circulating ADO", "TREATMENT", 56, 71], ["endothelial barrier integrity", "TREATMENT", 99, 128], ["pulmonary edema", "PROBLEM", 146, 161], ["the infiltration of inflammatory cells", "PROBLEM", 166, 204], ["robust", "OBSERVATION_MODIFIER", 23, 29], ["transient", "OBSERVATION_MODIFIER", 34, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["barrier integrity", "OBSERVATION", 111, 128], ["pulmonary", "ANATOMY", 146, 155], ["edema", "OBSERVATION", 156, 161], ["infiltration", "OBSERVATION", 170, 182], ["inflammatory cells", "OBSERVATION", 186, 204]]], ["In contrast, models of chronic airway diseases clearly show that the sustained elevation of airway ADO is associated with a wide array of detrimental effects, ranging from severe inflammation to airway remodeling and hyperresponsiveness.", [["airway", "ANATOMY", 31, 37], ["airway", "ANATOMY", 92, 98], ["airway", "ANATOMY", 195, 201], ["airway diseases", "DISEASE", 31, 46], ["ADO", "CHEMICAL", 99, 102], ["inflammation", "DISEASE", 179, 191], ["ADO", "CHEMICAL", 99, 102], ["airway", "MULTI-TISSUE_STRUCTURE", 31, 37], ["airway", "MULTI-TISSUE_STRUCTURE", 92, 98], ["airway", "MULTI-TISSUE_STRUCTURE", 195, 201], ["chronic airway diseases", "PROBLEM", 23, 46], ["the sustained elevation of airway ADO", "PROBLEM", 65, 102], ["detrimental effects", "PROBLEM", 138, 157], ["severe inflammation", "PROBLEM", 172, 191], ["airway remodeling", "PROBLEM", 195, 212], ["hyperresponsiveness", "PROBLEM", 217, 236], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["airway", "ANATOMY", 31, 37], ["diseases", "OBSERVATION", 38, 46], ["sustained", "OBSERVATION_MODIFIER", 69, 78], ["elevation", "OBSERVATION", 79, 88], ["airway", "ANATOMY", 92, 98], ["wide", "OBSERVATION_MODIFIER", 124, 128], ["detrimental effects", "OBSERVATION", 138, 157], ["severe", "OBSERVATION_MODIFIER", 172, 178], ["inflammation", "OBSERVATION", 179, 191], ["airway", "ANATOMY", 195, 201], ["hyperresponsiveness", "OBSERVATION", 217, 236]]], ["Therefore, any therapeutic strategy that will be envisioned to reduce purine-mediated lung complications must be carefully tailored with the most appropriate murine model.Can A 1 Rs Go Either Way?Ischemia-reperfusion injury causes significant morbidity and mortality, which remains a major obstacle after lung transplant.", [["lung", "ANATOMY", 86, 90], ["lung", "ANATOMY", 305, 309], ["purine", "CHEMICAL", 70, 76], ["lung complications", "DISEASE", 86, 104], ["Ischemia", "DISEASE", 196, 204], ["purine", "CHEMICAL", 70, 76], ["purine", "SIMPLE_CHEMICAL", 70, 76], ["lung", "ORGAN", 86, 90], ["murine", "ORGANISM", 158, 164], ["lung", "ORGAN", 305, 309], ["murine", "SPECIES", 158, 164], ["any therapeutic strategy", "TREATMENT", 11, 35], ["purine-mediated lung complications", "PROBLEM", 70, 104], ["Ischemia", "PROBLEM", 196, 204], ["reperfusion injury", "PROBLEM", 205, 223], ["significant morbidity", "PROBLEM", 231, 252], ["lung transplant", "TREATMENT", 305, 320], ["lung", "ANATOMY", 86, 90], ["complications", "OBSERVATION", 91, 104], ["reperfusion injury", "OBSERVATION", 205, 223], ["significant", "OBSERVATION_MODIFIER", 231, 242], ["morbidity", "OBSERVATION", 243, 252], ["lung", "ANATOMY", 305, 309], ["transplant", "OBSERVATION", 310, 320]]], ["Neely et al. provided evidence that A 1 R antagonists attenuate inflammation and injury in a feline model of ischemic lung injury [75] .", [["lung", "ANATOMY", 118, 122], ["inflammation", "DISEASE", 64, 76], ["ischemic lung injury", "DISEASE", 109, 129], ["A 1 R antagonists", "GENE_OR_GENE_PRODUCT", 36, 53], ["feline", "ORGANISM", 93, 99], ["lung", "ORGAN", 118, 122], ["A 1 R antagonists attenuate inflammation", "PROBLEM", 36, 76], ["injury", "PROBLEM", 81, 87], ["ischemic lung injury", "PROBLEM", 109, 129], ["inflammation", "OBSERVATION", 64, 76], ["injury", "OBSERVATION", 81, 87], ["ischemic", "OBSERVATION_MODIFIER", 109, 117], ["lung", "ANATOMY", 118, 122], ["injury", "OBSERVATION", 123, 129]]], ["In these animals, ischemia-reperfusion induced lung edema and the infiltration of inflammatory cells (neutrophils, macrophages and red blood cells) in the alveolar space.", [["lung", "ANATOMY", 47, 51], ["inflammatory cells", "ANATOMY", 82, 100], ["neutrophils", "ANATOMY", 102, 113], ["macrophages", "ANATOMY", 115, 126], ["red blood cells", "ANATOMY", 131, 146], ["alveolar space", "ANATOMY", 155, 169], ["ischemia", "DISEASE", 18, 26], ["lung edema", "DISEASE", 47, 57], ["lung", "ORGAN", 47, 51], ["inflammatory cells", "CELL", 82, 100], ["neutrophils", "CELL", 102, 113], ["macrophages", "CELL", 115, 126], ["red blood cells", "CELL", 131, 146], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 155, 169], ["inflammatory cells", "CELL_TYPE", 82, 100], ["neutrophils", "CELL_TYPE", 102, 113], ["macrophages", "CELL_TYPE", 115, 126], ["red blood cells", "CELL_TYPE", 131, 146], ["ischemia", "PROBLEM", 18, 26], ["reperfusion induced lung edema", "PROBLEM", 27, 57], ["the infiltration of inflammatory cells", "PROBLEM", 62, 100], ["neutrophils", "TEST", 102, 113], ["macrophages", "PROBLEM", 115, 126], ["red blood cells", "TEST", 131, 146], ["ischemia", "OBSERVATION", 18, 26], ["reperfusion", "OBSERVATION_MODIFIER", 27, 38], ["lung", "ANATOMY", 47, 51], ["edema", "OBSERVATION", 52, 57], ["infiltration", "OBSERVATION_MODIFIER", 66, 78], ["inflammatory cells", "OBSERVATION", 82, 100], ["neutrophils", "OBSERVATION_MODIFIER", 102, 113], ["blood cells", "OBSERVATION", 135, 146], ["alveolar space", "ANATOMY", 155, 169]]], ["Intralobar arterial infusion of an A 1 R antagonist, xanthine amine congener (XAC) or 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), before the onset of ischemia fully prevented alveolar injury.", [["arterial", "ANATOMY", 11, 19], ["alveolar", "ANATOMY", 175, 183], ["xanthine amine", "CHEMICAL", 53, 67], ["XAC", "CHEMICAL", 78, 81], ["1,3-dipropyl-8-cyclopentylxanthine", "CHEMICAL", 86, 120], ["DPCPX", "CHEMICAL", 122, 127], ["ischemia", "DISEASE", 150, 158], ["alveolar injury", "DISEASE", 175, 190], ["xanthine amine", "CHEMICAL", 53, 67], ["XAC", "CHEMICAL", 78, 81], ["1,3-dipropyl-8-cyclopentylxanthine", "CHEMICAL", 86, 120], ["DPCPX", "CHEMICAL", 122, 127], ["arterial", "MULTI-TISSUE_STRUCTURE", 11, 19], ["A 1 R antagonist", "SIMPLE_CHEMICAL", 35, 51], ["xanthine amine congener", "SIMPLE_CHEMICAL", 53, 76], ["XAC", "SIMPLE_CHEMICAL", 78, 81], ["1,3-dipropyl-8-cyclopentylxanthine", "SIMPLE_CHEMICAL", 86, 120], ["DPCPX", "SIMPLE_CHEMICAL", 122, 127], ["alveolar", "MULTI-TISSUE_STRUCTURE", 175, 183], ["Intralobar arterial infusion", "TREATMENT", 0, 28], ["an A 1 R antagonist", "TREATMENT", 32, 51], ["xanthine amine congener (XAC)", "TREATMENT", 53, 82], ["dipropyl", "TREATMENT", 90, 98], ["cyclopentylxanthine (DPCPX", "TREATMENT", 101, 127], ["ischemia", "PROBLEM", 150, 158], ["alveolar injury", "PROBLEM", 175, 190], ["arterial", "ANATOMY", 11, 19], ["ischemia", "OBSERVATION", 150, 158], ["alveolar injury", "OBSERVATION", 175, 190]]], ["This study suggests that a proactive treatment with A 1 R antagonists may reduce the ischemia-reperfusion injury developing after lung transplant surgery.Can A 1 Rs Go Either Way?Bacterial LPS initiates a number of pro-inflammatory responses, such as priming of neutrophils and macrophages, and the EGFR-mediated signaling cascades of cytokine and growth factor secretion from airway epithelial cells (see Chaps.", [["lung", "ANATOMY", 130, 134], ["neutrophils", "ANATOMY", 262, 273], ["macrophages", "ANATOMY", 278, 289], ["airway epithelial cells", "ANATOMY", 377, 400], ["ischemia-reperfusion injury", "DISEASE", 85, 112], ["LPS", "CHEMICAL", 189, 192], ["A 1 R antagonists", "GENE_OR_GENE_PRODUCT", 52, 69], ["lung", "ORGAN", 130, 134], ["neutrophils", "CELL", 262, 273], ["macrophages", "CELL", 278, 289], ["EGFR", "GENE_OR_GENE_PRODUCT", 299, 303], ["airway epithelial cells", "CELL", 377, 400], ["neutrophils", "CELL_TYPE", 262, 273], ["macrophages", "CELL_TYPE", 278, 289], ["EGFR", "PROTEIN", 299, 303], ["cytokine", "PROTEIN", 335, 343], ["growth factor", "PROTEIN", 348, 361], ["airway epithelial cells", "CELL_TYPE", 377, 400], ["This study", "TEST", 0, 10], ["a proactive treatment", "TREATMENT", 25, 46], ["A 1 R antagonists", "TREATMENT", 52, 69], ["the ischemia-reperfusion injury", "PROBLEM", 81, 112], ["lung transplant surgery", "TREATMENT", 130, 153], ["Bacterial LPS", "PROBLEM", 179, 192], ["neutrophils", "TEST", 262, 273], ["macrophages", "PROBLEM", 278, 289], ["the EGFR", "TEST", 295, 303], ["cytokine and growth factor secretion from airway epithelial cells", "PROBLEM", 335, 400], ["ischemia-reperfusion", "OBSERVATION_MODIFIER", 85, 105], ["injury", "OBSERVATION", 106, 112], ["lung", "ANATOMY", 130, 134], ["transplant", "OBSERVATION", 135, 145], ["LPS", "OBSERVATION", 189, 192], ["airway epithelial cells", "OBSERVATION", 377, 400]]], ["Yet, the specific mechanism by which LPS initiates these cascades of pathophysiological events in the lung has not been described.", [["lung", "ANATOMY", 102, 106], ["LPS", "CHEMICAL", 37, 40], ["LPS", "GENE_OR_GENE_PRODUCT", 37, 40], ["lung", "ORGAN", 102, 106], ["pathophysiological events in the lung", "PROBLEM", 69, 106], ["lung", "ANATOMY", 102, 106]]], ["Neely et al. used an intralobar arterial injection of LPS as a model of acute lung injury in spontaneously breathing cats [76] .", [["arterial", "ANATOMY", 32, 40], ["lung", "ANATOMY", 78, 82], ["LPS", "CHEMICAL", 54, 57], ["acute lung injury", "DISEASE", 72, 89], ["arterial", "MULTI-TISSUE_STRUCTURE", 32, 40], ["LPS", "SIMPLE_CHEMICAL", 54, 57], ["lung", "ORGAN", 78, 82], ["an intralobar arterial injection of LPS", "TREATMENT", 18, 57], ["acute lung injury", "PROBLEM", 72, 89], ["intralobar", "ANATOMY_MODIFIER", 21, 31], ["arterial", "ANATOMY", 32, 40], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["lung", "ANATOMY", 78, 82], ["injury", "OBSERVATION", 83, 89]]], ["These animals developed a dose-dependent lung injury characterized by the presence of macrophages, neutrophils and red blood cells in the alveoli, alveolar edema and necrosis.", [["lung", "ANATOMY", 41, 45], ["macrophages", "ANATOMY", 86, 97], ["neutrophils", "ANATOMY", 99, 110], ["red blood cells", "ANATOMY", 115, 130], ["alveoli", "ANATOMY", 138, 145], ["alveolar edema", "ANATOMY", 147, 161], ["lung injury", "DISEASE", 41, 52], ["alveolar edema", "DISEASE", 147, 161], ["necrosis", "DISEASE", 166, 174], ["lung", "ORGAN", 41, 45], ["macrophages", "CELL", 86, 97], ["neutrophils", "CELL", 99, 110], ["red blood cells", "CELL", 115, 130], ["alveoli", "MULTI-TISSUE_STRUCTURE", 138, 145], ["alveolar edema", "PATHOLOGICAL_FORMATION", 147, 161], ["macrophages", "CELL_TYPE", 86, 97], ["neutrophils", "CELL_TYPE", 99, 110], ["red blood cells", "CELL_TYPE", 115, 130], ["dependent lung injury", "PROBLEM", 31, 52], ["macrophages", "PROBLEM", 86, 97], ["neutrophils", "TEST", 99, 110], ["red blood cells", "TEST", 115, 130], ["alveolar edema", "PROBLEM", 147, 161], ["necrosis", "PROBLEM", 166, 174], ["dependent", "OBSERVATION_MODIFIER", 31, 40], ["lung", "ANATOMY", 41, 45], ["injury", "OBSERVATION", 46, 52], ["macrophages", "OBSERVATION", 86, 97], ["red blood cells", "OBSERVATION", 115, 130], ["alveoli", "ANATOMY_MODIFIER", 138, 145], ["alveolar", "ANATOMY_MODIFIER", 147, 155], ["edema", "OBSERVATION", 156, 161], ["necrosis", "OBSERVATION", 166, 174]]], ["Pre-treatment by intravenous bolus injection of DPCPX prevented all aspects of the acute lung injury.", [["intravenous", "ANATOMY", 17, 28], ["lung", "ANATOMY", 89, 93], ["DPCPX", "CHEMICAL", 48, 53], ["acute lung injury", "DISEASE", 83, 100], ["DPCPX", "CHEMICAL", 48, 53], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 28], ["DPCPX", "SIMPLE_CHEMICAL", 48, 53], ["lung", "ORGAN", 89, 93], ["Pre-treatment", "TREATMENT", 0, 13], ["intravenous bolus injection", "TREATMENT", 17, 44], ["DPCPX", "TREATMENT", 48, 53], ["the acute lung injury", "PROBLEM", 79, 100], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100]]], ["This study suggests that A 1 R antagonists may decrease the symptoms of adult respiratory distress syndrome induced by sepsis.", [["respiratory", "ANATOMY", 78, 89], ["respiratory distress syndrome", "DISEASE", 78, 107], ["sepsis", "DISEASE", 119, 125], ["A 1 R antagonists", "GENE_OR_GENE_PRODUCT", 25, 42], ["This study", "TEST", 0, 10], ["A 1 R antagonists", "TREATMENT", 25, 42], ["the symptoms", "PROBLEM", 56, 68], ["adult respiratory distress syndrome", "PROBLEM", 72, 107], ["sepsis", "PROBLEM", 119, 125], ["respiratory distress syndrome", "OBSERVATION", 78, 107], ["sepsis", "OBSERVATION", 119, 125]]], ["Based on the human model of fluid flux regulation, this approach may prevent edema by suppressing A 1 R-mediated CFTR activity and fluid secretion in the alveolar space ( Fig. 8.1 ).", [["fluid", "ANATOMY", 28, 33], ["edema", "ANATOMY", 77, 82], ["fluid", "ANATOMY", 131, 136], ["alveolar space", "ANATOMY", 154, 168], ["edema", "DISEASE", 77, 82], ["human", "ORGANISM", 13, 18], ["edema", "PATHOLOGICAL_FORMATION", 77, 82], ["A 1 R", "GENE_OR_GENE_PRODUCT", 98, 103], ["CFTR", "GENE_OR_GENE_PRODUCT", 113, 117], ["fluid", "ORGANISM_SUBSTANCE", 131, 136], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 154, 168], ["CFTR", "PROTEIN", 113, 117], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["fluid flux regulation", "TREATMENT", 28, 49], ["this approach", "TREATMENT", 51, 64], ["edema", "PROBLEM", 77, 82], ["A 1 R-mediated CFTR activity", "PROBLEM", 98, 126], ["fluid secretion in the alveolar space", "PROBLEM", 131, 168], ["fluid flux", "OBSERVATION", 28, 38], ["may prevent", "UNCERTAINTY", 65, 76], ["edema", "OBSERVATION", 77, 82], ["fluid secretion", "OBSERVATION", 131, 146], ["alveolar space", "ANATOMY", 154, 168]]], ["On the other hand, since few studies documented purinergic signaling in cats, it would be reassuring to repeat these experiments in mice, especially in the light of the following study.Can A 1 Rs Go Either Way?In mice, the administration of aerosolized LPS triggers classic manifestations of acute lung injury, summarized by microvascular leakage and neutrophil accumulation in the vascular, interstitial and alveolar compartments.", [["lung", "ANATOMY", 298, 302], ["microvascular", "ANATOMY", 325, 338], ["neutrophil", "ANATOMY", 351, 361], ["vascular", "ANATOMY", 382, 390], ["interstitial", "ANATOMY", 392, 404], ["alveolar compartments", "ANATOMY", 409, 430], ["LPS", "CHEMICAL", 253, 256], ["acute lung injury", "DISEASE", 292, 309], ["purinergic", "SIMPLE_CHEMICAL", 48, 58], ["cats", "ORGANISM", 72, 76], ["mice", "ORGANISM", 132, 136], ["mice", "ORGANISM", 213, 217], ["LPS", "SIMPLE_CHEMICAL", 253, 256], ["lung", "ORGAN", 298, 302], ["microvascular", "TISSUE", 325, 338], ["neutrophil", "CELL", 351, 361], ["vascular", "MULTI-TISSUE_STRUCTURE", 382, 390], ["interstitial", "MULTI-TISSUE_STRUCTURE", 392, 404], ["alveolar compartments", "MULTI-TISSUE_STRUCTURE", 409, 430], ["cats", "SPECIES", 72, 76], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 213, 217], ["few studies", "TEST", 25, 36], ["purinergic signaling in cats", "PROBLEM", 48, 76], ["the following study", "TEST", 165, 184], ["aerosolized LPS", "TREATMENT", 241, 256], ["acute lung injury", "PROBLEM", 292, 309], ["microvascular leakage", "PROBLEM", 325, 346], ["neutrophil accumulation in the vascular, interstitial and alveolar compartments", "PROBLEM", 351, 430], ["acute", "OBSERVATION_MODIFIER", 292, 297], ["lung", "ANATOMY", 298, 302], ["injury", "OBSERVATION", 303, 309], ["microvascular leakage", "OBSERVATION", 325, 346], ["neutrophil accumulation", "OBSERVATION", 351, 374], ["vascular", "ANATOMY", 382, 390], ["interstitial", "ANATOMY_MODIFIER", 392, 404], ["alveolar", "ANATOMY_MODIFIER", 409, 417]]], ["Interestingly, a study showed that LPS also causes a gradual increase in the total lung mRNA and protein level of A 1 Rs.", [["lung", "ANATOMY", 83, 87], ["LPS", "CHEMICAL", 35, 38], ["LPS", "SIMPLE_CHEMICAL", 35, 38], ["lung", "ORGAN", 83, 87], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 114, 120], ["lung mRNA", "RNA", 83, 92], ["a study", "TEST", 15, 22], ["LPS", "PROBLEM", 35, 38], ["a gradual increase in the total lung mRNA", "PROBLEM", 51, 92], ["gradual", "OBSERVATION_MODIFIER", 53, 60], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["total", "OBSERVATION_MODIFIER", 77, 82], ["lung", "ANATOMY", 83, 87], ["mRNA", "OBSERVATION", 88, 92]]], ["This response was considerably weaker in mice depleted in neutrophils by injection of anti-granulocyte antibodies [77] .", [["neutrophils", "ANATOMY", 58, 69], ["mice", "ORGANISM", 41, 45], ["neutrophils", "CELL", 58, 69], ["neutrophils", "CELL_TYPE", 58, 69], ["anti-granulocyte antibodies", "PROTEIN", 86, 113], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["anti-granulocyte antibodies", "TEST", 86, 113], ["considerably", "OBSERVATION_MODIFIER", 18, 30], ["weaker", "OBSERVATION_MODIFIER", 31, 37]]], ["Therefore, the authors tested whether this receptor regulates neutrophil recruitment by exposing knockout mice to aerosolized LPS.", [["neutrophil", "ANATOMY", 62, 72], ["LPS", "CHEMICAL", 126, 129], ["neutrophil", "CELL", 62, 72], ["mice", "ORGANISM", 106, 110], ["LPS", "SIMPLE_CHEMICAL", 126, 129], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["this receptor regulates neutrophil recruitment", "TREATMENT", 38, 84], ["aerosolized LPS", "TREATMENT", 114, 129], ["neutrophil recruitment", "OBSERVATION", 62, 84]]], ["These A 1 R \u00c0/\u00c0 mice developed exaggerated neutrophil migration and microvascular permeability to LPS, supporting an anti-inflammatory role for this ADO receptor.", [["neutrophil", "ANATOMY", 43, 53], ["microvascular", "ANATOMY", 68, 81], ["LPS", "CHEMICAL", 98, 101], ["ADO", "CHEMICAL", 149, 152], ["A 1 R", "GENE_OR_GENE_PRODUCT", 6, 11], ["neutrophil", "CELL", 43, 53], ["microvascular", "TISSUE", 68, 81], ["LPS", "SIMPLE_CHEMICAL", 98, 101], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 149, 161], ["ADO receptor", "PROTEIN", 149, 161], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["exaggerated neutrophil migration", "PROBLEM", 31, 63], ["microvascular permeability to LPS", "PROBLEM", 68, 101], ["an anti-inflammatory role", "TREATMENT", 114, 139], ["this ADO receptor", "TREATMENT", 144, 161], ["exaggerated", "OBSERVATION_MODIFIER", 31, 42], ["neutrophil migration", "OBSERVATION", 43, 63], ["microvascular permeability", "OBSERVATION", 68, 94]]], ["Incidentally, the pre-treatment of wild-type mice by intraperitoneal injection of the new A 1 R agonist, named 2'Me-2-chloro-N6-cyclopentyladenosine (2 0 Me-CCPA), significantly reduced vascular leakage and neutrophil counts in the interstitium and alveolar space.", [["intraperitoneal", "ANATOMY", 53, 68], ["vascular", "ANATOMY", 186, 194], ["neutrophil", "ANATOMY", 207, 217], ["interstitium", "ANATOMY", 232, 244], ["alveolar space", "ANATOMY", 249, 263], ["2'Me-2-chloro-N6-cyclopentyladenosine", "CHEMICAL", 111, 148], ["2'Me-2-chloro-N6-cyclopentyladenosine", "CHEMICAL", 111, 148], ["2 0 Me-CCPA", "CHEMICAL", 150, 161], ["mice", "ORGANISM", 45, 49], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 68], ["A 1 R", "GENE_OR_GENE_PRODUCT", 90, 95], ["2'Me-2-chloro-N6-cyclopentyladenosine", "SIMPLE_CHEMICAL", 111, 148], ["2 0 Me-CCPA", "SIMPLE_CHEMICAL", 150, 161], ["vascular", "MULTI-TISSUE_STRUCTURE", 186, 194], ["neutrophil", "CELL", 207, 217], ["interstitium", "TISSUE", 232, 244], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 249, 263], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["the new A 1 R agonist", "TREATMENT", 82, 103], ["2'Me", "TREATMENT", 111, 115], ["chloro", "TREATMENT", 118, 124], ["N6-cyclopentyladenosine", "TREATMENT", 125, 148], ["significantly reduced vascular leakage", "PROBLEM", 164, 202], ["neutrophil counts", "TEST", 207, 224], ["reduced", "OBSERVATION_MODIFIER", 178, 185], ["vascular", "ANATOMY", 186, 194], ["leakage", "OBSERVATION", 195, 202], ["neutrophil counts", "OBSERVATION", 207, 224], ["interstitium", "ANATOMY_MODIFIER", 232, 244], ["alveolar space", "ANATOMY", 249, 263]]], ["This agonist also reduced the accumulation of pro-inflammatory cytokines (TNF-a, IL-6 and CXCL2/3) in the BAL fluid.", [["BAL fluid", "ANATOMY", 106, 115], ["TNF-a", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["CXCL2", "GENE_OR_GENE_PRODUCT", 90, 95], ["3", "GENE_OR_GENE_PRODUCT", 96, 97], ["BAL fluid", "ORGANISM_SUBSTANCE", 106, 115], ["pro-inflammatory cytokines", "PROTEIN", 46, 72], ["TNF", "PROTEIN", 74, 77], ["IL-6", "PROTEIN", 81, 85], ["CXCL2", "PROTEIN", 90, 95], ["pro-inflammatory cytokines", "TEST", 46, 72], ["TNF", "TEST", 74, 77], ["IL", "TEST", 81, 83], ["CXCL2", "TEST", 90, 95], ["the BAL fluid", "TEST", 102, 115], ["accumulation", "OBSERVATION_MODIFIER", 30, 42], ["pro-inflammatory cytokines", "OBSERVATION", 46, 72], ["BAL", "ANATOMY", 106, 109], ["fluid", "OBSERVATION", 110, 115]]], ["A combination of in vivo and in vitro experiments revealed that A 1 Rs protect against the loss of endothelial and epithelial barrier permeability induced by LPS through inhibition of cytoskeletal rearrangement.", [["endothelial", "ANATOMY", 99, 110], ["epithelial barrier", "ANATOMY", 115, 133], ["cytoskeletal", "ANATOMY", 184, 196], ["LPS", "CHEMICAL", 158, 161], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 64, 70], ["endothelial", "CELL", 99, 110], ["epithelial barrier", "TISSUE", 115, 133], ["LPS", "SIMPLE_CHEMICAL", 158, 161], ["cytoskeletal", "CELLULAR_COMPONENT", 184, 196], ["vitro experiments", "TEST", 32, 49], ["the loss of endothelial", "PROBLEM", 87, 110], ["epithelial barrier permeability", "TREATMENT", 115, 146], ["cytoskeletal rearrangement", "PROBLEM", 184, 210], ["loss", "OBSERVATION", 91, 95], ["endothelial", "ANATOMY", 99, 110], ["epithelial", "ANATOMY_MODIFIER", 115, 125], ["barrier permeability", "OBSERVATION", 126, 146], ["cytoskeletal rearrangement", "OBSERVATION", 184, 210]]], ["Also, pre-treatment of neutrophils with 2 0 Me-CCPA reduced their transmigration across endothelial cells, supporting a role for A 1 Rs on the inflammatory cells.", [["neutrophils", "ANATOMY", 23, 34], ["endothelial cells", "ANATOMY", 88, 105], ["inflammatory cells", "ANATOMY", 143, 161], ["2 0 Me-CCPA", "CHEMICAL", 40, 51], ["neutrophils", "CELL", 23, 34], ["2 0 Me-CCPA", "SIMPLE_CHEMICAL", 40, 51], ["endothelial cells", "CELL", 88, 105], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 129, 135], ["cells", "CELL", 156, 161], ["neutrophils", "CELL_TYPE", 23, 34], ["endothelial cells", "CELL_TYPE", 88, 105], ["A 1 Rs", "PROTEIN", 129, 135], ["inflammatory cells", "CELL_TYPE", 143, 161], ["neutrophils", "TEST", 23, 34], ["their transmigration across endothelial cells", "PROBLEM", 60, 105], ["the inflammatory cells", "PROBLEM", 139, 161], ["endothelial cells", "OBSERVATION", 88, 105], ["inflammatory cells", "OBSERVATION", 143, 161]]], ["Since the receptor specificity of 2 0 Me-CCPA has been fully assessed [78] , this study supports the therapeutic potential of the agonist for the treatment of acute lung injury regarding airway bacterial infection.Can A 1 Rs Go Either Way?Chronic airway diseases are associated with higher mRNA levels of A 1 Rs in the animal models [39, 79, 80] , as well as bronchial epithelial and airway smooth muscle cells from asthmatic patients [81] .", [["lung", "ANATOMY", 165, 169], ["airway", "ANATOMY", 187, 193], ["airway", "ANATOMY", 247, 253], ["bronchial epithelial", "ANATOMY", 359, 379], ["airway smooth muscle cells", "ANATOMY", 384, 410], ["lung injury", "DISEASE", 165, 176], ["airway bacterial infection", "DISEASE", 187, 213], ["airway diseases", "DISEASE", 247, 262], ["asthmatic", "DISEASE", 416, 425], ["Me-CCPA", "GENE_OR_GENE_PRODUCT", 38, 45], ["lung", "ORGAN", 165, 169], ["airway", "MULTI-TISSUE_STRUCTURE", 247, 253], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 305, 311], ["bronchial epithelial", "CELL", 359, 379], ["airway smooth muscle cells", "CELL", 384, 410], ["patients", "ORGANISM", 426, 434], ["bronchial epithelial", "CELL_TYPE", 359, 379], ["airway smooth muscle cells", "CELL_TYPE", 384, 410], ["patients", "SPECIES", 426, 434], ["the receptor specificity", "TEST", 6, 30], ["this study", "TEST", 77, 87], ["the agonist", "TREATMENT", 126, 137], ["the treatment", "TREATMENT", 142, 155], ["acute lung injury", "PROBLEM", 159, 176], ["airway bacterial infection", "PROBLEM", 187, 213], ["Chronic airway diseases", "PROBLEM", 239, 262], ["higher mRNA levels", "PROBLEM", 283, 301], ["asthmatic patients", "PROBLEM", 416, 434], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["lung", "ANATOMY", 165, 169], ["injury", "OBSERVATION", 170, 176], ["airway", "ANATOMY", 187, 193], ["bacterial", "OBSERVATION_MODIFIER", 194, 203], ["infection", "OBSERVATION", 204, 213], ["airway", "ANATOMY", 247, 253], ["diseases", "OBSERVATION", 254, 262], ["higher mRNA", "OBSERVATION_MODIFIER", 283, 294], ["bronchial", "ANATOMY", 359, 368], ["epithelial", "ANATOMY_MODIFIER", 369, 379], ["airway smooth", "ANATOMY", 384, 397], ["muscle cells", "OBSERVATION", 398, 410]]], ["An up-regulation of this receptor in asthma supports a role in the pathophysiology of this disease, and the potential of selective antagonists for the treatment of asthmatics.", [["asthma", "DISEASE", 37, 43], ["this receptor", "TREATMENT", 20, 33], ["asthma", "PROBLEM", 37, 43], ["this disease", "PROBLEM", 86, 98], ["selective antagonists", "TREATMENT", 121, 142], ["asthmatics", "PROBLEM", 164, 174], ["asthma", "OBSERVATION", 37, 43], ["asthmatics", "OBSERVATION", 164, 174]]], ["In the dust mite-conditioned allergic model of asthma, rabbits receiving aerosolized antisense oligodeoxynucleotides targeting A 1 Rs were desensitized to subsequent challenges with ADO or dust mite [82] .", [["allergic", "DISEASE", 29, 37], ["asthma", "DISEASE", 47, 53], ["ADO", "CHEMICAL", 182, 185], ["ADO", "CHEMICAL", 182, 185], ["rabbits", "ORGANISM", 55, 62], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 127, 133], ["ADO", "SIMPLE_CHEMICAL", 182, 185], ["rabbits", "SPECIES", 55, 62], ["rabbits", "SPECIES", 55, 62], ["asthma", "PROBLEM", 47, 53], ["aerosolized antisense oligodeoxynucleotides", "TREATMENT", 73, 116], ["allergic model", "OBSERVATION", 29, 43], ["asthma", "OBSERVATION", 47, 53]]], ["The intratracheal ingestion of the water soluble A 1 R antagonist, L-97-1, also attenuated bronchoconstriction in this model [83] .", [["intratracheal", "ANATOMY", 4, 17], ["L-97-1", "CHEMICAL", 67, 73], ["A 1 R antagonist", "SIMPLE_CHEMICAL", 49, 65], ["L-97-1", "SIMPLE_CHEMICAL", 67, 73], ["the water soluble A 1 R antagonist", "TREATMENT", 31, 65], ["attenuated bronchoconstriction", "PROBLEM", 80, 110], ["intratracheal", "ANATOMY", 4, 17], ["attenuated", "OBSERVATION_MODIFIER", 80, 90], ["bronchoconstriction", "OBSERVATION", 91, 110]]], ["In addition, allergic animals pretreated with L-97-1 accumulated significantly less BAL eosinophils and neutrophils in response to a dust mite challenge than the untreated allergic animals [83] .", [["BAL eosinophils", "ANATOMY", 84, 99], ["neutrophils", "ANATOMY", 104, 115], ["allergic", "DISEASE", 13, 21], ["L-97-1", "CHEMICAL", 46, 52], ["allergic", "DISEASE", 172, 180], ["L-97-1", "GENE_OR_GENE_PRODUCT", 46, 52], ["BAL eosinophils", "CELL", 84, 99], ["neutrophils", "CELL", 104, 115], ["BAL eosinophils", "CELL_TYPE", 84, 99], ["neutrophils", "CELL_TYPE", 104, 115], ["allergic animals", "PROBLEM", 13, 29], ["significantly less BAL eosinophils", "PROBLEM", 65, 99], ["neutrophils", "TEST", 104, 115], ["a dust mite challenge", "TREATMENT", 131, 152], ["the untreated allergic animals", "PROBLEM", 158, 188], ["allergic", "OBSERVATION_MODIFIER", 13, 21], ["BAL eosinophils", "OBSERVATION", 84, 99]]], ["Whether ADO-induced bronchoconstriction is mediated via A 1 Rs expressed on airway smooth muscle, inflammatory cells or nerve endings is not clear.", [["airway smooth muscle", "ANATOMY", 76, 96], ["inflammatory cells", "ANATOMY", 98, 116], ["nerve endings", "ANATOMY", 120, 133], ["ADO", "CHEMICAL", 8, 11], ["ADO", "CHEMICAL", 8, 11], ["ADO", "SIMPLE_CHEMICAL", 8, 11], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 56, 62], ["airway smooth muscle", "TISSUE", 76, 96], ["inflammatory cells", "CELL", 98, 116], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 120, 133], ["A 1 Rs", "PROTEIN", 56, 62], ["inflammatory cells", "CELL_TYPE", 98, 116], ["bronchoconstriction", "PROBLEM", 20, 39], ["inflammatory cells", "PROBLEM", 98, 116], ["nerve endings", "PROBLEM", 120, 133], ["bronchoconstriction", "OBSERVATION", 20, 39], ["airway", "ANATOMY", 76, 82], ["smooth muscle", "ANATOMY", 83, 96], ["inflammatory cells", "OBSERVATION", 98, 116], ["nerve", "ANATOMY", 120, 125], ["not", "UNCERTAINTY", 137, 140], ["clear", "OBSERVATION", 141, 146]]], ["A recent study conducted with A 1 R \u00c0/\u00c0 mice supports a neuronal component [84] .", [["neuronal", "ANATOMY", 56, 64], ["mice", "ORGANISM", 40, 44], ["neuronal", "CELL", 56, 64], ["mice", "SPECIES", 40, 44], ["A 1 R \u00c0/\u00c0 mice", "SPECIES", 30, 44], ["A recent study", "TEST", 0, 14], ["A 1 R \u00c0/\u00c0 mice", "TREATMENT", 30, 44]]], ["But the fact that aerosolized and gastric deliveries of the A 1 R antagonist reduce hyperresponsiveness supports a multi-cellular mechanism (see Chap.", [["gastric", "ANATOMY", 34, 41], ["gastric", "ORGAN", 34, 41], ["A 1 R antagonist", "GENE_OR_GENE_PRODUCT", 60, 76], ["aerosolized and gastric deliveries", "TREATMENT", 18, 52], ["the A 1 R antagonist", "TREATMENT", 56, 76], ["hyperresponsiveness", "PROBLEM", 84, 103], ["aerosolized", "OBSERVATION", 18, 29], ["gastric", "ANATOMY", 34, 41], ["hyperresponsiveness", "OBSERVATION", 84, 103]]], ["Detrimental roles for the A 1 Rs in chronic diseases also include the capacity to raise the expression of MUC2 and MUC5AC [85] , which contributes to mucus overproduction, a major feature of asthma.Can A 1 Rs Go Either Way?Murine models of chronically-high ADO concentrations in the lung are associated with enhanced or induced A 1 Rs expression, depending on the cell type [86] .", [["mucus", "ANATOMY", 150, 155], ["lung", "ANATOMY", 283, 287], ["cell", "ANATOMY", 364, 368], ["chronic diseases", "DISEASE", 36, 52], ["asthma", "DISEASE", 191, 197], ["ADO", "CHEMICAL", 257, 260], ["ADO", "CHEMICAL", 257, 260], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 26, 32], ["MUC2", "GENE_OR_GENE_PRODUCT", 106, 110], ["MUC5AC [85]", "GENE_OR_GENE_PRODUCT", 115, 126], ["mucus", "ORGANISM_SUBSTANCE", 150, 155], ["Murine", "ORGANISM", 223, 229], ["ADO", "SIMPLE_CHEMICAL", 257, 260], ["lung", "ORGAN", 283, 287], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 328, 334], ["cell", "CELL", 364, 368], ["A 1 Rs", "PROTEIN", 26, 32], ["MUC2", "PROTEIN", 106, 110], ["MUC5AC", "PROTEIN", 115, 121], ["chronic diseases", "PROBLEM", 36, 52], ["the capacity", "PROBLEM", 66, 78], ["mucus overproduction", "PROBLEM", 150, 170], ["asthma", "PROBLEM", 191, 197], ["chronically-high ADO concentrations in the lung", "PROBLEM", 240, 287], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["diseases", "OBSERVATION", 44, 52], ["mucus overproduction", "OBSERVATION", 150, 170], ["asthma", "OBSERVATION", 191, 197], ["chronically", "OBSERVATION_MODIFIER", 240, 251], ["high ADO concentrations", "OBSERVATION", 252, 275], ["lung", "ANATOMY", 283, 287], ["enhanced", "OBSERVATION_MODIFIER", 308, 316]]], ["In the ADA-deficient mice, the transcript levels of A 1 Rs were threefold higher in lung tissue, and 50-fold higher in BAL cell pellet, compared to wild-type mice.", [["lung tissue", "ANATOMY", 84, 95], ["BAL cell pellet", "ANATOMY", 119, 134], ["ADA", "GENE_OR_GENE_PRODUCT", 7, 10], ["mice", "ORGANISM", 21, 25], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 52, 58], ["lung tissue", "TISSUE", 84, 95], ["BAL cell", "CELL", 119, 127], ["mice", "ORGANISM", 158, 162], ["ADA", "PROTEIN", 7, 10], ["A 1 Rs", "PROTEIN", 52, 58], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 158, 162], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 158, 162], ["the transcript levels", "TEST", 27, 48], ["A 1 Rs", "TEST", 52, 58], ["BAL cell pellet", "TEST", 119, 134], ["lung tissue", "ANATOMY", 84, 95], ["BAL cell pellet", "OBSERVATION", 119, 134]]], ["Immunolocalization showed enhanced protein expression on macrophages, and the receptor appeared on endothelial and epithelial cells.", [["macrophages", "ANATOMY", 57, 68], ["endothelial", "ANATOMY", 99, 110], ["epithelial cells", "ANATOMY", 115, 131], ["macrophages", "CELL", 57, 68], ["endothelial", "CELL", 99, 110], ["epithelial cells", "CELL", 115, 131], ["macrophages", "CELL_TYPE", 57, 68], ["endothelial and epithelial cells", "CELL_TYPE", 99, 131], ["Immunolocalization", "TEST", 0, 18], ["enhanced protein expression on macrophages", "PROBLEM", 26, 68], ["enhanced", "OBSERVATION_MODIFIER", 26, 34], ["protein expression", "OBSERVATION", 35, 53], ["macrophages", "OBSERVATION", 57, 68], ["endothelial", "ANATOMY", 99, 110], ["epithelial cells", "OBSERVATION", 115, 131]]], ["For these reasons, ADA/A 1 R double knockout mice were developed to determine the impact of A 1 R up-regulation on airway defenses.", [["airway", "ANATOMY", 115, 121], ["ADA/A 1 R", "GENE_OR_GENE_PRODUCT", 19, 28], ["mice", "ORGANISM", 45, 49], ["A 1 R", "GENE_OR_GENE_PRODUCT", 92, 97], ["airway", "MULTI-TISSUE_STRUCTURE", 115, 121], ["ADA", "PROTEIN", 19, 22], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["A 1 R double knockout mice", "TREATMENT", 23, 49], ["airway", "ANATOMY", 115, 121]]], ["The genetic removal of A 1 Rs from the ADA-deficient mice resulted in an additional twofold increase in the total lung ADO level.", [["lung", "ANATOMY", 114, 118], ["ADO", "CHEMICAL", 119, 122], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 23, 29], ["ADA", "GENE_OR_GENE_PRODUCT", 39, 42], ["mice", "ORGANISM", 53, 57], ["lung", "ORGAN", 114, 118], ["ADO", "SIMPLE_CHEMICAL", 119, 122], ["ADA", "PROTEIN", 39, 42], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["the ADA-deficient mice", "TREATMENT", 35, 57], ["the total lung ADO level", "TREATMENT", 104, 128], ["twofold", "OBSERVATION_MODIFIER", 84, 91], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["lung", "ANATOMY", 114, 118], ["ADO level", "OBSERVATION", 119, 128]]], ["Compared to the ADA-deficient mice, they had more severe pulmonary inflammation, mucus metaplasia and alveolar destruction, exaggerated expression of Th2 cytokines (IL-4 and IL-13) and matrix metalloproteinases.", [["pulmonary", "ANATOMY", 57, 66], ["mucus metaplasia", "ANATOMY", 81, 97], ["alveolar", "ANATOMY", 102, 110], ["pulmonary inflammation", "DISEASE", 57, 79], ["ADA", "GENE_OR_GENE_PRODUCT", 16, 19], ["mice", "ORGANISM", 30, 34], ["pulmonary", "ORGAN", 57, 66], ["mucus metaplasia", "PATHOLOGICAL_FORMATION", 81, 97], ["alveolar", "TISSUE", 102, 110], ["IL-4", "GENE_OR_GENE_PRODUCT", 165, 169], ["IL-13", "GENE_OR_GENE_PRODUCT", 174, 179], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 185, 210], ["ADA", "PROTEIN", 16, 19], ["Th2 cytokines", "PROTEIN", 150, 163], ["IL-4 and IL-13", "PROTEIN", 165, 179], ["matrix metalloproteinases", "PROTEIN", 185, 210], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["more severe pulmonary inflammation", "PROBLEM", 45, 79], ["mucus metaplasia", "PROBLEM", 81, 97], ["alveolar destruction", "PROBLEM", 102, 122], ["Th2 cytokines", "TEST", 150, 163], ["IL", "TEST", 165, 167], ["IL", "TEST", 174, 176], ["matrix metalloproteinases", "PROBLEM", 185, 210], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["pulmonary", "ANATOMY", 57, 66], ["inflammation", "OBSERVATION", 67, 79], ["mucus metaplasia", "OBSERVATION", 81, 97], ["alveolar", "ANATOMY_MODIFIER", 102, 110], ["destruction", "OBSERVATION", 111, 122], ["exaggerated", "OBSERVATION_MODIFIER", 124, 135], ["expression", "OBSERVATION_MODIFIER", 136, 146], ["Th2 cytokines", "OBSERVATION", 150, 163]]], ["This study suggests that, in the presence of chronically-high ADO, A 1 Rs are anti-inflammatory in the respiratory system.", [["respiratory system", "ANATOMY", 103, 121], ["ADO", "CHEMICAL", 62, 65], ["ADO", "SIMPLE_CHEMICAL", 62, 65], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 67, 73], ["This study", "TEST", 0, 10], ["anti-inflammatory in the respiratory system", "PROBLEM", 78, 121], ["chronically", "OBSERVATION_MODIFIER", 45, 56], ["high ADO", "OBSERVATION", 57, 65], ["anti-inflammatory", "OBSERVATION", 78, 95], ["respiratory system", "ANATOMY", 103, 121]]], ["On the other hand, it is important to note that these double knockout mice also exhibit a twofold decrease in A 2A R transcript, which mediates potent anti-inflammatory responses in the lung, as described in the section below.", [["lung", "ANATOMY", 186, 190], ["mice", "ORGANISM", 70, 74], ["A 2A R", "GENE_OR_GENE_PRODUCT", 110, 116], ["lung", "ORGAN", 186, 190], ["A 2A R transcript", "RNA", 110, 127], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["A 2A R transcript", "TREATMENT", 110, 127], ["decrease", "OBSERVATION_MODIFIER", 98, 106], ["potent", "OBSERVATION_MODIFIER", 144, 150], ["anti-inflammatory responses", "OBSERVATION", 151, 178], ["lung", "ANATOMY", 186, 190]]], ["A weaker protection by A 2A R may account, at least partially, for the severity of lung complications in ADA/ A 1 R knockout, compared to ADA-deficient mice.Can A 1 Rs Go Either Way?These animal models provide important information on the contribution of A 1 Rs to acute and chronic lung disorders.", [["lung", "ANATOMY", 83, 87], ["lung", "ANATOMY", 283, 287], ["lung complications", "DISEASE", 83, 101], ["chronic lung disorders", "DISEASE", 275, 297], ["A 2A R", "GENE_OR_GENE_PRODUCT", 23, 29], ["lung", "ORGAN", 83, 87], ["ADA/ A 1 R", "GENE_OR_GENE_PRODUCT", 105, 115], ["ADA", "GENE_OR_GENE_PRODUCT", 138, 141], ["mice", "ORGANISM", 152, 156], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 255, 261], ["lung", "ORGAN", 283, 287], ["ADA", "PROTEIN", 138, 141], ["mice", "SPECIES", 152, 156], ["mice", "SPECIES", 152, 156], ["A weaker protection", "PROBLEM", 0, 19], ["lung complications", "PROBLEM", 83, 101], ["acute and chronic lung disorders", "PROBLEM", 265, 297], ["weaker", "OBSERVATION_MODIFIER", 2, 8], ["protection", "OBSERVATION", 9, 19], ["lung", "ANATOMY", 83, 87], ["complications", "OBSERVATION", 88, 101], ["acute", "OBSERVATION_MODIFIER", 265, 270], ["chronic", "OBSERVATION_MODIFIER", 275, 282], ["lung", "ANATOMY", 283, 287], ["disorders", "OBSERVATION", 288, 297]]], ["However, work is needed to determine the role of this receptor, which is expected to appear on alveolar and airway epithelial cells of patients with high lung ADO content, as in asthma and COPD.", [["alveolar", "ANATOMY", 95, 103], ["airway epithelial cells", "ANATOMY", 108, 131], ["lung", "ANATOMY", 154, 158], ["ADO", "CHEMICAL", 159, 162], ["asthma", "DISEASE", 178, 184], ["COPD", "DISEASE", 189, 193], ["ADO", "CHEMICAL", 159, 162], ["alveolar", "CELL", 95, 103], ["airway epithelial cells", "CELL", 108, 131], ["patients", "ORGANISM", 135, 143], ["lung", "ORGAN", 154, 158], ["ADO", "SIMPLE_CHEMICAL", 159, 162], ["alveolar and airway epithelial cells", "CELL_TYPE", 95, 131], ["patients", "SPECIES", 135, 143], ["alveolar and airway epithelial cells", "PROBLEM", 95, 131], ["high lung ADO content", "PROBLEM", 149, 170], ["asthma", "PROBLEM", 178, 184], ["COPD", "PROBLEM", 189, 193], ["alveolar", "ANATOMY_MODIFIER", 95, 103], ["airway", "ANATOMY", 108, 114], ["epithelial cells", "OBSERVATION", 115, 131], ["high", "OBSERVATION_MODIFIER", 149, 153], ["lung", "ANATOMY", 154, 158], ["ADO content", "OBSERVATION", 159, 170], ["asthma", "OBSERVATION", 178, 184], ["COPD", "OBSERVATION", 189, 193]]], ["The murine study, which used the new selective A 1 R agonist, 2 0 Me-CCPA [77] , supports the benefits of this compound in chronic diseases.", [["chronic diseases", "DISEASE", 123, 139], ["2 0 Me-CCPA", "CHEMICAL", 62, 73], ["murine", "ORGANISM", 4, 10], ["A 1 R", "GENE_OR_GENE_PRODUCT", 47, 52], ["2 0 Me-CCPA", "SIMPLE_CHEMICAL", 62, 73], ["murine", "SPECIES", 4, 10], ["The murine study", "TEST", 0, 16], ["chronic diseases", "PROBLEM", 123, 139], ["chronic", "OBSERVATION_MODIFIER", 123, 130], ["diseases", "OBSERVATION", 131, 139]]], ["And yet, the delivery route is a key determinant in treatment design, as vascular administration reduces lung inflammation, whereas aerosolized agonists may induce bronchoconstriction.", [["vascular", "ANATOMY", 73, 81], ["lung", "ANATOMY", 105, 109], ["inflammation", "DISEASE", 110, 122], ["vascular", "MULTI-TISSUE_STRUCTURE", 73, 81], ["lung", "ORGAN", 105, 109], ["the delivery route", "TREATMENT", 9, 27], ["vascular administration", "TREATMENT", 73, 96], ["lung inflammation", "PROBLEM", 105, 122], ["aerosolized agonists", "TREATMENT", 132, 152], ["bronchoconstriction", "PROBLEM", 164, 183], ["vascular", "ANATOMY", 73, 81], ["lung", "ANATOMY", 105, 109], ["inflammation", "OBSERVATION", 110, 122]]], ["The A 1 R provides an excellent example for the importance of understanding the physiological background to develop a safe and efficient treatment.The All Mighty A 2A RsThe potent anti-inflammatory activities mediated by A 2A Rs on various cell types motivated the development of animal models to evaluate the potential of agonists for the treatment of inflammation and injury in pulmonary disorders (review: [87, 88] ).", [["cell", "ANATOMY", 240, 244], ["pulmonary", "ANATOMY", 380, 389], ["inflammation", "DISEASE", 353, 365], ["pulmonary disorders", "DISEASE", 380, 399], ["A 1 R", "GENE_OR_GENE_PRODUCT", 4, 9], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 221, 228], ["cell", "CELL", 240, 244], ["pulmonary", "ORGAN", 380, 389], ["a safe and efficient treatment", "TREATMENT", 116, 146], ["various cell types", "TREATMENT", 232, 250], ["agonists", "TREATMENT", 323, 331], ["inflammation", "PROBLEM", 353, 365], ["injury in pulmonary disorders", "PROBLEM", 370, 399], ["inflammation", "OBSERVATION", 353, 365], ["pulmonary", "ANATOMY", 380, 389]]], ["Sharma et al. conducted a series of studies to investigate the impact of A 2A Rs on the acute lung injury caused by ischemia-reperfusion [89] .", [["lung", "ANATOMY", 94, 98], ["lung injury", "DISEASE", 94, 105], ["ischemia", "DISEASE", 116, 124], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 73, 80], ["lung", "ORGAN", 94, 98], ["studies", "TEST", 36, 43], ["the acute lung injury", "PROBLEM", 84, 105], ["ischemia", "PROBLEM", 116, 124], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["lung", "ANATOMY", 94, 98], ["injury", "OBSERVATION", 99, 105], ["ischemia", "OBSERVATION", 116, 124], ["reperfusion", "OBSERVATION_MODIFIER", 125, 136]]], ["Perfused isolated lungs developed significant dysfunction (higher airway resistance, pulmonary artery pressure and lower compliance), tissue injury (vascular leakage and edema), and the accumulation of cytokines (TNFa, KC, MIP-2 and RANTES) in the BAL fluid.", [["lungs", "ANATOMY", 18, 23], ["airway", "ANATOMY", 66, 72], ["pulmonary artery", "ANATOMY", 85, 101], ["tissue", "ANATOMY", 134, 140], ["vascular", "ANATOMY", 149, 157], ["edema", "ANATOMY", 170, 175], ["BAL fluid", "ANATOMY", 248, 257], ["tissue injury", "DISEASE", 134, 147], ["edema", "DISEASE", 170, 175], ["lungs", "ORGAN", 18, 23], ["airway", "MULTI-TISSUE_STRUCTURE", 66, 72], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 85, 101], ["tissue", "TISSUE", 134, 140], ["vascular", "MULTI-TISSUE_STRUCTURE", 149, 157], ["edema", "PATHOLOGICAL_FORMATION", 170, 175], ["TNFa", "GENE_OR_GENE_PRODUCT", 213, 217], ["KC", "GENE_OR_GENE_PRODUCT", 219, 221], ["MIP-2", "GENE_OR_GENE_PRODUCT", 223, 228], ["RANTES", "GENE_OR_GENE_PRODUCT", 233, 239], ["BAL", "ORGANISM_SUBSTANCE", 248, 251], ["cytokines", "PROTEIN", 202, 211], ["TNFa", "PROTEIN", 213, 217], ["KC", "PROTEIN", 219, 221], ["MIP", "PROTEIN", 223, 226], ["RANTES", "PROTEIN", 233, 239], ["significant dysfunction", "PROBLEM", 34, 57], ["higher airway resistance", "PROBLEM", 59, 83], ["pulmonary artery pressure", "PROBLEM", 85, 110], ["tissue injury (vascular leakage", "PROBLEM", 134, 165], ["edema", "PROBLEM", 170, 175], ["cytokines", "TEST", 202, 211], ["TNFa", "TEST", 213, 217], ["KC", "TEST", 219, 221], ["MIP", "TEST", 223, 226], ["RANTES", "TEST", 233, 239], ["the BAL fluid", "TEST", 244, 257], ["lungs", "ANATOMY", 18, 23], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["dysfunction", "OBSERVATION", 46, 57], ["higher airway resistance", "OBSERVATION", 59, 83], ["pulmonary artery", "ANATOMY", 85, 101], ["pressure", "OBSERVATION_MODIFIER", 102, 110], ["lower compliance", "OBSERVATION", 115, 131], ["tissue", "ANATOMY", 134, 140], ["injury", "OBSERVATION", 141, 147], ["vascular", "ANATOMY", 149, 157], ["leakage", "OBSERVATION", 158, 165], ["edema", "OBSERVATION", 170, 175], ["accumulation", "OBSERVATION_MODIFIER", 186, 198], ["BAL", "ANATOMY", 248, 251], ["fluid", "OBSERVATION", 252, 257]]], ["The addition of the selective A 2A R agonist, ATL313, to the perfusate after ischemia reduced all reperfusion-related complications by at least 50%.", [["ATL313", "CHEMICAL", 46, 52], ["ischemia", "DISEASE", 77, 85], ["ATL313", "CHEMICAL", 46, 52], ["A 2A R", "GENE_OR_GENE_PRODUCT", 30, 36], ["ATL313", "SIMPLE_CHEMICAL", 46, 52], ["the selective A 2A R agonist", "TREATMENT", 16, 44], ["ATL313", "TREATMENT", 46, 52], ["ischemia", "PROBLEM", 77, 85], ["reperfusion", "OBSERVATION", 98, 109]]], ["This study shows that A 2A Rs expressed by resident cells, such as alveolar macrophages, endothelial and epithelial cells, play a major role in the anti-inflammatory properties of these receptors during acute lung injury.The All Mighty A 2A RsThe number of circulating neutrophils is regulated by IL-17A, a pro-inflammatory cytokine released by CD4+ T lymphocytes (review: [90] ).", [["cells", "ANATOMY", 52, 57], ["alveolar macrophages", "ANATOMY", 67, 87], ["endothelial", "ANATOMY", 89, 100], ["epithelial cells", "ANATOMY", 105, 121], ["lung", "ANATOMY", 209, 213], ["neutrophils", "ANATOMY", 269, 280], ["CD4+ T lymphocytes", "ANATOMY", 345, 363], ["acute lung injury", "DISEASE", 203, 220], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 22, 29], ["cells", "CELL", 52, 57], ["alveolar macrophages", "CELL", 67, 87], ["endothelial", "CELL", 89, 100], ["epithelial cells", "CELL", 105, 121], ["lung", "ORGAN", 209, 213], ["neutrophils", "CELL", 269, 280], ["IL-17A", "GENE_OR_GENE_PRODUCT", 297, 303], ["CD4", "GENE_OR_GENE_PRODUCT", 345, 348], ["A 2A Rs", "PROTEIN", 22, 29], ["resident cells", "CELL_TYPE", 43, 57], ["alveolar macrophages", "CELL_TYPE", 67, 87], ["endothelial and epithelial cells", "CELL_TYPE", 89, 121], ["Mighty A 2A Rs", "PROTEIN", 229, 243], ["circulating neutrophils", "CELL_TYPE", 257, 280], ["IL-17A", "PROTEIN", 297, 303], ["pro-inflammatory cytokine", "PROTEIN", 307, 332], ["CD4", "PROTEIN", 345, 348], ["T lymphocytes", "CELL_TYPE", 350, 363], ["This study", "TEST", 0, 10], ["alveolar macrophages", "PROBLEM", 67, 87], ["endothelial and epithelial cells", "PROBLEM", 89, 121], ["the anti-inflammatory properties", "TREATMENT", 144, 176], ["acute lung injury", "PROBLEM", 203, 220], ["circulating neutrophils", "TEST", 257, 280], ["a pro-inflammatory cytokine", "TEST", 305, 332], ["alveolar macrophages", "OBSERVATION", 67, 87], ["endothelial", "ANATOMY", 89, 100], ["epithelial cells", "OBSERVATION", 105, 121], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["lung", "ANATOMY", 209, 213], ["injury", "OBSERVATION", 214, 220]]], ["Sharma et al. used an in vivo murine model of ischemia-reperfusion to test whether the anti-inflammatory roles of the A 2A R include the suppression of CD4+ T cell activities [91] .", [["CD4+ T cell", "ANATOMY", 152, 163], ["ischemia", "DISEASE", 46, 54], ["murine", "ORGANISM", 30, 36], ["A 2A R", "GENE_OR_GENE_PRODUCT", 118, 124], ["CD4", "GENE_OR_GENE_PRODUCT", 152, 155], ["A 2A R", "PROTEIN", 118, 124], ["CD4", "PROTEIN", 152, 155], ["murine", "SPECIES", 30, 36], ["ischemia", "PROBLEM", 46, 54], ["ischemia", "OBSERVATION", 46, 54]]], ["As in the case of isolated lungs [89] , perfusion of the agonist, ATL313, significantly prevented lung injury and the loss of compliance in mice [91] .", [["lungs", "ANATOMY", 27, 32], ["lung", "ANATOMY", 98, 102], ["ATL313", "CHEMICAL", 66, 72], ["lung injury", "DISEASE", 98, 109], ["ATL313", "CHEMICAL", 66, 72], ["lungs", "ORGAN", 27, 32], ["ATL313", "SIMPLE_CHEMICAL", 66, 72], ["lung", "ORGAN", 98, 102], ["mice", "ORGANISM", 140, 144], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 140, 144], ["lung injury", "PROBLEM", 98, 109], ["lungs", "ANATOMY", 27, 32], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109], ["loss", "OBSERVATION_MODIFIER", 118, 122]]], ["The significant reduction of neutrophil infiltration was demonstrated by immunohistochemistry and BAL fluid myeloperoxidase activity.", [["neutrophil", "ANATOMY", 29, 39], ["BAL fluid", "ANATOMY", 98, 107], ["neutrophil", "CELL", 29, 39], ["myeloperoxidase", "SIMPLE_CHEMICAL", 108, 123], ["myeloperoxidase", "PROTEIN", 108, 123], ["neutrophil infiltration", "PROBLEM", 29, 52], ["immunohistochemistry", "TEST", 73, 93], ["BAL fluid myeloperoxidase activity", "TEST", 98, 132], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["neutrophil infiltration", "OBSERVATION", 29, 52], ["BAL fluid", "OBSERVATION", 98, 107], ["myeloperoxidase activity", "OBSERVATION", 108, 132]]], ["The mice subjected to ischemia-reperfusion after depletion of the CD4+ T cells or neutrophils also had significantly reduced lung injury and BAL fluid levels of inflammatory mediators, including IL-17A.", [["CD4+ T cells", "ANATOMY", 66, 78], ["neutrophils", "ANATOMY", 82, 93], ["lung", "ANATOMY", 125, 129], ["BAL fluid", "ANATOMY", 141, 150], ["lung injury", "DISEASE", 125, 136], ["mice", "ORGANISM", 4, 8], ["CD4", "GENE_OR_GENE_PRODUCT", 66, 69], ["neutrophils", "CELL", 82, 93], ["lung", "ORGAN", 125, 129], ["BAL fluid", "ORGANISM_SUBSTANCE", 141, 150], ["IL-17A", "GENE_OR_GENE_PRODUCT", 195, 201], ["CD4", "PROTEIN", 66, 69], ["T cells", "CELL_TYPE", 71, 78], ["neutrophils", "CELL_TYPE", 82, 93], ["inflammatory mediators", "PROTEIN", 161, 183], ["IL-17A", "PROTEIN", 195, 201], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["ischemia-reperfusion", "PROBLEM", 22, 42], ["the CD4", "TEST", 62, 69], ["T cells", "PROBLEM", 71, 78], ["neutrophils", "PROBLEM", 82, 93], ["significantly reduced lung injury", "PROBLEM", 103, 136], ["BAL fluid levels", "TEST", 141, 157], ["inflammatory mediators", "PROBLEM", 161, 183], ["ischemia-reperfusion", "OBSERVATION", 22, 42], ["significantly", "OBSERVATION_MODIFIER", 103, 116], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["lung", "ANATOMY", 125, 129], ["injury", "OBSERVATION", 130, 136], ["BAL fluid", "OBSERVATION", 141, 150], ["inflammatory", "OBSERVATION_MODIFIER", 161, 173]]], ["However, ATL313 further reduced the symptoms only in neutrophil-depleted mice.", [["neutrophil", "ANATOMY", 53, 63], ["ATL313", "CHEMICAL", 9, 15], ["ATL313", "CHEMICAL", 9, 15], ["ATL313", "SIMPLE_CHEMICAL", 9, 15], ["neutrophil", "CELL", 53, 63], ["mice", "ORGANISM", 73, 77], ["neutrophil", "CELL_TYPE", 53, 63], ["mice", "SPECIES", 73, 77], ["the symptoms", "PROBLEM", 32, 44], ["depleted mice", "OBSERVATION", 64, 77]]], ["This study shows that A 2A R activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation, and the subsequent neutrophil infiltration in the lung.", [["CD4+ T cell", "ANATOMY", 93, 104], ["neutrophil", "ANATOMY", 136, 146], ["lung", "ANATOMY", 167, 171], ["ischemia-reperfusion injury", "DISEASE", 51, 78], ["A 2A R", "GENE_OR_GENE_PRODUCT", 22, 28], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["neutrophil", "CELL", 136, 146], ["lung", "ORGAN", 167, 171], ["CD4", "PROTEIN", 93, 96], ["This study", "TEST", 0, 10], ["A 2A R activation attenuates ischemia-reperfusion injury", "PROBLEM", 22, 78], ["T cell activation", "PROBLEM", 98, 115], ["the subsequent neutrophil infiltration in the lung", "PROBLEM", 121, 171], ["attenuates", "OBSERVATION_MODIFIER", 40, 50], ["ischemia-reperfusion", "OBSERVATION_MODIFIER", 51, 71], ["injury", "OBSERVATION", 72, 78], ["cell activation", "OBSERVATION", 100, 115], ["neutrophil infiltration", "OBSERVATION", 136, 159], ["lung", "ANATOMY", 167, 171]]], ["Systemic administration of A 2A R agonists, before a transplant procedure, could offer two waves of protection against excessive inflammation and injury.The All Mighty A 2A RsThe airway defenses supported by the A 2A R are also sensitive to acute lung injury initiated within the airspace.", [["airway", "ANATOMY", 179, 185], ["lung", "ANATOMY", 247, 251], ["airspace", "ANATOMY", 280, 288], ["inflammation", "DISEASE", 129, 141], ["lung injury", "DISEASE", 247, 258], ["A 2A R", "GENE_OR_GENE_PRODUCT", 27, 33], ["airway", "MULTI-TISSUE_STRUCTURE", 179, 185], ["A 2A R", "GENE_OR_GENE_PRODUCT", 212, 218], ["lung", "ORGAN", 247, 251], ["airspace", "MULTI-TISSUE_STRUCTURE", 280, 288], ["Mighty A 2A Rs", "PROTEIN", 161, 175], ["A 2A R", "PROTEIN", 212, 218], ["A 2A R", "SPECIES", 212, 218], ["A 2A R agonists", "TREATMENT", 27, 42], ["a transplant procedure", "TREATMENT", 51, 73], ["protection", "TREATMENT", 100, 110], ["excessive inflammation", "PROBLEM", 119, 141], ["injury", "PROBLEM", 146, 152], ["acute lung injury", "PROBLEM", 241, 258], ["inflammation", "OBSERVATION", 129, 141], ["injury", "OBSERVATION", 146, 152], ["airway", "ANATOMY", 179, 185], ["acute", "OBSERVATION_MODIFIER", 241, 246], ["lung", "ANATOMY", 247, 251], ["injury", "OBSERVATION", 252, 258], ["airspace", "ANATOMY_MODIFIER", 280, 288]]], ["Aerosolized LPS was associated with an up-regulation of the ADO receptor [92] .", [["LPS", "CHEMICAL", 12, 15], ["ADO", "CHEMICAL", 60, 63], ["LPS", "SIMPLE_CHEMICAL", 12, 15], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 60, 72], ["ADO receptor", "PROTEIN", 60, 72], ["Aerosolized LPS", "PROBLEM", 0, 15], ["LPS", "OBSERVATION", 12, 15]]], ["Therefore, the consequences of this deregulation were determined by exposing A 2A R \u00c0/\u00c0 mice to aerosolized LPS.", [["LPS", "CHEMICAL", 108, 111], ["R", "GENE_OR_GENE_PRODUCT", 82, 83], ["mice", "ORGANISM", 88, 92], ["LPS", "SIMPLE_CHEMICAL", 108, 111], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["A 2A R \u00c0/\u00c0 mice", "TREATMENT", 77, 92], ["aerosolized LPS", "TREATMENT", 96, 111], ["aerosolized LPS", "OBSERVATION", 96, 111]]], ["Consistent with the anti-inflammatory role of this receptor, knockout mice accumulated more neutrophils into the lungs in response to LPS than the wild-type mice.", [["neutrophils", "ANATOMY", 92, 103], ["lungs", "ANATOMY", 113, 118], ["LPS", "CHEMICAL", 134, 137], ["mice", "ORGANISM", 70, 74], ["neutrophils", "CELL", 92, 103], ["lungs", "ORGAN", 113, 118], ["LPS", "SIMPLE_CHEMICAL", 134, 137], ["mice", "ORGANISM", 157, 161], ["neutrophils", "CELL_TYPE", 92, 103], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 157, 161], ["anti-inflammatory", "OBSERVATION_MODIFIER", 20, 37], ["lungs", "ANATOMY", 113, 118]]], ["Accordingly, intranasal instillation of the selective agonist, ATL 202, only reduced neutrophil transmigration in wild-type mice [92] .", [["neutrophil", "ANATOMY", 85, 95], ["ATL 202", "CHEMICAL", 63, 70], ["neutrophil", "CELL", 85, 95], ["mice", "ORGANISM", 124, 128], ["mice", "SPECIES", 124, 128], ["intranasal instillation", "TREATMENT", 13, 36], ["the selective agonist", "TREATMENT", 40, 61], ["ATL", "TREATMENT", 63, 66], ["reduced neutrophil transmigration", "TREATMENT", 77, 110], ["reduced", "OBSERVATION_MODIFIER", 77, 84], ["neutrophil transmigration", "OBSERVATION", 85, 110]]], ["Together, bone marrow transplant between wild-type and A 2A R \u00c0/\u00c0 mice, and conditional knockout mice lacking A 2A Rs on macrophages, demonstrated that A 2A R overexpression on macrophages plays a major role in the anti-inflammatory properties of airway ADO [92] .", [["bone marrow", "ANATOMY", 10, 21], ["macrophages", "ANATOMY", 121, 132], ["macrophages", "ANATOMY", 177, 188], ["airway", "ANATOMY", 247, 253], ["ADO", "CHEMICAL", 254, 257], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 10, 21], ["A 2A R \u00c0/\u00c0 mice", "ORGANISM", 55, 70], ["mice", "ORGANISM", 97, 101], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 110, 117], ["macrophages", "CELL", 121, 132], ["A 2A R", "GENE_OR_GENE_PRODUCT", 152, 158], ["macrophages", "CELL", 177, 188], ["airway", "MULTI-TISSUE_STRUCTURE", 247, 253], ["A 2A Rs", "PROTEIN", 110, 117], ["macrophages", "CELL_TYPE", 121, 132], ["macrophages", "CELL_TYPE", 177, 188], ["mice", "SPECIES", 66, 70], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["bone marrow transplant", "TREATMENT", 10, 32], ["bone", "ANATOMY", 10, 14], ["marrow transplant", "OBSERVATION", 15, 32], ["airway", "ANATOMY", 247, 253]]], ["Since LPS was added to the airways, it is not expected to affect endothelial barrier permeability.", [["airways", "ANATOMY", 27, 34], ["endothelial barrier", "ANATOMY", 65, 84], ["LPS", "CHEMICAL", 6, 9], ["LPS", "SIMPLE_CHEMICAL", 6, 9], ["airways", "MULTI-TISSUE_STRUCTURE", 27, 34], ["endothelial barrier", "TISSUE", 65, 84], ["LPS", "TREATMENT", 6, 9], ["airways", "ANATOMY", 27, 34], ["not expected", "UNCERTAINTY", 42, 54]]], ["Instead, LPS stimulates the secretion of pro-inflammatory cytokines (i.e. IL-1b, TNFa) from alveolar macrophages, which bind specific receptors on the epithelia to stimulate the release of neutrophil chemoattractants.", [["alveolar macrophages", "ANATOMY", 92, 112], ["epithelia", "ANATOMY", 151, 160], ["neutrophil", "ANATOMY", 189, 199], ["LPS", "CHEMICAL", 9, 12], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["IL-1b", "GENE_OR_GENE_PRODUCT", 74, 79], ["TNFa", "GENE_OR_GENE_PRODUCT", 81, 85], ["alveolar macrophages", "CELL", 92, 112], ["epithelia", "TISSUE", 151, 160], ["neutrophil", "CELL", 189, 199], ["pro-inflammatory cytokines", "PROTEIN", 41, 67], ["IL-1b", "PROTEIN", 74, 79], ["TNFa", "PROTEIN", 81, 85], ["alveolar macrophages", "CELL_TYPE", 92, 112], ["neutrophil chemoattractants", "PROTEIN", 189, 216], ["LPS", "TREATMENT", 9, 12], ["pro-inflammatory cytokines", "TEST", 41, 67], ["IL", "TEST", 74, 76], ["alveolar macrophages", "PROBLEM", 92, 112], ["neutrophil chemoattractants", "TREATMENT", 189, 216], ["alveolar macrophages", "ANATOMY", 92, 112], ["neutrophil chemoattractants", "OBSERVATION", 189, 216]]], ["On macrophages, A 2A R activation suppresses the production and secretion of these cytokines [93] [94] [95] .", [["macrophages", "ANATOMY", 3, 14], ["macrophages", "CELL", 3, 14], ["A 2A R", "GENE_OR_GENE_PRODUCT", 16, 22], ["macrophages", "CELL_TYPE", 3, 14], ["cytokines", "PROTEIN", 83, 92], ["these cytokines", "TEST", 77, 92], ["macrophages", "OBSERVATION", 3, 14]]], ["During an acute airborne insult, the overexpression of A 2A Rs on resident macrophages would prevent the development of excessive inflammatory responses.The All Mighty A 2A RsThe intense preclinical research on A 2A R agonists currently conducted in murine models of chronic airway diseases is not surprising, given the multiple roles of this P1 receptor in the prevention of excessive and damaging airway inflammation.", [["macrophages", "ANATOMY", 75, 86], ["airway", "ANATOMY", 275, 281], ["airway", "ANATOMY", 399, 405], ["airway diseases", "DISEASE", 275, 290], ["airway inflammation", "DISEASE", 399, 418], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 55, 62], ["macrophages", "CELL", 75, 86], ["A 2A R", "GENE_OR_GENE_PRODUCT", 211, 217], ["murine", "ORGANISM", 250, 256], ["airway", "MULTI-TISSUE_STRUCTURE", 275, 281], ["P1 receptor", "GENE_OR_GENE_PRODUCT", 343, 354], ["airway", "MULTI-TISSUE_STRUCTURE", 399, 405], ["A 2A Rs", "PROTEIN", 55, 62], ["resident macrophages", "CELL_TYPE", 66, 86], ["P1 receptor", "PROTEIN", 343, 354], ["murine", "SPECIES", 250, 256], ["an acute airborne insult", "PROBLEM", 7, 31], ["excessive inflammatory responses", "PROBLEM", 120, 152], ["A 2A R agonists", "TREATMENT", 211, 226], ["chronic airway diseases", "PROBLEM", 267, 290], ["this P1 receptor", "TREATMENT", 338, 354], ["excessive and damaging airway inflammation", "PROBLEM", 376, 418], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["airborne insult", "OBSERVATION", 16, 31], ["excessive", "OBSERVATION_MODIFIER", 120, 129], ["inflammatory", "OBSERVATION", 130, 142], ["chronic", "OBSERVATION_MODIFIER", 267, 274], ["airway", "ANATOMY", 275, 281], ["diseases", "OBSERVATION", 282, 290], ["airway", "ANATOMY", 399, 405], ["inflammation", "OBSERVATION", 406, 418]]], ["Interestingly, contrary to the up-regulating effect of acute insults, chronic exposures to ragweed or Th2 cytokines (IL-4 or IL-13) are all associated with a down-regulation of A 2A Rs [79, 80, 96] .", [["IL-4", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL-13", "GENE_OR_GENE_PRODUCT", 125, 130], ["ragweed or Th2 cytokines", "PROTEIN", 91, 115], ["IL-4 or IL-13", "PROTEIN", 117, 130], ["acute insults", "PROBLEM", 55, 68], ["chronic exposures", "PROBLEM", 70, 87], ["Th2 cytokines (IL", "TREATMENT", 102, 119], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["insults", "OBSERVATION", 61, 68], ["chronic", "OBSERVATION_MODIFIER", 70, 77]]], ["Similar findings were observed in the ADA-deficient model of chronically-elevated lung ADO [39] .", [["lung", "ANATOMY", 82, 86], ["ADO", "CHEMICAL", 87, 90], ["ADA", "GENE_OR_GENE_PRODUCT", 38, 41], ["lung", "ORGAN", 82, 86], ["ADA", "PROTEIN", 38, 41], ["elevated lung ADO", "PROBLEM", 73, 90], ["chronically", "OBSERVATION_MODIFIER", 61, 72], ["elevated", "OBSERVATION_MODIFIER", 73, 81], ["lung", "ANATOMY", 82, 86]]], ["The ragweed sensitization/challenge caused more severe airway inflammation and hyperresponsiveness in the A 2A R \u00c0/\u00c0 mice than in the wild-type mice [96] .", [["airway", "ANATOMY", 55, 61], ["inflammation", "DISEASE", 62, 74], ["airway", "MULTI-TISSUE_STRUCTURE", 55, 61], ["R", "GENE_OR_GENE_PRODUCT", 111, 112], ["mice", "ORGANISM", 144, 148], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 144, 148], ["The ragweed sensitization", "TREATMENT", 0, 25], ["more severe airway inflammation", "PROBLEM", 43, 74], ["hyperresponsiveness", "PROBLEM", 79, 98], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["airway", "ANATOMY", 55, 61], ["inflammation", "OBSERVATION", 62, 74], ["hyperresponsiveness", "OBSERVATION", 79, 98]]], ["Altogether, these studies suggest that the down-regulation of A 2A Rs contributes to disease severity in Th2 driven chronic lung disorders.", [["lung", "ANATOMY", 124, 128], ["chronic lung disorders", "DISEASE", 116, 138], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 62, 69], ["lung", "ORGAN", 124, 128], ["A 2A Rs", "PROTEIN", 62, 69], ["these studies", "TEST", 12, 25], ["disease severity in Th2 driven chronic lung disorders", "PROBLEM", 85, 138], ["disease", "OBSERVATION", 85, 92], ["lung", "ANATOMY", 124, 128], ["disorders", "OBSERVATION", 129, 138]]], ["Therefore, preclinical studies support a substantial benefit for A 2A R-based aerosolized therapies in chronic diseases.", [["chronic diseases", "DISEASE", 103, 119], ["A 2A R", "SIMPLE_CHEMICAL", 65, 71], ["preclinical studies", "TEST", 11, 30], ["A 2A R-based aerosolized therapies", "TREATMENT", 65, 99], ["chronic diseases", "PROBLEM", 103, 119], ["aerosolized therapies", "OBSERVATION", 78, 99], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["diseases", "OBSERVATION", 111, 119]]], ["In mice subjected to the OVA sensitization/ challenge model of allergic asthma, the intratracheal instillation of CGS 21680 before the last challenge significantly reduced lung inflammation, quantified in BAL fluid in terms of leukocyte numbers, neutrophil myeloperoxidase and eosinophil peroxidase activities [97] .", [["intratracheal", "ANATOMY", 84, 97], ["lung", "ANATOMY", 172, 176], ["BAL fluid", "ANATOMY", 205, 214], ["leukocyte", "ANATOMY", 227, 236], ["neutrophil", "ANATOMY", 246, 256], ["eosinophil", "ANATOMY", 277, 287], ["allergic asthma", "DISEASE", 63, 78], ["CGS 21680", "CHEMICAL", 114, 123], ["lung inflammation", "DISEASE", 172, 189], ["CGS 21680", "CHEMICAL", 114, 123], ["mice", "ORGANISM", 3, 7], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 97], ["CGS", "SIMPLE_CHEMICAL", 114, 117], ["lung", "ORGAN", 172, 176], ["BAL fluid", "ORGANISM_SUBSTANCE", 205, 214], ["leukocyte", "CELL", 227, 236], ["neutrophil", "CELL", 246, 256], ["myeloperoxidase", "SIMPLE_CHEMICAL", 257, 272], ["eosinophil peroxidase", "GENE_OR_GENE_PRODUCT", 277, 298], ["neutrophil myeloperoxidase", "PROTEIN", 246, 272], ["eosinophil peroxidase", "PROTEIN", 277, 298], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["the OVA sensitization", "TREATMENT", 21, 42], ["allergic asthma", "PROBLEM", 63, 78], ["the intratracheal instillation of CGS", "TREATMENT", 80, 117], ["reduced lung inflammation", "PROBLEM", 164, 189], ["BAL fluid", "TEST", 205, 214], ["leukocyte numbers", "TEST", 227, 244], ["neutrophil myeloperoxidase", "TEST", 246, 272], ["eosinophil peroxidase activities", "TEST", 277, 309], ["allergic asthma", "OBSERVATION", 63, 78], ["reduced", "OBSERVATION_MODIFIER", 164, 171], ["lung", "ANATOMY", 172, 176], ["inflammation", "OBSERVATION", 177, 189], ["BAL fluid", "OBSERVATION", 205, 214], ["leukocyte", "ANATOMY", 227, 236], ["neutrophil myeloperoxidase", "OBSERVATION", 246, 272]]], ["A similar protective effect of intratracheal CGS 21680 was reported in Norway rats subjected to this OVA exposure protocol [97] .", [["intratracheal", "ANATOMY", 31, 44], ["CGS 21680", "CHEMICAL", 45, 54], ["CGS 21680", "CHEMICAL", 45, 54], ["intratracheal CGS 21680", "SIMPLE_CHEMICAL", 31, 54], ["rats", "ORGANISM", 78, 82], ["rats", "SPECIES", 78, 82], ["intratracheal CGS", "TREATMENT", 31, 48], ["this OVA exposure protocol", "TREATMENT", 96, 122]]], ["On the other hand, airway hyperresponsiveness and mucus hypersecretion are not treated by A 2A R agonists, in accordance with the lack of regulation of these functions by this receptor [84, 98] .", [["airway", "ANATOMY", 19, 25], ["mucus", "ANATOMY", 50, 55], ["airway", "MULTI-TISSUE_STRUCTURE", 19, 25], ["mucus", "ORGANISM_SUBSTANCE", 50, 55], ["A 2A R", "GENE_OR_GENE_PRODUCT", 90, 96], ["airway hyperresponsiveness", "PROBLEM", 19, 45], ["mucus hypersecretion", "PROBLEM", 50, 70], ["A 2A R agonists", "TREATMENT", 90, 105], ["airway", "ANATOMY", 19, 25], ["hyperresponsiveness", "OBSERVATION", 26, 45], ["mucus hypersecretion", "OBSERVATION", 50, 70]]], ["Aerosolized A 2A R agonists are expected to target specifically the activities of immune and inflammatory cells, and their recruitment (see Chap.", [["inflammatory cells", "ANATOMY", 93, 111], ["A 2A R", "GENE_OR_GENE_PRODUCT", 12, 18], ["immune", "CELL", 82, 88], ["inflammatory cells", "CELL", 93, 111], ["immune and inflammatory cells", "CELL_TYPE", 82, 111], ["Chap", "PROTEIN", 140, 144], ["Aerosolized A 2A R agonists", "TREATMENT", 0, 27], ["immune and inflammatory cells", "PROBLEM", 82, 111], ["inflammatory cells", "OBSERVATION", 93, 111]]], ["7 for details).The All Mighty A 2A RsLung transplant is currently the preferred option for various end-stage pulmonary diseases.", [["pulmonary", "ANATOMY", 109, 118], ["end-stage pulmonary diseases", "DISEASE", 99, 127], ["pulmonary", "ORGAN", 109, 118], ["A 2A RsLung transplant", "TREATMENT", 30, 52], ["various end-stage pulmonary diseases", "PROBLEM", 91, 127], ["transplant", "OBSERVATION", 42, 52], ["stage", "OBSERVATION_MODIFIER", 103, 108], ["pulmonary", "ANATOMY", 109, 118], ["diseases", "OBSERVATION", 119, 127]]], ["While remarkable progress in the outcome has been made, chronic allograft rejection still leads to the development of bronchiolitis obliterans, a chronic inflammatory disorder.", [["allograft", "ANATOMY", 64, 73], ["bronchiolitis obliterans", "DISEASE", 118, 142], ["inflammatory disorder", "DISEASE", 154, 175], ["allograft", "ORGAN", 64, 73], ["chronic allograft rejection", "PROBLEM", 56, 83], ["bronchiolitis obliterans", "PROBLEM", 118, 142], ["a chronic inflammatory disorder", "PROBLEM", 144, 175], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["allograft rejection", "OBSERVATION", 64, 83], ["bronchiolitis obliterans", "OBSERVATION", 118, 142], ["chronic", "OBSERVATION_MODIFIER", 146, 153], ["inflammatory", "OBSERVATION_MODIFIER", 154, 166]]], ["Given the well established anti-inflammatory profile of A 2A R signaling, a study examined the therapeutic potential of A 2A R agonists in a murine model of transplant rejection [99] .", [["A 2A R", "GENE_OR_GENE_PRODUCT", 56, 62], ["A 2A R", "GENE_OR_GENE_PRODUCT", 120, 126], ["murine", "ORGANISM", 141, 147], ["murine", "SPECIES", 141, 147], ["a study", "TEST", 74, 81], ["A 2A R agonists", "TREATMENT", 120, 135], ["transplant rejection", "PROBLEM", 157, 177], ["transplant rejection", "OBSERVATION", 157, 177]]], ["Non-revascularized tracheal transplants exhibited precocious signs of rejection in A 2A R knockout mice, compared to wild-type mice, manifested by enhanced inflammation, epithelial loss and fibrosis.", [["tracheal", "ANATOMY", 19, 27], ["epithelial", "ANATOMY", 170, 180], ["inflammation", "DISEASE", 156, 168], ["epithelial loss", "DISEASE", 170, 185], ["fibrosis", "DISEASE", 190, 198], ["tracheal", "ORGAN", 19, 27], ["A 2A R", "GENE_OR_GENE_PRODUCT", 83, 89], ["mice", "ORGANISM", 99, 103], ["mice", "ORGANISM", 127, 131], ["epithelial", "TISSUE", 170, 180], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 127, 131], ["Non-revascularized tracheal transplants", "TREATMENT", 0, 39], ["rejection", "PROBLEM", 70, 79], ["enhanced inflammation", "PROBLEM", 147, 168], ["epithelial loss", "PROBLEM", 170, 185], ["fibrosis", "PROBLEM", 190, 198], ["tracheal", "ANATOMY", 19, 27], ["transplants", "OBSERVATION", 28, 39], ["precocious", "OBSERVATION_MODIFIER", 50, 60], ["rejection", "OBSERVATION", 70, 79], ["enhanced", "OBSERVATION_MODIFIER", 147, 155], ["inflammation", "OBSERVATION", 156, 168], ["epithelial loss", "OBSERVATION", 170, 185], ["fibrosis", "OBSERVATION", 190, 198]]], ["Pre-treatment of the wild-type mice with an A 2A R agonist (ATL 313) before receiving the transplant significantly protected against the infiltration of inflammatory cells (lymphocytes, macrophages and neutrophils) and luminal occlusion by collagen deposition, measured over 21 days.", [["inflammatory cells", "ANATOMY", 153, 171], ["lymphocytes", "ANATOMY", 173, 184], ["macrophages", "ANATOMY", 186, 197], ["neutrophils", "ANATOMY", 202, 213], ["luminal", "ANATOMY", 219, 226], ["ATL 313", "CHEMICAL", 60, 67], ["luminal", "CHEMICAL", 219, 226], ["mice", "ORGANISM", 31, 35], ["A 2A R", "GENE_OR_GENE_PRODUCT", 44, 50], ["inflammatory cells", "CELL", 153, 171], ["lymphocytes", "CELL", 173, 184], ["macrophages", "CELL", 186, 197], ["neutrophils", "CELL", 202, 213], ["luminal", "MULTI-TISSUE_STRUCTURE", 219, 226], ["collagen", "GENE_OR_GENE_PRODUCT", 240, 248], ["inflammatory cells", "CELL_TYPE", 153, 171], ["lymphocytes", "CELL_TYPE", 173, 184], ["macrophages", "CELL_TYPE", 186, 197], ["neutrophils", "CELL_TYPE", 202, 213], ["collagen", "PROTEIN", 240, 248], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["an A 2A R agonist", "TREATMENT", 41, 58], ["the transplant", "TREATMENT", 86, 100], ["inflammatory cells", "PROBLEM", 153, 171], ["lymphocytes", "TEST", 173, 184], ["macrophages", "PROBLEM", 186, 197], ["neutrophils", "TEST", 202, 213], ["luminal occlusion by collagen deposition", "PROBLEM", 219, 259], ["infiltration", "OBSERVATION", 137, 149], ["inflammatory cells", "OBSERVATION", 153, 171], ["neutrophils", "ANATOMY", 202, 213], ["luminal", "ANATOMY_MODIFIER", 219, 226], ["occlusion", "OBSERVATION", 227, 236], ["collagen deposition", "OBSERVATION", 240, 259]]], ["This approach shows potential for the prevention of bronchiolitis obliterans in lung transplant.The All Mighty A 2A RsCollectively, these studies support an anti-inflammatory role for A 2A Rs in acute and chronic lung diseases.", [["lung", "ANATOMY", 80, 84], ["lung", "ANATOMY", 213, 217], ["bronchiolitis obliterans", "DISEASE", 52, 76], ["chronic lung diseases", "DISEASE", 205, 226], ["lung", "ORGAN", 80, 84], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 184, 191], ["lung", "ORGAN", 213, 217], ["bronchiolitis obliterans", "PROBLEM", 52, 76], ["lung transplant", "TREATMENT", 80, 95], ["these studies", "TEST", 132, 145], ["acute and chronic lung diseases", "PROBLEM", 195, 226], ["bronchiolitis", "OBSERVATION_MODIFIER", 52, 65], ["obliterans", "OBSERVATION", 66, 76], ["lung", "ANATOMY", 80, 84], ["transplant", "OBSERVATION", 85, 95], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["chronic", "OBSERVATION_MODIFIER", 205, 212], ["lung", "ANATOMY", 213, 217], ["diseases", "OBSERVATION", 218, 226]]], ["The expression of this receptor on key regulatory and effector cells, such as lymphocytes, neutrophils and macrophages, suppresses their migration and the secretion of cytokines and chemokines to dampen immune responses.", [["effector cells", "ANATOMY", 54, 68], ["lymphocytes", "ANATOMY", 78, 89], ["neutrophils", "ANATOMY", 91, 102], ["macrophages", "ANATOMY", 107, 118], ["effector cells", "CELL", 54, 68], ["lymphocytes", "CELL", 78, 89], ["neutrophils", "CELL", 91, 102], ["macrophages", "CELL", 107, 118], ["regulatory and effector cells", "CELL_TYPE", 39, 68], ["lymphocytes", "CELL_TYPE", 78, 89], ["neutrophils", "CELL_TYPE", 91, 102], ["macrophages", "CELL_TYPE", 107, 118], ["cytokines", "PROTEIN", 168, 177], ["chemokines", "PROTEIN", 182, 192], ["effector cells", "PROBLEM", 54, 68], ["lymphocytes", "TEST", 78, 89], ["neutrophils", "TEST", 91, 102], ["macrophages", "PROBLEM", 107, 118], ["the secretion of cytokines", "TREATMENT", 151, 177], ["chemokines", "TREATMENT", 182, 192], ["effector cells", "OBSERVATION", 54, 68]]], ["Hence, there is substantial preclinical evidence that A 2A R agonists may be useful to treat inflammatory features in acute lung injuries and chronic lung diseases.A 2B Rs: Balancing Clearance and InflammationOver the past 5 years, models of acute lung injury applied to A 2B R \u00c0/\u00c0 mice have assigned a protective role to the receptor (review: [100] ).", [["lung", "ANATOMY", 124, 128], ["lung", "ANATOMY", 150, 154], ["lung", "ANATOMY", 248, 252], ["acute lung injuries", "DISEASE", 118, 137], ["chronic lung diseases", "DISEASE", 142, 163], ["acute lung injury", "DISEASE", 242, 259], ["A 2A R", "GENE_OR_GENE_PRODUCT", 54, 60], ["lung", "ORGAN", 124, 128], ["lung", "ORGAN", 150, 154], ["lung", "ORGAN", 248, 252], ["mice", "ORGANISM", 282, 286], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 282, 286], ["A 2A R agonists", "TREATMENT", 54, 69], ["inflammatory features", "PROBLEM", 93, 114], ["acute lung injuries", "PROBLEM", 118, 137], ["chronic lung diseases", "PROBLEM", 142, 163], ["Balancing Clearance", "PROBLEM", 173, 192], ["acute lung injury", "PROBLEM", 242, 259], ["inflammatory", "OBSERVATION", 93, 105], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["lung", "ANATOMY", 124, 128], ["injuries", "OBSERVATION", 129, 137], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["lung", "ANATOMY", 150, 154], ["diseases", "OBSERVATION", 155, 163], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["lung", "ANATOMY", 248, 252], ["injury", "OBSERVATION", 253, 259]]], ["The first model considered was the hypoxia-induced vascular leakage and recruitment of inflammatory mediators to the lungs.", [["vascular", "ANATOMY", 51, 59], ["lungs", "ANATOMY", 117, 122], ["hypoxia", "DISEASE", 35, 42], ["vascular", "MULTI-TISSUE_STRUCTURE", 51, 59], ["lungs", "ORGAN", 117, 122], ["inflammatory mediators", "PROTEIN", 87, 109], ["the hypoxia", "PROBLEM", 31, 42], ["induced vascular leakage", "PROBLEM", 43, 67], ["inflammatory mediators to the lungs", "PROBLEM", 87, 122], ["hypoxia", "OBSERVATION", 35, 42], ["vascular", "ANATOMY", 51, 59], ["leakage", "OBSERVATION", 60, 67], ["recruitment", "OBSERVATION_MODIFIER", 72, 83], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["lungs", "ANATOMY", 117, 122]]], ["Initial profiling of each ADO receptor was obtained by silencing RNA techniques in human microvascular endothelial cells.", [["microvascular endothelial cells", "ANATOMY", 89, 120], ["ADO", "CHEMICAL", 26, 29], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 26, 38], ["human", "ORGANISM", 83, 88], ["microvascular endothelial cells", "CELL", 89, 120], ["ADO receptor", "PROTEIN", 26, 38], ["human microvascular endothelial cells", "CELL_TYPE", 83, 120], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["each ADO receptor", "TREATMENT", 21, 38], ["microvascular endothelial cells", "OBSERVATION", 89, 120]]], ["The results showed that only A 2B R elimination resulted in a significant increase in endothelial leakage in response to hypoxia [11] .", [["endothelial", "ANATOMY", 86, 97], ["hypoxia", "DISEASE", 121, 128], ["A 2B R", "GENE_OR_GENE_PRODUCT", 29, 35], ["endothelial", "TISSUE", 86, 97], ["A 2B R elimination", "TREATMENT", 29, 47], ["a significant increase in endothelial leakage", "PROBLEM", 60, 105], ["hypoxia", "PROBLEM", 121, 128], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["endothelial leakage", "OBSERVATION", 86, 105]]], ["The same selective response was reported in knockout mice exposed to normobaric hypoxia [11] .", [["hypoxia", "DISEASE", 80, 87], ["mice", "ORGANISM", 53, 57], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["normobaric hypoxia", "PROBLEM", 69, 87], ["selective", "OBSERVATION_MODIFIER", 9, 18], ["normobaric hypoxia", "OBSERVATION", 69, 87]]], ["Only the A 2B R \u00c0/\u00c0 mice exhibited enhanced pulmonary edema and vascular leakage, compared to the hypoxic wild-type mice.", [["pulmonary", "ANATOMY", 44, 53], ["vascular", "ANATOMY", 64, 72], ["pulmonary edema", "DISEASE", 44, 59], ["R", "GENE_OR_GENE_PRODUCT", 14, 15], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 44, 59], ["vascular", "MULTI-TISSUE_STRUCTURE", 64, 72], ["mice", "ORGANISM", 116, 120], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 20, 24], ["enhanced pulmonary edema", "PROBLEM", 35, 59], ["vascular leakage", "PROBLEM", 64, 80], ["enhanced", "OBSERVATION_MODIFIER", 35, 43], ["pulmonary", "ANATOMY", 44, 53], ["edema", "OBSERVATION", 54, 59], ["vascular", "ANATOMY", 64, 72], ["leakage", "OBSERVATION", 73, 80], ["hypoxic", "OBSERVATION_MODIFIER", 98, 105]]], ["Interestingly, hypoxia selectively up-regulated A 2B Rs, likely as a defense mechanism against vascular leakage [11] .", [["vascular", "ANATOMY", 95, 103], ["hypoxia", "DISEASE", 15, 22], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 48, 55], ["vascular", "MULTI-TISSUE_STRUCTURE", 95, 103], ["A 2B Rs", "PROTEIN", 48, 55], ["hypoxia", "PROBLEM", 15, 22], ["vascular leakage", "PROBLEM", 95, 111], ["vascular", "ANATOMY", 95, 103], ["leakage", "OBSERVATION", 104, 111]]], ["Therefore, agonists and antagonists were evaluated in wild-type mice for their capacity to prevent acute lung injury.", [["lung", "ANATOMY", 105, 109], ["acute lung injury", "DISEASE", 99, 116], ["mice", "ORGANISM", 64, 68], ["lung", "ORGAN", 105, 109], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["agonists", "TREATMENT", 11, 19], ["antagonists", "TREATMENT", 24, 35], ["their capacity", "PROBLEM", 73, 87], ["acute lung injury", "PROBLEM", 99, 116], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["lung", "ANATOMY", 105, 109], ["injury", "OBSERVATION", 110, 116]]], ["Pretreatment of the mice by intraperitoneal injection of an agonist (BAY60-6583) almost completely prevented hypoxia-induced injury, whereas an antagonist (PSB1115) aggravated these lung complications.", [["intraperitoneal", "ANATOMY", 28, 43], ["lung", "ANATOMY", 182, 186], ["BAY60-6583", "CHEMICAL", 69, 79], ["hypoxia", "DISEASE", 109, 116], ["PSB1115", "CHEMICAL", 156, 163], ["lung complications", "DISEASE", 182, 200], ["BAY60-6583", "CHEMICAL", 69, 79], ["PSB1115", "CHEMICAL", 156, 163], ["mice", "ORGANISM", 20, 24], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 43], ["BAY60-6583", "SIMPLE_CHEMICAL", 69, 79], ["lung", "ORGAN", 182, 186], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["hypoxia", "PROBLEM", 109, 116], ["induced injury", "PROBLEM", 117, 131], ["these lung complications", "PROBLEM", 176, 200], ["hypoxia", "OBSERVATION", 109, 116], ["injury", "OBSERVATION", 125, 131], ["lung", "ANATOMY", 182, 186], ["complications", "OBSERVATION", 187, 200]]], ["To determine the relative contribution of A 2B Rs expressed on pulmonary or hematopoietic cells to the vascular leakage during hypoxia, the authors generated bone marrow chimeric mice.", [["pulmonary", "ANATOMY", 63, 72], ["hematopoietic cells", "ANATOMY", 76, 95], ["vascular", "ANATOMY", 103, 111], ["bone marrow", "ANATOMY", 158, 169], ["hypoxia", "DISEASE", 127, 134], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 42, 49], ["pulmonary", "ORGAN", 63, 72], ["hematopoietic cells", "CELL", 76, 95], ["vascular", "MULTI-TISSUE_STRUCTURE", 103, 111], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 158, 169], ["mice", "ORGANISM", 179, 183], ["A 2B Rs", "PROTEIN", 42, 49], ["pulmonary or hematopoietic cells", "CELL_TYPE", 63, 95], ["mice", "SPECIES", 179, 183], ["mice", "SPECIES", 179, 183], ["pulmonary or hematopoietic cells", "PROBLEM", 63, 95], ["the vascular leakage", "PROBLEM", 99, 119], ["hypoxia", "PROBLEM", 127, 134], ["pulmonary", "ANATOMY", 63, 72], ["hematopoietic cells", "OBSERVATION", 76, 95], ["vascular", "ANATOMY", 103, 111], ["leakage", "OBSERVATION", 112, 119], ["hypoxia", "OBSERVATION", 127, 134]]], ["Mice expressing A 2B Rs on the tissues, but not on the hematopoietic cells, showed reduced Evan's blue extravasation in response to BAY 60-6583, whereas the opposite chimera offered no protection.", [["tissues", "ANATOMY", 31, 38], ["hematopoietic cells", "ANATOMY", 55, 74], ["BAY 60-6583", "CHEMICAL", 132, 143], ["BAY 60-6583", "CHEMICAL", 132, 143], ["Mice", "ORGANISM", 0, 4], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 16, 23], ["tissues", "TISSUE", 31, 38], ["hematopoietic cells", "CELL", 55, 74], ["BAY 60-6583", "SIMPLE_CHEMICAL", 132, 143], ["A 2B Rs", "PROTEIN", 16, 23], ["hematopoietic cells", "CELL_TYPE", 55, 74], ["Mice", "SPECIES", 0, 4], ["reduced Evan's blue extravasation", "PROBLEM", 83, 116], ["tissues", "ANATOMY", 31, 38], ["hematopoietic", "ANATOMY", 55, 68]]], ["Taken together, these studies provide pharmacological and genetic evidence for vascular A 2B R signaling as a central control point of hypoxia-associated vascular leak.", [["vascular", "ANATOMY", 79, 87], ["vascular", "ANATOMY", 154, 162], ["hypoxia", "DISEASE", 135, 142], ["vascular A 2B R", "GENE_OR_GENE_PRODUCT", 79, 94], ["vascular", "MULTI-TISSUE_STRUCTURE", 154, 162], ["these studies", "TEST", 16, 29], ["hypoxia", "PROBLEM", 135, 142], ["associated vascular leak", "PROBLEM", 143, 167], ["vascular", "ANATOMY", 79, 87], ["hypoxia", "OBSERVATION", 135, 142], ["vascular", "ANATOMY", 154, 162], ["leak", "OBSERVATION", 163, 167]]], ["These data are consistent with the purinergic regulation of vascular permeability in human lungs ( Fig. 8.1 ), thereby supporting a role for A 2B R agonists in the treatment of hypoxia-related acute lung injury.A 2B Rs: Balancing Clearance and InflammationBacterial infection triggers an acute increase in A 2B R expression throughout the respiratory system, by a mechanism involving cytokine release and autocrine responses.", [["vascular", "ANATOMY", 60, 68], ["lungs", "ANATOMY", 91, 96], ["lung", "ANATOMY", 199, 203], ["respiratory system", "ANATOMY", 339, 357], ["hypoxia", "DISEASE", 177, 184], ["acute lung injury", "DISEASE", 193, 210], ["Bacterial infection", "DISEASE", 256, 275], ["vascular", "MULTI-TISSUE_STRUCTURE", 60, 68], ["human", "ORGANISM", 85, 90], ["lungs", "ORGAN", 91, 96], ["A 2B R", "GENE_OR_GENE_PRODUCT", 141, 147], ["lung", "ORGAN", 199, 203], ["A 2B R", "GENE_OR_GENE_PRODUCT", 306, 312], ["cytokine", "PROTEIN", 384, 392], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["These data", "TEST", 0, 10], ["vascular permeability in human lungs", "PROBLEM", 60, 96], ["A 2B R agonists", "TREATMENT", 141, 156], ["hypoxia", "PROBLEM", 177, 184], ["acute lung injury", "PROBLEM", 193, 210], ["Balancing Clearance", "PROBLEM", 220, 239], ["InflammationBacterial infection", "PROBLEM", 244, 275], ["an acute increase", "PROBLEM", 285, 302], ["consistent with", "UNCERTAINTY", 15, 30], ["vascular", "ANATOMY", 60, 68], ["permeability", "OBSERVATION", 69, 81], ["lungs", "ANATOMY", 91, 96], ["hypoxia", "OBSERVATION", 177, 184], ["acute", "OBSERVATION_MODIFIER", 193, 198], ["lung", "ANATOMY", 199, 203], ["injury", "OBSERVATION", 204, 210], ["Inflammation", "OBSERVATION_MODIFIER", 244, 256], ["Bacterial", "OBSERVATION_MODIFIER", 256, 265], ["infection", "OBSERVATION", 266, 275], ["acute", "OBSERVATION_MODIFIER", 288, 293], ["increase", "OBSERVATION_MODIFIER", 294, 302], ["respiratory system", "ANATOMY", 339, 357]]], ["In cultured human microvascular endothelial cells and A549 alveolar epithelial cells, IL-1b, IL-4, IL-6 and prostaglandin E2 induce a progressive increase in A 2B R mRNA levels, reaching more than sixfold higher values after 12 h, then returning to baseline within 24 h [101] .", [["microvascular endothelial cells", "ANATOMY", 18, 49], ["A549 alveolar epithelial cells", "ANATOMY", 54, 84], ["prostaglandin E2", "CHEMICAL", 108, 124], ["prostaglandin E2", "CHEMICAL", 108, 124], ["human", "ORGANISM", 12, 17], ["microvascular endothelial cells", "CELL", 18, 49], ["A549 alveolar epithelial cells", "CELL", 54, 84], ["IL-1b", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL-4", "GENE_OR_GENE_PRODUCT", 93, 97], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["prostaglandin E2", "SIMPLE_CHEMICAL", 108, 124], ["A 2B R", "GENE_OR_GENE_PRODUCT", 158, 164], ["cultured human microvascular endothelial cells", "CELL_LINE", 3, 49], ["A549 alveolar epithelial cells", "CELL_LINE", 54, 84], ["IL-6", "PROTEIN", 99, 103], ["A 2B R mRNA", "RNA", 158, 169], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["human microvascular endothelial cells", "TEST", 12, 49], ["A549 alveolar epithelial cells", "TEST", 54, 84], ["IL", "TEST", 86, 88], ["IL", "TEST", 93, 95], ["IL", "TEST", 99, 101], ["prostaglandin E2", "TREATMENT", 108, 124], ["a progressive increase", "PROBLEM", 132, 154], ["A 2B R mRNA levels", "TEST", 158, 176], ["microvascular endothelial cells", "OBSERVATION", 18, 49], ["alveolar", "ANATOMY_MODIFIER", 59, 67], ["epithelial cells", "OBSERVATION", 68, 84], ["progressive", "OBSERVATION_MODIFIER", 134, 145], ["increase", "OBSERVATION_MODIFIER", 146, 154]]], ["These findings were reproduced in vivo, as mice responded to LPS inhalation by a nearly fivefold increase in total lung A 2B R transcript and protein levels.", [["lung", "ANATOMY", 115, 119], ["LPS", "CHEMICAL", 61, 64], ["mice", "ORGANISM", 43, 47], ["LPS", "SIMPLE_CHEMICAL", 61, 64], ["lung A 2B R", "GENE_OR_GENE_PRODUCT", 115, 126], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["LPS inhalation", "TREATMENT", 61, 75], ["protein levels", "TEST", 142, 156], ["lung", "ANATOMY", 115, 119]]], ["When the mice were pre-treated by inhalation of an A 2B R antagonist (MRS 1754), they reacted to LPS by dramatically more severe lung edema, higher BAL fluid cytokine concentrations (IL-1b and TNFa) and neutrophil myeloperoxidase activity.", [["lung", "ANATOMY", 129, 133], ["BAL fluid", "ANATOMY", 148, 157], ["neutrophil", "ANATOMY", 203, 213], ["MRS 1754", "CHEMICAL", 70, 78], ["LPS", "CHEMICAL", 97, 100], ["lung edema", "DISEASE", 129, 139], ["MRS 1754", "CHEMICAL", 70, 78], ["mice", "ORGANISM", 9, 13], ["A 2B R antagonist", "SIMPLE_CHEMICAL", 51, 68], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["lung", "ORGAN", 129, 133], ["IL-1b", "GENE_OR_GENE_PRODUCT", 183, 188], ["TNFa", "GENE_OR_GENE_PRODUCT", 193, 197], ["neutrophil", "CELL", 203, 213], ["myeloperoxidase", "SIMPLE_CHEMICAL", 214, 229], ["cytokine", "PROTEIN", 158, 166], ["TNFa", "PROTEIN", 193, 197], ["myeloperoxidase", "PROTEIN", 214, 229], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["MRS", "TEST", 70, 73], ["LPS", "TEST", 97, 100], ["dramatically more severe lung edema", "PROBLEM", 104, 139], ["higher BAL fluid cytokine concentrations", "PROBLEM", 141, 181], ["IL", "TEST", 183, 185], ["TNFa", "TEST", 193, 197], ["neutrophil myeloperoxidase activity", "TEST", 203, 238], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["lung", "ANATOMY", 129, 133], ["edema", "OBSERVATION", 134, 139], ["higher", "OBSERVATION_MODIFIER", 141, 147], ["BAL", "OBSERVATION", 148, 151], ["fluid cytokine concentrations", "OBSERVATION", 152, 181], ["neutrophil myeloperoxidase activity", "OBSERVATION", 203, 238]]], ["Similar findings were obtained with A 2B R \u00c0/\u00c0 mice.", [["mice", "ORGANISM", 47, 51], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51]]], ["As in the case of hypoxia [11] , the bone marrow chimeric mice support a predominant role for A 2B Rs expressed on pulmonary cells, not hematopoietic cells, in the protection against acute lung injury.", [["bone marrow", "ANATOMY", 37, 48], ["pulmonary cells", "ANATOMY", 115, 130], ["hematopoietic cells", "ANATOMY", 136, 155], ["lung", "ANATOMY", 189, 193], ["hypoxia", "DISEASE", 18, 25], ["acute lung injury", "DISEASE", 183, 200], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 37, 48], ["mice", "ORGANISM", 58, 62], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 94, 101], ["pulmonary cells", "CELL", 115, 130], ["hematopoietic cells", "CELL", 136, 155], ["lung", "ORGAN", 189, 193], ["A 2B Rs", "PROTEIN", 94, 101], ["pulmonary cells", "CELL_TYPE", 115, 130], ["hematopoietic cells", "CELL_TYPE", 136, 155], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["hypoxia", "PROBLEM", 18, 25], ["the bone marrow chimeric mice support", "TREATMENT", 33, 70], ["pulmonary cells", "PROBLEM", 115, 130], ["hematopoietic cells", "PROBLEM", 136, 155], ["acute lung injury", "PROBLEM", 183, 200], ["bone", "ANATOMY", 37, 41], ["pulmonary cells", "ANATOMY", 115, 130], ["not", "UNCERTAINTY", 132, 135], ["hematopoietic cells", "OBSERVATION", 136, 155], ["acute", "OBSERVATION_MODIFIER", 183, 188], ["lung", "ANATOMY", 189, 193], ["injury", "OBSERVATION", 194, 200]]], ["Accordingly, the A 2B R agonist BAY 60-6583 clearly prevented LPS-mediated lung inflammation and edema.", [["lung", "ANATOMY", 75, 79], ["edema", "ANATOMY", 97, 102], ["BAY 60-6583", "CHEMICAL", 32, 43], ["LPS", "CHEMICAL", 62, 65], ["lung inflammation", "DISEASE", 75, 92], ["edema", "DISEASE", 97, 102], ["BAY 60-6583", "CHEMICAL", 32, 43], ["A 2B R", "GENE_OR_GENE_PRODUCT", 17, 23], ["BAY 60-6583", "SIMPLE_CHEMICAL", 32, 43], ["LPS", "SIMPLE_CHEMICAL", 62, 65], ["lung", "ORGAN", 75, 79], ["edema", "PATHOLOGICAL_FORMATION", 97, 102], ["LPS", "PROBLEM", 62, 65], ["mediated lung inflammation", "PROBLEM", 66, 92], ["edema", "PROBLEM", 97, 102], ["lung", "ANATOMY", 75, 79], ["inflammation", "OBSERVATION", 80, 92], ["edema", "OBSERVATION", 97, 102]]], ["Collectively, these studies show that hypoxia and bacterial infection acutely up-regulate A 2B Rs as a defense mechanism, which offers a platform for the effective treatment of acute lung injury.A 2B Rs: Balancing Clearance and InflammationContrary to acute lung injury, abundant literature supports pro-fibrotic and tissue destructive roles for A 2B Rs in chronic lung diseases, such as asthma, COPD and fibrotic pulmonary diseases [102, 103] .", [["lung", "ANATOMY", 183, 187], ["lung", "ANATOMY", 258, 262], ["tissue", "ANATOMY", 317, 323], ["lung", "ANATOMY", 365, 369], ["pulmonary", "ANATOMY", 414, 423], ["hypoxia", "DISEASE", 38, 45], ["infection", "DISEASE", 60, 69], ["acute lung injury", "DISEASE", 177, 194], ["acute lung injury", "DISEASE", 252, 269], ["chronic lung diseases", "DISEASE", 357, 378], ["asthma", "DISEASE", 388, 394], ["COPD", "DISEASE", 396, 400], ["fibrotic pulmonary diseases", "DISEASE", 405, 432], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 90, 97], ["lung", "ORGAN", 183, 187], ["lung", "ORGAN", 258, 262], ["tissue", "TISSUE", 317, 323], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 346, 353], ["lung", "ORGAN", 365, 369], ["pulmonary", "ORGAN", 414, 423], ["A 2B Rs", "PROTEIN", 90, 97], ["these studies", "TEST", 14, 27], ["hypoxia", "PROBLEM", 38, 45], ["bacterial infection", "PROBLEM", 50, 69], ["acute lung injury", "PROBLEM", 177, 194], ["Balancing Clearance", "PROBLEM", 204, 223], ["acute lung injury", "PROBLEM", 252, 269], ["pro-fibrotic and tissue destructive roles", "PROBLEM", 300, 341], ["chronic lung diseases", "PROBLEM", 357, 378], ["asthma", "PROBLEM", 388, 394], ["COPD", "PROBLEM", 396, 400], ["fibrotic pulmonary diseases", "PROBLEM", 405, 432], ["hypoxia", "OBSERVATION", 38, 45], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["infection", "OBSERVATION", 60, 69], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["lung", "ANATOMY", 183, 187], ["injury", "OBSERVATION", 188, 194], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["lung", "ANATOMY", 258, 262], ["injury", "OBSERVATION", 263, 269], ["pro-fibrotic", "OBSERVATION_MODIFIER", 300, 312], ["tissue", "OBSERVATION_MODIFIER", 317, 323], ["destructive", "OBSERVATION_MODIFIER", 324, 335], ["chronic", "OBSERVATION_MODIFIER", 357, 364], ["lung", "ANATOMY", 365, 369], ["diseases", "OBSERVATION", 370, 378], ["asthma", "OBSERVATION", 388, 394], ["COPD", "OBSERVATION", 396, 400], ["fibrotic", "OBSERVATION_MODIFIER", 405, 413], ["pulmonary", "ANATOMY", 414, 423], ["diseases", "OBSERVATION", 424, 432]]], ["Numerous studies demonstrated the ability of A 2B R activation to induce the expression and secretion of pro-inflammatory mediators from various cell types, including IL-4, IL-8 and IL-13 from mast cells [104] [105] [106] , IL-6 and IL-19 from airway epithelial cells [107, 108] and monocyte chemoattractant protein-1 from bronchial smooth muscle cells [109] .", [["cell", "ANATOMY", 145, 149], ["mast cells", "ANATOMY", 193, 203], ["airway epithelial cells", "ANATOMY", 244, 267], ["bronchial smooth muscle cells", "ANATOMY", 323, 352], ["A 2B R", "GENE_OR_GENE_PRODUCT", 45, 51], ["cell", "CELL", 145, 149], ["IL-4", "GENE_OR_GENE_PRODUCT", 167, 171], ["IL-8", "GENE_OR_GENE_PRODUCT", 173, 177], ["IL-13", "GENE_OR_GENE_PRODUCT", 182, 187], ["mast cells", "CELL", 193, 203], ["IL-6", "GENE_OR_GENE_PRODUCT", 224, 228], ["IL-19", "GENE_OR_GENE_PRODUCT", 233, 238], ["airway epithelial cells", "CELL", 244, 267], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 283, 317], ["bronchial smooth muscle cells", "CELL", 323, 352], ["pro-inflammatory mediators", "PROTEIN", 105, 131], ["IL-13", "PROTEIN", 182, 187], ["mast cells", "CELL_TYPE", 193, 203], ["IL-19", "PROTEIN", 233, 238], ["airway epithelial cells", "CELL_TYPE", 244, 267], ["monocyte chemoattractant protein-1", "PROTEIN", 283, 317], ["bronchial smooth muscle cells", "CELL_TYPE", 323, 352], ["Numerous studies", "TEST", 0, 16], ["A 2B R activation", "TREATMENT", 45, 62], ["secretion of pro-inflammatory mediators", "PROBLEM", 92, 131], ["various cell types", "TEST", 137, 155], ["IL", "TEST", 167, 169], ["IL", "TEST", 173, 175], ["IL", "TEST", 182, 184], ["mast cells", "TEST", 193, 203], ["IL", "TEST", 224, 226], ["IL", "TEST", 233, 235], ["airway epithelial cells", "TEST", 244, 267], ["monocyte chemoattractant protein", "TEST", 283, 315], ["bronchial smooth muscle cells", "TEST", 323, 352], ["various cell types", "OBSERVATION", 137, 155], ["airway epithelial", "ANATOMY", 244, 261], ["bronchial", "ANATOMY", 323, 332], ["smooth muscle", "ANATOMY", 333, 346]]], ["Consequently, it is not surprising that A 2B R \u00c0/\u00c0 mice, subjected to the OVA sensitization/challenge model of allergic asthma, develop milder features of pulmonary inflammation and airway remodeling than wild-type mice [110] .", [["pulmonary", "ANATOMY", 155, 164], ["airway", "ANATOMY", 182, 188], ["allergic asthma", "DISEASE", 111, 126], ["pulmonary inflammation", "DISEASE", 155, 177], ["A 2B", "ORGANISM", 40, 44], ["R \u00c0/\u00c0 mice", "ORGANISM", 45, 55], ["pulmonary", "ORGAN", 155, 164], ["airway", "MULTI-TISSUE_STRUCTURE", 182, 188], ["mice", "ORGANISM", 215, 219], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 51, 55], ["the OVA sensitization", "TREATMENT", 70, 91], ["allergic asthma", "PROBLEM", 111, 126], ["pulmonary inflammation", "PROBLEM", 155, 177], ["airway remodeling", "PROBLEM", 182, 199], ["allergic asthma", "OBSERVATION", 111, 126], ["milder", "OBSERVATION_MODIFIER", 136, 142], ["pulmonary", "ANATOMY", 155, 164], ["inflammation", "OBSERVATION", 165, 177], ["airway", "ANATOMY", 182, 188], ["remodeling", "OBSERVATION", 189, 199]]], ["Major inflammatory findings included a reduced production of IL-4 and lower airway eosinophil numbers in A 2B R \u00c0/\u00c0 mice chronically exposed to the allergen.", [["airway eosinophil", "ANATOMY", 76, 93], ["IL-4", "GENE_OR_GENE_PRODUCT", 61, 65], ["airway eosinophil", "CELL", 76, 93], ["mice", "ORGANISM", 116, 120], ["IL-4", "PROTEIN", 61, 65], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["Major inflammatory findings", "PROBLEM", 0, 27], ["a reduced production of IL", "PROBLEM", 37, 63], ["lower airway eosinophil numbers", "PROBLEM", 70, 101], ["inflammatory", "OBSERVATION", 6, 18], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["production", "OBSERVATION_MODIFIER", 47, 57], ["IL", "OBSERVATION_MODIFIER", 61, 63], ["lower", "ANATOMY_MODIFIER", 70, 75], ["airway", "ANATOMY", 76, 82], ["eosinophil numbers", "OBSERVATION", 83, 101]]], ["With respect to airway remodeling, these mice presented lower levels of TGFb, mucus cell metaplasia and thickening of the smooth muscle layer surrounding bronchial airways.", [["airway", "ANATOMY", 16, 22], ["mucus cell metaplasia", "ANATOMY", 78, 99], ["smooth muscle layer", "ANATOMY", 122, 141], ["bronchial airways", "ANATOMY", 154, 171], ["airway", "MULTI-TISSUE_STRUCTURE", 16, 22], ["mice", "ORGANISM", 41, 45], ["TGFb", "GENE_OR_GENE_PRODUCT", 72, 76], ["mucus cell", "CELL", 78, 88], ["smooth muscle layer", "TISSUE", 122, 141], ["bronchial airways", "MULTI-TISSUE_STRUCTURE", 154, 171], ["TGFb", "PROTEIN", 72, 76], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["airway remodeling", "PROBLEM", 16, 33], ["lower levels of TGFb", "PROBLEM", 56, 76], ["mucus cell metaplasia", "PROBLEM", 78, 99], ["thickening of the smooth muscle layer surrounding bronchial airways", "PROBLEM", 104, 171], ["airway", "ANATOMY", 16, 22], ["remodeling", "OBSERVATION", 23, 33], ["lower", "OBSERVATION_MODIFIER", 56, 61], ["TGFb", "OBSERVATION_MODIFIER", 72, 76], ["mucus cell metaplasia", "OBSERVATION", 78, 99], ["thickening", "OBSERVATION", 104, 114], ["smooth", "ANATOMY_MODIFIER", 122, 128], ["muscle", "ANATOMY", 129, 135], ["layer", "ANATOMY_MODIFIER", 136, 141], ["bronchial airways", "ANATOMY", 154, 171]]], ["Similar data were reported for mice subjected to the ragweed sensitization/ NECA challenge model of allergic asthma [111] .", [["NECA", "CHEMICAL", 76, 80], ["allergic asthma", "DISEASE", 100, 115], ["NECA", "CHEMICAL", 76, 80], ["mice", "ORGANISM", 31, 35], ["NECA", "SIMPLE_CHEMICAL", 76, 80], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["the ragweed sensitization", "PROBLEM", 49, 74], ["NECA challenge", "TREATMENT", 76, 90], ["allergic asthma", "PROBLEM", 100, 115], ["allergic asthma", "OBSERVATION", 100, 115]]], ["In the sensitized mice, pretreatment by intraperitoneal injection of an A 2B R antagonist (CVT-6883) significantly attenuated the airway inflammation and hyperresponsiveness induced by nebulized NECA.", [["intraperitoneal", "ANATOMY", 40, 55], ["airway", "ANATOMY", 130, 136], ["CVT-6883", "CHEMICAL", 91, 99], ["airway inflammation", "DISEASE", 130, 149], ["NECA", "CHEMICAL", 195, 199], ["CVT-6883", "CHEMICAL", 91, 99], ["NECA", "CHEMICAL", 195, 199], ["mice", "ORGANISM", 18, 22], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 55], ["A 2B R antagonist", "SIMPLE_CHEMICAL", 72, 89], ["CVT-6883", "SIMPLE_CHEMICAL", 91, 99], ["airway", "MULTI-TISSUE_STRUCTURE", 130, 136], ["NECA", "SIMPLE_CHEMICAL", 195, 199], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["intraperitoneal injection", "TREATMENT", 40, 65], ["an A 2B R antagonist", "TREATMENT", 69, 89], ["CVT", "TEST", 91, 94], ["the airway inflammation", "PROBLEM", 126, 149], ["hyperresponsiveness", "PROBLEM", 154, 173], ["nebulized NECA", "TREATMENT", 185, 199], ["airway", "ANATOMY", 130, 136], ["inflammation", "OBSERVATION", 137, 149], ["hyperresponsiveness", "OBSERVATION", 154, 173]]], ["These studies provide evidence for the potential of A 2B R antagonists in the treatment of chronic diseases, like asthma.A 2B Rs: Balancing Clearance and InflammationThe contribution of A 2B Rs to chronic lung disease is further supported by studies conducted in the ADA-deficient model of ADO-mediated lung injury [103] .", [["lung", "ANATOMY", 205, 209], ["lung", "ANATOMY", 303, 307], ["chronic diseases", "DISEASE", 91, 107], ["asthma", "DISEASE", 114, 120], ["Inflammation", "DISEASE", 154, 166], ["chronic lung disease", "DISEASE", 197, 217], ["ADO", "CHEMICAL", 290, 293], ["lung injury", "DISEASE", 303, 314], ["ADO", "CHEMICAL", 290, 293], ["A 2B R antagonists", "GENE_OR_GENE_PRODUCT", 52, 70], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 186, 193], ["lung", "ORGAN", 205, 209], ["ADA", "SIMPLE_CHEMICAL", 267, 270], ["ADO", "SIMPLE_CHEMICAL", 290, 293], ["lung", "ORGAN", 303, 307], ["ADA", "PROTEIN", 267, 270], ["These studies", "TEST", 0, 13], ["A 2B R antagonists", "TREATMENT", 52, 70], ["chronic diseases", "PROBLEM", 91, 107], ["asthma", "PROBLEM", 114, 120], ["Balancing Clearance", "PROBLEM", 130, 149], ["Inflammation", "PROBLEM", 154, 166], ["chronic lung disease", "PROBLEM", 197, 217], ["studies", "TEST", 242, 249], ["the ADA", "TEST", 263, 270], ["ADO-mediated lung injury", "PROBLEM", 290, 314], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["diseases", "OBSERVATION", 99, 107], ["asthma", "OBSERVATION", 114, 120], ["Balancing Clearance", "OBSERVATION", 130, 149], ["Inflammation", "OBSERVATION", 154, 166], ["chronic", "OBSERVATION_MODIFIER", 197, 204], ["lung", "ANATOMY", 205, 209], ["disease", "OBSERVATION", 210, 217], ["lung", "ANATOMY", 303, 307], ["injury", "OBSERVATION", 308, 314]]], ["These mice develop progressive increases in total lung ADO level, in association with inflammation and tissue remodeling [37, 45] .", [["lung", "ANATOMY", 50, 54], ["tissue", "ANATOMY", 103, 109], ["ADO", "CHEMICAL", 55, 58], ["inflammation", "DISEASE", 86, 98], ["ADO", "CHEMICAL", 55, 58], ["mice", "ORGANISM", 6, 10], ["lung", "ORGAN", 50, 54], ["ADO", "SIMPLE_CHEMICAL", 55, 58], ["tissue", "TISSUE", 103, 109], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["progressive increases in total lung ADO level", "PROBLEM", 19, 64], ["inflammation", "PROBLEM", 86, 98], ["tissue remodeling", "PROBLEM", 103, 120], ["progressive", "OBSERVATION_MODIFIER", 19, 30], ["increases", "OBSERVATION_MODIFIER", 31, 40], ["total", "OBSERVATION_MODIFIER", 44, 49], ["lung", "ANATOMY", 50, 54], ["ADO level", "OBSERVATION", 55, 64], ["inflammation", "OBSERVATION", 86, 98], ["tissue", "OBSERVATION_MODIFIER", 103, 109], ["remodeling", "OBSERVATION_MODIFIER", 110, 120]]], ["This model is characterized by the accumulation of activated alveolar macrophages producing various inflammatory mediators, alveolar airspace destruction, mucus cell metaplasia and fibrosis.", [["alveolar macrophages", "ANATOMY", 61, 81], ["alveolar airspace", "ANATOMY", 124, 141], ["mucus cell metaplasia", "ANATOMY", 155, 176], ["fibrosis", "DISEASE", 181, 189], ["alveolar macrophages", "CELL", 61, 81], ["alveolar airspace", "TISSUE", 124, 141], ["mucus cell metaplasia", "CANCER", 155, 176], ["activated alveolar macrophages", "CELL_TYPE", 51, 81], ["inflammatory mediators", "PROTEIN", 100, 122], ["activated alveolar macrophages", "PROBLEM", 51, 81], ["various inflammatory mediators", "PROBLEM", 92, 122], ["alveolar airspace destruction", "PROBLEM", 124, 153], ["mucus cell metaplasia", "PROBLEM", 155, 176], ["fibrosis", "PROBLEM", 181, 189], ["accumulation", "OBSERVATION_MODIFIER", 35, 47], ["activated", "OBSERVATION_MODIFIER", 51, 60], ["alveolar macrophages", "OBSERVATION", 61, 81], ["various", "OBSERVATION_MODIFIER", 92, 99], ["inflammatory", "OBSERVATION_MODIFIER", 100, 112], ["alveolar", "ANATOMY_MODIFIER", 124, 132], ["airspace", "ANATOMY_MODIFIER", 133, 141], ["destruction", "OBSERVATION", 142, 153], ["mucus cell metaplasia", "OBSERVATION", 155, 176], ["fibrosis", "OBSERVATION", 181, 189]]], ["The expression of the A 2B R is elevated in the lungs of ADA-deficient mice.", [["lungs", "ANATOMY", 48, 53], ["A 2B R", "GENE_OR_GENE_PRODUCT", 22, 28], ["lungs", "ORGAN", 48, 53], ["ADA", "GENE_OR_GENE_PRODUCT", 57, 60], ["mice", "ORGANISM", 71, 75], ["A 2B R", "PROTEIN", 22, 28], ["ADA", "PROTEIN", 57, 60], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["elevated", "OBSERVATION", 32, 40], ["lungs", "ANATOMY", 48, 53]]], ["Once lung complications are established, the selective A 2B R antagonist CVT-6883 significantly reduced the production of pro-inflammatory and pro-fibrotic mediators, alveolar airspace enlargement and fibrosis [112] .", [["lung", "ANATOMY", 5, 9], ["alveolar airspace", "ANATOMY", 167, 184], ["lung complications", "DISEASE", 5, 23], ["CVT-6883", "CHEMICAL", 73, 81], ["fibrosis", "DISEASE", 201, 209], ["CVT-6883", "CHEMICAL", 73, 81], ["lung", "ORGAN", 5, 9], ["A 2B R", "GENE_OR_GENE_PRODUCT", 55, 61], ["CVT-6883", "SIMPLE_CHEMICAL", 73, 81], ["alveolar airspace", "MULTI-TISSUE_STRUCTURE", 167, 184], ["pro-fibrotic mediators", "PROTEIN", 143, 165], ["lung complications", "PROBLEM", 5, 23], ["A 2B R antagonist CVT", "TEST", 55, 76], ["pro-inflammatory and pro-fibrotic mediators", "PROBLEM", 122, 165], ["alveolar airspace enlargement", "PROBLEM", 167, 196], ["fibrosis", "PROBLEM", 201, 209], ["lung", "ANATOMY", 5, 9], ["complications", "OBSERVATION", 10, 23], ["pro-inflammatory", "OBSERVATION_MODIFIER", 122, 138], ["pro-fibrotic", "OBSERVATION_MODIFIER", 143, 155], ["alveolar", "ANATOMY_MODIFIER", 167, 175], ["airspace", "ANATOMY_MODIFIER", 176, 184], ["enlargement", "OBSERVATION", 185, 196], ["fibrosis", "OBSERVATION", 201, 209]]], ["Similar findings were observed in the bleomycin model of pulmonary fibrosis [112] .", [["pulmonary", "ANATOMY", 57, 66], ["bleomycin", "CHEMICAL", 38, 47], ["pulmonary fibrosis", "DISEASE", 57, 75], ["bleomycin", "CHEMICAL", 38, 47], ["bleomycin", "SIMPLE_CHEMICAL", 38, 47], ["pulmonary", "ORGAN", 57, 66], ["pulmonary fibrosis", "PROBLEM", 57, 75], ["bleomycin", "OBSERVATION", 38, 47], ["pulmonary", "ANATOMY", 57, 66], ["fibrosis", "OBSERVATION", 67, 75]]], ["Interestingly, A 2B Rs are also up-regulated in the lungs of IL-4 [80] and IL-13 [79] overexpressing mice which develop features of asthma, COPD and pulmonary fibrosis.", [["lungs", "ANATOMY", 52, 57], ["pulmonary", "ANATOMY", 149, 158], ["asthma", "DISEASE", 132, 138], ["COPD", "DISEASE", 140, 144], ["pulmonary fibrosis", "DISEASE", 149, 167], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 15, 22], ["lungs", "ORGAN", 52, 57], ["IL-4", "GENE_OR_GENE_PRODUCT", 61, 65], ["IL-13", "GENE_OR_GENE_PRODUCT", 75, 80], ["mice", "ORGANISM", 101, 105], ["pulmonary", "ORGAN", 149, 158], ["A 2B Rs", "PROTEIN", 15, 22], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["A 2B Rs", "TEST", 15, 22], ["IL", "TEST", 61, 63], ["IL", "TEST", 75, 77], ["asthma", "PROBLEM", 132, 138], ["COPD", "PROBLEM", 140, 144], ["pulmonary fibrosis", "PROBLEM", 149, 167], ["lungs", "ANATOMY", 52, 57], ["asthma", "OBSERVATION", 132, 138], ["COPD", "OBSERVATION", 140, 144], ["pulmonary", "ANATOMY", 149, 158], ["fibrosis", "OBSERVATION", 159, 167]]], ["Moreover, high A 2B R expression was recently described as a feature of patients with accelerated pulmonary fibrosis [113] .", [["pulmonary", "ANATOMY", 98, 107], ["pulmonary fibrosis", "DISEASE", 98, 116], ["high A 2B R", "GENE_OR_GENE_PRODUCT", 10, 21], ["patients", "ORGANISM", 72, 80], ["pulmonary", "ORGAN", 98, 107], ["A 2B R", "PROTEIN", 15, 21], ["patients", "SPECIES", 72, 80], ["accelerated pulmonary fibrosis", "PROBLEM", 86, 116], ["pulmonary", "ANATOMY", 98, 107], ["fibrosis", "OBSERVATION", 108, 116]]], ["Thus, the exaggerated activation of A 2B R signaling pathways appears to constitute a widespread feature of chronic airway diseases with fibrosis.", [["airway", "ANATOMY", 116, 122], ["airway diseases", "DISEASE", 116, 131], ["fibrosis", "DISEASE", 137, 145], ["A 2B R", "GENE_OR_GENE_PRODUCT", 36, 42], ["airway", "MULTI-TISSUE_STRUCTURE", 116, 122], ["A 2B R", "PROTEIN", 36, 42], ["chronic airway diseases", "PROBLEM", 108, 131], ["fibrosis", "PROBLEM", 137, 145], ["widespread", "OBSERVATION_MODIFIER", 86, 96], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["airway", "ANATOMY", 116, 122], ["diseases", "OBSERVATION", 123, 131], ["fibrosis", "OBSERVATION", 137, 145]]], ["In support of this, A 2B R activation has been shown to promote the differentiation of human pulmonary fibroblast into collagen producing myofibroblasts [114] , and to stimulate the production of pro-fibrotic fibronectin in alveolar epithelial cells [115] .", [["pulmonary fibroblast", "ANATOMY", 93, 113], ["myofibroblasts", "ANATOMY", 138, 152], ["alveolar epithelial cells", "ANATOMY", 224, 249], ["A 2B R", "GENE_OR_GENE_PRODUCT", 20, 26], ["human", "ORGANISM", 87, 92], ["pulmonary fibroblast", "CELL", 93, 113], ["collagen", "GENE_OR_GENE_PRODUCT", 119, 127], ["myofibroblasts", "CELL", 138, 152], ["fibronectin", "GENE_OR_GENE_PRODUCT", 209, 220], ["alveolar epithelial cells", "CELL", 224, 249], ["human pulmonary fibroblast", "CELL_TYPE", 87, 113], ["collagen producing myofibroblasts", "CELL_TYPE", 119, 152], ["pro-fibrotic fibronectin", "PROTEIN", 196, 220], ["alveolar epithelial cells", "CELL_TYPE", 224, 249], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["A 2B R activation", "TREATMENT", 20, 37], ["human pulmonary fibroblast into collagen producing myofibroblasts", "PROBLEM", 87, 152], ["pro-fibrotic fibronectin in alveolar epithelial cells", "PROBLEM", 196, 249], ["pulmonary fibroblast", "ANATOMY", 93, 113], ["pro-fibrotic", "OBSERVATION_MODIFIER", 196, 208], ["fibronectin", "OBSERVATION", 209, 220], ["alveolar epithelial cells", "OBSERVATION", 224, 249]]], ["These findings suggest that the sustained up-regulation and engagement of A 2B Rs might collectively serve to enhance chronic remodeling features of chronic lung diseases.A 2B Rs: Balancing Clearance and InflammationAs in chronic lung diseases, the post-transplant bronchiolitis obliterans syndrome presents many histological characteristics of allograft injury and inflammation consistent with the pro-inflammatory and pro-fibrotic effects of A 2B R activation (review: [116] ).", [["lung", "ANATOMY", 157, 161], ["lung", "ANATOMY", 230, 234], ["allograft", "ANATOMY", 345, 354], ["chronic lung diseases", "DISEASE", 149, 170], ["chronic lung diseases", "DISEASE", 222, 243], ["bronchiolitis obliterans syndrome", "DISEASE", 265, 298], ["allograft injury", "DISEASE", 345, 361], ["inflammation", "DISEASE", 366, 378], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 74, 81], ["lung", "ORGAN", 157, 161], ["lung", "ORGAN", 230, 234], ["allograft", "TISSUE", 345, 354], ["A 2B R", "GENE_OR_GENE_PRODUCT", 444, 450], ["A 2B Rs", "PROTEIN", 74, 81], ["the sustained up-regulation", "PROBLEM", 28, 55], ["chronic lung diseases", "PROBLEM", 149, 170], ["Balancing Clearance", "PROBLEM", 180, 199], ["InflammationAs", "PROBLEM", 204, 218], ["chronic lung diseases", "PROBLEM", 222, 243], ["the post-transplant bronchiolitis obliterans syndrome", "PROBLEM", 245, 298], ["allograft injury", "PROBLEM", 345, 361], ["inflammation", "PROBLEM", 366, 378], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["remodeling", "OBSERVATION", 126, 136], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["lung", "ANATOMY", 157, 161], ["diseases", "OBSERVATION", 162, 170], ["Balancing Clearance", "OBSERVATION", 180, 199], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["lung", "ANATOMY", 230, 234], ["diseases", "OBSERVATION", 235, 243], ["post-transplant", "OBSERVATION_MODIFIER", 249, 264], ["bronchiolitis obliterans syndrome", "OBSERVATION", 265, 298], ["allograft injury", "OBSERVATION", 345, 361], ["inflammation", "OBSERVATION", 366, 378], ["consistent with", "UNCERTAINTY", 379, 394], ["pro-inflammatory", "OBSERVATION_MODIFIER", 399, 415], ["pro-fibrotic", "OBSERVATION", 420, 432]]], ["Therefore, a murine model of tracheal transplant rejection was used to determine the role of A 2B Rs in the development of bronchiolitis obliterans [117] .", [["tracheal", "ANATOMY", 29, 37], ["bronchiolitis obliterans", "DISEASE", 123, 147], ["murine", "ORGANISM", 13, 19], ["tracheal", "ORGAN", 29, 37], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 93, 100], ["A 2B Rs", "PROTEIN", 93, 100], ["murine", "SPECIES", 13, 19], ["tracheal transplant rejection", "TREATMENT", 29, 58], ["bronchiolitis obliterans", "PROBLEM", 123, 147], ["tracheal", "ANATOMY", 29, 37], ["transplant", "OBSERVATION", 38, 48], ["rejection", "OBSERVATION", 49, 58], ["bronchiolitis obliterans", "OBSERVATION", 123, 147]]], ["When the tracheas were transplanted into A 2B R \u00c0/\u00c0 mice, they exhibited less luminal obliteration and inflammatory cell infiltration (macrophages, neutrophils, CD3+ T cells) after 21 days, than in wild-type recipients.", [["tracheas", "ANATOMY", 9, 17], ["luminal", "ANATOMY", 78, 85], ["inflammatory cell", "ANATOMY", 103, 120], ["macrophages", "ANATOMY", 135, 146], ["neutrophils", "ANATOMY", 148, 159], ["CD3+ T cells", "ANATOMY", 161, 173], ["luminal", "CHEMICAL", 78, 85], ["tracheas", "ORGAN", 9, 17], ["R", "GENE_OR_GENE_PRODUCT", 46, 47], ["mice", "ORGANISM", 52, 56], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 85], ["inflammatory cell", "CELL", 103, 120], ["macrophages", "CELL", 135, 146], ["neutrophils", "CELL", 148, 159], ["CD3", "GENE_OR_GENE_PRODUCT", 161, 164], ["recipients", "ORGANISM", 208, 218], ["macrophages", "CELL_TYPE", 135, 146], ["neutrophils", "CELL_TYPE", 148, 159], ["CD3", "PROTEIN", 161, 164], ["T cells", "CELL_TYPE", 166, 173], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["A 2B R \u00c0/\u00c0 mice", "TREATMENT", 41, 56], ["less luminal obliteration", "PROBLEM", 73, 98], ["inflammatory cell infiltration", "PROBLEM", 103, 133], ["macrophages", "TEST", 135, 146], ["neutrophils", "TEST", 148, 159], ["CD3+ T cells", "PROBLEM", 161, 173], ["tracheas", "ANATOMY", 9, 17], ["less", "OBSERVATION_MODIFIER", 73, 77], ["luminal", "ANATOMY_MODIFIER", 78, 85], ["obliteration", "OBSERVATION", 86, 98], ["inflammatory cell infiltration", "OBSERVATION", 103, 133], ["macrophages", "ANATOMY", 135, 146]]], ["In contrast, the allografts of the A 2B R \u00c0/\u00c0 mice contained higher numbers of the immunosuppressive CD4/CD25/Foxp3 T regulatory (Treg) cells [117] .", [["allografts", "ANATOMY", 17, 27], ["CD4/CD25/Foxp3 T regulatory (Treg) cells", "ANATOMY", 101, 141], ["allografts", "TISSUE", 17, 27], ["A 2B", "ORGANISM", 35, 39], ["R", "GENE_OR_GENE_PRODUCT", 40, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 101, 104], ["CD25", "GENE_OR_GENE_PRODUCT", 105, 109], ["Foxp3", "GENE_OR_GENE_PRODUCT", 110, 115], ["immunosuppressive CD4/CD25/Foxp3 T regulatory (Treg) cells", "CELL_TYPE", 83, 141], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["the immunosuppressive CD4", "TEST", 79, 104], ["CD25", "TEST", 105, 109], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["numbers", "OBSERVATION_MODIFIER", 68, 75], ["immunosuppressive CD4", "OBSERVATION", 83, 104]]], ["Therefore, apart from the well-known pro-inflammatory and pro-fibrotic effects of A 2B R activation, this receptor may also stimulate the development of bronchiolitis obliterans by inhibiting the recruitment of the immunosuppressive Treg cells into the allograft.The A 3 R Models the InfiltratesAs with the other ADO receptors, A 3 Rs play complex roles in inflammation, with both pro-and anti-inflammatory functions being described in different models [118] .", [["Treg cells", "ANATOMY", 233, 243], ["allograft", "ANATOMY", 253, 262], ["bronchiolitis obliterans", "DISEASE", 153, 177], ["ADO", "CHEMICAL", 313, 316], ["inflammation", "DISEASE", 357, 369], ["A 2B R", "GENE_OR_GENE_PRODUCT", 82, 88], ["Treg cells", "CELL", 233, 243], ["allograft", "TISSUE", 253, 262], ["A 3 R", "GENE_OR_GENE_PRODUCT", 267, 272], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 313, 326], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 328, 334], ["Treg cells", "CELL_TYPE", 233, 243], ["ADO receptors", "PROTEIN", 313, 326], ["A 3 Rs", "PROTEIN", 328, 334], ["A 2B R activation", "TREATMENT", 82, 99], ["this receptor", "TREATMENT", 101, 114], ["bronchiolitis obliterans", "PROBLEM", 153, 177], ["the immunosuppressive", "TREATMENT", 211, 232], ["Treg cells into the allograft", "TREATMENT", 233, 262], ["the InfiltratesAs", "PROBLEM", 280, 297], ["the other ADO receptors", "PROBLEM", 303, 326], ["inflammation", "PROBLEM", 357, 369], ["both pro-and anti-inflammatory functions", "TREATMENT", 376, 416], ["pro-inflammatory", "OBSERVATION_MODIFIER", 37, 53], ["pro-fibrotic", "OBSERVATION", 58, 70], ["bronchiolitis obliterans", "OBSERVATION", 153, 177], ["immunosuppressive", "OBSERVATION_MODIFIER", 215, 232], ["allograft", "OBSERVATION", 253, 262], ["inflammation", "OBSERVATION", 357, 369]]], ["Pharmacological studies have demonstrated that treatment with A 3 R agonists is beneficial in the feline model of reperfusion injury [119] , as documented above for A 1 Rs [75] .", [["reperfusion injury", "DISEASE", 114, 132], ["A 3 R", "GENE_OR_GENE_PRODUCT", 62, 67], ["feline", "ORGANISM", 98, 104], ["Pharmacological studies", "TEST", 0, 23], ["A 3 R agonists", "TREATMENT", 62, 76], ["reperfusion injury", "PROBLEM", 114, 132]]], ["In spontaneously breathing cats subjected to ischemia-reperfusion in the left lower lobe, the perfusion of IB-MECA or MRS 3558 before ischemia reduced acute lung injury, which was quantified by the number of apoptotic cells, lung edema, and BAL fluid neutrophil myeloperoxidase assay.", [["left lower lobe", "ANATOMY", 73, 88], ["lung", "ANATOMY", 157, 161], ["cells", "ANATOMY", 218, 223], ["lung", "ANATOMY", 225, 229], ["BAL fluid", "ANATOMY", 241, 250], ["IB-MECA", "CHEMICAL", 107, 114], ["MRS 3558", "CHEMICAL", 118, 126], ["ischemia", "DISEASE", 134, 142], ["acute lung injury", "DISEASE", 151, 168], ["lung edema", "DISEASE", 225, 235], ["IB-MECA", "CHEMICAL", 107, 114], ["MRS 3558", "CHEMICAL", 118, 126], ["cats", "ORGANISM", 27, 31], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 78, 88], ["IB-MECA", "SIMPLE_CHEMICAL", 107, 114], ["lung", "ORGAN", 157, 161], ["cells", "CELL", 218, 223], ["lung", "ORGAN", 225, 229], ["neutrophil", "CELL", 251, 261], ["apoptotic cells", "CELL_TYPE", 208, 223], ["myeloperoxidase", "PROTEIN", 262, 277], ["ischemia-reperfusion in the left lower lobe", "PROBLEM", 45, 88], ["MRS", "TEST", 118, 121], ["ischemia", "PROBLEM", 134, 142], ["acute lung injury", "PROBLEM", 151, 168], ["apoptotic cells", "PROBLEM", 208, 223], ["lung edema", "PROBLEM", 225, 235], ["BAL fluid neutrophil myeloperoxidase assay", "TEST", 241, 283], ["breathing cats", "OBSERVATION", 17, 31], ["ischemia-reperfusion", "OBSERVATION", 45, 65], ["left lower lobe", "ANATOMY", 73, 88], ["perfusion", "OBSERVATION_MODIFIER", 94, 103], ["reduced", "OBSERVATION_MODIFIER", 143, 150], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["lung", "ANATOMY", 157, 161], ["injury", "OBSERVATION", 162, 168], ["apoptotic cells", "OBSERVATION", 208, 223], ["lung", "ANATOMY", 225, 229], ["edema", "OBSERVATION", 230, 235], ["BAL", "ANATOMY", 241, 244], ["fluid neutrophil myeloperoxidase", "OBSERVATION", 245, 277]]], ["Western blots conducted on tissue samples collected over 10 h indicated that A 3 R engagement activates the secondary messengers extracellular signal-regulated kinases 1 and 2 (ERK1/2), but not c-Jun amino-terminal protein kinase (JNK) and p38, which essentially shifts the signaling balance from cell death to cell survival.", [["tissue samples", "ANATOMY", 27, 41], ["cell", "ANATOMY", 297, 301], ["cell", "ANATOMY", 311, 315], ["death", "DISEASE", 302, 307], ["amino", "CHEMICAL", 200, 205], ["tissue samples", "CANCER", 27, 41], ["A 3 R", "GENE_OR_GENE_PRODUCT", 77, 82], ["extracellular signal-regulated kinases 1", "GENE_OR_GENE_PRODUCT", 129, 169], ["2", "GENE_OR_GENE_PRODUCT", 174, 175], ["ERK1", "GENE_OR_GENE_PRODUCT", 177, 181], ["2", "GENE_OR_GENE_PRODUCT", 182, 183], ["c-Jun amino-terminal protein kinase", "GENE_OR_GENE_PRODUCT", 194, 229], ["JNK", "GENE_OR_GENE_PRODUCT", 231, 234], ["p38", "GENE_OR_GENE_PRODUCT", 240, 243], ["cell", "CELL", 297, 301], ["cell", "CELL", 311, 315], ["extracellular signal-regulated kinases 1 and 2 (ERK1/2", "PROTEIN", 129, 183], ["Jun amino-terminal protein kinase", "PROTEIN", 196, 229], ["JNK", "PROTEIN", 231, 234], ["p38", "PROTEIN", 240, 243], ["tissue samples", "TEST", 27, 41], ["A 3 R engagement", "TREATMENT", 77, 93], ["extracellular signal", "TEST", 129, 149], ["kinases", "TEST", 160, 167], ["ERK1", "TEST", 177, 181], ["Jun amino", "TEST", 196, 205], ["p38", "TEST", 240, 243], ["cell death", "PROBLEM", 297, 307], ["cell survival", "TREATMENT", 311, 324], ["cell survival", "OBSERVATION", 311, 324]]], ["Therefore, A 3 R agonists offer a therapeutic benefit for the treatment of acute lung injury related to ischemia-reperfusion.The A 3 R Models the InfiltratesThe role of A 3 Rs in acute lung injury was also recently documented in a murine model of airway infection [120] .", [["lung", "ANATOMY", 81, 85], ["lung", "ANATOMY", 185, 189], ["airway", "ANATOMY", 247, 253], ["acute lung injury", "DISEASE", 75, 92], ["lung injury", "DISEASE", 185, 196], ["airway infection", "DISEASE", 247, 263], ["A 3 R", "GENE_OR_GENE_PRODUCT", 11, 16], ["lung", "ORGAN", 81, 85], ["A 3 R", "GENE_OR_GENE_PRODUCT", 129, 134], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 169, 175], ["lung", "ORGAN", 185, 189], ["murine", "ORGANISM", 231, 237], ["airway", "MULTI-TISSUE_STRUCTURE", 247, 253], ["murine", "SPECIES", 231, 237], ["A 3 R agonists", "TREATMENT", 11, 25], ["the treatment", "TREATMENT", 58, 71], ["acute lung injury", "PROBLEM", 75, 92], ["ischemia-reperfusion", "PROBLEM", 104, 124], ["the Infiltrates", "PROBLEM", 142, 157], ["acute lung injury", "PROBLEM", 179, 196], ["airway infection", "PROBLEM", 247, 263], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["lung", "ANATOMY", 81, 85], ["injury", "OBSERVATION", 86, 92], ["ischemia-reperfusion", "OBSERVATION", 104, 124], ["Infiltrates", "OBSERVATION", 146, 157], ["acute", "OBSERVATION_MODIFIER", 179, 184], ["lung", "ANATOMY", 185, 189], ["injury", "OBSERVATION", 190, 196], ["airway", "ANATOMY", 247, 253], ["infection", "OBSERVATION", 254, 263]]], ["In mice, LPS inhalation triggered general characteristics of acute lung injury, including neutrophil accumulation in all lung compartments, as well as an up-regulation of the A 3 R. Therefore, pharmacological experiments were initiated to determine the directionality of A 3 R-mediated responses, with respect to the neutrophilic inflammation.", [["lung", "ANATOMY", 67, 71], ["neutrophil", "ANATOMY", 90, 100], ["lung compartments", "ANATOMY", 121, 138], ["neutrophilic", "ANATOMY", 317, 329], ["LPS", "CHEMICAL", 9, 12], ["acute lung injury", "DISEASE", 61, 78], ["inflammation", "DISEASE", 330, 342], ["mice", "ORGANISM", 3, 7], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["lung", "ORGAN", 67, 71], ["neutrophil", "CELL", 90, 100], ["lung compartments", "MULTI-TISSUE_STRUCTURE", 121, 138], ["A 3 R", "GENE_OR_GENE_PRODUCT", 271, 276], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["LPS inhalation", "TEST", 9, 23], ["acute lung injury", "PROBLEM", 61, 78], ["neutrophil accumulation in all lung compartments", "PROBLEM", 90, 138], ["pharmacological experiments", "TEST", 193, 220], ["the neutrophilic inflammation", "PROBLEM", 313, 342], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["lung", "ANATOMY", 67, 71], ["injury", "OBSERVATION", 72, 78], ["neutrophil accumulation", "OBSERVATION", 90, 113], ["all", "ANATOMY_MODIFIER", 117, 120], ["lung", "ANATOMY", 121, 125], ["compartments", "ANATOMY_MODIFIER", 126, 138], ["neutrophilic", "OBSERVATION_MODIFIER", 317, 329], ["inflammation", "OBSERVATION", 330, 342]]], ["Mice pretreated by intralobar arterial infusion of the specific A 3 R agonist, Cl-IB-MECA, responded to aerosolized LPS by significantly lower neutrophil counts into the interstitium and alveolar airspace, but not the vasculature.", [["arterial", "ANATOMY", 30, 38], ["neutrophil", "ANATOMY", 143, 153], ["interstitium", "ANATOMY", 170, 182], ["alveolar airspace", "ANATOMY", 187, 204], ["vasculature", "ANATOMY", 218, 229], ["Cl-IB-MECA", "CHEMICAL", 79, 89], ["LPS", "CHEMICAL", 116, 119], ["Cl-IB-MECA", "CHEMICAL", 79, 89], ["Mice", "ORGANISM", 0, 4], ["arterial", "MULTI-TISSUE_STRUCTURE", 30, 38], ["A 3 R", "GENE_OR_GENE_PRODUCT", 64, 69], ["Cl-IB-MECA", "SIMPLE_CHEMICAL", 79, 89], ["LPS", "SIMPLE_CHEMICAL", 116, 119], ["neutrophil", "CELL", 143, 153], ["interstitium", "TISSUE", 170, 182], ["alveolar airspace", "MULTI-TISSUE_STRUCTURE", 187, 204], ["vasculature", "MULTI-TISSUE_STRUCTURE", 218, 229], ["Mice", "SPECIES", 0, 4], ["intralobar arterial infusion", "TREATMENT", 19, 47], ["Cl", "TEST", 79, 81], ["aerosolized LPS", "TREATMENT", 104, 119], ["significantly lower neutrophil counts into the interstitium and alveolar airspace", "PROBLEM", 123, 204], ["intralobar", "ANATOMY_MODIFIER", 19, 29], ["arterial", "ANATOMY", 30, 38], ["IB", "ANATOMY", 82, 84], ["MECA", "ANATOMY", 85, 89], ["significantly", "OBSERVATION_MODIFIER", 123, 136], ["lower", "OBSERVATION_MODIFIER", 137, 142], ["neutrophil counts", "OBSERVATION", 143, 160], ["interstitium", "ANATOMY_MODIFIER", 170, 182], ["alveolar", "ANATOMY_MODIFIER", 187, 195], ["airspace", "ANATOMY_MODIFIER", 196, 204], ["vasculature", "ANATOMY", 218, 229]]], ["Incidentally, measurement of Evans blue extravasation showed that Cl-IB-MECA inhibits the LPS-induced increases in endothelial barrier permeability.", [["endothelial barrier", "ANATOMY", 115, 134], ["Cl-IB-MECA", "CHEMICAL", 66, 76], ["LPS", "CHEMICAL", 90, 93], ["Cl-IB-MECA", "CHEMICAL", 66, 76], ["Evans blue", "SIMPLE_CHEMICAL", 29, 39], ["Cl-IB-MECA", "SIMPLE_CHEMICAL", 66, 76], ["LPS", "SIMPLE_CHEMICAL", 90, 93], ["endothelial barrier", "TISSUE", 115, 134], ["Evans blue extravasation", "TEST", 29, 53], ["Cl", "TEST", 66, 68], ["MECA", "PROBLEM", 72, 76], ["the LPS", "TREATMENT", 86, 93], ["endothelial barrier permeability", "TREATMENT", 115, 147], ["LPS", "OBSERVATION_MODIFIER", 90, 93], ["increases", "OBSERVATION_MODIFIER", 102, 111], ["endothelial", "ANATOMY", 115, 126], ["barrier permeability", "OBSERVATION", 127, 147]]], ["The mechanism was addressed in vitro using cultures of pulmonary microvascular endothelial cells.", [["pulmonary microvascular endothelial cells", "ANATOMY", 55, 96], ["pulmonary microvascular endothelial cells", "CELL", 55, 96], ["pulmonary microvascular endothelial cells", "CELL_TYPE", 55, 96], ["cultures", "TEST", 43, 51], ["pulmonary microvascular endothelial cells", "PROBLEM", 55, 96], ["pulmonary microvascular", "ANATOMY", 55, 78], ["endothelial cells", "OBSERVATION", 79, 96]]], ["The A 3 R agonist interfered with the LPS-induced cytoskeletal rearrangement and cell retraction known to initiate vascular leakage.", [["cytoskeletal", "ANATOMY", 50, 62], ["cell", "ANATOMY", 81, 85], ["vascular", "ANATOMY", 115, 123], ["LPS", "CHEMICAL", 38, 41], ["A 3 R", "GENE_OR_GENE_PRODUCT", 4, 9], ["LPS", "SIMPLE_CHEMICAL", 38, 41], ["cytoskeletal", "CELLULAR_COMPONENT", 50, 62], ["cell", "CELL", 81, 85], ["vascular", "MULTI-TISSUE_STRUCTURE", 115, 123], ["The A 3 R agonist", "TREATMENT", 0, 17], ["the LPS", "TREATMENT", 34, 41], ["cytoskeletal rearrangement", "PROBLEM", 50, 76], ["cell retraction", "PROBLEM", 81, 96], ["vascular leakage", "PROBLEM", 115, 131], ["cytoskeletal rearrangement", "OBSERVATION", 50, 76], ["cell retraction", "OBSERVATION", 81, 96], ["vascular", "ANATOMY", 115, 123], ["leakage", "OBSERVATION", 124, 131]]], ["On the other hand, experiments conducted with bone marrow chimeric mice revealed that Cl-IB-MECA requires A 3 Rs expressed, both, on hematopoietic cells and pulmonary cells to suppress the transmigration of neutrophils in vivo.", [["bone marrow", "ANATOMY", 46, 57], ["hematopoietic cells", "ANATOMY", 133, 152], ["pulmonary cells", "ANATOMY", 157, 172], ["neutrophils", "ANATOMY", 207, 218], ["Cl", "CHEMICAL", 86, 88], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 46, 57], ["mice", "ORGANISM", 67, 71], ["Cl-IB-MECA", "GENE_OR_GENE_PRODUCT", 86, 96], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 106, 112], ["hematopoietic cells", "CELL", 133, 152], ["pulmonary cells", "CELL", 157, 172], ["neutrophils", "CELL", 207, 218], ["IB", "PROTEIN", 89, 91], ["MECA", "PROTEIN", 92, 96], ["A 3 Rs", "PROTEIN", 106, 112], ["hematopoietic cells", "CELL_TYPE", 133, 152], ["pulmonary cells", "CELL_TYPE", 157, 172], ["neutrophils", "CELL_TYPE", 207, 218], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 67, 71], ["bone marrow chimeric mice", "TEST", 46, 71], ["Cl", "TEST", 86, 88], ["hematopoietic cells", "TREATMENT", 133, 152], ["pulmonary cells", "TREATMENT", 157, 172], ["neutrophils in vivo", "TREATMENT", 207, 226], ["hematopoietic cells", "OBSERVATION", 133, 152], ["pulmonary", "ANATOMY", 157, 166]]], ["Possible mechanisms include cell adhesion or the secretion of mediators (see Chap.", [["cell", "ANATOMY", 28, 32], ["cell", "CELL", 28, 32], ["Chap", "PROTEIN", 77, 81], ["cell adhesion", "PROBLEM", 28, 41], ["cell adhesion", "OBSERVATION", 28, 41]]], ["Regardless, this study proposes a new role for A 3 Rs in the recruitment of neutrophils to the airways.", [["neutrophils", "ANATOMY", 76, 87], ["airways", "ANATOMY", 95, 102], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 47, 53], ["neutrophils", "CELL", 76, 87], ["airways", "MULTI-TISSUE_STRUCTURE", 95, 102], ["neutrophils", "CELL_TYPE", 76, 87], ["this study", "TEST", 12, 22], ["A 3 Rs", "TREATMENT", 47, 53], ["airways", "ANATOMY", 95, 102]]], ["Whereas A 3 Rs expressed on neutrophils were shown to accelerate chemotaxis (review: [121] ), the present study demonstrates that A 3 Rs also restricts neutrophil infiltration into the lung tissue and airspace.", [["neutrophils", "ANATOMY", 28, 39], ["neutrophil", "ANATOMY", 152, 162], ["lung tissue", "ANATOMY", 185, 196], ["airspace", "ANATOMY", 201, 209], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 8, 14], ["neutrophils", "CELL", 28, 39], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 130, 136], ["neutrophil", "CELL", 152, 162], ["lung tissue", "TISSUE", 185, 196], ["airspace", "MULTI-TISSUE_STRUCTURE", 201, 209], ["A 3 Rs", "PROTEIN", 8, 14], ["neutrophils", "CELL_TYPE", 28, 39], ["neutrophils", "TEST", 28, 39], ["the present study", "TEST", 94, 111], ["neutrophil infiltration into the lung tissue", "PROBLEM", 152, 196], ["airspace", "PROBLEM", 201, 209], ["neutrophil infiltration", "OBSERVATION", 152, 175], ["lung", "ANATOMY", 185, 189], ["tissue", "ANATOMY_MODIFIER", 190, 196], ["airspace", "ANATOMY_MODIFIER", 201, 209]]], ["The administration of Cl-IB-MECA into the bloodstream may be useful to suppress the damaging neutrophilic inflammation associated with sepsis.The A 3 R Models the InfiltratesIntratracheal instillation of bleomycin ranks among the most popular models of acute lung injury.", [["bloodstream", "ANATOMY", 42, 53], ["neutrophilic", "ANATOMY", 93, 105], ["lung", "ANATOMY", 259, 263], ["Cl-IB-MECA", "CHEMICAL", 22, 32], ["inflammation", "DISEASE", 106, 118], ["sepsis", "DISEASE", 135, 141], ["bleomycin", "CHEMICAL", 204, 213], ["acute lung injury", "DISEASE", 253, 270], ["Cl-IB-MECA", "CHEMICAL", 22, 32], ["bleomycin", "CHEMICAL", 204, 213], ["Cl-IB-MECA", "SIMPLE_CHEMICAL", 22, 32], ["bloodstream", "ORGANISM_SUBSTANCE", 42, 53], ["bleomycin", "SIMPLE_CHEMICAL", 204, 213], ["lung", "ORGAN", 259, 263], ["Cl", "TEST", 22, 24], ["the damaging neutrophilic inflammation", "PROBLEM", 80, 118], ["sepsis", "PROBLEM", 135, 141], ["the InfiltratesIntratracheal instillation of bleomycin ranks", "TREATMENT", 159, 219], ["acute lung injury", "PROBLEM", 253, 270], ["neutrophilic", "OBSERVATION_MODIFIER", 93, 105], ["inflammation", "OBSERVATION", 106, 118], ["sepsis", "OBSERVATION", 135, 141], ["Infiltrates", "OBSERVATION", 163, 174], ["Intratracheal", "OBSERVATION_MODIFIER", 174, 187], ["instillation", "OBSERVATION_MODIFIER", 188, 200], ["bleomycin ranks", "OBSERVATION", 204, 219], ["most popular", "OBSERVATION_MODIFIER", 230, 242], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["lung", "ANATOMY", 259, 263], ["injury", "OBSERVATION", 264, 270]]], ["The mice transiently develop damage to the alveolar epithelial and endothelial barriers, extensive fibrosis, thrombus formation in the microvasculature and the accumulation of inflammatory cells in the interstitial space (review: [65] ).", [["alveolar epithelial", "ANATOMY", 43, 62], ["endothelial", "ANATOMY", 67, 78], ["thrombus", "ANATOMY", 109, 117], ["microvasculature", "ANATOMY", 135, 151], ["inflammatory cells", "ANATOMY", 176, 194], ["interstitial space", "ANATOMY", 202, 220], ["fibrosis", "DISEASE", 99, 107], ["thrombus", "DISEASE", 109, 117], ["mice", "ORGANISM", 4, 8], ["alveolar epithelial", "TISSUE", 43, 62], ["endothelial", "TISSUE", 67, 78], ["thrombus", "PATHOLOGICAL_FORMATION", 109, 117], ["microvasculature", "TISSUE", 135, 151], ["cells", "CELL", 189, 194], ["interstitial space", "MULTI-TISSUE_STRUCTURE", 202, 220], ["inflammatory cells", "CELL_TYPE", 176, 194], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["damage to the alveolar epithelial and endothelial barriers", "PROBLEM", 29, 87], ["extensive fibrosis", "PROBLEM", 89, 107], ["thrombus formation in the microvasculature", "PROBLEM", 109, 151], ["inflammatory cells in the interstitial space", "PROBLEM", 176, 220], ["damage", "OBSERVATION", 29, 35], ["alveolar", "ANATOMY_MODIFIER", 43, 51], ["epithelial", "ANATOMY_MODIFIER", 52, 62], ["endothelial", "ANATOMY", 67, 78], ["extensive", "OBSERVATION_MODIFIER", 89, 98], ["fibrosis", "OBSERVATION", 99, 107], ["thrombus", "OBSERVATION", 109, 117], ["microvasculature", "ANATOMY", 135, 151], ["accumulation", "OBSERVATION_MODIFIER", 160, 172], ["inflammatory cells", "OBSERVATION", 176, 194], ["interstitial", "ANATOMY_MODIFIER", 202, 214]]], ["Genetic deletion of the A 3 R yielded no significant phenotype, but the mice reacted more strongly to the bleomycin challenge [122] .", [["bleomycin", "CHEMICAL", 106, 115], ["bleomycin", "CHEMICAL", 106, 115], ["A 3 R", "GENE_OR_GENE_PRODUCT", 24, 29], ["mice", "ORGANISM", 72, 76], ["bleomycin", "SIMPLE_CHEMICAL", 106, 115], ["A 3 R", "DNA", 24, 29], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["Genetic deletion", "PROBLEM", 0, 16], ["significant phenotype", "PROBLEM", 41, 62], ["the bleomycin challenge", "TREATMENT", 102, 125], ["no", "UNCERTAINTY", 38, 40], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["phenotype", "OBSERVATION", 53, 62]]], ["After 14 days, the lungs of A 3 R \u00c0/\u00c0 mice accumulated three times more inflammatory cells than the wild-type mice, including eosinophils.", [["lungs", "ANATOMY", 19, 24], ["inflammatory cells", "ANATOMY", 72, 90], ["eosinophils", "ANATOMY", 126, 137], ["lungs", "ORGAN", 19, 24], ["R", "GENE_OR_GENE_PRODUCT", 32, 33], ["mice", "ORGANISM", 38, 42], ["cells", "CELL", 85, 90], ["mice", "ORGANISM", 110, 114], ["eosinophils", "CELL", 126, 137], ["inflammatory cells", "CELL_TYPE", 72, 90], ["eosinophils", "CELL_TYPE", 126, 137], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 110, 114], ["inflammatory cells", "PROBLEM", 72, 90], ["eosinophils", "TEST", 126, 137], ["lungs", "ANATOMY", 19, 24], ["inflammatory cells", "OBSERVATION", 72, 90]]], ["Interestingly, whereas bleomycin caused an increase in eosinophil peroxidase activity in the BAL fluid of wildtype and A 3 R \u00c0/\u00c0 mice, the secreted enzyme activity was only higher in the wild-type mice.", [["eosinophil", "ANATOMY", 55, 65], ["BAL fluid", "ANATOMY", 93, 102], ["bleomycin", "CHEMICAL", 23, 32], ["bleomycin", "CHEMICAL", 23, 32], ["bleomycin", "SIMPLE_CHEMICAL", 23, 32], ["eosinophil", "CELL", 55, 65], ["peroxidase", "GENE_OR_GENE_PRODUCT", 66, 76], ["BAL fluid", "ORGANISM_SUBSTANCE", 93, 102], ["A 3 R \u00c0/\u00c0 mice", "ORGANISM", 119, 133], ["mice", "ORGANISM", 197, 201], ["eosinophil peroxidase", "PROTEIN", 55, 76], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 197, 201], ["A 3 R \u00c0/\u00c0 mice", "SPECIES", 119, 133], ["bleomycin", "TREATMENT", 23, 32], ["an increase in eosinophil peroxidase activity", "PROBLEM", 40, 85], ["the secreted enzyme activity", "TEST", 135, 163], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["eosinophil peroxidase activity", "OBSERVATION", 55, 85], ["BAL fluid", "OBSERVATION", 93, 102], ["higher", "OBSERVATION_MODIFIER", 173, 179]]], ["These data show that eosinophils require the A 3 R for degranulation.", [["eosinophils", "ANATOMY", 21, 32], ["eosinophils", "CELL", 21, 32], ["A 3 R", "GENE_OR_GENE_PRODUCT", 45, 50], ["eosinophils", "CELL_TYPE", 21, 32], ["These data", "TEST", 0, 10], ["eosinophils", "PROBLEM", 21, 32], ["degranulation", "PROBLEM", 55, 68], ["eosinophils", "OBSERVATION", 21, 32]]], ["On the other hand, the loss of this receptor did not influence the formation of pulmonary fibrosis in response to bleomycin, as shown by measurement of collagen and a1procollagen in lung tissue.", [["pulmonary", "ANATOMY", 80, 89], ["lung tissue", "ANATOMY", 182, 193], ["fibrosis", "DISEASE", 90, 98], ["bleomycin", "CHEMICAL", 114, 123], ["bleomycin", "CHEMICAL", 114, 123], ["pulmonary", "ORGAN", 80, 89], ["bleomycin", "SIMPLE_CHEMICAL", 114, 123], ["collagen", "GENE_OR_GENE_PRODUCT", 152, 160], ["a1procollagen", "GENE_OR_GENE_PRODUCT", 165, 178], ["lung tissue", "TISSUE", 182, 193], ["collagen", "PROTEIN", 152, 160], ["a1procollagen", "PROTEIN", 165, 178], ["pulmonary fibrosis", "PROBLEM", 80, 98], ["bleomycin", "TREATMENT", 114, 123], ["collagen and a1procollagen in lung tissue", "TREATMENT", 152, 193], ["pulmonary", "ANATOMY", 80, 89], ["fibrosis", "OBSERVATION", 90, 98], ["lung", "ANATOMY", 182, 186], ["tissue", "ANATOMY_MODIFIER", 187, 193]]], ["Altogether, these data suggest that A 3 Rs generally serve anti-inflammatory functions in the bleomycin model of acute lung injury, without affecting pulmonary fibrosis.", [["lung", "ANATOMY", 119, 123], ["pulmonary", "ANATOMY", 150, 159], ["bleomycin", "CHEMICAL", 94, 103], ["acute lung injury", "DISEASE", 113, 130], ["fibrosis", "DISEASE", 160, 168], ["bleomycin", "CHEMICAL", 94, 103], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 36, 42], ["bleomycin", "SIMPLE_CHEMICAL", 94, 103], ["lung", "ORGAN", 119, 123], ["pulmonary", "ORGAN", 150, 159], ["anti-inflammatory functions", "TREATMENT", 59, 86], ["acute lung injury", "PROBLEM", 113, 130], ["pulmonary fibrosis", "PROBLEM", 150, 168], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["lung", "ANATOMY", 119, 123], ["injury", "OBSERVATION", 124, 130], ["without", "UNCERTAINTY", 132, 139], ["pulmonary", "ANATOMY", 150, 159], ["fibrosis", "OBSERVATION", 160, 168]]], ["On the other hand, lung complications associated with a predominant eosinophilic inflammation would ascribe a pro-inflammatory role to this receptor, such as asthma.", [["lung", "ANATOMY", 19, 23], ["eosinophilic", "ANATOMY", 68, 80], ["lung complications", "DISEASE", 19, 37], ["inflammation", "DISEASE", 81, 93], ["asthma", "DISEASE", 158, 164], ["lung", "ORGAN", 19, 23], ["lung complications", "PROBLEM", 19, 37], ["a predominant eosinophilic inflammation", "PROBLEM", 54, 93], ["this receptor", "TREATMENT", 135, 148], ["asthma", "PROBLEM", 158, 164], ["lung", "ANATOMY", 19, 23], ["complications", "OBSERVATION", 24, 37], ["predominant", "OBSERVATION_MODIFIER", 56, 67], ["eosinophilic", "OBSERVATION_MODIFIER", 68, 80], ["inflammation", "OBSERVATION", 81, 93], ["asthma", "OBSERVATION", 158, 164]]], ["This study highlights the disease-specificity of purinergic regulation which arises from the cell type specificity of receptor expression.The A 3 R Models the InfiltratesChronic lung diseases are generally associated with an up-regulation of the A 3 R, reported in the lung biopsies of asthmatic and COPD patients [123] .", [["cell", "ANATOMY", 93, 97], ["lung", "ANATOMY", 178, 182], ["lung biopsies", "ANATOMY", 269, 282], ["Chronic lung diseases", "DISEASE", 170, 191], ["asthmatic", "DISEASE", 286, 295], ["COPD", "DISEASE", 300, 304], ["cell", "CELL", 93, 97], ["A 3 R", "GENE_OR_GENE_PRODUCT", 142, 147], ["lung", "ORGAN", 178, 182], ["A 3 R", "GENE_OR_GENE_PRODUCT", 246, 251], ["lung biopsies", "MULTI-TISSUE_STRUCTURE", 269, 282], ["patients", "ORGANISM", 305, 313], ["A 3 R", "PROTEIN", 246, 251], ["patients", "SPECIES", 305, 313], ["This study", "TEST", 0, 10], ["the disease", "PROBLEM", 22, 33], ["purinergic regulation", "PROBLEM", 49, 70], ["the InfiltratesChronic lung diseases", "PROBLEM", 155, 191], ["the lung biopsies", "TEST", 265, 282], ["asthmatic and COPD patients", "PROBLEM", 286, 313], ["disease", "OBSERVATION", 26, 33], ["receptor expression", "OBSERVATION", 118, 137], ["Infiltrates", "OBSERVATION", 159, 170], ["Chronic", "OBSERVATION_MODIFIER", 170, 177], ["lung", "ANATOMY", 178, 182], ["diseases", "OBSERVATION", 183, 191], ["up-regulation", "OBSERVATION", 225, 238], ["lung", "ANATOMY", 269, 273], ["biopsies", "OBSERVATION", 274, 282], ["asthmatic", "OBSERVATION", 286, 295], ["COPD", "OBSERVATION", 300, 304]]], ["The importance of this disturbance in purinergic regulation is highlighted by three murine models of Th2-mediated airway inflammation and remodeling, which are also associated with enhanced A 3 R expression [67, 79, 124] .", [["airway", "ANATOMY", 114, 120], ["airway inflammation", "DISEASE", 114, 133], ["murine", "ORGANISM", 84, 90], ["Th2", "GENE_OR_GENE_PRODUCT", 101, 104], ["airway", "MULTI-TISSUE_STRUCTURE", 114, 120], ["A 3 R", "GENE_OR_GENE_PRODUCT", 190, 195], ["murine", "SPECIES", 84, 90], ["this disturbance in purinergic regulation", "PROBLEM", 18, 59], ["Th2-mediated airway inflammation", "PROBLEM", 101, 133], ["airway", "ANATOMY", 114, 120], ["inflammation", "OBSERVATION", 121, 133], ["remodeling", "OBSERVATION_MODIFIER", 138, 148]]], ["This receptor affects several aspects of the lung disease.", [["lung", "ANATOMY", 45, 49], ["lung disease", "DISEASE", 45, 57], ["lung", "ORGAN", 45, 49], ["the lung disease", "PROBLEM", 41, 57], ["several", "OBSERVATION_MODIFIER", 22, 29], ["lung", "ANATOMY", 45, 49], ["disease", "OBSERVATION", 50, 57]]], ["First, human and murine eosinophils abundantly express A 3 Rs, to inhibit chemokine-induced migration [123] [124] [125] , whereas it accelerates neutrophil chemotaxis [121] .", [["eosinophils", "ANATOMY", 24, 35], ["neutrophil", "ANATOMY", 145, 155], ["human", "ORGANISM", 7, 12], ["murine", "ORGANISM", 17, 23], ["eosinophils", "CELL", 24, 35], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 55, 61], ["neutrophil", "CELL", 145, 155], ["human and murine eosinophils", "CELL_TYPE", 7, 35], ["A 3 Rs", "PROTEIN", 55, 61], ["chemokine", "PROTEIN", 74, 83], ["human", "SPECIES", 7, 12], ["murine", "SPECIES", 17, 23], ["human", "SPECIES", 7, 12], ["neutrophil chemotaxis", "TEST", 145, 166]]], ["The airway epithelial cells of wild-type mice do not normally express A 3 Rs.", [["airway epithelial cells", "ANATOMY", 4, 27], ["airway epithelial cells", "CELL", 4, 27], ["mice", "ORGANISM", 41, 45], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 70, 76], ["airway epithelial cells", "CELL_TYPE", 4, 27], ["A 3 Rs", "PROTEIN", 70, 76], ["mice", "SPECIES", 41, 45], ["mice", "SPECIES", 41, 45], ["airway", "ANATOMY", 4, 10], ["epithelial cells", "OBSERVATION", 11, 27]]], ["However, the receptor appears selectively on the hyperplastic mucin-secreting cells of the OVA sensitized/challenge mice, IL-13 transgenic mice and ADA-deficient mice [67, 79, 124] .", [["hyperplastic mucin", "ANATOMY", 49, 67], ["cells", "ANATOMY", 78, 83], ["mucin", "GENE_OR_GENE_PRODUCT", 62, 67], ["cells", "CELL", 78, 83], ["OVA", "ORGANISM", 91, 94], ["mice", "ORGANISM", 116, 120], ["IL-13", "GENE_OR_GENE_PRODUCT", 122, 127], ["mice", "ORGANISM", 139, 143], ["ADA", "GENE_OR_GENE_PRODUCT", 148, 151], ["mice", "ORGANISM", 162, 166], ["hyperplastic mucin-secreting cells", "CELL_TYPE", 49, 83], ["ADA", "PROTEIN", 148, 151], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 162, 166], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 162, 166], ["the OVA sensitized", "TREATMENT", 87, 105], ["IL", "TEST", 122, 124], ["hyperplastic", "OBSERVATION_MODIFIER", 49, 61], ["secreting cells", "OBSERVATION", 68, 83]]], ["Young et al. determined that the receptor does not regulate the mRNA expression or packaging of mucins into granules, as wild-type and A 3 R \u00c0/\u00c0 mice exhibit similar storage sizes following OVA sensitization/challenge [67] .", [["granules", "ANATOMY", 108, 116], ["mucins", "GENE_OR_GENE_PRODUCT", 96, 102], ["granules", "ORGANISM_SUBSTANCE", 108, 116], ["A 3 R \u00c0/\u00c0 mice", "ORGANISM", 135, 149], ["mice", "SPECIES", 145, 149], ["mice", "SPECIES", 145, 149], ["mucins into granules", "PROBLEM", 96, 116], ["OVA sensitization", "TREATMENT", 190, 207], ["sizes", "OBSERVATION_MODIFIER", 174, 179]]], ["In contrast, the selective A 3 R agonist, IB-MECA, stimulated mucin secretion in the OVA challenged, but not the untreated, animals.", [["IB-MECA", "CHEMICAL", 42, 49], ["IB-MECA", "CHEMICAL", 42, 49], ["A 3 R", "GENE_OR_GENE_PRODUCT", 27, 32], ["IB-MECA", "SIMPLE_CHEMICAL", 42, 49], ["mucin", "GENE_OR_GENE_PRODUCT", 62, 67]]], ["This study supports a role for A 3 R induction in the mucin hypersecretion and airway obstruction reported in many chronic airway diseases, including asthma, COPD and CF (review: [126] ).", [["airway", "ANATOMY", 79, 85], ["airway", "ANATOMY", 123, 129], ["airway obstruction", "DISEASE", 79, 97], ["chronic airway diseases", "DISEASE", 115, 138], ["asthma", "DISEASE", 150, 156], ["COPD", "DISEASE", 158, 162], ["CF", "DISEASE", 167, 169], ["A 3 R", "GENE_OR_GENE_PRODUCT", 31, 36], ["mucin", "GENE_OR_GENE_PRODUCT", 54, 59], ["airway obstruction", "PATHOLOGICAL_FORMATION", 79, 97], ["airway", "MULTI-TISSUE_STRUCTURE", 123, 129], ["This study", "TEST", 0, 10], ["A 3 R induction", "TREATMENT", 31, 46], ["the mucin hypersecretion", "PROBLEM", 50, 74], ["airway obstruction", "PROBLEM", 79, 97], ["many chronic airway diseases", "PROBLEM", 110, 138], ["asthma", "PROBLEM", 150, 156], ["COPD", "PROBLEM", 158, 162], ["hypersecretion", "OBSERVATION", 60, 74], ["airway", "ANATOMY", 79, 85], ["obstruction", "OBSERVATION", 86, 97], ["many", "OBSERVATION_MODIFIER", 110, 114], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["airway", "ANATOMY", 123, 129], ["diseases", "OBSERVATION", 130, 138], ["asthma", "OBSERVATION", 150, 156], ["COPD", "OBSERVATION", 158, 162]]], ["On the other hand, the induction of A 3 R expression during mucus cell metaplasia and hyperplasia remains to be confirmed in human airways, where mucin secretion is normally mediated by ATP (P2Y 2 ) receptors (reviews: [98, 127] ) (see Chap.", [["mucus cell metaplasia", "ANATOMY", 60, 81], ["airways", "ANATOMY", 131, 138], ["hyperplasia", "DISEASE", 86, 97], ["ATP", "CHEMICAL", 186, 189], ["ATP", "CHEMICAL", 186, 189], ["A 3 R", "GENE_OR_GENE_PRODUCT", 36, 41], ["mucus cell", "CELL", 60, 70], ["human", "ORGANISM", 125, 130], ["airways", "MULTI-TISSUE_STRUCTURE", 131, 138], ["mucin", "GENE_OR_GENE_PRODUCT", 146, 151], ["ATP", "SIMPLE_CHEMICAL", 186, 189], ["P2Y 2 ) receptors", "GENE_OR_GENE_PRODUCT", 191, 208], ["A 3 R", "PROTEIN", 36, 41], ["ATP (P2Y 2 ) receptors", "PROTEIN", 186, 208], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["A 3 R expression", "TREATMENT", 36, 52], ["mucus cell metaplasia", "PROBLEM", 60, 81], ["hyperplasia", "PROBLEM", 86, 97], ["mucin secretion", "PROBLEM", 146, 161], ["mucus cell metaplasia", "OBSERVATION", 60, 81], ["hyperplasia", "OBSERVATION", 86, 97], ["airways", "ANATOMY", 131, 138]]], ["5 for details).General Patterns in Acute and Chronic DisordersThis area of purinergic research is evolving so rapidly that the notions formulated when this book was initially designed had to be revised along the way.", [["Chronic Disorders", "DISEASE", 45, 62], ["Acute and Chronic Disorders", "PROBLEM", 35, 62], ["Acute", "OBSERVATION_MODIFIER", 35, 40], ["Chronic", "OBSERVATION_MODIFIER", 45, 52], ["Disorders", "OBSERVATION", 53, 62], ["purinergic research", "OBSERVATION", 75, 94]]], ["Thankfully, we can finally discern general patterns of behavior for each ADO receptor in murine models of acute and chronic lung complications.", [["lung", "ANATOMY", 124, 128], ["ADO", "CHEMICAL", 73, 76], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 73, 85], ["murine", "ORGANISM", 89, 95], ["lung", "ORGAN", 124, 128], ["ADO receptor", "PROTEIN", 73, 85], ["murine", "SPECIES", 89, 95], ["acute and chronic lung complications", "PROBLEM", 106, 142], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["chronic", "OBSERVATION_MODIFIER", 116, 123], ["lung", "ANATOMY", 124, 128], ["complications", "OBSERVATION", 129, 142]]], ["First, the literature shows that acute and chronic disorders up-regulate all ADO receptors, except for a downregulation of the A 2A R in chronic lung diseases.", [["lung", "ANATOMY", 145, 149], ["ADO", "CHEMICAL", 77, 80], ["chronic lung diseases", "DISEASE", 137, 158], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 77, 90], ["A 2A R", "GENE_OR_GENE_PRODUCT", 127, 133], ["lung", "ORGAN", 145, 149], ["ADO receptors", "PROTEIN", 77, 90], ["A 2A R", "PROTEIN", 127, 133], ["acute and chronic disorders", "PROBLEM", 33, 60], ["all ADO receptors", "TREATMENT", 73, 90], ["chronic lung diseases", "PROBLEM", 137, 158], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["disorders", "OBSERVATION", 51, 60], ["chronic", "OBSERVATION_MODIFIER", 137, 144], ["lung", "ANATOMY", 145, 149], ["diseases", "OBSERVATION", 150, 158]]], ["Such general mobilization of the purinergic network is a testimony to the critical role of ADO in airway defenses against insults and intruders.", [["airway", "ANATOMY", 98, 104], ["ADO", "CHEMICAL", 91, 94], ["purinergic network", "MULTI-TISSUE_STRUCTURE", 33, 51], ["ADO", "SIMPLE_CHEMICAL", 91, 94], ["airway", "MULTI-TISSUE_STRUCTURE", 98, 104], ["insults", "PROBLEM", 122, 129], ["intruders", "PROBLEM", 134, 143], ["airway", "ANATOMY", 98, 104]]], ["Second, knockout mice do not present any intrinsic phenotype, but respond dramatically to insults or exposures, supporting the primary role of this network in alarm situations.", [["mice", "ORGANISM", 17, 21], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21]]], ["This inductive behavior would prioritize the receptors responding to abnormally high ADO concentrations generated in circulation and airway secretions by ATP release and metabolism: A 2A Rs and A 2B Rs (see Chap.", [["airway", "ANATOMY", 133, 139], ["ADO", "CHEMICAL", 85, 88], ["ATP", "CHEMICAL", 154, 157], ["ADO", "CHEMICAL", 85, 88], ["ATP", "CHEMICAL", 154, 157], ["ADO", "SIMPLE_CHEMICAL", 85, 88], ["airway secretions", "ORGANISM_SUBSTANCE", 133, 150], ["ATP", "SIMPLE_CHEMICAL", 154, 157], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 194, 201], ["Chap", "PROTEIN", 207, 211], ["This inductive behavior", "PROBLEM", 0, 23], ["abnormally high ADO concentrations", "PROBLEM", 69, 103], ["airway secretions", "PROBLEM", 133, 150], ["ATP release", "TEST", 154, 165], ["airway", "ANATOMY", 133, 139], ["secretions", "OBSERVATION", 140, 150]]], ["7, Table 7 .1).General Patterns in Acute and Chronic DisordersA summary of the effects of agonists/antagonists in the murine studies identify aspects of acute and chronic lung complications regulated by each ADO receptor ( Fig. 8.2) .", [["lung", "ANATOMY", 171, 175], ["ADO", "CHEMICAL", 208, 211], ["ADO", "CHEMICAL", 208, 211], ["murine", "ORGANISM", 118, 124], ["lung", "ORGAN", 171, 175], ["ADO receptor", "GENE_OR_GENE_PRODUCT", 208, 220], ["ADO receptor", "PROTEIN", 208, 220], ["murine", "SPECIES", 118, 124], ["Acute and Chronic DisordersA", "PROBLEM", 35, 63], ["agonists/antagonists", "TREATMENT", 90, 110], ["the murine studies", "TEST", 114, 132], ["acute and chronic lung complications", "PROBLEM", 153, 189], ["Acute", "OBSERVATION_MODIFIER", 35, 40], ["Chronic", "OBSERVATION_MODIFIER", 45, 52], ["DisordersA", "OBSERVATION", 53, 63], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["chronic", "OBSERVATION_MODIFIER", 163, 170], ["lung", "ANATOMY", 171, 175], ["complications", "OBSERVATION", 176, 189]]], ["Regardless of the exposure protocol, the engagement of all receptors initiated anti-inflammatory and protective responses against acute lung injury.", [["lung", "ANATOMY", 136, 140], ["acute lung injury", "DISEASE", 130, 147], ["lung", "ORGAN", 136, 140], ["the exposure protocol", "TREATMENT", 14, 35], ["all receptors", "TREATMENT", 55, 68], ["anti-inflammatory and protective responses", "TREATMENT", 79, 121], ["acute lung injury", "PROBLEM", 130, 147], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["lung", "ANATOMY", 136, 140], ["injury", "OBSERVATION", 141, 147]]], ["This came as a surprise, considering their widespread biphasic effects on immune and inflammatory cells (see Chap.", [["inflammatory cells", "ANATOMY", 85, 103], ["immune", "CELL", 74, 80], ["inflammatory cells", "CELL", 85, 103], ["immune and inflammatory cells", "CELL_TYPE", 74, 103], ["Chap", "PROTEIN", 109, 113], ["their widespread biphasic effects on immune and inflammatory cells", "PROBLEM", 37, 103], ["widespread", "OBSERVATION_MODIFIER", 43, 53], ["biphasic effects", "OBSERVATION", 54, 70], ["inflammatory cells", "OBSERVATION", 85, 103]]], ["Then again, the initial inflammatory response to an insult is the recruitment of hematopoietic cells to the lung tissue.", [["hematopoietic cells", "ANATOMY", 81, 100], ["lung tissue", "ANATOMY", 108, 119], ["hematopoietic cells", "CELL", 81, 100], ["lung tissue", "TISSUE", 108, 119], ["hematopoietic cells", "CELL_TYPE", 81, 100], ["the initial inflammatory response", "PROBLEM", 12, 45], ["an insult", "PROBLEM", 49, 58], ["hematopoietic cells", "PROBLEM", 81, 100], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["insult", "OBSERVATION", 52, 58], ["hematopoietic cells", "OBSERVATION", 81, 100], ["lung", "ANATOMY", 108, 112], ["tissue", "ANATOMY_MODIFIER", 113, 119]]], ["Since they must all cross the endothelial barrier, this site constitutes a bottle neck for airway defenses to efficiently regulate the extent of airway inflammatory responses.", [["endothelial barrier", "ANATOMY", 30, 49], ["site", "ANATOMY", 56, 60], ["bottle neck", "ANATOMY", 75, 86], ["airway", "ANATOMY", 91, 97], ["airway", "ANATOMY", 145, 151], ["endothelial barrier", "TISSUE", 30, 49], ["airway", "MULTI-TISSUE_STRUCTURE", 91, 97], ["airway", "MULTI-TISSUE_STRUCTURE", 145, 151], ["the endothelial barrier", "TREATMENT", 26, 49], ["airway defenses", "PROBLEM", 91, 106], ["airway", "ANATOMY", 91, 97], ["airway", "ANATOMY", 145, 151], ["inflammatory", "OBSERVATION", 152, 164]]], ["The fact that all ADO receptors participate in the maintenance of barrier integrity identifies the endothelium as primary site for therapeutic applications regarding hypoxia, acute lung injury and sepsis.", [["barrier", "ANATOMY", 66, 73], ["endothelium", "ANATOMY", 99, 110], ["primary site", "ANATOMY", 114, 126], ["lung", "ANATOMY", 181, 185], ["ADO", "CHEMICAL", 18, 21], ["hypoxia", "DISEASE", 166, 173], ["acute lung injury", "DISEASE", 175, 192], ["sepsis", "DISEASE", 197, 203], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 18, 31], ["barrier", "TISSUE", 66, 73], ["endothelium", "TISSUE", 99, 110], ["lung", "ORGAN", 181, 185], ["ADO receptors", "PROTEIN", 18, 31], ["all ADO receptors", "TREATMENT", 14, 31], ["barrier integrity", "TREATMENT", 66, 83], ["therapeutic applications", "TREATMENT", 131, 155], ["hypoxia", "PROBLEM", 166, 173], ["acute lung injury", "PROBLEM", 175, 192], ["sepsis", "PROBLEM", 197, 203], ["endothelium", "ANATOMY", 99, 110], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["lung", "ANATOMY", 181, 185], ["injury", "OBSERVATION", 186, 192], ["sepsis", "OBSERVATION", 197, 203]]], ["The A 2A R agonists represent the safest choice because the receptor only supports protective or anti-inflammatory responses.General Patterns in Acute and Chronic DisordersThe ADA-deficient mouse model conceptualizes the consequences of maintaining lung ADO concentrations elevated in chronic respiratory diseases, including asthma, CF and COPD.", [["lung", "ANATOMY", 249, 253], ["respiratory", "ANATOMY", 293, 304], ["Chronic Disorders", "DISEASE", 155, 172], ["ADO", "CHEMICAL", 254, 257], ["chronic respiratory diseases", "DISEASE", 285, 313], ["asthma", "DISEASE", 325, 331], ["CF", "DISEASE", 333, 335], ["COPD", "DISEASE", 340, 344], ["ADO", "CHEMICAL", 254, 257], ["A 2A R", "GENE_OR_GENE_PRODUCT", 4, 10], ["ADA", "GENE_OR_GENE_PRODUCT", 176, 179], ["mouse", "ORGANISM", 190, 195], ["lung", "ORGAN", 249, 253], ["ADO", "SIMPLE_CHEMICAL", 254, 257], ["ADA", "PROTEIN", 176, 179], ["mouse", "SPECIES", 190, 195], ["mouse", "SPECIES", 190, 195], ["A 2A R agonists", "TREATMENT", 4, 19], ["Acute and Chronic Disorders", "PROBLEM", 145, 172], ["The ADA", "TEST", 172, 179], ["lung ADO concentrations", "PROBLEM", 249, 272], ["chronic respiratory diseases", "PROBLEM", 285, 313], ["asthma", "PROBLEM", 325, 331], ["CF", "PROBLEM", 333, 335], ["COPD", "PROBLEM", 340, 344], ["Acute", "OBSERVATION_MODIFIER", 145, 150], ["Chronic", "OBSERVATION_MODIFIER", 155, 162], ["Disorders", "OBSERVATION", 163, 172], ["deficient mouse model", "OBSERVATION", 180, 201], ["lung", "ANATOMY", 249, 253], ["ADO concentrations", "OBSERVATION", 254, 272], ["elevated", "OBSERVATION_MODIFIER", 273, 281], ["chronic", "OBSERVATION_MODIFIER", 285, 292], ["respiratory diseases", "OBSERVATION", 293, 313], ["asthma", "OBSERVATION", 325, 331], ["COPD", "OBSERVATION", 340, 344]]], ["The severity of the purine-related complications results from the combined effects of A 2A R down-regulation and A 2B R up-regulation, which dramatically shifts the balance in favor of pro-inflammatory and remodeling responses to ADO concentrations capable of significantly activating low-affinity receptors.", [["purine", "CHEMICAL", 20, 26], ["ADO", "CHEMICAL", 230, 233], ["purine", "CHEMICAL", 20, 26], ["ADO", "CHEMICAL", 230, 233], ["purine", "SIMPLE_CHEMICAL", 20, 26], ["A 2A R", "GENE_OR_GENE_PRODUCT", 86, 92], ["A 2B R", "GENE_OR_GENE_PRODUCT", 113, 119], ["ADO", "SIMPLE_CHEMICAL", 230, 233], ["low-affinity receptors", "PROTEIN", 285, 307], ["the purine-related complications", "PROBLEM", 16, 48], ["A 2A R down-regulation", "TREATMENT", 86, 108], ["ADO concentrations", "TREATMENT", 230, 248], ["pro-inflammatory", "OBSERVATION_MODIFIER", 185, 201]]], ["The murine models of chronic lung diseases revealed that ADO receptors inhibiting cAMP production (A 1 Rs and A 3 Rs) promote mucin hypersecretion and bronchoconstriction.", [["lung", "ANATOMY", 29, 33], ["chronic lung diseases", "DISEASE", 21, 42], ["ADO", "CHEMICAL", 57, 60], ["cAMP", "CHEMICAL", 82, 86], ["ADO", "CHEMICAL", 57, 60], ["cAMP", "CHEMICAL", 82, 86], ["murine", "ORGANISM", 4, 10], ["lung", "ORGAN", 29, 33], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 57, 70], ["cAMP", "SIMPLE_CHEMICAL", 82, 86], ["A 1 Rs", "GENE_OR_GENE_PRODUCT", 99, 105], ["A 3 Rs", "GENE_OR_GENE_PRODUCT", 110, 116], ["mucin", "GENE_OR_GENE_PRODUCT", 126, 131], ["ADO receptors", "PROTEIN", 57, 70], ["murine", "SPECIES", 4, 10], ["chronic lung diseases", "PROBLEM", 21, 42], ["ADO receptors", "PROBLEM", 57, 70], ["cAMP production", "PROBLEM", 82, 97], ["mucin hypersecretion", "PROBLEM", 126, 146], ["bronchoconstriction", "PROBLEM", 151, 170], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["lung", "ANATOMY", 29, 33], ["diseases", "OBSERVATION", 34, 42], ["mucin hypersecretion", "OBSERVATION", 126, 146], ["bronchoconstriction", "OBSERVATION", 151, 170]]], ["On the other hand, A 2B R activation stimulates most aspects of the inflammatory responses, remodeling and fibrosis.", [["fibrosis", "DISEASE", 107, 115], ["A 2B R", "GENE_OR_GENE_PRODUCT", 19, 25], ["A 2B R activation", "TREATMENT", 19, 36], ["the inflammatory responses", "PROBLEM", 64, 90], ["fibrosis", "PROBLEM", 107, 115], ["inflammatory", "OBSERVATION", 68, 80], ["fibrosis", "OBSERVATION", 107, 115]]], ["The ideal aerosolized therapy would combine A 1 R and A 2B R antagonists to address all aspects of inflammatory diseases associated with airway hyperresponsiveness.", [["airway", "ANATOMY", 137, 143], ["inflammatory diseases", "DISEASE", 99, 120], ["airway hyperresponsiveness", "DISEASE", 137, 163], ["A 1 R", "GENE_OR_GENE_PRODUCT", 44, 49], ["A 2B R antagonists", "GENE_OR_GENE_PRODUCT", 54, 72], ["airway", "MULTI-TISSUE_STRUCTURE", 137, 143], ["The ideal aerosolized therapy", "TREATMENT", 0, 29], ["A 2B R antagonists", "TREATMENT", 54, 72], ["inflammatory diseases", "PROBLEM", 99, 120], ["airway hyperresponsiveness", "PROBLEM", 137, 163], ["aerosolized therapy", "OBSERVATION", 10, 29], ["inflammatory", "OBSERVATION", 99, 111], ["airway", "ANATOMY", 137, 143], ["hyperresponsiveness", "OBSERVATION", 144, 163]]], ["On the other hand, careful dosing will be required for A 2B R antagonists to minimize side-effects regarding the mucociliary clearance of allergen and infectious particles, as this receptor plays critical roles in fluid secretion and cilia beating (see Chap.", [["mucociliary", "ANATOMY", 113, 124], ["fluid", "ANATOMY", 214, 219], ["cilia", "ANATOMY", 234, 239], ["A 2B R antagonists", "GENE_OR_GENE_PRODUCT", 55, 73], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 113, 124], ["fluid", "ORGANISM_SUBSTANCE", 214, 219], ["A 2B R antagonists", "TREATMENT", 55, 73], ["side-effects", "PROBLEM", 86, 98], ["the mucociliary clearance of allergen", "TREATMENT", 109, 146], ["infectious particles", "PROBLEM", 151, 171], ["fluid secretion", "PROBLEM", 214, 229], ["cilia beating", "PROBLEM", 234, 247], ["fluid secretion", "OBSERVATION", 214, 229]]], ["The importance of findings in pre-clinical and cellular models will have to be validated in carefully designed clinical trials that take into account the potential impact of ADO receptors signaling in acute and chronic lung disorders.Murine Models Targeting ATP ReceptorsThe field of purinergic inflammation formulated the unifying concept that ATP is released as a \"danger signal\" to induce inflammatory responses upon binding cell surface purinergic receptors (see Chap.", [["cellular", "ANATOMY", 47, 55], ["lung", "ANATOMY", 219, 223], ["cell surface", "ANATOMY", 428, 440], ["ADO", "CHEMICAL", 174, 177], ["chronic lung disorders", "DISEASE", 211, 233], ["ATP", "CHEMICAL", 258, 261], ["inflammation", "DISEASE", 295, 307], ["ATP", "CHEMICAL", 345, 348], ["ATP", "CHEMICAL", 258, 261], ["ATP", "CHEMICAL", 345, 348], ["cellular", "CELL", 47, 55], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 174, 187], ["lung", "ORGAN", 219, 223], ["Murine", "ORGANISM", 234, 240], ["ATP Receptors", "GENE_OR_GENE_PRODUCT", 258, 271], ["ATP", "SIMPLE_CHEMICAL", 345, 348], ["cell", "CELL", 428, 432], ["surface purinergic receptors", "GENE_OR_GENE_PRODUCT", 433, 461], ["ADO receptors", "PROTEIN", 174, 187], ["ATP Receptors", "PROTEIN", 258, 271], ["binding cell surface purinergic receptors", "PROTEIN", 420, 461], ["Chap", "PROTEIN", 467, 471], ["Murine", "SPECIES", 234, 240], ["ADO receptors signaling", "PROBLEM", 174, 197], ["acute and chronic lung disorders", "PROBLEM", 201, 233], ["ATP Receptors", "TREATMENT", 258, 271], ["purinergic inflammation", "PROBLEM", 284, 307], ["inflammatory responses", "PROBLEM", 392, 414], ["acute", "OBSERVATION_MODIFIER", 201, 206], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["lung", "ANATOMY", 219, 223], ["disorders", "OBSERVATION", 224, 233], ["ATP Receptors", "OBSERVATION", 258, 271], ["purinergic inflammation", "OBSERVATION", 284, 307], ["inflammatory", "OBSERVATION", 392, 404]]], ["Our current understanding of purinergic signaling in the respiratory system suggests that this concept can be extended to airway defenses against infection and obstruction (see Chap.", [["respiratory system", "ANATOMY", 57, 75], ["airway", "ANATOMY", 122, 128], ["infection", "DISEASE", 146, 155], ["obstruction", "DISEASE", 160, 171], ["airway", "MULTI-TISSUE_STRUCTURE", 122, 128], ["purinergic signaling in the respiratory system", "PROBLEM", 29, 75], ["infection", "PROBLEM", 146, 155], ["obstruction", "PROBLEM", 160, 171], ["respiratory system", "ANATOMY", 57, 75], ["infection", "OBSERVATION", 146, 155], ["obstruction", "OBSERVATION", 160, 171]]], ["The mouse models currently available for P2X and P2Y receptors, and for ectonucleotidases, highlight the airway functions particularly targeted by ATP and altered under pathological conditions.", [["airway", "ANATOMY", 105, 111], ["ATP", "CHEMICAL", 147, 150], ["ATP", "CHEMICAL", 147, 150], ["mouse", "ORGANISM", 4, 9], ["P2X", "GENE_OR_GENE_PRODUCT", 41, 44], ["P2Y receptors", "GENE_OR_GENE_PRODUCT", 49, 62], ["ectonucleotidases", "GENE_OR_GENE_PRODUCT", 72, 89], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["ATP", "SIMPLE_CHEMICAL", 147, 150], ["P2X and P2Y receptors", "PROTEIN", 41, 62], ["ectonucleotidases", "PROTEIN", 72, 89], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["P2X", "PROBLEM", 41, 44], ["P2Y receptors", "TREATMENT", 49, 62], ["ectonucleotidases", "PROBLEM", 72, 89], ["altered under pathological conditions", "PROBLEM", 155, 192], ["airway", "ANATOMY", 105, 111]]], ["In general, these mice present no apparent phenotype or lung complication, unless they are subjected to an insult.", [["lung", "ANATOMY", 56, 60], ["mice", "ORGANISM", 18, 22], ["lung", "ORGAN", 56, 60], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["apparent phenotype", "PROBLEM", 34, 52], ["lung complication", "PROBLEM", 56, 73], ["an insult", "PROBLEM", 104, 113], ["no apparent", "UNCERTAINTY", 31, 42], ["lung", "ANATOMY", 56, 60], ["complication", "OBSERVATION", 61, 73]]], ["As such, this section exposes the critical role of extracellular ATP in acute lung injury and chronic respiratory diseases.The P2Y 2 R in Acute and Chronic DisordersThe most convincing evidence that the P2Y 2 R is engaged primarily during alarm situations is derived from studies conducted on the knockout mice [128, 129] .", [["extracellular", "ANATOMY", 51, 64], ["lung", "ANATOMY", 78, 82], ["respiratory", "ANATOMY", 102, 113], ["ATP", "CHEMICAL", 65, 68], ["lung injury", "DISEASE", 78, 89], ["chronic respiratory diseases", "DISEASE", 94, 122], ["ATP", "CHEMICAL", 65, 68], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["ATP", "SIMPLE_CHEMICAL", 65, 68], ["lung", "ORGAN", 78, 82], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 127, 134], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 203, 210], ["mice", "ORGANISM", 306, 310], ["P2Y 2 R", "PROTEIN", 203, 210], ["mice", "SPECIES", 306, 310], ["this section", "TREATMENT", 9, 21], ["extracellular ATP", "PROBLEM", 51, 68], ["acute lung injury", "PROBLEM", 72, 89], ["chronic respiratory diseases", "PROBLEM", 94, 122], ["Acute and Chronic Disorders", "PROBLEM", 138, 165], ["extracellular ATP", "OBSERVATION", 51, 68], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["lung", "ANATOMY", 78, 82], ["injury", "OBSERVATION", 83, 89], ["chronic", "OBSERVATION_MODIFIER", 94, 101], ["respiratory diseases", "OBSERVATION", 102, 122], ["Acute", "OBSERVATION_MODIFIER", 138, 143], ["Chronic", "OBSERVATION_MODIFIER", 148, 155], ["Disorders", "OBSERVATION", 156, 165], ["most convincing evidence", "UNCERTAINTY", 169, 193]]], ["They are fertile, undistinguishable from their wild-type littermates, and show no abnormality in their organs, including the heart, lung, pancreas, intestines, kidneys and trachea.", [["organs", "ANATOMY", 103, 109], ["heart", "ANATOMY", 125, 130], ["lung", "ANATOMY", 132, 136], ["pancreas", "ANATOMY", 138, 146], ["intestines", "ANATOMY", 148, 158], ["kidneys", "ANATOMY", 160, 167], ["trachea", "ANATOMY", 172, 179], ["wild-type littermates", "ORGANISM", 47, 68], ["organs", "ORGAN", 103, 109], ["heart", "ORGAN", 125, 130], ["lung", "ORGAN", 132, 136], ["pancreas", "ORGAN", 138, 146], ["intestines", "ORGAN", 148, 158], ["kidneys", "ORGAN", 160, 167], ["trachea", "ORGAN", 172, 179], ["abnormality in their organs, including the heart, lung, pancreas, intestines, kidneys and trachea", "PROBLEM", 82, 179], ["fertile", "OBSERVATION", 9, 16], ["no", "UNCERTAINTY", 79, 81], ["abnormality", "OBSERVATION", 82, 93], ["organs", "ANATOMY", 103, 109], ["heart", "ANATOMY", 125, 130], ["lung", "ANATOMY", 132, 136], ["pancreas", "ANATOMY", 138, 146], ["intestines", "ANATOMY", 148, 158], ["kidneys", "ANATOMY", 160, 167], ["trachea", "ANATOMY", 172, 179]]], ["The fact that their airways are not obstructed is consistent with the distinct roles of P2Y 2 R-CaCC and A 2B R-CFTR signaling pathways in mucociliary clearance (MCC), established using cultures of human airway epithelial cells (review: [24] ).", [["airways", "ANATOMY", 20, 27], ["mucociliary", "ANATOMY", 139, 150], ["airway epithelial cells", "ANATOMY", 204, 227], ["airways", "MULTI-TISSUE_STRUCTURE", 20, 27], ["P2Y 2 R-CaCC", "GENE_OR_GENE_PRODUCT", 88, 100], ["A 2B R", "GENE_OR_GENE_PRODUCT", 105, 111], ["CFTR", "GENE_OR_GENE_PRODUCT", 112, 116], ["mucociliary", "ORGAN", 139, 150], ["human", "ORGANISM", 198, 203], ["airway epithelial cells", "CELL", 204, 227], ["CaCC", "PROTEIN", 96, 100], ["CFTR", "PROTEIN", 112, 116], ["human airway epithelial cells", "CELL_TYPE", 198, 227], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["obstructed", "PROBLEM", 36, 46], ["P2Y", "TEST", 88, 91], ["CaCC", "TEST", 96, 100], ["CFTR signaling pathways", "PROBLEM", 112, 135], ["mucociliary clearance", "TEST", 139, 160], ["cultures", "TEST", 186, 194], ["airways", "ANATOMY", 20, 27], ["obstructed", "OBSERVATION", 36, 46], ["consistent with", "UNCERTAINTY", 50, 65], ["airway", "ANATOMY", 204, 210], ["epithelial cells", "OBSERVATION", 211, 227]]], ["Under the steady-state (baseline) conditions, the surface ADO concentrations partially activate A 2B Rs, which maintains sufficient CFTR-mediated fluid secretion for MCC in a sterile environment.", [["surface", "ANATOMY", 50, 57], ["fluid", "ANATOMY", 146, 151], ["ADO", "CHEMICAL", 58, 61], ["ADO", "CHEMICAL", 58, 61], ["surface", "CELLULAR_COMPONENT", 50, 57], ["ADO", "SIMPLE_CHEMICAL", 58, 61], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 96, 103], ["CFTR", "GENE_OR_GENE_PRODUCT", 132, 136], ["fluid", "ORGANISM_SUBSTANCE", 146, 151], ["MCC", "CANCER", 166, 169], ["A 2B Rs", "PROTEIN", 96, 103], ["CFTR", "PROTEIN", 132, 136], ["the surface ADO concentrations", "TREATMENT", 46, 76], ["A 2B Rs", "TEST", 96, 103], ["fluid secretion", "PROBLEM", 146, 161], ["MCC", "PROBLEM", 166, 169], ["a sterile environment", "TREATMENT", 173, 194], ["fluid secretion", "OBSERVATION", 146, 161]]], ["In contrast, the surface ATP concentrations periodically reach the activation threshold of P2Y 2 Rs during normal tidal breathing, as a result of mechanical stress-induced nucleotide release.", [["surface", "ANATOMY", 17, 24], ["ATP", "CHEMICAL", 25, 28], ["nucleotide", "CHEMICAL", 172, 182], ["ATP", "CHEMICAL", 25, 28], ["nucleotide", "CHEMICAL", 172, 182], ["surface", "CELLULAR_COMPONENT", 17, 24], ["ATP", "SIMPLE_CHEMICAL", 25, 28], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 91, 99], ["nucleotide", "SIMPLE_CHEMICAL", 172, 182], ["the surface ATP concentrations", "TREATMENT", 13, 43], ["P2Y", "TEST", 91, 94], ["mechanical stress", "PROBLEM", 146, 163], ["induced nucleotide release", "TREATMENT", 164, 190], ["tidal breathing", "OBSERVATION", 114, 129]]], ["This transient and weak activation stimulates fluid and mucin secretion to maintain a thin shield above the ciliated epithelium.", [["fluid", "ANATOMY", 46, 51], ["ciliated epithelium", "ANATOMY", 108, 127], ["fluid", "ORGANISM_SUBSTANCE", 46, 51], ["mucin", "GENE_OR_GENE_PRODUCT", 56, 61], ["ciliated epithelium", "TISSUE", 108, 127], ["This transient and weak activation stimulates fluid", "PROBLEM", 0, 51], ["mucin secretion", "PROBLEM", 56, 71], ["weak", "OBSERVATION_MODIFIER", 19, 23], ["ciliated", "ANATOMY_MODIFIER", 108, 116], ["epithelium", "ANATOMY_MODIFIER", 117, 127]]], ["Together, these ADO-and ATP-mediated signaling events continuously produce and evacuate this protective film along the ciliary escalator.", [["ciliary", "ANATOMY", 119, 126], ["ADO", "CHEMICAL", 16, 19], ["ATP", "CHEMICAL", 24, 27], ["ADO", "CHEMICAL", 16, 19], ["ATP", "CHEMICAL", 24, 27], ["ADO", "SIMPLE_CHEMICAL", 16, 19], ["ATP", "SIMPLE_CHEMICAL", 24, 27], ["these ADO", "TEST", 10, 19], ["ATP", "TEST", 24, 27], ["signaling events", "PROBLEM", 37, 53], ["this protective film", "TEST", 88, 108], ["ciliary escalator", "OBSERVATION", 119, 136]]], ["On the other hand, an alarm situation, sensed by the interaction of an irritant or pathogen with the epithelium, initiates a robust and transient MCC response through ATP release and P2Y 2 R activation.", [["epithelium", "ANATOMY", 101, 111], ["ATP", "CHEMICAL", 167, 170], ["ATP", "CHEMICAL", 167, 170], ["epithelium", "TISSUE", 101, 111], ["MCC", "CANCER", 146, 149], ["ATP", "SIMPLE_CHEMICAL", 167, 170], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 183, 190], ["an alarm situation", "PROBLEM", 19, 37], ["ATP release", "TREATMENT", 167, 178], ["P2Y", "TEST", 183, 186]]], ["The most powerful trigger for this flushing mechanism is a cough.", [["cough", "DISEASE", 59, 64], ["this flushing mechanism", "PROBLEM", 30, 53], ["a cough", "PROBLEM", 57, 64], ["cough", "OBSERVATION", 59, 64]]], ["The rapid metabolism of ATP into ADO by ectonucleotidases triggers a second wave of fluid secretion through enhanced A 2B R-CFTR activity and ciliary beating, both gradually returning to baseline with ADO concentration.", [["fluid", "ANATOMY", 84, 89], ["ciliary", "ANATOMY", 142, 149], ["ATP", "CHEMICAL", 24, 27], ["ADO", "CHEMICAL", 33, 36], ["ADO", "CHEMICAL", 201, 204], ["ATP", "CHEMICAL", 24, 27], ["ADO", "CHEMICAL", 33, 36], ["ADO", "CHEMICAL", 201, 204], ["ATP", "SIMPLE_CHEMICAL", 24, 27], ["ADO", "SIMPLE_CHEMICAL", 33, 36], ["ectonucleotidases", "SIMPLE_CHEMICAL", 40, 57], ["fluid", "ORGANISM_SUBSTANCE", 84, 89], ["A 2B", "GENE_OR_GENE_PRODUCT", 117, 121], ["R-CFTR", "GENE_OR_GENE_PRODUCT", 122, 128], ["ciliary", "MULTI-TISSUE_STRUCTURE", 142, 149], ["ADO", "SIMPLE_CHEMICAL", 201, 204], ["CFTR", "PROTEIN", 124, 128], ["fluid secretion", "PROBLEM", 84, 99], ["CFTR activity", "PROBLEM", 124, 137], ["ciliary beating", "PROBLEM", 142, 157], ["ADO concentration", "TREATMENT", 201, 218], ["fluid secretion", "OBSERVATION", 84, 99], ["CFTR activity", "OBSERVATION", 124, 137], ["ciliary beating", "OBSERVATION", 142, 157], ["both", "OBSERVATION_MODIFIER", 159, 163], ["gradually", "OBSERVATION_MODIFIER", 164, 173]]], ["Hence, P2Y 2 R-mediated MCC only predominates during alarm situations.The P2Y 2 R in Acute and Chronic DisordersThe possibility that different P2 receptors may predominate in humans and rodents was addressed by comparing the capacity of airway epithelia from wild-type and P2Y 2 R \u00c0/\u00c0 mice to regulate ion and fluid secretion.", [["airway epithelia", "ANATOMY", 237, 253], ["fluid", "ANATOMY", 310, 315], ["P2Y 2 R", "CHEMICAL", 74, 81], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 7, 14], ["MCC", "CANCER", 24, 27], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 74, 81], ["P2 receptors", "GENE_OR_GENE_PRODUCT", 143, 155], ["humans", "ORGANISM", 175, 181], ["airway epithelia", "TISSUE", 237, 253], ["P2Y 2 R \u00c0/\u00c0 mice", "ORGANISM", 273, 289], ["ion", "SIMPLE_CHEMICAL", 302, 305], ["fluid", "ORGANISM_SUBSTANCE", 310, 315], ["P2Y 2 R", "PROTEIN", 7, 14], ["P2 receptors", "PROTEIN", 143, 155], ["humans", "SPECIES", 175, 181], ["mice", "SPECIES", 285, 289], ["humans", "SPECIES", 175, 181], ["P2Y", "TEST", 7, 10], ["MCC", "PROBLEM", 24, 27], ["Acute and Chronic Disorders", "PROBLEM", 85, 112], ["different P2 receptors", "TREATMENT", 133, 155], ["airway epithelia", "PROBLEM", 237, 253], ["P2Y", "TEST", 273, 276], ["fluid secretion", "PROBLEM", 310, 325], ["alarm situations", "OBSERVATION", 53, 69], ["Acute", "OBSERVATION_MODIFIER", 85, 90], ["Chronic", "OBSERVATION_MODIFIER", 95, 102], ["Disorders", "OBSERVATION", 103, 112], ["airway", "ANATOMY", 237, 243], ["fluid secretion", "OBSERVATION", 310, 325]]], ["Measurements of ion channel activity in Ussing chambers indicated that the loss of P2Y 2 R decreases ATP-induced Clsecretion by 75% in the nose and 90% in the trachea [129] .", [["nose", "ANATOMY", 139, 143], ["trachea", "ANATOMY", 159, 166], ["P2Y 2 R", "CHEMICAL", 83, 90], ["ATP", "CHEMICAL", 101, 104], ["ATP", "CHEMICAL", 101, 104], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 83, 90], ["ATP", "SIMPLE_CHEMICAL", 101, 104], ["nose", "ORGAN", 139, 143], ["trachea", "ORGAN", 159, 166], ["ion channel activity", "TREATMENT", 16, 36], ["Ussing chambers", "TEST", 40, 55], ["the loss of P2Y", "PROBLEM", 71, 86], ["ATP", "TEST", 101, 104], ["Clsecretion", "TEST", 113, 124], ["ion channel", "OBSERVATION_MODIFIER", 16, 27], ["nose", "ANATOMY", 139, 143], ["trachea", "ANATOMY", 159, 166]]], ["Also, mucin secretion induced by the selective P2Y 2 R agonist, ATPgS, was reduced by >80% in P2Y 2 R \u00c0/\u00c0 mice, compared to their wild-type littermates [130] .", [["ATPgS", "CHEMICAL", 64, 69], ["mucin", "GENE_OR_GENE_PRODUCT", 6, 11], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 47, 54], ["ATPgS", "GENE_OR_GENE_PRODUCT", 64, 69], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 94, 101], ["mice", "SPECIES", 106, 110], ["mucin secretion", "PROBLEM", 6, 21], ["the selective P2Y", "TREATMENT", 33, 50], ["ATPgS", "TEST", 64, 69], ["P2Y", "TEST", 94, 97], ["mucin secretion", "OBSERVATION", 6, 21]]], ["These studies demonstrate that the \"danger signal\", provided by stress-induced ATP release, triggers airway clearance primarily by P2Y 2 R activation in murine airway epithelia.The P2Y 2 R in Acute and Chronic DisordersThe beneficial effects of P2Y 2 R signaling is extended to the mobilization of cells engaged in the destruction of inhaled pathogens, including monocytes/macrophages and leukocytes.", [["airway", "ANATOMY", 101, 107], ["airway epithelia", "ANATOMY", 160, 176], ["cells", "ANATOMY", 298, 303], ["monocytes", "ANATOMY", 363, 372], ["macrophages", "ANATOMY", 373, 384], ["leukocytes", "ANATOMY", 389, 399], ["ATP", "CHEMICAL", 79, 82], ["Chronic Disorders", "DISEASE", 202, 219], ["ATP", "CHEMICAL", 79, 82], ["ATP", "SIMPLE_CHEMICAL", 79, 82], ["airway", "MULTI-TISSUE_STRUCTURE", 101, 107], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 131, 138], ["murine", "ORGANISM", 153, 159], ["airway epithelia", "TISSUE", 160, 176], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 181, 188], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 245, 252], ["cells", "CELL", 298, 303], ["monocytes", "CELL", 363, 372], ["macrophages", "CELL", 373, 384], ["leukocytes", "CELL", 389, 399], ["P2Y 2 R", "PROTEIN", 131, 138], ["monocytes", "CELL_TYPE", 363, 372], ["macrophages", "CELL_TYPE", 373, 384], ["leukocytes", "CELL_TYPE", 389, 399], ["murine", "SPECIES", 153, 159], ["These studies", "TEST", 0, 13], ["airway clearance", "TEST", 101, 117], ["P2Y", "TEST", 131, 134], ["Acute and Chronic Disorders", "PROBLEM", 192, 219], ["P2Y 2 R signaling", "PROBLEM", 245, 262], ["the mobilization of cells", "TREATMENT", 278, 303], ["the destruction of inhaled pathogens", "PROBLEM", 315, 351], ["monocytes", "TEST", 363, 372], ["macrophages", "PROBLEM", 373, 384], ["leukocytes", "TEST", 389, 399], ["airway", "ANATOMY", 101, 107], ["airway epithelia", "OBSERVATION", 160, 176], ["Acute", "OBSERVATION_MODIFIER", 192, 197], ["Chronic", "OBSERVATION_MODIFIER", 202, 209], ["Disorders", "OBSERVATION", 210, 219], ["mobilization", "OBSERVATION_MODIFIER", 282, 294], ["destruction", "OBSERVATION_MODIFIER", 319, 330], ["inhaled pathogens", "OBSERVATION", 334, 351], ["macrophages", "OBSERVATION", 373, 384], ["leukocytes", "OBSERVATION_MODIFIER", 389, 399]]], ["In most instances, these actions are essential to resolve airway infection.", [["airway", "ANATOMY", 58, 64], ["airway infection", "DISEASE", 58, 74], ["airway", "MULTI-TISSUE_STRUCTURE", 58, 64], ["airway infection", "PROBLEM", 58, 74], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["airway", "ANATOMY", 58, 64], ["infection", "OBSERVATION", 65, 74]]], ["On the other hand, chronic or exaggerated activation of these functions lead to irreversible damage to the respiratory system.", [["respiratory system", "ANATOMY", 107, 125], ["chronic or exaggerated activation of these functions", "PROBLEM", 19, 71], ["irreversible damage to the respiratory system", "PROBLEM", 80, 125], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["irreversible", "OBSERVATION_MODIFIER", 80, 92], ["damage", "OBSERVATION", 93, 99], ["respiratory system", "ANATOMY", 107, 125]]], ["Whether P2Y 2 Rs are beneficial or detrimental in these two scenarios was examined using models of acute and chronic lung complications.The P2Y 2 R in Acute and Chronic DisordersThe overall impact of P2Y receptors on the susceptibility to airway infection was investigated using P2Y 1 R/P2Y 2 R double knockout mice [131] .", [["lung", "ANATOMY", 117, 121], ["airway", "ANATOMY", 239, 245], ["airway infection", "DISEASE", 239, 255], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 8, 16], ["lung", "ORGAN", 117, 121], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 140, 147], ["P2Y receptors", "GENE_OR_GENE_PRODUCT", 200, 213], ["airway", "MULTI-TISSUE_STRUCTURE", 239, 245], ["P2Y 1 R", "GENE_OR_GENE_PRODUCT", 279, 286], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 287, 294], ["P2Y 2 Rs", "PROTEIN", 8, 16], ["P2Y 2 R", "PROTEIN", 140, 147], ["P2Y receptors", "PROTEIN", 200, 213], ["mice", "SPECIES", 311, 315], ["acute and chronic lung complications", "PROBLEM", 99, 135], ["Acute and Chronic Disorders", "PROBLEM", 151, 178], ["P2Y receptors", "TREATMENT", 200, 213], ["airway infection", "PROBLEM", 239, 255], ["P2Y", "TEST", 279, 282], ["P2Y", "TEST", 287, 290], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["lung", "ANATOMY", 117, 121], ["complications", "OBSERVATION", 122, 135], ["Acute", "OBSERVATION_MODIFIER", 151, 156], ["Chronic", "OBSERVATION_MODIFIER", 161, 168], ["Disorders", "OBSERVATION", 169, 178], ["airway", "ANATOMY", 239, 245], ["infection", "OBSERVATION", 246, 255]]], ["When subjected to intra-tracheal instillation of the common airway pathogen, Pseudomonas aeruginosa, all the double knockout mice succumbed within 30 h, whereas 85% of the wild-type mice lived a normal lifespan.", [["airway", "ANATOMY", 60, 66], ["airway", "ORGANISM_SUBDIVISION", 60, 66], ["Pseudomonas aeruginosa", "ORGANISM", 77, 99], ["mice", "ORGANISM", 125, 129], ["mice", "ORGANISM", 182, 186], ["Pseudomonas aeruginosa", "SPECIES", 77, 99], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 182, 186], ["Pseudomonas aeruginosa", "SPECIES", 77, 99], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 182, 186], ["intra-tracheal instillation", "TREATMENT", 18, 45], ["the common airway pathogen", "PROBLEM", 49, 75], ["Pseudomonas aeruginosa", "PROBLEM", 77, 99], ["common airway", "ANATOMY", 53, 66], ["Pseudomonas aeruginosa", "OBSERVATION", 77, 99], ["normal lifespan", "OBSERVATION", 195, 210]]], ["After 24 h, the BAL fluid of P2Y 1 R/ P2Y 2 R \u00c0/\u00c0 mice contained more proteins as a measure of edema, but less proinflammatory mediators (IL-1b, IL-6, GM-GSF and MIP-2).", [["BAL fluid", "ANATOMY", 16, 25], ["edema", "ANATOMY", 95, 100], ["edema", "DISEASE", 95, 100], ["P2Y 1 R", "GENE_OR_GENE_PRODUCT", 29, 36], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 38, 45], ["edema", "PATHOLOGICAL_FORMATION", 95, 100], ["IL-1b", "GENE_OR_GENE_PRODUCT", 138, 143], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["GM-GSF", "GENE_OR_GENE_PRODUCT", 151, 157], ["MIP-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["proinflammatory mediators", "PROTEIN", 111, 136], ["IL-1b, IL-6", "PROTEIN", 138, 149], ["GM", "PROTEIN", 151, 153], ["GSF", "PROTEIN", 154, 157], ["MIP", "PROTEIN", 162, 165], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["the BAL fluid", "TEST", 12, 25], ["P2Y", "TEST", 29, 32], ["P2Y", "TEST", 38, 41], ["edema", "PROBLEM", 95, 100], ["proinflammatory mediators", "TEST", 111, 136], ["IL", "TEST", 138, 140], ["IL", "TEST", 145, 147], ["GM", "TEST", 151, 153], ["MIP", "TEST", 162, 165], ["edema", "OBSERVATION", 95, 100]]], ["In contrast, the two mouse groups presented similar total cell counts and cell composition, which were primarily neutrophils (>80%).", [["cell", "ANATOMY", 58, 62], ["cell", "ANATOMY", 74, 78], ["neutrophils", "ANATOMY", 113, 124], ["mouse", "ORGANISM", 21, 26], ["cell", "CELL", 58, 62], ["cell", "CELL", 74, 78], ["neutrophils", "CELL", 113, 124], ["neutrophils", "CELL_TYPE", 113, 124], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["total cell counts", "TEST", 52, 69], ["cell composition", "TEST", 74, 90], ["neutrophils", "TEST", 113, 124], ["total cell counts", "OBSERVATION", 52, 69], ["cell composition", "OBSERVATION", 74, 90]]], ["These data suggest that P2Y receptors exert a protective role during lung infection by suppressing pulmonary edema, while promoting the inflammatory responses required to eradicate the infection.", [["lung", "ANATOMY", 69, 73], ["pulmonary", "ANATOMY", 99, 108], ["lung infection", "DISEASE", 69, 83], ["pulmonary edema", "DISEASE", 99, 114], ["infection", "DISEASE", 185, 194], ["P2Y receptors", "GENE_OR_GENE_PRODUCT", 24, 37], ["lung", "ORGAN", 69, 73], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 99, 114], ["P2Y receptors", "PROTEIN", 24, 37], ["These data", "TEST", 0, 10], ["P2Y receptors", "PROBLEM", 24, 37], ["lung infection", "PROBLEM", 69, 83], ["suppressing pulmonary edema", "PROBLEM", 87, 114], ["the inflammatory responses", "PROBLEM", 132, 158], ["the infection", "PROBLEM", 181, 194], ["lung", "ANATOMY", 69, 73], ["infection", "OBSERVATION", 74, 83], ["pulmonary", "ANATOMY", 99, 108], ["edema", "OBSERVATION", 109, 114], ["inflammatory", "OBSERVATION_MODIFIER", 136, 148], ["infection", "OBSERVATION", 185, 194]]], ["The severe pulmonary edema developed by the P2Y 1 R/P2Y 2 R \u00c0/\u00c0 mice is consistent with our model of fluid regulation (Fig. 8.1) , whereby the loss of endothelial P2Y 2 Rs would prevent ATP from protecting barrier functions.", [["pulmonary", "ANATOMY", 11, 20], ["fluid", "ANATOMY", 101, 106], ["endothelial", "ANATOMY", 151, 162], ["barrier", "ANATOMY", 206, 213], ["pulmonary edema", "DISEASE", 11, 26], ["ATP", "CHEMICAL", 186, 189], ["ATP", "CHEMICAL", 186, 189], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 11, 26], ["P2Y 1 R", "GENE_OR_GENE_PRODUCT", 44, 51], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 52, 59], ["fluid", "ORGANISM_SUBSTANCE", 101, 106], ["endothelial", "CELL", 151, 162], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 163, 171], ["ATP", "SIMPLE_CHEMICAL", 186, 189], ["barrier", "TISSUE", 206, 213], ["endothelial P2Y 2 Rs", "PROTEIN", 151, 171], ["mice", "SPECIES", 64, 68], ["The severe pulmonary edema", "PROBLEM", 0, 26], ["the P2Y", "TEST", 40, 47], ["P2Y", "TEST", 52, 55], ["fluid regulation", "TEST", 101, 117], ["endothelial P2Y", "TREATMENT", 151, 166], ["ATP", "PROBLEM", 186, 189], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["pulmonary", "ANATOMY", 11, 20], ["edema", "OBSERVATION", 21, 26], ["consistent with", "UNCERTAINTY", 72, 87], ["fluid regulation", "OBSERVATION", 101, 117], ["endothelial", "ANATOMY", 151, 162]]], ["On the other hand, it is intriguing that these mice accumulate BAL neutrophils to the same extent as the wild-type mice, given the critical role of P2Y 2 Rs for their chemotaxis (see Chap.", [["BAL neutrophils", "ANATOMY", 63, 78], ["mice", "ORGANISM", 47, 51], ["BAL neutrophils", "CELL", 63, 78], ["mice", "ORGANISM", 115, 119], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 148, 156], ["BAL neutrophils", "CELL_TYPE", 63, 78], ["P2Y 2 Rs", "PROTEIN", 148, 156], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 47, 51], ["BAL neutrophils", "TEST", 63, 78], ["their chemotaxis", "PROBLEM", 161, 177], ["BAL neutrophils", "OBSERVATION", 63, 78]]], ["Unfortunately, double knockout mice are of limited value to discriminate the roles of each receptor.The P2Y 2 R in Acute and Chronic DisordersAn acute model of airway infection was used to determine the impact of P2Y 2 Rs localized in the vasculature, on circulating cells or the endothelial surface [132] .", [["airway", "ANATOMY", 160, 166], ["vasculature", "ANATOMY", 239, 250], ["cells", "ANATOMY", 267, 272], ["endothelial surface", "ANATOMY", 280, 299], ["P2Y 2 R", "CHEMICAL", 104, 111], ["airway infection", "DISEASE", 160, 176], ["mice", "ORGANISM", 31, 35], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 104, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 160, 166], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 213, 221], ["vasculature", "MULTI-TISSUE_STRUCTURE", 239, 250], ["cells", "CELL", 267, 272], ["endothelial surface", "CELLULAR_COMPONENT", 280, 299], ["P2Y 2 Rs", "PROTEIN", 213, 221], ["circulating cells", "CELL_TYPE", 255, 272], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["double knockout mice", "TREATMENT", 15, 35], ["Acute and Chronic Disorders", "PROBLEM", 115, 142], ["airway infection", "PROBLEM", 160, 176], ["the endothelial surface", "TEST", 276, 299], ["Acute", "OBSERVATION_MODIFIER", 115, 120], ["Chronic", "OBSERVATION_MODIFIER", 125, 132], ["Disorders", "OBSERVATION", 133, 142], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["airway", "ANATOMY", 160, 166], ["infection", "OBSERVATION", 167, 176], ["vasculature", "ANATOMY", 239, 250], ["circulating cells", "OBSERVATION", 255, 272], ["endothelial", "ANATOMY", 280, 291], ["surface", "OBSERVATION_MODIFIER", 292, 299]]], ["Wild-type mice received intravenous saline, or a selective P2Y 2 R agonist (ATPgS), before intranasal instillation of LPS.", [["intravenous", "ANATOMY", 24, 35], ["ATPgS", "CHEMICAL", 76, 81], ["LPS", "CHEMICAL", 118, 121], ["mice", "ORGANISM", 10, 14], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["saline", "SIMPLE_CHEMICAL", 36, 42], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 59, 66], ["ATPgS", "SIMPLE_CHEMICAL", 76, 81], ["LPS", "SIMPLE_CHEMICAL", 118, 121], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["intravenous saline", "TREATMENT", 24, 42], ["a selective P2Y 2 R agonist (ATPgS)", "TREATMENT", 47, 82], ["intranasal instillation of LPS", "TREATMENT", 91, 121]]], ["The mice which received the P2Y 2 R agonist exhibited about 50% less inflammatory cells, cytokines and proteins in the BAL fluid, than the saline-treated LPS-exposed mice.", [["inflammatory cells", "ANATOMY", 69, 87], ["BAL fluid", "ANATOMY", 119, 128], ["LPS", "CHEMICAL", 154, 157], ["mice", "ORGANISM", 4, 8], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 28, 35], ["inflammatory cells", "CELL", 69, 87], ["BAL fluid", "ORGANISM_SUBSTANCE", 119, 128], ["saline", "SIMPLE_CHEMICAL", 139, 145], ["LPS", "SIMPLE_CHEMICAL", 154, 157], ["mice", "ORGANISM", 166, 170], ["inflammatory cells", "CELL_TYPE", 69, 87], ["cytokines", "PROTEIN", 89, 98], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 166, 170], ["the P2Y 2 R agonist", "TREATMENT", 24, 43], ["50% less inflammatory cells", "PROBLEM", 60, 87], ["cytokines and proteins in the BAL fluid", "PROBLEM", 89, 128], ["the saline", "TREATMENT", 135, 145], ["inflammatory cells", "OBSERVATION", 69, 87], ["BAL", "ANATOMY", 119, 122], ["fluid", "OBSERVATION", 123, 128]]], ["The protective effect of ATPgS against vascular leakage was confirmed by Evans blue albumin extravasation into the lung tissue, pointing toward a primary function at the endothelial barrier.", [["vascular", "ANATOMY", 39, 47], ["lung tissue", "ANATOMY", 115, 126], ["endothelial barrier", "ANATOMY", 170, 189], ["ATPgS", "CHEMICAL", 25, 30], ["ATPgS", "SIMPLE_CHEMICAL", 25, 30], ["vascular", "MULTI-TISSUE_STRUCTURE", 39, 47], ["Evans blue albumin", "SIMPLE_CHEMICAL", 73, 91], ["lung tissue", "TISSUE", 115, 126], ["endothelial barrier", "TISSUE", 170, 189], ["ATPgS", "TREATMENT", 25, 30], ["vascular leakage", "PROBLEM", 39, 55], ["Evans blue albumin extravasation into the lung tissue", "PROBLEM", 73, 126], ["the endothelial barrier", "TREATMENT", 166, 189], ["vascular", "ANATOMY", 39, 47], ["leakage", "OBSERVATION", 48, 55], ["lung", "ANATOMY", 115, 119], ["tissue", "ANATOMY_MODIFIER", 120, 126], ["endothelial barrier", "OBSERVATION", 170, 189]]], ["This was confirmed in vitro in human lung microvascular endothelial cultures, where ATPgS significantly inhibited the LPS-mediated reduction of transmembrane electrical resistance.", [["lung microvascular endothelial cultures", "ANATOMY", 37, 76], ["transmembrane", "ANATOMY", 144, 157], ["ATPgS", "CHEMICAL", 84, 89], ["LPS", "CHEMICAL", 118, 121], ["ATPgS", "CHEMICAL", 84, 89], ["human", "ORGANISM", 31, 36], ["lung microvascular endothelial cultures", "CELL", 37, 76], ["ATPgS", "SIMPLE_CHEMICAL", 84, 89], ["LPS", "SIMPLE_CHEMICAL", 118, 121], ["human lung microvascular endothelial cultures", "CELL_LINE", 31, 76], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["vitro in human lung microvascular endothelial cultures", "TEST", 22, 76], ["ATPgS", "TEST", 84, 89], ["the LPS", "TEST", 114, 121], ["transmembrane electrical resistance", "PROBLEM", 144, 179], ["lung", "ANATOMY", 37, 41], ["microvascular endothelial", "ANATOMY", 42, 67], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["transmembrane electrical resistance", "OBSERVATION", 144, 179]]], ["These data suggest that intravenous P2Y 2 R agonists may reduce the airway inflammatory responses and lung injury caused by airborne pathogens.", [["intravenous", "ANATOMY", 24, 35], ["airway", "ANATOMY", 68, 74], ["lung", "ANATOMY", 102, 106], ["lung injury", "DISEASE", 102, 113], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 36, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 68, 74], ["lung", "ORGAN", 102, 106], ["intravenous P2Y 2 R agonists", "TREATMENT", 24, 52], ["the airway inflammatory responses", "PROBLEM", 64, 97], ["lung injury", "PROBLEM", 102, 113], ["airborne pathogens", "PROBLEM", 124, 142], ["airway", "ANATOMY", 68, 74], ["inflammatory", "OBSERVATION", 75, 87], ["lung", "ANATOMY", 102, 106], ["injury", "OBSERVATION", 107, 113], ["airborne pathogens", "OBSERVATION", 124, 142]]], ["Using this administration route, ATPgS would not promote neutrophil chemotaxis through tissue along a chemotactic gradient [121] , which is a major role postulated for this P2Y receptor.The P2Y 2 R in Acute and Chronic DisordersOn inflammatory cells, P2Y 2 R activation initiates the pro-inflammatory responses required to eradicate microbial pathogens through a series of highly coordinated events culminating in phagocytosis and destruction.", [["neutrophil", "ANATOMY", 57, 67], ["tissue", "ANATOMY", 87, 93], ["Chronic DisordersOn inflammatory cells", "ANATOMY", 211, 249], ["ATPgS", "CHEMICAL", 33, 38], ["ATPgS", "SIMPLE_CHEMICAL", 33, 38], ["neutrophil", "CELL", 57, 67], ["tissue", "TISSUE", 87, 93], ["P2Y receptor", "GENE_OR_GENE_PRODUCT", 173, 185], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 190, 197], ["cells", "CELL", 244, 249], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 251, 258], ["ATPgS", "PROTEIN", 33, 38], ["P2Y receptor", "PROTEIN", 173, 185], ["P2Y 2 R", "PROTEIN", 190, 197], ["this administration route", "TREATMENT", 6, 31], ["ATPgS", "TREATMENT", 33, 38], ["a chemotactic gradient", "TEST", 100, 122], ["this P2Y receptor", "TREATMENT", 168, 185], ["The P2Y", "TEST", 186, 193], ["Acute and Chronic DisordersOn inflammatory cells", "PROBLEM", 201, 249], ["P2Y", "TEST", 251, 254], ["the pro-inflammatory responses", "PROBLEM", 280, 310], ["microbial pathogens", "PROBLEM", 333, 352], ["highly coordinated events", "PROBLEM", 373, 398], ["phagocytosis", "PROBLEM", 414, 426], ["destruction", "PROBLEM", 431, 442], ["neutrophil chemotaxis", "OBSERVATION", 57, 78], ["Acute", "OBSERVATION_MODIFIER", 201, 206], ["Chronic", "OBSERVATION_MODIFIER", 211, 218], ["DisordersOn", "OBSERVATION_MODIFIER", 219, 230], ["inflammatory cells", "OBSERVATION", 231, 249], ["phagocytosis", "OBSERVATION_MODIFIER", 414, 426], ["destruction", "OBSERVATION", 431, 442]]], ["In pathological circumstances, like sepsis, they release antimicrobial compounds which cause injury and death of bacteria and host cells (see Chap.", [["cells", "ANATOMY", 131, 136], ["sepsis", "DISEASE", 36, 42], ["death", "DISEASE", 104, 109], ["host cells", "CELL", 126, 136], ["host cells", "CELL_TYPE", 126, 136], ["sepsis", "PROBLEM", 36, 42], ["antimicrobial compounds", "TREATMENT", 57, 80], ["injury", "PROBLEM", 93, 99], ["death", "PROBLEM", 104, 109], ["bacteria", "PROBLEM", 113, 121], ["host cells", "PROBLEM", 126, 136], ["sepsis", "OBSERVATION", 36, 42]]], ["The lung damage associated with excessive neutrophilia contributes to a wide array of respiratory complications, including ARDS, COPD and CF (review: [133] ).", [["lung", "ANATOMY", 4, 8], ["respiratory", "ANATOMY", 86, 97], ["lung damage", "DISEASE", 4, 15], ["neutrophilia", "DISEASE", 42, 54], ["respiratory complications", "DISEASE", 86, 111], ["ARDS", "DISEASE", 123, 127], ["COPD", "DISEASE", 129, 133], ["CF", "DISEASE", 138, 140], ["lung", "ORGAN", 4, 8], ["The lung damage", "PROBLEM", 0, 15], ["excessive neutrophilia", "PROBLEM", 32, 54], ["respiratory complications", "PROBLEM", 86, 111], ["ARDS", "PROBLEM", 123, 127], ["COPD", "PROBLEM", 129, 133], ["lung", "ANATOMY", 4, 8], ["damage", "OBSERVATION", 9, 15], ["excessive", "OBSERVATION_MODIFIER", 32, 41], ["neutrophilia", "OBSERVATION", 42, 54], ["wide", "OBSERVATION_MODIFIER", 72, 76], ["respiratory complications", "OBSERVATION", 86, 111], ["ARDS", "OBSERVATION", 123, 127], ["COPD", "OBSERVATION", 129, 133]]], ["Incidentally, genetic deletion of the P2Y 2 R improves the survival of mice subjected to sepsis by cecal ligation and puncture [134] .", [["cecal", "ANATOMY", 99, 104], ["sepsis", "DISEASE", 89, 95], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 38, 45], ["mice", "ORGANISM", 71, 75], ["P2Y 2 R", "PROTEIN", 38, 45], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75], ["genetic deletion of the P2Y", "PROBLEM", 14, 41], ["sepsis", "PROBLEM", 89, 95], ["cecal ligation", "TREATMENT", 99, 113], ["puncture", "TEST", 118, 126], ["sepsis", "OBSERVATION", 89, 95], ["cecal", "ANATOMY", 99, 104], ["ligation", "OBSERVATION", 105, 113]]], ["These mice exhibited fewer lung neutrophils and less pulmonary damage than wild-type mice.", [["lung neutrophils", "ANATOMY", 27, 43], ["pulmonary", "ANATOMY", 53, 62], ["pulmonary damage", "DISEASE", 53, 69], ["mice", "ORGANISM", 6, 10], ["lung neutrophils", "CELL", 27, 43], ["pulmonary", "ORGAN", 53, 62], ["mice", "ORGANISM", 85, 89], ["lung neutrophils", "CELL_TYPE", 27, 43], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 85, 89], ["fewer lung neutrophils", "PROBLEM", 21, 43], ["less pulmonary damage", "PROBLEM", 48, 69], ["fewer", "OBSERVATION_MODIFIER", 21, 26], ["lung", "ANATOMY", 27, 31], ["neutrophils", "OBSERVATION", 32, 43], ["less", "OBSERVATION_MODIFIER", 48, 52], ["pulmonary", "ANATOMY", 53, 62], ["damage", "OBSERVATION", 63, 69]]], ["Since P2Y 2 R activation provides directionality during neutrophil chemotaxis [121] , the leukocytes of P2Y 2 R \u00c0/\u00c0 mice lack the ability to follow an ATP gradient toward the lung.", [["neutrophil", "ANATOMY", 56, 66], ["leukocytes", "ANATOMY", 90, 100], ["lung", "ANATOMY", 175, 179], ["ATP", "CHEMICAL", 151, 154], ["ATP", "CHEMICAL", 151, 154], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 6, 13], ["neutrophil", "CELL", 56, 66], ["leukocytes", "CELL", 90, 100], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 104, 111], ["ATP", "SIMPLE_CHEMICAL", 151, 154], ["lung", "ORGAN", 175, 179], ["P2Y 2 R", "PROTEIN", 6, 13], ["neutrophil", "CELL_TYPE", 56, 66], ["leukocytes", "CELL_TYPE", 90, 100], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["neutrophil chemotaxis", "TEST", 56, 77], ["the leukocytes", "TEST", 86, 100], ["P2Y", "TEST", 104, 107], ["an ATP gradient", "TEST", 148, 163], ["lung", "ANATOMY", 175, 179]]], ["This study suggests that intraperitoneal P2Y 2 R antagonists may improve the survival of sepsis patients.The P2Y 2 R in Acute and Chronic DisordersChronic respiratory diseases are commonly associated with elevated airway ATP concentrations, as reported in CF, IPF and COPD patients [135] [136] [137] [138] , and they are raised by allergens in asthmatic patients [68] .", [["intraperitoneal", "ANATOMY", 25, 40], ["respiratory", "ANATOMY", 155, 166], ["airway", "ANATOMY", 214, 220], ["sepsis", "DISEASE", 89, 95], ["P2Y 2 R", "CHEMICAL", 109, 116], ["Chronic respiratory diseases", "DISEASE", 147, 175], ["ATP", "CHEMICAL", 221, 224], ["IPF", "DISEASE", 260, 263], ["COPD", "DISEASE", 268, 272], ["asthmatic", "DISEASE", 344, 353], ["ATP", "CHEMICAL", 221, 224], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 40], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 41, 48], ["patients", "ORGANISM", 96, 104], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 109, 116], ["airway", "MULTI-TISSUE_STRUCTURE", 214, 220], ["ATP", "SIMPLE_CHEMICAL", 221, 224], ["patients", "ORGANISM", 273, 281], ["patients", "ORGANISM", 354, 362], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 273, 281], ["patients", "SPECIES", 354, 362], ["This study", "TEST", 0, 10], ["intraperitoneal P2Y 2 R antagonists", "TREATMENT", 25, 60], ["sepsis patients", "PROBLEM", 89, 104], ["Acute and Chronic Disorders", "PROBLEM", 120, 147], ["Chronic respiratory diseases", "PROBLEM", 147, 175], ["elevated airway ATP concentrations", "PROBLEM", 205, 239], ["IPF", "PROBLEM", 260, 263], ["COPD", "PROBLEM", 268, 272], ["intraperitoneal", "ANATOMY", 25, 40], ["sepsis", "OBSERVATION", 89, 95], ["Acute", "OBSERVATION_MODIFIER", 120, 125], ["Chronic", "OBSERVATION_MODIFIER", 130, 137], ["Disorders", "OBSERVATION", 138, 147], ["Chronic", "OBSERVATION_MODIFIER", 147, 154], ["respiratory diseases", "OBSERVATION", 155, 175], ["airway", "ANATOMY", 214, 220], ["ATP concentrations", "OBSERVATION", 221, 239], ["IPF", "OBSERVATION", 260, 263], ["COPD", "OBSERVATION", 268, 272]]], ["The expression of P2Y 2 Rs is also expected to be elevated in these diseases, as chronic exposure to pathogens or allergens up-regulate the receptor in animal models.", [["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 18, 26], ["P2Y 2 Rs", "PROTEIN", 18, 26], ["these diseases", "PROBLEM", 62, 76], ["chronic exposure to pathogens", "PROBLEM", 81, 110], ["allergens", "PROBLEM", 114, 123], ["elevated", "OBSERVATION_MODIFIER", 50, 58], ["diseases", "OBSERVATION", 68, 76], ["chronic", "OBSERVATION_MODIFIER", 81, 88]]], ["For instance, house dust mites caused an increase in P2Y 2 R expression in eosinophils and dendritic cells from asthmatic patients, which significantly enhanced chemotaxis [139] .", [["eosinophils", "ANATOMY", 75, 86], ["dendritic cells", "ANATOMY", 91, 106], ["asthmatic", "DISEASE", 112, 121], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 53, 60], ["eosinophils", "CELL", 75, 86], ["dendritic cells", "CELL", 91, 106], ["patients", "ORGANISM", 122, 130], ["P2Y 2 R", "PROTEIN", 53, 60], ["eosinophils", "CELL_TYPE", 75, 86], ["dendritic cells", "CELL_TYPE", 91, 106], ["patients", "SPECIES", 122, 130], ["an increase in P2Y 2 R expression in eosinophils", "PROBLEM", 38, 86], ["dendritic cells", "PROBLEM", 91, 106], ["asthmatic patients", "PROBLEM", 112, 130], ["significantly enhanced chemotaxis", "PROBLEM", 138, 171], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["eosinophils", "ANATOMY", 75, 86], ["dendritic cells", "OBSERVATION", 91, 106], ["asthmatic patients", "OBSERVATION", 112, 130]]], ["It is important to point out that cells from healthy subjects did not up-regulate P2Y 2 Rs in response to house dust mites, indicating that the purinergic regulation of inflammatory responses is not normally modified by allergens in the general population.", [["cells", "ANATOMY", 34, 39], ["cells", "CELL", 34, 39], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 82, 90], ["P2Y 2 Rs", "PROTEIN", 82, 90], ["inflammatory responses", "PROBLEM", 169, 191], ["inflammatory", "OBSERVATION", 169, 181]]], ["On the other hand, rat alveolar Type 2 cells exposed overnight to LPS reacted by raising P2Y 2 R transcripts by threefold, which resulted in a significant increase in the ATPmediated surfactant secretion [30] .", [["alveolar Type 2 cells", "ANATOMY", 23, 44], ["LPS", "CHEMICAL", 66, 69], ["rat", "ORGANISM", 19, 22], ["alveolar Type 2 cells", "CELL", 23, 44], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 89, 96], ["rat alveolar Type 2 cells", "CELL_LINE", 19, 44], ["P2Y 2 R transcripts", "RNA", 89, 108], ["rat", "SPECIES", 19, 22], ["rat alveolar Type 2 cells", "PROBLEM", 19, 44], ["LPS", "TEST", 66, 69], ["P2Y", "TEST", 89, 92], ["a significant increase", "PROBLEM", 141, 163], ["the ATPmediated surfactant secretion", "PROBLEM", 167, 203], ["alveolar", "ANATOMY", 23, 31], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["increase", "OBSERVATION_MODIFIER", 155, 163]]], ["Whereas P2Y 2 R overexpression may improve MCC, the pro-inflammatory reactions of immune and inflammatory cells may aggravate airway inflammation.", [["MCC", "ANATOMY", 43, 46], ["inflammatory cells", "ANATOMY", 93, 111], ["airway", "ANATOMY", 126, 132], ["airway inflammation", "DISEASE", 126, 145], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 8, 15], ["MCC", "CANCER", 43, 46], ["immune", "CELL", 82, 88], ["inflammatory cells", "CELL", 93, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 126, 132], ["P2Y 2 R", "PROTEIN", 8, 15], ["immune and inflammatory cells", "CELL_TYPE", 82, 111], ["MCC", "PROBLEM", 43, 46], ["the pro-inflammatory reactions", "PROBLEM", 48, 78], ["immune and inflammatory cells", "PROBLEM", 82, 111], ["airway inflammation", "PROBLEM", 126, 145], ["pro-inflammatory", "OBSERVATION_MODIFIER", 52, 68], ["inflammatory cells", "OBSERVATION", 93, 111], ["airway", "ANATOMY", 126, 132], ["inflammation", "OBSERVATION", 133, 145]]], ["Therefore, it is particularly important to understand the costs and benefits of P2Y 2 Rs in chronic diseases before we can envision therapeutic applications.The P2Y 2 R in Acute and Chronic DisordersAsthmatic patients maintain normal airway ATP levels, but these concentrations rise tenfold in response to an allergen [68] .", [["airway", "ANATOMY", 234, 240], ["chronic diseases", "DISEASE", 92, 108], ["ATP", "CHEMICAL", 241, 244], ["ATP", "CHEMICAL", 241, 244], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 80, 88], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 161, 168], ["patients", "ORGANISM", 209, 217], ["airway", "MULTI-TISSUE_STRUCTURE", 234, 240], ["ATP", "SIMPLE_CHEMICAL", 241, 244], ["patients", "SPECIES", 209, 217], ["chronic diseases", "PROBLEM", 92, 108], ["therapeutic applications", "TREATMENT", 132, 156], ["Acute and Chronic DisordersAsthmatic patients", "PROBLEM", 172, 217], ["these concentrations rise tenfold", "PROBLEM", 257, 290], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["diseases", "OBSERVATION", 100, 108], ["Acute", "OBSERVATION_MODIFIER", 172, 177], ["Chronic", "OBSERVATION_MODIFIER", 182, 189], ["DisordersAsthmatic", "OBSERVATION", 190, 208], ["normal airway", "OBSERVATION", 227, 240], ["ATP levels", "OBSERVATION", 241, 251]]], ["The consequences of this excess ATP were examined in the OVA sensitization/challenge model of allergic asthma [68] .", [["ATP", "CHEMICAL", 32, 35], ["allergic asthma", "DISEASE", 94, 109], ["ATP", "CHEMICAL", 32, 35], ["ATP", "SIMPLE_CHEMICAL", 32, 35], ["this excess ATP", "PROBLEM", 20, 35], ["the OVA sensitization", "TREATMENT", 53, 74], ["allergic asthma", "PROBLEM", 94, 109], ["allergic asthma", "OBSERVATION", 94, 109]]], ["The mice are sensitized by intra-peritoneal injection, and then challenged by nebulization 10 days later.", [["intra-peritoneal", "ANATOMY", 27, 43], ["mice", "ORGANISM", 4, 8], ["intra-peritoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 43], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["intra-peritoneal injection", "TREATMENT", 27, 53], ["intra-peritoneal", "ANATOMY", 27, 43]]], ["After 24 h, their BAL fluid had accumulated eightfold higher ATP concentrations than in the saline-challenged control animals, as reported in the allergen-challenged asthmatic patients.", [["BAL fluid", "ANATOMY", 18, 27], ["ATP", "CHEMICAL", 61, 64], ["asthmatic", "DISEASE", 166, 175], ["ATP", "CHEMICAL", 61, 64], ["BAL fluid", "ORGANISM_SUBSTANCE", 18, 27], ["ATP", "SIMPLE_CHEMICAL", 61, 64], ["saline", "SIMPLE_CHEMICAL", 92, 98], ["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["their BAL fluid", "TEST", 12, 27], ["the saline", "TREATMENT", 88, 98], ["eightfold", "OBSERVATION_MODIFIER", 44, 53], ["higher", "OBSERVATION_MODIFIER", 54, 60], ["ATP concentrations", "OBSERVATION", 61, 79], ["asthmatic patients", "OBSERVATION", 166, 184]]], ["They also developed all major features of allergic asthma, including eosinophil-dominant lung infiltrates, goblet cell metaplasia, hyperresponsiveness to methacholine and Th2 inflammation in the lymph nodes (IL-4, IL-5 and IL-13).", [["eosinophil", "ANATOMY", 69, 79], ["lung", "ANATOMY", 89, 93], ["goblet cell metaplasia", "ANATOMY", 107, 129], ["lymph nodes", "ANATOMY", 195, 206], ["allergic asthma", "DISEASE", 42, 57], ["methacholine", "CHEMICAL", 154, 166], ["methacholine", "CHEMICAL", 154, 166], ["eosinophil", "CELL", 69, 79], ["lung infiltrates", "PATHOLOGICAL_FORMATION", 89, 105], ["goblet cell metaplasia", "CELL", 107, 129], ["methacholine", "SIMPLE_CHEMICAL", 154, 166], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 195, 206], ["IL-4", "GENE_OR_GENE_PRODUCT", 208, 212], ["IL-5", "GENE_OR_GENE_PRODUCT", 214, 218], ["IL-13", "GENE_OR_GENE_PRODUCT", 223, 228], ["allergic asthma", "PROBLEM", 42, 57], ["eosinophil-dominant lung infiltrates", "PROBLEM", 69, 105], ["goblet cell metaplasia", "PROBLEM", 107, 129], ["hyperresponsiveness", "PROBLEM", 131, 150], ["methacholine", "TREATMENT", 154, 166], ["Th2 inflammation in the lymph nodes", "PROBLEM", 171, 206], ["IL", "TEST", 208, 210], ["IL", "TEST", 214, 216], ["allergic asthma", "OBSERVATION", 42, 57], ["eosinophil", "OBSERVATION_MODIFIER", 69, 79], ["dominant", "OBSERVATION_MODIFIER", 80, 88], ["lung", "ANATOMY", 89, 93], ["infiltrates", "OBSERVATION", 94, 105], ["goblet cell metaplasia", "OBSERVATION", 107, 129], ["Th2 inflammation", "OBSERVATION", 171, 187], ["lymph nodes", "OBSERVATION", 195, 206]]], ["These complications were significantly reduced when the OVA challenges were conducted in the presence of an ATPmetabolizing enzyme (apyrase) or P2Y receptor antagonist (PPADS or suramin).", [["apyrase", "CHEMICAL", 132, 139], ["PPADS", "CHEMICAL", 169, 174], ["suramin", "CHEMICAL", 178, 185], ["PPADS", "CHEMICAL", 169, 174], ["suramin", "CHEMICAL", 178, 185], ["apyrase", "SIMPLE_CHEMICAL", 132, 139], ["P2Y receptor antagonist", "GENE_OR_GENE_PRODUCT", 144, 167], ["PPADS", "SIMPLE_CHEMICAL", 169, 174], ["suramin", "SIMPLE_CHEMICAL", 178, 185], ["ATPmetabolizing enzyme", "PROTEIN", 108, 130], ["These complications", "PROBLEM", 0, 19], ["the OVA challenges", "TREATMENT", 52, 70], ["an ATPmetabolizing enzyme (apyrase", "TREATMENT", 105, 139], ["P2Y receptor antagonist (PPADS", "TREATMENT", 144, 174], ["suramin", "TREATMENT", 178, 185]]], ["Through a series of elegant in vivo and in vitro protocols, Idzko et al. demonstrated that the excess ATP generated after an allergen challenge triggers airway inflammation by the activation of resident dendritic cells, and their mobilization to the lymph nodes to trigger a Th2 type of inflammation.", [["airway", "ANATOMY", 153, 159], ["dendritic cells", "ANATOMY", 203, 218], ["lymph nodes", "ANATOMY", 250, 261], ["ATP", "CHEMICAL", 102, 105], ["inflammation", "DISEASE", 160, 172], ["inflammation", "DISEASE", 287, 299], ["ATP", "CHEMICAL", 102, 105], ["ATP", "SIMPLE_CHEMICAL", 102, 105], ["airway", "MULTI-TISSUE_STRUCTURE", 153, 159], ["dendritic cells", "CELL", 203, 218], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 250, 261], ["resident dendritic cells", "CELL_TYPE", 194, 218], ["elegant in vivo", "TREATMENT", 20, 35], ["vitro protocols", "TREATMENT", 43, 58], ["the excess ATP", "PROBLEM", 91, 105], ["an allergen challenge", "TREATMENT", 122, 143], ["airway inflammation", "PROBLEM", 153, 172], ["dendritic cells", "PROBLEM", 203, 218], ["the lymph nodes", "PROBLEM", 246, 261], ["inflammation", "PROBLEM", 287, 299], ["airway", "ANATOMY", 153, 159], ["inflammation", "OBSERVATION", 160, 172], ["dendritic cells", "OBSERVATION", 203, 218], ["lymph nodes", "OBSERVATION", 250, 261], ["inflammation", "OBSERVATION", 287, 299]]], ["It is interesting that excess ATP in the BAL fluid was not detected 10 min, but rather 24 h, after the challenge in asthmatic patients and in the mice.", [["BAL fluid", "ANATOMY", 41, 50], ["ATP", "CHEMICAL", 30, 33], ["asthmatic", "DISEASE", 116, 125], ["ATP", "CHEMICAL", 30, 33], ["ATP", "SIMPLE_CHEMICAL", 30, 33], ["BAL fluid", "ORGANISM_SUBSTANCE", 41, 50], ["patients", "ORGANISM", 126, 134], ["mice", "ORGANISM", 146, 150], ["patients", "SPECIES", 126, 134], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["excess ATP", "PROBLEM", 23, 33], ["the BAL fluid", "TEST", 37, 50], ["excess ATP", "OBSERVATION", 23, 33], ["BAL", "ANATOMY", 41, 44], ["fluid", "OBSERVATION", 45, 50]]], ["The mechanisms behind the delayed accumulation of ATP into the airways have not been identified.", [["airways", "ANATOMY", 63, 70], ["ATP", "CHEMICAL", 50, 53], ["ATP", "CHEMICAL", 50, 53], ["ATP", "SIMPLE_CHEMICAL", 50, 53], ["airways", "MULTI-TISSUE_STRUCTURE", 63, 70], ["the delayed accumulation of ATP into the airways", "PROBLEM", 22, 70], ["delayed", "OBSERVATION_MODIFIER", 26, 33], ["accumulation", "OBSERVATION", 34, 46], ["airways", "ANATOMY", 63, 70]]], ["However, oxidative stress building gradually with airway inflammation has been shown to inhibit CD39 [140] , and ATP-hydrolyzing ectonucleotidases expressed on airway epithelial [141] , immune and inflammatory [142] cells.", [["airway", "ANATOMY", 50, 56], ["airway epithelial [141]", "ANATOMY", 160, 183], ["inflammatory [142] cells", "ANATOMY", 197, 221], ["airway inflammation", "DISEASE", 50, 69], ["ATP", "CHEMICAL", 113, 116], ["ATP", "CHEMICAL", 113, 116], ["airway", "MULTI-TISSUE_STRUCTURE", 50, 56], ["CD39 [140]", "GENE_OR_GENE_PRODUCT", 96, 106], ["ATP", "SIMPLE_CHEMICAL", 113, 116], ["ectonucleotidases", "GENE_OR_GENE_PRODUCT", 129, 146], ["airway epithelial [141]", "CELL", 160, 183], ["immune", "CELL", 186, 192], ["inflammatory [142] cells", "CELL", 197, 221], ["CD39", "PROTEIN", 96, 100], ["ectonucleotidases", "PROTEIN", 129, 146], ["immune and inflammatory [142] cells", "CELL_LINE", 186, 221], ["oxidative stress building", "PROBLEM", 9, 34], ["airway inflammation", "PROBLEM", 50, 69], ["CD39", "TEST", 96, 100], ["ATP", "TEST", 113, 116], ["hydrolyzing ectonucleotidases", "PROBLEM", 117, 146], ["airway epithelial", "TEST", 160, 177], ["immune and inflammatory [142] cells", "PROBLEM", 186, 221], ["airway", "ANATOMY", 50, 56], ["inflammation", "OBSERVATION", 57, 69], ["airway epithelial", "ANATOMY", 160, 177], ["inflammatory", "OBSERVATION_MODIFIER", 197, 209]]], ["Consequently, this study supports the therapeutic potential of P2Y receptor antagonists for the treatment of airway inflammation in asthmatic patients.The P2Y 2 R in Acute and Chronic DisordersMore recently, P2Y 2 R \u00c0/\u00c0 mice were subjected to this model of allergic asthma to identify the mechanism by which P2Y 2 Rs promote eosinophilia [139, 143] .", [["airway", "ANATOMY", 109, 115], ["airway inflammation", "DISEASE", 109, 128], ["asthmatic", "DISEASE", 132, 141], ["allergic asthma", "DISEASE", 257, 272], ["eosinophilia", "DISEASE", 325, 337], ["P2Y receptor antagonists", "GENE_OR_GENE_PRODUCT", 63, 87], ["airway", "MULTI-TISSUE_STRUCTURE", 109, 115], ["patients", "ORGANISM", 142, 150], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 155, 162], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 208, 215], ["mice", "ORGANISM", 220, 224], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 308, 316], ["patients", "SPECIES", 142, 150], ["mice", "SPECIES", 220, 224], ["mice", "SPECIES", 220, 224], ["this study", "TEST", 14, 24], ["P2Y receptor antagonists", "TREATMENT", 63, 87], ["airway inflammation", "PROBLEM", 109, 128], ["asthmatic patients", "PROBLEM", 132, 150], ["Acute and Chronic Disorders", "PROBLEM", 166, 193], ["P2Y", "TEST", 208, 211], ["mice", "PROBLEM", 220, 224], ["allergic asthma", "PROBLEM", 257, 272], ["P2Y", "TEST", 308, 311], ["eosinophilia", "TEST", 325, 337], ["airway", "ANATOMY", 109, 115], ["inflammation", "OBSERVATION", 116, 128], ["Acute", "OBSERVATION_MODIFIER", 166, 171], ["Chronic", "OBSERVATION_MODIFIER", 176, 183], ["Disorders", "OBSERVATION", 184, 193], ["allergic asthma", "OBSERVATION", 257, 272], ["eosinophilia", "OBSERVATION", 325, 337]]], ["The P2Y 2 R \u00c0/\u00c0 mice exhibited a weaker capacity to recruit eosinophils in response to the OVA exposure protocol than the wild-type mice [143] .", [["eosinophils", "ANATOMY", 60, 71], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 4, 11], ["eosinophils", "CELL", 60, 71], ["OVA", "SIMPLE_CHEMICAL", 91, 94], ["mice", "ORGANISM", 132, 136], ["eosinophils", "CELL_TYPE", 60, 71], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 132, 136], ["The P2Y", "TEST", 0, 7], ["a weaker capacity", "PROBLEM", 31, 48], ["eosinophils", "TEST", 60, 71], ["the OVA exposure protocol", "TREATMENT", 87, 112], ["eosinophils", "OBSERVATION", 60, 71]]], ["In vitro assays showed that circulating dendritic cells and bone marrow eosinophils collected from P2Y 2 R \u00c0/\u00c0 mice fail to migrate within an ATP gradient [139] .", [["dendritic cells", "ANATOMY", 40, 55], ["bone marrow eosinophils", "ANATOMY", 60, 83], ["ATP", "CHEMICAL", 142, 145], ["ATP", "CHEMICAL", 142, 145], ["dendritic cells", "CELL", 40, 55], ["bone marrow eosinophils", "CELL", 60, 83], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 99, 106], ["ATP", "SIMPLE_CHEMICAL", 142, 145], ["circulating dendritic cells", "CELL_TYPE", 28, 55], ["bone marrow eosinophils", "CELL_TYPE", 60, 83], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["vitro assays", "TEST", 3, 15], ["circulating dendritic cells", "PROBLEM", 28, 55], ["bone marrow eosinophils", "TEST", 60, 83], ["P2Y", "TEST", 99, 102], ["an ATP gradient", "TEST", 139, 154], ["dendritic cells", "OBSERVATION", 40, 55], ["bone", "ANATOMY", 60, 64], ["marrow eosinophils", "OBSERVATION", 65, 83]]], ["Three findings support a role for the P2Y 2 R-mediated up-regulation of VCAM-1 in the purinergic stimulation of lung eosinophilia.", [["lung", "ANATOMY", 112, 116], ["lung eosinophilia", "DISEASE", 112, 129], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 38, 45], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 72, 78], ["lung", "ORGAN", 112, 116], ["P2Y 2 R", "PROTEIN", 38, 45], ["VCAM-1", "PROTEIN", 72, 78], ["the P2Y", "TEST", 34, 41], ["VCAM", "TEST", 72, 76], ["lung eosinophilia", "PROBLEM", 112, 129], ["lung", "ANATOMY", 112, 116], ["eosinophilia", "OBSERVATION", 117, 129]]], ["This molecule is a potent chemoattractant and adhesion molecule for eosinophils (review: [144] ).", [["eosinophils", "ANATOMY", 68, 79], ["eosinophils", "CELL", 68, 79], ["adhesion molecule", "PROTEIN", 46, 63], ["eosinophils", "CELL_TYPE", 68, 79], ["potent chemoattractant", "OBSERVATION_MODIFIER", 19, 41]]], ["First, the OVA challenge caused the accumulation of soluble VCAM-1 in the BAL fluid, but to a lower level in P2Y 2 R \u00c0/\u00c0 mice [143] .", [["BAL fluid", "ANATOMY", 74, 83], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 60, 66], ["BAL fluid", "ORGANISM_SUBSTANCE", 74, 83], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 109, 116], ["VCAM", "PROTEIN", 60, 64], ["mice", "SPECIES", 121, 125], ["the OVA challenge", "TREATMENT", 7, 24], ["soluble VCAM", "TEST", 52, 64], ["the BAL fluid", "TEST", 70, 83], ["P2Y", "TEST", 109, 112], ["BAL", "ANATOMY", 74, 77], ["fluid", "OBSERVATION", 78, 83]]], ["Second, OVA also induced an up-regulation of membranebound VCAM-1 at the surface of lung endothelial cells, but to a lower extent in P2Y 2 R \u00c0/\u00c0 mice.", [["surface", "ANATOMY", 73, 80], ["lung endothelial cells", "ANATOMY", 84, 106], ["OVA", "SIMPLE_CHEMICAL", 8, 11], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 59, 65], ["surface", "CELLULAR_COMPONENT", 73, 80], ["lung endothelial cells", "CELL", 84, 106], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 133, 140], ["membranebound VCAM-1", "PROTEIN", 45, 65], ["lung endothelial cells", "CELL_TYPE", 84, 106], ["mice", "SPECIES", 145, 149], ["OVA", "PROBLEM", 8, 11], ["membranebound VCAM", "TEST", 45, 63], ["lung endothelial cells", "PROBLEM", 84, 106], ["P2Y", "TEST", 133, 136], ["lung", "ANATOMY", 84, 88], ["endothelial cells", "OBSERVATION", 89, 106], ["lower extent", "OBSERVATION_MODIFIER", 117, 129]]], ["Finally, adhesion assays confirmed that ATP promotes eosinophil adhesion to the endothelial surface through a P2Y 2 R-mediated increase in VCAM-1 surface expression.", [["eosinophil", "ANATOMY", 53, 63], ["endothelial surface", "ANATOMY", 80, 99], ["surface", "ANATOMY", 146, 153], ["ATP", "CHEMICAL", 40, 43], ["ATP", "CHEMICAL", 40, 43], ["ATP", "SIMPLE_CHEMICAL", 40, 43], ["eosinophil", "CELL", 53, 63], ["endothelial surface", "CELLULAR_COMPONENT", 80, 99], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 110, 117], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 139, 145], ["P2Y 2 R", "PROTEIN", 110, 117], ["VCAM", "PROTEIN", 139, 143], ["adhesion assays", "TEST", 9, 24], ["ATP", "PROBLEM", 40, 43], ["eosinophil adhesion", "TREATMENT", 53, 72], ["a P2Y", "TEST", 108, 113], ["VCAM", "TEST", 139, 143], ["eosinophil adhesion", "OBSERVATION", 53, 72], ["endothelial", "ANATOMY", 80, 91], ["increase", "OBSERVATION_MODIFIER", 127, 135]]], ["Collectively, these studies suggest that an amplification of the ATP-P2Y 2 R signaling in asthmatic patients during an allergic reaction, contributes to the development of lung eosinophilia.", [["lung", "ANATOMY", 172, 176], ["ATP", "CHEMICAL", 65, 68], ["asthmatic", "DISEASE", 90, 99], ["allergic reaction", "DISEASE", 119, 136], ["lung eosinophilia", "DISEASE", 172, 189], ["ATP", "CHEMICAL", 65, 68], ["ATP-P2Y 2 R", "GENE_OR_GENE_PRODUCT", 65, 76], ["patients", "ORGANISM", 100, 108], ["lung", "ORGAN", 172, 176], ["patients", "SPECIES", 100, 108], ["these studies", "TEST", 14, 27], ["the ATP", "TEST", 61, 68], ["P2Y", "PROBLEM", 69, 72], ["asthmatic patients", "PROBLEM", 90, 108], ["an allergic reaction", "PROBLEM", 116, 136], ["lung eosinophilia", "PROBLEM", 172, 189], ["asthmatic", "OBSERVATION", 90, 99], ["allergic reaction", "OBSERVATION", 119, 136], ["lung", "ANATOMY", 172, 176], ["eosinophilia", "OBSERVATION", 177, 189]]], ["Accordingly, asthmatic patients may benefit from the intravenous injection of P2Y 2 R antagonists to suppress eosinophil recruitment to the airways.The P2Y 2 R in Acute and Chronic DisordersChronic obstructive pulmonary disease is another interesting example of P2Y 2 Rdominant lung pathology.", [["intravenous", "ANATOMY", 53, 64], ["eosinophil", "ANATOMY", 110, 120], ["airways", "ANATOMY", 140, 147], ["pulmonary", "ANATOMY", 210, 219], ["lung", "ANATOMY", 278, 282], ["asthmatic", "DISEASE", 13, 22], ["P2Y 2 R", "CHEMICAL", 152, 159], ["Chronic obstructive pulmonary disease", "DISEASE", 190, 227], ["patients", "ORGANISM", 23, 31], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 64], ["P2Y 2 R antagonists", "GENE_OR_GENE_PRODUCT", 78, 97], ["eosinophil", "CELL", 110, 120], ["airways", "MULTI-TISSUE_STRUCTURE", 140, 147], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 152, 159], ["pulmonary", "ORGAN", 210, 219], ["P2Y 2", "GENE_OR_GENE_PRODUCT", 262, 267], ["lung", "ORGAN", 278, 282], ["patients", "SPECIES", 23, 31], ["the intravenous injection", "TREATMENT", 49, 74], ["P2Y 2 R antagonists", "TREATMENT", 78, 97], ["eosinophil recruitment", "TREATMENT", 110, 132], ["Acute and Chronic Disorders", "PROBLEM", 163, 190], ["Chronic obstructive pulmonary disease", "PROBLEM", 190, 227], ["P2Y 2 Rdominant lung pathology", "PROBLEM", 262, 292], ["eosinophil recruitment", "OBSERVATION", 110, 132], ["airways", "ANATOMY", 140, 147], ["Acute", "OBSERVATION_MODIFIER", 163, 168], ["Chronic", "OBSERVATION_MODIFIER", 173, 180], ["Disorders", "OBSERVATION", 181, 190], ["Chronic", "OBSERVATION_MODIFIER", 190, 197], ["obstructive", "OBSERVATION_MODIFIER", 198, 209], ["pulmonary", "ANATOMY", 210, 219], ["disease", "OBSERVATION", 220, 227], ["lung", "ANATOMY", 278, 282], ["pathology", "OBSERVATION", 283, 292]]], ["The discovery that the murine model of smoke-induced lung inflammation and emphysema reproduces the high airway ATP concentrations of COPD patients provided the necessary tools to investigate the role of purinergic deregulation in the pathogenesis of this disease [145] .", [["lung", "ANATOMY", 53, 57], ["airway", "ANATOMY", 105, 111], ["smoke", "CHEMICAL", 39, 44], ["lung inflammation", "DISEASE", 53, 70], ["emphysema", "DISEASE", 75, 84], ["ATP", "CHEMICAL", 112, 115], ["COPD", "DISEASE", 134, 138], ["ATP", "CHEMICAL", 112, 115], ["murine", "ORGANISM", 23, 29], ["lung", "ORGAN", 53, 57], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["ATP", "SIMPLE_CHEMICAL", 112, 115], ["patients", "ORGANISM", 139, 147], ["purinergic", "SIMPLE_CHEMICAL", 204, 214], ["murine", "SPECIES", 23, 29], ["patients", "SPECIES", 139, 147], ["lung inflammation", "PROBLEM", 53, 70], ["emphysema", "PROBLEM", 75, 84], ["the high airway ATP concentrations of COPD", "PROBLEM", 96, 138], ["purinergic deregulation", "PROBLEM", 204, 227], ["this disease", "PROBLEM", 251, 263], ["lung", "ANATOMY", 53, 57], ["inflammation", "OBSERVATION", 58, 70], ["emphysema", "OBSERVATION", 75, 84], ["purinergic deregulation", "OBSERVATION", 204, 227]]], ["First, the role of ATP in the early events of airway inflammation was investigated using an acute cigarette smoke exposure protocol, which consisted of a daily 20 min session for 4 days.", [["airway", "ANATOMY", 46, 52], ["ATP", "CHEMICAL", 19, 22], ["airway inflammation", "DISEASE", 46, 65], ["ATP", "CHEMICAL", 19, 22], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["airway", "MULTI-TISSUE_STRUCTURE", 46, 52], ["ATP", "TREATMENT", 19, 22], ["airway inflammation", "PROBLEM", 46, 65], ["an acute cigarette smoke exposure protocol", "TREATMENT", 89, 131], ["airway", "ANATOMY", 46, 52], ["inflammation", "OBSERVATION", 53, 65]]], ["This acute insult caused an eightfold increase in BAL fluid ATP level, the typical macrophage and neutrophil infiltrates, and the accumulation of their cytokines (IL-1b, IL-6, IFNg, MIP-2 and KC).", [["BAL fluid", "ANATOMY", 50, 59], ["macrophage", "ANATOMY", 83, 93], ["neutrophil infiltrates", "ANATOMY", 98, 120], ["ATP", "CHEMICAL", 60, 63], ["ATP", "CHEMICAL", 60, 63], ["BAL fluid", "ORGANISM_SUBSTANCE", 50, 59], ["ATP", "SIMPLE_CHEMICAL", 60, 63], ["macrophage", "CELL", 83, 93], ["neutrophil", "CELL", 98, 108], ["IL-1b", "GENE_OR_GENE_PRODUCT", 163, 168], ["IL-6", "GENE_OR_GENE_PRODUCT", 170, 174], ["IFNg", "GENE_OR_GENE_PRODUCT", 176, 180], ["MIP-2", "GENE_OR_GENE_PRODUCT", 182, 187], ["KC", "GENE_OR_GENE_PRODUCT", 192, 194], ["neutrophil infiltrates", "CELL_TYPE", 98, 120], ["cytokines", "PROTEIN", 152, 161], ["IL-1b, IL-6", "PROTEIN", 163, 174], ["IFNg", "PROTEIN", 176, 180], ["MIP", "PROTEIN", 182, 185], ["KC", "PROTEIN", 192, 194], ["This acute insult", "PROBLEM", 0, 17], ["an eightfold increase in BAL fluid ATP level", "PROBLEM", 25, 69], ["the typical macrophage", "PROBLEM", 71, 93], ["neutrophil infiltrates", "PROBLEM", 98, 120], ["their cytokines", "TEST", 146, 161], ["IL", "TEST", 163, 165], ["IL", "TEST", 170, 172], ["IFNg", "TEST", 176, 180], ["MIP", "TEST", 182, 185], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["insult", "OBSERVATION", 11, 17], ["eightfold", "OBSERVATION_MODIFIER", 28, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["BAL fluid ATP level", "OBSERVATION", 50, 69], ["typical", "OBSERVATION_MODIFIER", 75, 82], ["macrophage", "OBSERVATION_MODIFIER", 83, 93], ["neutrophil infiltrates", "OBSERVATION", 98, 120], ["accumulation", "OBSERVATION_MODIFIER", 130, 142]]], ["Intratracheal instillation of the ATP-metabolizing apyrase, or a P2Y receptor antagonist (PPADS or suramin), before each smoke inhalation reduced all inflammatory parameters by more than 50%.", [["Intratracheal", "ANATOMY", 0, 13], ["ATP", "CHEMICAL", 34, 37], ["PPADS", "CHEMICAL", 90, 95], ["suramin", "CHEMICAL", 99, 106], ["ATP", "CHEMICAL", 34, 37], ["PPADS", "CHEMICAL", 90, 95], ["suramin", "CHEMICAL", 99, 106], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["ATP", "SIMPLE_CHEMICAL", 34, 37], ["apyrase", "SIMPLE_CHEMICAL", 51, 58], ["PPADS", "SIMPLE_CHEMICAL", 90, 95], ["suramin", "SIMPLE_CHEMICAL", 99, 106], ["Intratracheal instillation", "TREATMENT", 0, 26], ["the ATP", "TREATMENT", 30, 37], ["metabolizing apyrase", "TREATMENT", 38, 58], ["a P2Y receptor antagonist (PPADS", "TREATMENT", 63, 95], ["suramin)", "TREATMENT", 99, 107], ["each smoke inhalation", "TREATMENT", 116, 137], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162]]], ["This acute protocol shows that the excess ATP, accumulating after the first cigarettes, is critical to the early development of smoke-induced airway inflammation.The P2Y 2 R in Acute and Chronic DisordersThe contribution of ATP-induced inflammatory responses to the development of emphysema was studied using a chronic smoke exposure protocol lasting 4 months [145] .", [["airway", "ANATOMY", 142, 148], ["ATP", "CHEMICAL", 42, 45], ["smoke", "CHEMICAL", 128, 133], ["airway inflammation", "DISEASE", 142, 161], ["P2Y 2 R", "CHEMICAL", 166, 173], ["ATP", "CHEMICAL", 224, 227], ["emphysema", "DISEASE", 281, 290], ["ATP", "CHEMICAL", 42, 45], ["ATP", "CHEMICAL", 224, 227], ["ATP", "SIMPLE_CHEMICAL", 42, 45], ["airway", "MULTI-TISSUE_STRUCTURE", 142, 148], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 166, 173], ["ATP", "SIMPLE_CHEMICAL", 224, 227], ["emphysema", "PATHOLOGICAL_FORMATION", 281, 290], ["This acute protocol", "TEST", 0, 19], ["the excess ATP", "PROBLEM", 31, 45], ["airway inflammation", "PROBLEM", 142, 161], ["Acute and Chronic Disorders", "PROBLEM", 177, 204], ["ATP", "PROBLEM", 224, 227], ["inflammatory responses", "PROBLEM", 236, 258], ["emphysema", "PROBLEM", 281, 290], ["a chronic smoke exposure protocol", "TREATMENT", 309, 342], ["excess ATP", "OBSERVATION", 35, 45], ["smoke", "OBSERVATION", 128, 133], ["airway", "ANATOMY", 142, 148], ["inflammation", "OBSERVATION", 149, 161], ["Acute", "OBSERVATION_MODIFIER", 177, 182], ["Chronic", "OBSERVATION_MODIFIER", 187, 194], ["Disorders", "OBSERVATION", 195, 204], ["inflammatory", "OBSERVATION_MODIFIER", 236, 248], ["emphysema", "OBSERVATION", 281, 290]]], ["These mice developed foci of emphysema throughout the parenchyma, which was essentially prevented by oral administration of a P2Y receptor antagonists, suramin or PPADS.", [["foci", "ANATOMY", 21, 25], ["parenchyma", "ANATOMY", 54, 64], ["oral", "ANATOMY", 101, 105], ["emphysema", "DISEASE", 29, 38], ["suramin", "CHEMICAL", 152, 159], ["PPADS", "CHEMICAL", 163, 168], ["suramin", "CHEMICAL", 152, 159], ["PPADS", "CHEMICAL", 163, 168], ["mice", "ORGANISM", 6, 10], ["emphysema", "PATHOLOGICAL_FORMATION", 29, 38], ["parenchyma", "TISSUE", 54, 64], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["P2Y receptor antagonists", "GENE_OR_GENE_PRODUCT", 126, 150], ["suramin", "SIMPLE_CHEMICAL", 152, 159], ["PPADS", "SIMPLE_CHEMICAL", 163, 168], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["emphysema throughout the parenchyma", "PROBLEM", 29, 64], ["a P2Y receptor antagonists", "TREATMENT", 124, 150], ["suramin", "TREATMENT", 152, 159], ["PPADS", "TREATMENT", 163, 168], ["foci", "OBSERVATION_MODIFIER", 21, 25], ["emphysema", "OBSERVATION", 29, 38], ["parenchyma", "ANATOMY", 54, 64]]], ["Real-time PCR analysis of P2 receptor expression in the inflammatory cells and lung parenchyma revealed a dramatic (eightfold) and selective up-regulation of P2Y 2 Rs in the neutrophils of smoke-exposed, compared to air-exposed, animals.", [["inflammatory cells", "ANATOMY", 56, 74], ["lung parenchyma", "ANATOMY", 79, 94], ["neutrophils", "ANATOMY", 174, 185], ["smoke", "CHEMICAL", 189, 194], ["P2 receptor", "GENE_OR_GENE_PRODUCT", 26, 37], ["inflammatory cells", "CELL", 56, 74], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 79, 94], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 158, 166], ["neutrophils", "CELL", 174, 185], ["P2 receptor", "PROTEIN", 26, 37], ["inflammatory cells", "CELL_TYPE", 56, 74], ["P2Y 2 Rs", "PROTEIN", 158, 166], ["neutrophils", "CELL_TYPE", 174, 185], ["Real-time PCR analysis", "TEST", 0, 22], ["P2 receptor expression", "TEST", 26, 48], ["the inflammatory cells", "TEST", 52, 74], ["lung parenchyma", "TEST", 79, 94], ["a dramatic (eightfold)", "PROBLEM", 104, 126], ["P2Y", "TEST", 158, 161], ["inflammatory cells", "OBSERVATION", 56, 74], ["lung", "ANATOMY", 79, 83], ["parenchyma", "ANATOMY_MODIFIER", 84, 94], ["dramatic", "OBSERVATION_MODIFIER", 106, 114], ["neutrophils", "ANATOMY", 174, 185], ["smoke", "OBSERVATION", 189, 194]]], ["The importance of the amplified ATP-P2Y 2 R signaling axis in the development of smoke-induced airway inflammation and emphysema was clearly demonstrated using P2Y 2 R \u00c0/\u00c0 mice and chimera [137] .", [["airway", "ANATOMY", 95, 101], ["ATP", "CHEMICAL", 32, 35], ["smoke", "CHEMICAL", 81, 86], ["airway inflammation", "DISEASE", 95, 114], ["emphysema", "DISEASE", 119, 128], ["ATP", "CHEMICAL", 32, 35], ["ATP-P2Y 2 R", "GENE_OR_GENE_PRODUCT", 32, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 95, 101], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 160, 167], ["mice", "SPECIES", 172, 176], ["the amplified ATP", "TREATMENT", 18, 35], ["P2Y", "TEST", 36, 39], ["airway inflammation", "PROBLEM", 95, 114], ["emphysema", "PROBLEM", 119, 128], ["P2Y", "TEST", 160, 163], ["smoke", "OBSERVATION", 81, 86], ["airway", "ANATOMY", 95, 101], ["inflammation", "OBSERVATION", 102, 114], ["emphysema", "OBSERVATION", 119, 128]]], ["While the source of BAL fluid ATP has not been addressed, in vitro experiments showed that human neutrophils release ATP in response to cigarette smoke in a dosedependent manner, and as efficiently as fMLP [137] .", [["BAL fluid", "ANATOMY", 20, 29], ["neutrophils", "ANATOMY", 97, 108], ["ATP", "CHEMICAL", 30, 33], ["ATP", "CHEMICAL", 117, 120], ["smoke", "CHEMICAL", 146, 151], ["fMLP", "CHEMICAL", 201, 205], ["ATP", "CHEMICAL", 30, 33], ["ATP", "CHEMICAL", 117, 120], ["BAL", "ORGANISM_SUBSTANCE", 20, 23], ["ATP", "SIMPLE_CHEMICAL", 30, 33], ["human", "ORGANISM", 91, 96], ["neutrophils", "CELL", 97, 108], ["ATP", "SIMPLE_CHEMICAL", 117, 120], ["fMLP", "SIMPLE_CHEMICAL", 201, 205], ["human neutrophils", "CELL_TYPE", 91, 108], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["BAL fluid ATP", "TEST", 20, 33], ["human neutrophils release ATP", "PROBLEM", 91, 120]]], ["Also, cigarette smoke induced an ATP-dependent secretion of neutrophil elastase, which is an important mediator of lung destruction in emphysema (review: [146] ).", [["neutrophil", "ANATOMY", 60, 70], ["lung", "ANATOMY", 115, 119], ["smoke", "CHEMICAL", 16, 21], ["ATP", "CHEMICAL", 33, 36], ["lung destruction", "DISEASE", 115, 131], ["emphysema", "DISEASE", 135, 144], ["ATP", "CHEMICAL", 33, 36], ["cigarette", "ORGANISM", 6, 15], ["ATP", "SIMPLE_CHEMICAL", 33, 36], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 60, 79], ["lung", "ORGAN", 115, 119], ["emphysema", "PATHOLOGICAL_FORMATION", 135, 144], ["neutrophil elastase", "PROTEIN", 60, 79], ["an ATP", "PROBLEM", 30, 36], ["neutrophil elastase", "PROBLEM", 60, 79], ["lung destruction in emphysema", "PROBLEM", 115, 144], ["ATP-dependent", "OBSERVATION_MODIFIER", 33, 46], ["secretion", "OBSERVATION_MODIFIER", 47, 56], ["neutrophil elastase", "OBSERVATION", 60, 79], ["lung", "ANATOMY", 115, 119], ["destruction", "OBSERVATION", 120, 131], ["emphysema", "OBSERVATION", 135, 144]]], ["These studies suggest that the initial increase in BAL fluid ATP concentration detected after the first cigarette exposures initiates the development of airway inflammation, which is amplified over time by an up-regulation of P2Y 2 Rs on immune and inflammatory cells (see Chap.", [["BAL fluid", "ANATOMY", 51, 60], ["airway", "ANATOMY", 153, 159], ["inflammatory cells", "ANATOMY", 249, 267], ["ATP", "CHEMICAL", 61, 64], ["airway inflammation", "DISEASE", 153, 172], ["ATP", "CHEMICAL", 61, 64], ["BAL fluid", "ORGANISM_SUBSTANCE", 51, 60], ["ATP", "SIMPLE_CHEMICAL", 61, 64], ["airway", "MULTI-TISSUE_STRUCTURE", 153, 159], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 226, 234], ["immune", "CELL", 238, 244], ["inflammatory cells", "CELL", 249, 267], ["P2Y 2 Rs", "PROTEIN", 226, 234], ["immune and inflammatory cells", "CELL_TYPE", 238, 267], ["Chap", "PROTEIN", 273, 277], ["These studies", "TEST", 0, 13], ["the initial increase", "PROBLEM", 27, 47], ["BAL fluid ATP concentration", "TEST", 51, 78], ["airway inflammation", "PROBLEM", 153, 172], ["an up-regulation of P2Y", "TREATMENT", 206, 229], ["inflammatory cells", "PROBLEM", 249, 267], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["BAL fluid", "OBSERVATION", 51, 60], ["ATP concentration", "OBSERVATION", 61, 78], ["airway", "ANATOMY", 153, 159], ["inflammation", "OBSERVATION", 160, 172], ["inflammatory cells", "OBSERVATION", 249, 267]]], ["Therefore, the oral prescription of apyrase, or a P2 receptor antagonist, could prevent and reduce the irreversible lung damage and loss of lung function in COPD patients.The P2X 7 R in Chronic Lung DiseasesFor years, the importance of P2X 7 Rs for ATP-mediated inflammatory responses has been largely underestimated on the premise that the EC 50 of this receptor is orders of magnitude above that of P2Y 2 Rs (review: [9] ).", [["oral", "ANATOMY", 15, 19], ["lung", "ANATOMY", 116, 120], ["lung", "ANATOMY", 140, 144], ["Lung", "ANATOMY", 194, 198], ["EC", "ANATOMY", 341, 343], ["apyrase", "CHEMICAL", 36, 43], ["lung damage", "DISEASE", 116, 127], ["loss of lung function", "DISEASE", 132, 153], ["COPD", "DISEASE", 157, 161], ["Lung Diseases", "DISEASE", 194, 207], ["ATP", "CHEMICAL", 249, 252], ["ATP", "CHEMICAL", 249, 252], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["apyrase", "SIMPLE_CHEMICAL", 36, 43], ["lung", "ORGAN", 116, 120], ["lung", "ORGAN", 140, 144], ["patients", "ORGANISM", 162, 170], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 175, 182], ["Lung", "ORGAN", 194, 198], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 236, 244], ["ATP", "SIMPLE_CHEMICAL", 249, 252], ["EC", "CELL", 341, 343], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 401, 409], ["P2X 7 R", "PROTEIN", 175, 182], ["P2X 7 Rs", "PROTEIN", 236, 244], ["patients", "SPECIES", 162, 170], ["apyrase", "TREATMENT", 36, 43], ["a P2 receptor antagonist", "TREATMENT", 48, 72], ["the irreversible lung damage", "PROBLEM", 99, 127], ["loss of lung function in COPD patients", "PROBLEM", 132, 170], ["Chronic Lung Diseases", "PROBLEM", 186, 207], ["P2X", "TEST", 236, 239], ["ATP-mediated inflammatory responses", "PROBLEM", 249, 284], ["irreversible", "OBSERVATION_MODIFIER", 103, 115], ["lung", "ANATOMY", 116, 120], ["damage", "OBSERVATION", 121, 127], ["lung", "ANATOMY", 140, 144], ["7 R", "OBSERVATION_MODIFIER", 179, 182], ["Chronic", "OBSERVATION_MODIFIER", 186, 193], ["Lung", "ANATOMY", 194, 198], ["Diseases", "OBSERVATION", 199, 207], ["inflammatory", "OBSERVATION", 262, 274]]], ["However, the elegant work of Di Virgilio et al. clearly demonstrated that sites of inflammation or tissue injury accumulate ATP in the high micromolar range in vivo, above the activation threshold of P2X 7 Rs (Chap.", [["sites", "ANATOMY", 74, 79], ["tissue", "ANATOMY", 99, 105], ["inflammation", "DISEASE", 83, 95], ["ATP", "CHEMICAL", 124, 127], ["ATP", "CHEMICAL", 124, 127], ["tissue", "TISSUE", 99, 105], ["ATP", "SIMPLE_CHEMICAL", 124, 127], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 200, 208], ["P2X 7 Rs", "PROTEIN", 200, 208], ["Chap", "PROTEIN", 210, 214], ["inflammation", "PROBLEM", 83, 95], ["tissue injury", "PROBLEM", 99, 112], ["ATP", "TEST", 124, 127], ["inflammation", "OBSERVATION", 83, 95], ["tissue", "OBSERVATION_MODIFIER", 99, 105], ["injury", "OBSERVATION", 106, 112], ["high micromolar", "OBSERVATION_MODIFIER", 135, 150]]], ["The recent finding that major pro-inflammatory cytokines involved in the initiation of airway inflammatory responses (i.e. IL-1b) depend on the P2X 7 R for their production, maturation and secretion (see Chap.", [["airway", "ANATOMY", 87, 93], ["airway", "MULTI-TISSUE_STRUCTURE", 87, 93], ["IL-1b", "GENE_OR_GENE_PRODUCT", 123, 128], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 144, 151], ["pro-inflammatory cytokines", "PROTEIN", 30, 56], ["P2X 7 R", "PROTEIN", 144, 151], ["major pro-inflammatory cytokines", "PROBLEM", 24, 56], ["airway inflammatory responses", "PROBLEM", 87, 116], ["major", "OBSERVATION_MODIFIER", 24, 29], ["pro-inflammatory cytokines", "OBSERVATION", 30, 56], ["airway", "ANATOMY", 87, 93], ["inflammatory", "OBSERVATION", 94, 106]]], ["7 for details) is only one example of the many critical roles emerging for this receptor.", [["this receptor", "TREATMENT", 75, 88]]], ["Therefore, it is not surprising that the inhibition or deletion of P2X 7 Rs has such profound implications for airway defenses.The P2X 7 R in Chronic Lung DiseasesThe mouse model of COPD, described above by Idzko et al., revealed a remarkable up-regulating effect (10-to 20-fold) of cigarette smoke on the P2X 7 Rs of neutrophils and macrophages within 4 days [145] .", [["airway", "ANATOMY", 111, 117], ["Lung", "ANATOMY", 150, 154], ["neutrophils", "ANATOMY", 318, 329], ["macrophages", "ANATOMY", 334, 345], ["Lung Diseases", "DISEASE", 150, 163], ["COPD", "DISEASE", 182, 186], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 67, 75], ["airway", "MULTI-TISSUE_STRUCTURE", 111, 117], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 131, 138], ["Lung", "ORGAN", 150, 154], ["mouse", "ORGANISM", 167, 172], ["cigarette", "ORGANISM", 283, 292], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 306, 314], ["neutrophils", "CELL", 318, 329], ["macrophages", "CELL", 334, 345], ["P2X 7 Rs", "PROTEIN", 67, 75], ["P2X 7 R", "PROTEIN", 131, 138], ["P2X 7 Rs", "PROTEIN", 306, 314], ["neutrophils", "CELL_TYPE", 318, 329], ["macrophages", "CELL_TYPE", 334, 345], ["mouse", "SPECIES", 167, 172], ["mouse", "SPECIES", 167, 172], ["deletion of P2X", "PROBLEM", 55, 70], ["airway defenses", "PROBLEM", 111, 126], ["Chronic Lung Diseases", "PROBLEM", 142, 163], ["COPD", "PROBLEM", 182, 186], ["neutrophils", "TEST", 318, 329], ["macrophages", "PROBLEM", 334, 345], ["airway", "ANATOMY", 111, 117], ["7 R", "OBSERVATION_MODIFIER", 135, 138], ["Chronic", "OBSERVATION_MODIFIER", 142, 149], ["Lung", "ANATOMY", 150, 154], ["Diseases", "OBSERVATION", 155, 163], ["mouse model", "OBSERVATION_MODIFIER", 167, 178], ["COPD", "OBSERVATION", 182, 186]]], ["The use of selective antagonists demonstrated that P2X 7 R activation on these cells promotes all aspects of airway inflammation and fibrosis leading to the development of COPD and emphysema.", [["cells", "ANATOMY", 79, 84], ["airway", "ANATOMY", 109, 115], ["airway inflammation", "DISEASE", 109, 128], ["fibrosis", "DISEASE", 133, 141], ["COPD", "DISEASE", 172, 176], ["emphysema", "DISEASE", 181, 190], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 51, 58], ["cells", "CELL", 79, 84], ["airway", "MULTI-TISSUE_STRUCTURE", 109, 115], ["emphysema", "PATHOLOGICAL_FORMATION", 181, 190], ["P2X 7 R", "PROTEIN", 51, 58], ["selective antagonists", "TREATMENT", 11, 32], ["P2X", "PROBLEM", 51, 54], ["these cells", "TREATMENT", 73, 84], ["airway inflammation", "PROBLEM", 109, 128], ["fibrosis", "PROBLEM", 133, 141], ["COPD", "PROBLEM", 172, 176], ["emphysema", "PROBLEM", 181, 190], ["airway", "ANATOMY", 109, 115], ["inflammation", "OBSERVATION", 116, 128], ["fibrosis", "OBSERVATION", 133, 141], ["COPD", "OBSERVATION", 172, 176], ["emphysema", "OBSERVATION", 181, 190]]], ["In wild-type mice subjected to the acute smoke protocol, intratracheal injection of KN62 or A438079, before each exposure, markedly reduced the accumulation of macrophages, neutrophils and their cytokines (IL-1b, IL-6, IFNg, MIP-2 and KC) in the BAL fluid [147] .", [["intratracheal", "ANATOMY", 57, 70], ["macrophages", "ANATOMY", 160, 171], ["neutrophils", "ANATOMY", 173, 184], ["BAL fluid", "ANATOMY", 246, 255], ["KN62", "CHEMICAL", 84, 88], ["A438079", "CHEMICAL", 92, 99], ["KN62", "CHEMICAL", 84, 88], ["A438079", "CHEMICAL", 92, 99], ["mice", "ORGANISM", 13, 17], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["KN62", "SIMPLE_CHEMICAL", 84, 88], ["A438079", "SIMPLE_CHEMICAL", 92, 99], ["macrophages", "CELL", 160, 171], ["neutrophils", "CELL", 173, 184], ["IL-1b", "GENE_OR_GENE_PRODUCT", 206, 211], ["IL-6", "GENE_OR_GENE_PRODUCT", 213, 217], ["IFNg", "GENE_OR_GENE_PRODUCT", 219, 223], ["MIP-2", "GENE_OR_GENE_PRODUCT", 225, 230], ["KC", "GENE_OR_GENE_PRODUCT", 235, 237], ["macrophages", "CELL_TYPE", 160, 171], ["neutrophils", "CELL_TYPE", 173, 184], ["cytokines", "PROTEIN", 195, 204], ["IL-1b, IL-6", "PROTEIN", 206, 217], ["IFNg", "PROTEIN", 219, 223], ["MIP", "PROTEIN", 225, 228], ["KC", "PROTEIN", 235, 237], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["the acute smoke protocol", "TREATMENT", 31, 55], ["intratracheal injection of KN62", "TREATMENT", 57, 88], ["markedly reduced the accumulation of macrophages", "PROBLEM", 123, 171], ["neutrophils", "TEST", 173, 184], ["their cytokines", "TEST", 189, 204], ["IL", "TEST", 206, 208], ["IL", "TEST", 213, 215], ["IFNg", "TEST", 219, 223], ["MIP", "TEST", 225, 228], ["the BAL fluid", "TEST", 242, 255], ["reduced", "OBSERVATION_MODIFIER", 132, 139], ["accumulation of macrophages", "OBSERVATION", 144, 171], ["BAL", "ANATOMY", 246, 249]]], ["In mice subjected to the chronic exposure protocol, these agents prevented the development of fibrosis and emphysema.", [["fibrosis", "DISEASE", 94, 102], ["emphysema", "DISEASE", 107, 116], ["mice", "ORGANISM", 3, 7], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["the chronic exposure protocol", "TREATMENT", 21, 50], ["these agents", "TREATMENT", 52, 64], ["fibrosis", "PROBLEM", 94, 102], ["emphysema", "PROBLEM", 107, 116], ["fibrosis", "OBSERVATION", 94, 102], ["emphysema", "OBSERVATION", 107, 116]]], ["The widespread effects of P2X 7 Rs on airway inflammation are explained by their pivotal role in the secretion of IL-1b from the resident macrophages, which initiate the events leading to leukocyte recruitment.", [["airway", "ANATOMY", 38, 44], ["macrophages", "ANATOMY", 138, 149], ["leukocyte", "ANATOMY", 188, 197], ["airway inflammation", "DISEASE", 38, 57], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 26, 34], ["airway", "MULTI-TISSUE_STRUCTURE", 38, 44], ["IL-1b", "GENE_OR_GENE_PRODUCT", 114, 119], ["macrophages", "CELL", 138, 149], ["leukocyte", "CELL", 188, 197], ["P2X 7 Rs", "PROTEIN", 26, 34], ["IL-1b", "PROTEIN", 114, 119], ["resident macrophages", "CELL_TYPE", 129, 149], ["P2X", "PROBLEM", 26, 29], ["airway inflammation", "PROBLEM", 38, 57], ["the events", "PROBLEM", 166, 176], ["leukocyte recruitment", "PROBLEM", 188, 209], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["effects", "OBSERVATION_MODIFIER", 15, 22], ["airway", "ANATOMY", 38, 44], ["inflammation", "OBSERVATION", 45, 57], ["macrophages", "OBSERVATION", 138, 149], ["leukocyte recruitment", "OBSERVATION", 188, 209]]], ["Furthermore, P2X 7 R-overexpressing neutrophils and macrophages would cause considerable lung destruction by massive discharge of potent cytotoxic molecules which do not discriminate between the bacteria and host cells [146] (see Chap.", [["neutrophils", "ANATOMY", 36, 47], ["macrophages", "ANATOMY", 52, 63], ["lung", "ANATOMY", 89, 93], ["cells", "ANATOMY", 213, 218], ["lung destruction", "DISEASE", 89, 105], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 13, 20], ["neutrophils", "CELL", 36, 47], ["macrophages", "CELL", 52, 63], ["lung", "ORGAN", 89, 93], ["host cells", "CELL", 208, 218], ["P2X 7 R", "PROTEIN", 13, 20], ["neutrophils", "CELL_TYPE", 36, 47], ["macrophages", "CELL_TYPE", 52, 63], ["host cells", "CELL_TYPE", 208, 218], ["P2X", "TEST", 13, 16], ["R-overexpressing neutrophils", "TEST", 19, 47], ["macrophages", "PROBLEM", 52, 63], ["considerable lung destruction", "PROBLEM", 76, 105], ["potent cytotoxic molecules", "PROBLEM", 130, 156], ["the bacteria", "PROBLEM", 191, 203], ["lung", "ANATOMY", 89, 93], ["destruction", "OBSERVATION", 94, 105], ["massive", "OBSERVATION_MODIFIER", 109, 116], ["potent", "OBSERVATION_MODIFIER", 130, 136], ["cytotoxic molecules", "OBSERVATION", 137, 156]]], ["Since smoke triggers such dramatic increases in BAL fluid ATP level [145] and P2X7R expression, an early treatment with aerosolized antagonists may reduce disease progression and prevent emphysema.The P2X 7 R in Chronic Lung DiseasesIdiopathic pulmonary fibrosis (IPF) is a fatal respiratory disorder characterized by inflammation, tissue fibrosis and destruction of the alveolar architecture.", [["BAL fluid", "ANATOMY", 48, 57], ["Lung", "ANATOMY", 220, 224], ["pulmonary", "ANATOMY", 244, 253], ["respiratory", "ANATOMY", 280, 291], ["tissue", "ANATOMY", 332, 338], ["alveolar", "ANATOMY", 371, 379], ["smoke", "CHEMICAL", 6, 11], ["ATP", "CHEMICAL", 58, 61], ["emphysema", "DISEASE", 187, 196], ["Lung Diseases", "DISEASE", 220, 233], ["Idiopathic pulmonary fibrosis", "DISEASE", 233, 262], ["IPF", "DISEASE", 264, 267], ["respiratory disorder", "DISEASE", 280, 300], ["inflammation", "DISEASE", 318, 330], ["fibrosis", "DISEASE", 339, 347], ["ATP", "CHEMICAL", 58, 61], ["BAL", "ORGANISM_SUBSTANCE", 48, 51], ["ATP", "SIMPLE_CHEMICAL", 58, 61], ["P2X7R", "GENE_OR_GENE_PRODUCT", 78, 83], ["emphysema", "PATHOLOGICAL_FORMATION", 187, 196], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 201, 208], ["Lung", "ORGAN", 220, 224], ["pulmonary", "ORGAN", 244, 253], ["tissue", "TISSUE", 332, 338], ["alveolar architecture", "MULTI-TISSUE_STRUCTURE", 371, 392], ["P2X7R", "PROTEIN", 78, 83], ["P2X 7 R", "PROTEIN", 201, 208], ["BAL fluid ATP level", "TEST", 48, 67], ["P2X7R expression", "TREATMENT", 78, 94], ["an early treatment", "TREATMENT", 96, 114], ["aerosolized antagonists", "TREATMENT", 120, 143], ["disease progression", "PROBLEM", 155, 174], ["emphysema", "PROBLEM", 187, 196], ["The P2X", "TEST", 197, 204], ["Chronic Lung Diseases", "PROBLEM", 212, 233], ["Idiopathic pulmonary fibrosis", "PROBLEM", 233, 262], ["IPF", "PROBLEM", 264, 267], ["a fatal respiratory disorder", "PROBLEM", 272, 300], ["inflammation", "PROBLEM", 318, 330], ["tissue fibrosis", "PROBLEM", 332, 347], ["destruction of the alveolar architecture", "PROBLEM", 352, 392], ["dramatic", "OBSERVATION_MODIFIER", 26, 34], ["increases", "OBSERVATION_MODIFIER", 35, 44], ["emphysema", "OBSERVATION", 187, 196], ["P2X", "OBSERVATION_MODIFIER", 201, 204], ["7 R", "OBSERVATION_MODIFIER", 205, 208], ["Chronic", "OBSERVATION_MODIFIER", 212, 219], ["Lung", "ANATOMY", 220, 224], ["Diseases", "OBSERVATION", 225, 233], ["Idiopathic", "OBSERVATION_MODIFIER", 233, 243], ["pulmonary", "ANATOMY", 244, 253], ["fibrosis", "OBSERVATION", 254, 262], ["IPF", "OBSERVATION", 264, 267], ["fatal", "OBSERVATION_MODIFIER", 274, 279], ["respiratory disorder", "OBSERVATION", 280, 300], ["inflammation", "OBSERVATION", 318, 330], ["tissue", "OBSERVATION_MODIFIER", 332, 338], ["fibrosis", "OBSERVATION", 339, 347], ["destruction", "OBSERVATION", 352, 363], ["alveolar", "ANATOMY_MODIFIER", 371, 379]]], ["Since the IPF patients maintain high airway ATP concentrations [138] , the bleomycininduced murine model of lung fibrosis was used to test the contribution of purinergic deregulation to the pathogenesis of this disease [138] .", [["airway", "ANATOMY", 37, 43], ["lung", "ANATOMY", 108, 112], ["IPF", "DISEASE", 10, 13], ["ATP", "CHEMICAL", 44, 47], ["lung fibrosis", "DISEASE", 108, 121], ["ATP", "CHEMICAL", 44, 47], ["patients", "ORGANISM", 14, 22], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["ATP", "SIMPLE_CHEMICAL", 44, 47], ["murine", "ORGANISM", 92, 98], ["lung", "ORGAN", 108, 112], ["patients", "SPECIES", 14, 22], ["murine", "SPECIES", 92, 98], ["high airway ATP concentrations", "PROBLEM", 32, 62], ["lung fibrosis", "PROBLEM", 108, 121], ["purinergic deregulation", "PROBLEM", 159, 182], ["this disease", "PROBLEM", 206, 218], ["high", "OBSERVATION_MODIFIER", 32, 36], ["airway", "ANATOMY", 37, 43], ["lung", "ANATOMY", 108, 112], ["fibrosis", "OBSERVATION", 113, 121], ["purinergic deregulation", "OBSERVATION", 159, 182]]], ["In mice, the intratracheal administration of bleomycin initiates neutrophil recruitment within 24 h, which normalizes around day 11.", [["intratracheal", "ANATOMY", 13, 26], ["neutrophil", "ANATOMY", 65, 75], ["bleomycin", "CHEMICAL", 45, 54], ["bleomycin", "CHEMICAL", 45, 54], ["mice", "ORGANISM", 3, 7], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["bleomycin", "SIMPLE_CHEMICAL", 45, 54], ["neutrophil", "CELL", 65, 75], ["neutrophil", "CELL_TYPE", 65, 75], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["the intratracheal administration of bleomycin", "TREATMENT", 9, 54], ["neutrophil recruitment", "TREATMENT", 65, 87], ["intratracheal", "ANATOMY", 13, 26]]], ["First signs of fibrosis appear around day 11, and are reversed within 10 days (review: [65] ).", [["fibrosis", "DISEASE", 15, 23], ["fibrosis", "PROBLEM", 15, 23], ["fibrosis", "OBSERVATION", 15, 23]]], ["Time-course analysis indicated that bleomycin induces a transient increase in BAL fluid ATP level over the first 6 h, which is followed by the initiation of neutrophil recruitment.", [["BAL fluid", "ANATOMY", 78, 87], ["neutrophil", "ANATOMY", 157, 167], ["bleomycin", "CHEMICAL", 36, 45], ["ATP", "CHEMICAL", 88, 91], ["bleomycin", "CHEMICAL", 36, 45], ["ATP", "CHEMICAL", 88, 91], ["bleomycin", "SIMPLE_CHEMICAL", 36, 45], ["BAL fluid", "ORGANISM_SUBSTANCE", 78, 87], ["ATP", "SIMPLE_CHEMICAL", 88, 91], ["neutrophil", "CELL", 157, 167], ["bleomycin", "TREATMENT", 36, 45], ["a transient increase in BAL fluid ATP level", "PROBLEM", 54, 97], ["neutrophil recruitment", "TREATMENT", 157, 179], ["transient", "OBSERVATION_MODIFIER", 56, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["BAL fluid", "OBSERVATION", 78, 87], ["neutrophil recruitment", "OBSERVATION", 157, 179]]], ["This time line supports a role for an ATP gradient in neutrophil recruitment to the lungs.", [["neutrophil", "ANATOMY", 54, 64], ["lungs", "ANATOMY", 84, 89], ["ATP", "CHEMICAL", 38, 41], ["ATP", "CHEMICAL", 38, 41], ["ATP", "SIMPLE_CHEMICAL", 38, 41], ["neutrophil", "CELL", 54, 64], ["lungs", "ORGAN", 84, 89], ["an ATP gradient", "TREATMENT", 35, 50], ["neutrophil recruitment", "TREATMENT", 54, 76], ["neutrophil recruitment", "OBSERVATION", 54, 76], ["lungs", "ANATOMY", 84, 89]]], ["Disruption of this ATP gradient by apyrase treatment reduced by >60% the BAL content in neutrophils, myeloperoxidase and metalloproteinases.", [["BAL", "ANATOMY", 73, 76], ["neutrophils", "ANATOMY", 88, 99], ["ATP", "CHEMICAL", 19, 22], ["apyrase", "CHEMICAL", 35, 42], ["ATP", "CHEMICAL", 19, 22], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["apyrase", "SIMPLE_CHEMICAL", 35, 42], ["BAL", "ORGANISM_SUBSTANCE", 73, 76], ["neutrophils", "CELL", 88, 99], ["myeloperoxidase", "SIMPLE_CHEMICAL", 101, 116], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 121, 139], ["neutrophils", "CELL_TYPE", 88, 99], ["myeloperoxidase", "PROTEIN", 101, 116], ["metalloproteinases", "PROTEIN", 121, 139], ["this ATP gradient", "PROBLEM", 14, 31], ["apyrase treatment", "TREATMENT", 35, 52], ["the BAL content", "TEST", 69, 84], ["neutrophils", "TEST", 88, 99], ["myeloperoxidase", "TEST", 101, 116], ["metalloproteinases", "PROBLEM", 121, 139], ["ATP gradient", "OBSERVATION", 19, 31], ["BAL content", "OBSERVATION", 73, 84], ["neutrophils", "ANATOMY", 88, 99]]], ["Similar findings were obtained when comparing wild-type and P2X 7 R \u00c0/\u00c0 mice after bleomycin exposure [138] .", [["bleomycin", "CHEMICAL", 83, 92], ["bleomycin", "CHEMICAL", 83, 92], ["P2X 7", "ORGANISM", 60, 65], ["R", "GENE_OR_GENE_PRODUCT", 66, 67], ["bleomycin", "SIMPLE_CHEMICAL", 83, 92], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["P2X", "TEST", 60, 63], ["bleomycin exposure", "TREATMENT", 83, 101]]], ["This study suggests that the higher availability of ATP for P2X 7 R activation contributes to the inflammatory processes launching tissue fibrosis and lung destruction.The P2X 7 R in Chronic Lung DiseasesIn asthmatic patients, airway ATP concentrations only rise following an allergen challenge [68] .", [["tissue", "ANATOMY", 131, 137], ["lung", "ANATOMY", 151, 155], ["Lung", "ANATOMY", 191, 195], ["airway", "ANATOMY", 227, 233], ["ATP", "CHEMICAL", 52, 55], ["fibrosis", "DISEASE", 138, 146], ["lung destruction", "DISEASE", 151, 167], ["Lung DiseasesIn asthmatic", "DISEASE", 191, 216], ["ATP", "CHEMICAL", 234, 237], ["ATP", "CHEMICAL", 52, 55], ["ATP", "CHEMICAL", 234, 237], ["ATP", "SIMPLE_CHEMICAL", 52, 55], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 60, 67], ["tissue", "TISSUE", 131, 137], ["lung", "ORGAN", 151, 155], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 172, 179], ["Lung", "ORGAN", 191, 195], ["patients", "ORGANISM", 217, 225], ["airway", "MULTI-TISSUE_STRUCTURE", 227, 233], ["ATP", "SIMPLE_CHEMICAL", 234, 237], ["P2X 7 R", "PROTEIN", 60, 67], ["P2X 7 R", "PROTEIN", 172, 179], ["patients", "SPECIES", 217, 225], ["This study", "TEST", 0, 10], ["P2X", "PROBLEM", 60, 63], ["the inflammatory processes launching tissue fibrosis", "PROBLEM", 94, 146], ["lung destruction", "PROBLEM", 151, 167], ["Chronic Lung DiseasesIn asthmatic patients", "PROBLEM", 183, 225], ["airway ATP concentrations", "PROBLEM", 227, 252], ["an allergen challenge", "TREATMENT", 273, 294], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110], ["launching tissue", "OBSERVATION_MODIFIER", 121, 137], ["fibrosis", "OBSERVATION", 138, 146], ["lung", "ANATOMY", 151, 155], ["destruction", "OBSERVATION", 156, 167], ["P2X", "OBSERVATION", 172, 175], ["7 R", "OBSERVATION_MODIFIER", 176, 179], ["Chronic", "OBSERVATION_MODIFIER", 183, 190], ["Lung", "ANATOMY", 191, 195], ["DiseasesIn asthmatic", "OBSERVATION", 196, 216], ["airway", "ANATOMY", 227, 233], ["ATP concentrations", "OBSERVATION", 234, 252]]], ["On the other hand, the purinergic network is permanently altered in these patients, as P2X 7 R expression is up-regulated in BAL fluid macrophages and circulating eosinophils, compared to healthy subjects [148] .", [["BAL fluid macrophages", "ANATOMY", 125, 146], ["eosinophils", "ANATOMY", 163, 174], ["purinergic network", "MULTI-TISSUE_STRUCTURE", 23, 41], ["patients", "ORGANISM", 74, 82], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 87, 94], ["BAL fluid macrophages", "CELL", 125, 146], ["eosinophils", "CELL", 163, 174], ["P2X 7 R", "PROTEIN", 87, 94], ["BAL fluid macrophages", "CELL_TYPE", 125, 146], ["circulating eosinophils", "CELL_TYPE", 151, 174], ["patients", "SPECIES", 74, 82], ["P2X", "TEST", 87, 90], ["BAL fluid macrophages", "TEST", 125, 146], ["circulating eosinophils", "TEST", 151, 174], ["BAL", "ANATOMY", 125, 128], ["fluid macrophages", "OBSERVATION", 129, 146], ["circulating eosinophils", "OBSERVATION", 151, 174]]], ["A murine model of allergic asthma was used to determine the consequences for airway defenses.", [["airway", "ANATOMY", 77, 83], ["allergic asthma", "DISEASE", 18, 33], ["murine", "ORGANISM", 2, 8], ["airway", "MULTI-TISSUE_STRUCTURE", 77, 83], ["murine", "SPECIES", 2, 8], ["allergic asthma", "PROBLEM", 18, 33], ["airway defenses", "PROBLEM", 77, 92], ["allergic asthma", "OBSERVATION", 18, 33], ["airway", "ANATOMY", 77, 83]]], ["Mice sensitized and challenged with OVA summarize the inflammatory responses of asthmatic patients during an allergic reaction [148] .", [["asthmatic", "DISEASE", 80, 89], ["allergic reaction", "DISEASE", 109, 126], ["Mice", "ORGANISM", 0, 4], ["patients", "ORGANISM", 90, 98], ["Mice", "SPECIES", 0, 4], ["patients", "SPECIES", 90, 98], ["OVA", "TREATMENT", 36, 39], ["asthmatic patients", "PROBLEM", 80, 98], ["an allergic reaction", "PROBLEM", 106, 126], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66]]], ["The lung infiltrates contain mainly eosinophils, followed by mast cells, neutrophils and lymphocytes, whereas BAL fluid exhibits the typical Th2 inflammation (IL-4, IL-5 and IL-13).", [["lung infiltrates", "ANATOMY", 4, 20], ["eosinophils", "ANATOMY", 36, 47], ["mast cells", "ANATOMY", 61, 71], ["neutrophils", "ANATOMY", 73, 84], ["lymphocytes", "ANATOMY", 89, 100], ["BAL fluid", "ANATOMY", 110, 119], ["lung", "ORGAN", 4, 8], ["eosinophils", "CELL", 36, 47], ["mast cells", "CELL", 61, 71], ["neutrophils", "CELL", 73, 84], ["lymphocytes", "CELL", 89, 100], ["BAL fluid", "ORGANISM_SUBSTANCE", 110, 119], ["IL-4", "GENE_OR_GENE_PRODUCT", 159, 163], ["IL-5", "GENE_OR_GENE_PRODUCT", 165, 169], ["IL-13", "GENE_OR_GENE_PRODUCT", 174, 179], ["eosinophils", "CELL_TYPE", 36, 47], ["mast cells", "CELL_TYPE", 61, 71], ["neutrophils", "CELL_TYPE", 73, 84], ["lymphocytes", "CELL_TYPE", 89, 100], ["IL", "PROTEIN", 174, 176], ["The lung infiltrates", "PROBLEM", 0, 20], ["mainly eosinophils", "PROBLEM", 29, 47], ["mast cells", "TEST", 61, 71], ["neutrophils", "TEST", 73, 84], ["lymphocytes", "TEST", 89, 100], ["BAL fluid", "TEST", 110, 119], ["the typical Th2 inflammation", "PROBLEM", 129, 157], ["IL", "TEST", 159, 161], ["IL", "TEST", 165, 167], ["IL", "TEST", 174, 176], ["lung", "ANATOMY", 4, 8], ["infiltrates", "OBSERVATION", 9, 20], ["mainly", "OBSERVATION_MODIFIER", 29, 35], ["eosinophils", "OBSERVATION", 36, 47], ["mast cells", "OBSERVATION", 61, 71], ["lymphocytes", "ANATOMY", 89, 100], ["BAL fluid", "OBSERVATION", 110, 119], ["typical", "OBSERVATION_MODIFIER", 133, 140], ["Th2 inflammation", "OBSERVATION", 141, 157]]], ["As reported in asthmatic patients, the P2X 7 R was up-regulated 15-fold in the inflammatory cells and lung tissue of OVA-treated mice.", [["inflammatory cells", "ANATOMY", 79, 97], ["lung tissue", "ANATOMY", 102, 113], ["asthmatic", "DISEASE", 15, 24], ["patients", "ORGANISM", 25, 33], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 39, 46], ["cells", "CELL", 92, 97], ["lung tissue", "TISSUE", 102, 113], ["OVA", "SIMPLE_CHEMICAL", 117, 120], ["mice", "ORGANISM", 129, 133], ["P2X 7 R", "PROTEIN", 39, 46], ["inflammatory cells", "CELL_TYPE", 79, 97], ["patients", "SPECIES", 25, 33], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["the P2X", "TEST", 35, 42], ["the inflammatory cells", "PROBLEM", 75, 97], ["lung tissue of OVA", "PROBLEM", 102, 120], ["15-fold", "OBSERVATION_MODIFIER", 64, 71], ["inflammatory cells", "OBSERVATION", 79, 97], ["lung", "ANATOMY", 102, 106], ["tissue", "ANATOMY_MODIFIER", 107, 113], ["OVA", "OBSERVATION", 117, 120]]], ["The use of a selective P2X 7 R antagonist (KN62) on OVA-treated wild-type mice, or OVA-treated P2X 7 R \u00c0/\u00c0 mice, was associated with milder lung inflammation compared to OVA-treated wild-type mice.", [["lung", "ANATOMY", 140, 144], ["KN62", "CHEMICAL", 43, 47], ["lung inflammation", "DISEASE", 140, 157], ["OVA", "CHEMICAL", 170, 173], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 23, 30], ["KN62", "SIMPLE_CHEMICAL", 43, 47], ["OVA", "SIMPLE_CHEMICAL", 52, 55], ["mice", "ORGANISM", 74, 78], ["OVA", "SIMPLE_CHEMICAL", 83, 86], ["P2X 7 R \u00c0/\u00c0 mice", "ORGANISM", 95, 111], ["lung", "ORGAN", 140, 144], ["OVA", "SIMPLE_CHEMICAL", 170, 173], ["mice", "ORGANISM", 192, 196], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 192, 196], ["a selective P2X 7 R antagonist (KN62)", "TREATMENT", 11, 48], ["OVA", "TREATMENT", 52, 55], ["OVA", "PROBLEM", 83, 86], ["milder lung inflammation", "PROBLEM", 133, 157], ["lung", "ANATOMY", 140, 144], ["inflammation", "OBSERVATION", 145, 157]]], ["The mechanism behind the pro-inflammatory role of P2X 7 Rs in allergic asthma was investigated using bone marrow-derived dendritic cells from wild-type and P2X 7 R \u00c0/\u00c0 mice.", [["bone marrow", "ANATOMY", 101, 112], ["dendritic cells", "ANATOMY", 121, 136], ["allergic asthma", "DISEASE", 62, 77], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 50, 58], ["bone marrow-derived dendritic cells", "CELL", 101, 136], ["P2X 7", "ORGANISM", 156, 161], ["R", "GENE_OR_GENE_PRODUCT", 162, 163], ["P2X 7 Rs", "PROTEIN", 50, 58], ["bone marrow-derived dendritic cells", "CELL_TYPE", 101, 136], ["mice", "SPECIES", 168, 172], ["P2X", "PROBLEM", 50, 53], ["allergic asthma", "PROBLEM", 62, 77], ["bone marrow", "TEST", 101, 112], ["dendritic cells", "PROBLEM", 121, 136], ["P2X", "TEST", 156, 159], ["pro-inflammatory", "OBSERVATION_MODIFIER", 25, 41], ["allergic asthma", "OBSERVATION", 62, 77], ["bone", "ANATOMY", 101, 105], ["dendritic cells", "OBSERVATION", 121, 136]]], ["The loss of P2X 7 Rs reduced the capacity of OVA-treated dendritic cells to induce Th2 immunity in vivo.", [["dendritic cells", "ANATOMY", 57, 72], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 12, 20], ["OVA", "SIMPLE_CHEMICAL", 45, 48], ["dendritic cells", "CELL", 57, 72], ["Th2", "GENE_OR_GENE_PRODUCT", 83, 86], ["P2X 7 Rs", "PROTEIN", 12, 20], ["OVA-treated dendritic cells", "CELL_LINE", 45, 72], ["The loss of P2X", "PROBLEM", 0, 15], ["OVA", "PROBLEM", 45, 48], ["dendritic cells", "PROBLEM", 57, 72], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["dendritic cells", "OBSERVATION", 57, 72]]], ["This study highlights another critical role of P2X 7 Rs in the early events initiating an inflammatory response to an airborne insult, and the potential of selective antagonists for the suppression of Th2 inflammation in asthma.ConclusionAll animal models of acute lung injury and chronic lung diseases are associated with an accumulation of extracellular purines, and an up-regulation of their receptors, except for the anti-inflammatory A 2A R. Such massive amplification of purinergic signals in response to hypoxia, ischemia-reperfusion, mechanical ventilation, bacterial products and allergens supports critical and widespread functions in airway defenses.", [["lung", "ANATOMY", 265, 269], ["lung", "ANATOMY", 289, 293], ["extracellular", "ANATOMY", 342, 355], ["airway", "ANATOMY", 645, 651], ["inflammation", "DISEASE", 205, 217], ["asthma", "DISEASE", 221, 227], ["lung injury", "DISEASE", 265, 276], ["chronic lung diseases", "DISEASE", 281, 302], ["purines", "CHEMICAL", 356, 363], ["hypoxia", "DISEASE", 511, 518], ["ischemia", "DISEASE", 520, 528], ["purines", "CHEMICAL", 356, 363], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 47, 55], ["Th2", "GENE_OR_GENE_PRODUCT", 201, 204], ["lung", "ORGAN", 265, 269], ["lung", "ORGAN", 289, 293], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 342, 355], ["purines", "SIMPLE_CHEMICAL", 356, 363], ["airway", "MULTI-TISSUE_STRUCTURE", 645, 651], ["P2X 7 Rs", "PROTEIN", 47, 55], ["This study", "TEST", 0, 10], ["an inflammatory response", "PROBLEM", 87, 111], ["an airborne insult", "PROBLEM", 115, 133], ["selective antagonists", "TREATMENT", 156, 177], ["Th2 inflammation", "PROBLEM", 201, 217], ["asthma", "PROBLEM", 221, 227], ["acute lung injury", "PROBLEM", 259, 276], ["chronic lung diseases", "PROBLEM", 281, 302], ["an accumulation of extracellular purines", "PROBLEM", 323, 363], ["purinergic signals", "PROBLEM", 477, 495], ["hypoxia", "PROBLEM", 511, 518], ["ischemia", "PROBLEM", 520, 528], ["reperfusion", "TREATMENT", 529, 540], ["mechanical ventilation", "TREATMENT", 542, 564], ["bacterial products", "TREATMENT", 566, 584], ["allergens", "PROBLEM", 589, 598], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["airborne insult", "OBSERVATION", 118, 133], ["Th2 inflammation", "OBSERVATION", 201, 217], ["asthma", "OBSERVATION", 221, 227], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["lung", "ANATOMY", 265, 269], ["injury", "OBSERVATION", 270, 276], ["chronic", "OBSERVATION_MODIFIER", 281, 288], ["lung", "ANATOMY", 289, 293], ["diseases", "OBSERVATION", 294, 302], ["accumulation", "OBSERVATION_MODIFIER", 326, 338], ["extracellular purines", "OBSERVATION", 342, 363], ["purinergic signals", "OBSERVATION", 477, 495], ["hypoxia", "OBSERVATION", 511, 518], ["ischemia", "OBSERVATION", 520, 528], ["reperfusion", "OBSERVATION_MODIFIER", 529, 540], ["mechanical ventilation", "OBSERVATION", 542, 564], ["bacterial products", "OBSERVATION", 566, 584], ["airway", "ANATOMY", 645, 651]]], ["During an acute lung injury, all ADO receptors provide protection against excessive lung inflammation, damage and pulmonary edema.", [["lung", "ANATOMY", 16, 20], ["lung", "ANATOMY", 84, 88], ["pulmonary", "ANATOMY", 114, 123], ["lung injury", "DISEASE", 16, 27], ["ADO", "CHEMICAL", 33, 36], ["lung inflammation", "DISEASE", 84, 101], ["pulmonary edema", "DISEASE", 114, 129], ["lung", "ORGAN", 16, 20], ["ADO receptors", "GENE_OR_GENE_PRODUCT", 33, 46], ["lung", "ORGAN", 84, 88], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 114, 129], ["ADO receptors", "PROTEIN", 33, 46], ["an acute lung injury", "PROBLEM", 7, 27], ["all ADO receptors", "TREATMENT", 29, 46], ["excessive lung inflammation", "PROBLEM", 74, 101], ["damage", "PROBLEM", 103, 109], ["pulmonary edema", "PROBLEM", 114, 129], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["lung", "ANATOMY", 16, 20], ["injury", "OBSERVATION", 21, 27], ["lung", "ANATOMY", 84, 88], ["inflammation", "OBSERVATION", 89, 101], ["pulmonary", "ANATOMY", 114, 123], ["edema", "OBSERVATION", 124, 129]]], ["The intravenous administration of agonists yielded the most effective resolution of all lung complications, which identified the microvascular endothelial barrier as primary target.", [["intravenous", "ANATOMY", 4, 15], ["lung", "ANATOMY", 88, 92], ["microvascular endothelial", "ANATOMY", 129, 154], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 15], ["lung", "ORGAN", 88, 92], ["microvascular endothelial barrier", "TISSUE", 129, 162], ["The intravenous administration of agonists", "TREATMENT", 0, 42], ["all lung complications", "PROBLEM", 84, 106], ["the microvascular endothelial barrier", "TREATMENT", 125, 162], ["lung", "ANATOMY", 88, 92], ["complications", "OBSERVATION", 93, 106], ["microvascular endothelial", "ANATOMY", 129, 154]]], ["Treatments should focus on agonists of the high-capacity A 2A Rs and A 2B Rs to minimize receptor desensitization (Chap.", [["A 2B Rs", "GENE_OR_GENE_PRODUCT", 69, 76], ["high-capacity A 2A Rs", "PROTEIN", 43, 64], ["A 2B Rs", "PROTEIN", 69, 76], ["Treatments", "TREATMENT", 0, 10], ["A 2B Rs", "TREATMENT", 69, 76], ["receptor desensitization", "TREATMENT", 89, 113]]], ["Whereas P2Y 2 R agonists may also be considered, possible side-effects may arise from their role in neutrophil and eosinophil recruitment.", [["neutrophil", "ANATOMY", 100, 110], ["eosinophil", "ANATOMY", 115, 125], ["P2Y 2 R", "GENE_OR_GENE_PRODUCT", 8, 15], ["neutrophil", "CELL", 100, 110], ["eosinophil", "CELL", 115, 125], ["neutrophil", "CELL_TYPE", 100, 110], ["P2Y 2 R agonists", "TREATMENT", 8, 24], ["side-effects", "PROBLEM", 58, 70], ["eosinophil recruitment", "TREATMENT", 115, 137], ["eosinophil recruitment", "OBSERVATION", 115, 137]]], ["All models of chronic lung diseases are associated with a down-regulation of the anti-inflammatory A 2A Rs in inflammatory cells and lung tissue, which tilts the balance toward pro-inflammatory responses to ADO.", [["lung", "ANATOMY", 22, 26], ["inflammatory cells", "ANATOMY", 110, 128], ["lung tissue", "ANATOMY", 133, 144], ["chronic lung diseases", "DISEASE", 14, 35], ["ADO", "CHEMICAL", 207, 210], ["ADO", "CHEMICAL", 207, 210], ["lung", "ORGAN", 22, 26], ["A 2A Rs", "GENE_OR_GENE_PRODUCT", 99, 106], ["inflammatory cells", "CELL", 110, 128], ["lung tissue", "TISSUE", 133, 144], ["ADO", "SIMPLE_CHEMICAL", 207, 210], ["anti-inflammatory A 2A Rs", "PROTEIN", 81, 106], ["inflammatory cells", "CELL_TYPE", 110, 128], ["chronic lung diseases", "PROBLEM", 14, 35], ["inflammatory cells", "PROBLEM", 110, 128], ["lung tissue", "PROBLEM", 133, 144], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["lung", "ANATOMY", 22, 26], ["diseases", "OBSERVATION", 27, 35], ["anti-inflammatory", "OBSERVATION_MODIFIER", 81, 98], ["inflammatory cells", "OBSERVATION", 110, 128], ["lung", "ANATOMY", 133, 137], ["tissue", "OBSERVATION", 138, 144]]], ["Whereas A 2A R agonists were shown to suppress airway inflammation, they would not address airway hyper-responsiveness, remodeling and fibrosis.", [["airway", "ANATOMY", 47, 53], ["airway", "ANATOMY", 91, 97], ["airway inflammation", "DISEASE", 47, 66], ["fibrosis", "DISEASE", 135, 143], ["A 2A R", "GENE_OR_GENE_PRODUCT", 8, 14], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["airway", "MULTI-TISSUE_STRUCTURE", 91, 97], ["A 2A R agonists", "TREATMENT", 8, 23], ["airway inflammation", "PROBLEM", 47, 66], ["airway hyper-responsiveness", "PROBLEM", 91, 118], ["remodeling and fibrosis", "PROBLEM", 120, 143], ["airway", "ANATOMY", 47, 53], ["inflammation", "OBSERVATION", 54, 66], ["fibrosis", "OBSERVATION", 135, 143]]], ["Alternatively, the models of asthma, COPD and emphysema suggest that aerosolized antagonists of A 2B Rs, P2Y 2 Rs and P2X 7 Rs resolve most lung complications.", [["lung", "ANATOMY", 140, 144], ["asthma", "DISEASE", 29, 35], ["COPD", "DISEASE", 37, 41], ["emphysema", "DISEASE", 46, 55], ["lung complications", "DISEASE", 140, 158], ["A 2B Rs", "GENE_OR_GENE_PRODUCT", 96, 103], ["P2Y 2 Rs", "GENE_OR_GENE_PRODUCT", 105, 113], ["P2X 7 Rs", "GENE_OR_GENE_PRODUCT", 118, 126], ["lung", "ORGAN", 140, 144], ["asthma", "PROBLEM", 29, 35], ["COPD", "PROBLEM", 37, 41], ["emphysema", "PROBLEM", 46, 55], ["aerosolized antagonists", "TREATMENT", 69, 92], ["P2Y", "TEST", 105, 108], ["P2X", "TEST", 118, 121], ["most lung complications", "PROBLEM", 135, 158], ["asthma", "OBSERVATION", 29, 35], ["COPD", "OBSERVATION", 37, 41], ["emphysema", "OBSERVATION", 46, 55], ["aerosolized antagonists", "OBSERVATION", 69, 92], ["lung", "ANATOMY", 140, 144], ["complications", "OBSERVATION", 145, 158]]], ["However, the A 2B R or P2Y 2 R antagonists must be carefully dosed to avoid any significant impairment of the mucociliary clearance mechanisms.", [["mucociliary", "ANATOMY", 110, 121], ["A 2B R", "GENE_OR_GENE_PRODUCT", 13, 19], ["P2Y 2 R antagonists", "GENE_OR_GENE_PRODUCT", 23, 42], ["mucociliary", "ORGAN", 110, 121], ["P2Y 2 R antagonists", "TREATMENT", 23, 42], ["the mucociliary clearance mechanisms", "PROBLEM", 106, 142], ["significant", "OBSERVATION_MODIFIER", 80, 91], ["impairment", "OBSERVATION", 92, 102], ["mucociliary clearance", "OBSERVATION", 110, 131]]], ["Of particular interest are the P2X 7 R antagonists, which show tremendous benefits in reducing the development of COPD and emphysema in smokers through a reduction of macrophage activities responsible for the initiation of leukocyte recruitment to the airways.", [["macrophage", "ANATOMY", 167, 177], ["leukocyte", "ANATOMY", 223, 232], ["airways", "ANATOMY", 252, 259], ["COPD", "DISEASE", 114, 118], ["emphysema", "DISEASE", 123, 132], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 31, 38], ["macrophage", "CELL", 167, 177], ["leukocyte", "CELL", 223, 232], ["airways", "MULTI-TISSUE_STRUCTURE", 252, 259], ["the P2X 7 R antagonists", "TREATMENT", 27, 50], ["COPD", "PROBLEM", 114, 118], ["emphysema", "PROBLEM", 123, 132], ["a reduction of macrophage activities", "TREATMENT", 152, 188], ["leukocyte recruitment", "TREATMENT", 223, 244], ["tremendous", "OBSERVATION_MODIFIER", 63, 73], ["COPD", "OBSERVATION", 114, 118], ["emphysema", "OBSERVATION", 123, 132], ["macrophage activities", "OBSERVATION", 167, 188], ["leukocyte recruitment", "OBSERVATION", 223, 244], ["airways", "ANATOMY", 252, 259]]], ["In asthma, aerosolized P2X 7 R antagonists may prevent resident dendritic cells from initiating the Th2 immunity.", [["dendritic cells", "ANATOMY", 64, 79], ["asthma", "DISEASE", 3, 9], ["P2X 7 R", "GENE_OR_GENE_PRODUCT", 23, 30], ["dendritic cells", "CELL", 64, 79], ["resident dendritic cells", "CELL_TYPE", 55, 79], ["asthma", "PROBLEM", 3, 9], ["aerosolized P2X 7 R antagonists", "TREATMENT", 11, 42], ["dendritic cells", "PROBLEM", 64, 79], ["the Th2 immunity", "TREATMENT", 96, 112], ["asthma", "OBSERVATION", 3, 9], ["dendritic cells", "OBSERVATION", 64, 79]]], ["One important point to remember is that delivery route will dictate the cost/benefits of a purine drug depending on the local effects of the target receptor, and whether a treatment is corrective or preventive.", [["purine", "CHEMICAL", 91, 97], ["purine", "CHEMICAL", 91, 97], ["purine", "SIMPLE_CHEMICAL", 91, 97], ["target receptor", "PROTEIN", 141, 156], ["a purine drug", "TREATMENT", 89, 102], ["a treatment", "TREATMENT", 170, 181]]]], "9aeaf5696d213e2ac53875e6fa122d9828f3eae0": [["As many countries across the globe are struggling with the Covid-19 virus, a discussion is taking place about the possible use of (a wide variety of) contact tracing apps.", [["globe", "ORGAN", 29, 34], ["Covid-19 virus", "ORGANISM", 59, 73], ["Covid-19 virus", "SPECIES", 59, 73], ["globe", "ANATOMY", 29, 34]]], ["The goal is to gain insight in the spread of the corona-virus which, in many cases, requires location data and biometric information.", [["location data", "TEST", 93, 106]]]]}